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Abstract 
The treatment of cancer with chemotherapeutic drugs is strongly limited by intrinsic or 
aquired resistance of the cancer cells. This is the main reason of a failure of the therapy. 
The cellular resistance mostly originates from an overexpression of ABC transport 
proteins that efflux many structurally diverse molecules, including several 
chemotherapeutic drugs, out of the cells. Due to the reduced concentration of cytostatic 
drugs in the resistant cancer cells higher doses of the cytostatic agent are required, leading 
to systemic toxic effects, and may render the therapy ineffective. A possible way to 
overcome this so-called multidrug resistance (MDR) is to target the efflux transport 
proteins with suitable inhibitors.  
In this study several inhibitors of ABCG2 - one of three major ABC transport proteins 
that are associated with MDR - were synthesized. To date, only few potent, selective and 
nontoxic inhibitors have been discovered for ABCG2. For this reason a library of 219 
novel compounds based on a quinazoline scaffold or closely related structures was 
developed and investigated in several functional assays. The investigations comprise the 
determination of the inhibitory potency and selectivity toward ABCG2 as well as the 
cytotoxicity of the compounds. Further studies aimed to explore the ability of a compound 
to reverse the MDR toward common cytostatic drugs such as SN-38 and mitoxantrone 
(MX). Other studies were used to help shed some light on the function of the protein. 
Thus, enzyme kinetic investigations of several compounds were carried out in the 
presence of the substrate Hoechst 33342 to gain insights into the different binding modes 
of the inhibitors. Complementary to that, a conformation sensitive 5D3 antibody binding 
assay was conducted to find patterns among the inhibitors to provide a meaningful 
classification. The investigation of the ATPase activity obtained some information related 
to the transport activity of the protein in co-administration of inhibitors. 
Overall, this work yielded 40 highly potent inhibitors of ABCG2, with IC50 values below 
100 nM in the Hoechst 33342 acumulation assay. For comparison, Ko143, which is 
considered as one of the most potent inhibitors of ABCG2 in literature, possessed an IC50 
value of 227 nM. Important molecular features that are vital for the activity of the 
corresponding quinazoline derivatives could be deduced via a SAR analysis. Moreover, 
the crucial factors regarding the selectivity of a compound could be determined, which 
can be beneficial for the specific synthesis of either selective or broadspectrum inhibitors. 
Also, the cytotoxicity of the quinazoline derivatives could be modulated, either by 
modification of the scaffold or specific substitution patterns, leading to several nontoxic 
compounds. The multidrug resistance toward commercial chemotherapeutic drugs was 
successfully reversed and the potency of the reversal could thereby be determined. 
Additionally, strong evidence for the existance of several binding sites in ABCG2 and 
possibly different modes of interaction of the inhibitors with the protein was provided by 
the different results in the investigation of the interaction type with Hoechst 33342, 5D3 
shift, and ATPase assays. The collected data could contribute to the synthesis of further 
potent inhibitors with the desired characteristics and lead to a better understanding of the 
function of ABCG2. Owing to the excellent properties of some of the synthesized 
compounds the transfer of the in vitro experiments to in vivo studies is a promising 
prospect for continuative studies. 
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1 Introduction  7
1 Introduction 
1.1 The occurrence of multidrug resistance 
(MDR) and chemotherapy 
 
An estimate of roughly 1,700,000 new cases and 600,000 cancer deaths were predicted 
in the United States for the year 2016.1 The majority of these deaths are most likely 
attributed to the resistance of the cancer cells toward the chemotherapeutic treatment.2  
In many cases this resistance is associated with the expression of ATP binding cassette 
(ABC) transport proteins, most notably P-glycoprotein (P-gp, ABCB1), the multidrug 
resistance-associated protein 1 (MRP1, ABCC1) and the breast cancer resistance protein 
(BCRP, ABCG2).3 These transport a wide variety of structurally unrelated substrates, 
including many chemotherapeutic drugs, against a concentration gradient out of the cell, 
using ATP hydrolysis as a source of energy.4 In such cases a chemotherapeutic cancer 
treatment may result in failure, owing to the decreased intracellular drug concentration in 
resistant cancer cells. 5,6   
The resistance of the cells can either be preexisting (intrinsic) or induced by the drugs 
(acquired resistance), following a chemotherapeutic treatment or after a change in therapy 
by a relapse of resistant cells.7 This phenomenon of cellular resistance against various 
xenobiotics is termed multidrug resistance (MDR). Although there are also other 
mechanisms for cancer cells to become resistant to anticancer drugs, such as activation 
of DNA repair, decreased influx, activation of detoxifying systems, or blocked apoptosis, 
the increased efflux by transport proteins is by far of greatest importance.8  
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1.2 ATP-binding cassette transport proteins 
 
The ATP-binding cassette transport proteins comprise one of the largest superfamily of 
proteins in eukaryotic and prokaryotic organisms.9 These integral membrane proteins 
transport structurally diverse substrates across the membrane using hydrolysation of ATP 
to ADP and orthophosphate (Pi) as a source of energy.10 ABC transporters can be 
classified as importers or exporters that mediate the cellular uptake of nutrients (e.g. 
amino acids, sugars, essential metals) or excretion of various molecules (e.g. lipids, 
toxins, cholesterol, chemotherapeutic drugs).11 Importers and exporters are both present 
in prokaryotes, whereas in eukaryotes almost exclusively exporters are found.12 
 By definition, ABC transport proteins contain an ATP binding cassette, referred to as the 
nucleotide-binding domain (NBD), which contains the highly conserved motifs Walker 
A and Walker B sequences, the ABC signature motif, the H loop and the Q loop.13 In its 
smallest functional form they consist of at least two transmembrane domains (TMDs) and 
two nucleotide-binding domains (NBDs), of which the NBDs are highly conserved in 
structure and sequence among all ABC transporters.14  
For the transport of substrates at least 12 membrane spanning α-helices are required, and 
a large binding-pocket is suggested to be located at the TMDs.15 Besides full transporters 
such as ABCB1 (P-gp) possessing the mentioned core requirements for transport, there 
also exist half-transporters such as ABCG2 (BCRP). These half transporter must form 
dimers or oligomers to achieve a fully functioning transport protein and are reviewed in 
more detail for ABCG2 in chapter 1.2.4.2.   
In the human genome 48 ABC genes were identified that could be arranged in the seven 
subfamilies ABC-A to ABC-G, based on phylogenetic similarity.6 The subfamily ABCA 
contains 12 genes that are mostly related to lipid trafficking in various organs.16 Some 
genes have been associated with several diseases, such as Alzheimer’s (mutation in 
ABCA2), Tangier disease (mutation in ABCA1), familial high-density cholesterol 
deficiency syndrome (mutation in ABCA1) or harlequin ichthyosis congenital skin 
disease (mutation in ABCA12).17,18  
The subfamily ABCB contains 11 genes and is the only group containing both full- and 
half-transport proteins.19 Here, the most prominent member is ABCB1 which is related 
to multidrug resistance in cells with an overexpression of this gene. Mutations in the 
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ABCB family have been implicated for instance in diabetes type 2, coeliac disease or 
cholestatic liver diseases.13  
The subfamily ABCC contains 13 members of which 9 are associated with MDR. Similar 
to ABCB and ABCG this subfamily complies a protective function by effluxing toxins 
and other harmful molecules out of cells. In this regard, ABCC1 is the most notorious 
member associated with MDR and is able to efflux mostly glutathione and other 
conjugates of many toxic compounds.19  
The subfamily ABCD contains four genes where the function of ABCD2, ABCD3 and 
ABCD4 is not yet clear. Mutation in ABCD1 however was associated with the X-linked 
form of Adrenoleukodystrophy (ALD) resulting in neurodegeneration and adrenal 
deficiency.20 Moreover, ALD patients often exhibited an accumulation of fatty acids in 
cells leading to the assumption that ABCD1 and possibly the other genes of this subfamily 
play a role in fatty acid metabolism.19  
The subfamily ABCE consist only of the gene ABCE1 which is an organic anion binding 
protein. It is associated with the inhibition of 2-5A/RNase L system, the assembly of HIV-
1 capsids, and eukaryotic translation fields and carcinogenesis. However, the involved 
processes are not fully elucidated and no diseases have been attributed to ABCE1, yet.21 
Interestingly, ABCE1 and the ABCF members contain ATP-binding domains, but no 
TMDs, assuming that they are unable to transport substrates. The ABCF subfamily 
contains three different genes which could play a role in inflammatory processes, but have 
not been associated with any diseases so far.13  
The subfamily ABCG consists of 5 genes and shows a reversed orientation regarding the 
sequence of NBD and TMD, where the NBD is at the N-terminus and the TMD at the C-
terminus. Being half-transporters, they must at least dimerize to form a functional 
transporter. Most notably, the gene ABCG2 confers cellular resistance toward many 
cytostatic drugs and other structurally unrelated molecules that can lead to MDR. ABCG5 
and ABCG8 mediate the transport of sterols and can lead to sitosterolaemia in the case of 
mutation in one of these genes. 13,22 More detailed information regarding ABCG2 is 
provided in chapter 1.2.4.  
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1.2.1 Suggested transport mechanisms  
 
Most eukariotic ABC transport proteins are ATP denpendend exporters, that effectuate 
the active transport of various molecules across membrane lipid bilayers, even against a 
concentration gradient. Unfortunately, the exact mechanism that is involved in the 
transport of substrates is not fully understood in the various systems.  
Initial evidence regarding the transport mechanism was collected by investigating 
different crystal structures in importers and exporters.23 In the year 2002, the first crystal 
structure of an intact ABC importer was published for the E. coli vitamin B12 importer 
BtuCD.7 Four years later, the first reliable crystal structure of an exporter, namely the 
multidrug efflux pump Sav1866, was published after purification from Staphylococcus 
aureus.24 Unfortunately, all crystal structures lacked a high diffraction resolution which 
could lead to wrong assessments and had to be handled with caution.11  
The NBDs of ABC transport proteins displayed a high identity in the amino acid sequence 
and also in some characteristic motifs.25 It was found, that the NBDs undergo a 
considerable conformational change due to ATP binding and also after the hydrolysis of 
ATP.26 As depicted in Figure 1, each of the two NBDs is coupled with a single TMD via 
flexible coupling helices. In the ATP-unbound form, the TMDs are facing inward, 
providing binding pockets for substrates. According to the ATP-Switch-Model, binding 
of substrates to the TMDs induce a conformational change in the initial open dimer form 
of the disengaged NBDs, by which their binding affinity to ATP increases. Subsequent 
binding of two ATP molecules induces a putative nucleotide „sandwich dimer“ leading 
to a closed NBD-ATP complex. During this binding process, the TMDs change from the 
inward facing to the outward facing arrangement, releasing the substrate in the 
extracellular space.27 Sequential hydrolysis of ATP to ADP and Pi resets the tranport 
protein to the initial state with a inward facing high affinity drug-binding cavity at the 
TMDs and an open low affinity nucleotid binding site at the NDBs.   
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Figure 1: Schematic model of the transport mechanism of substrates by ABC transport protein exporters 
modified from S. Wilkens.12 Hydrolysis of the bound ATP in the NBDs on the right hand side resets the 
transport protein to its initial inward facing state illustrated on the left hand side. In the ATP-Switch-Model 
the two NBDs are found in a disengaged open form, while they stay engaged in the Constant-Contact-
Model. 
 
Based on the work of Senior et al. a similar model termed Constant-Contact-Model was 
proposed.28 Here, an alternating process of ATP binding and hydrolysis is proposed, 
where one site opens due to ATP hydrolysis while the corresponding other site remains 
closed by bound ATP. This induces the formation of the inward facing form (binding of 
substrates) followed by the outward facing form (release of the substrate), completing the 
cycle. Although both models can be involved in the transport mechanism, different crystal 
structures of several exporters provided substantial evidence that is in good accordance 
with the ATP-Switch-Model.29  
 
1.2.2 P-glycoprotein (P-gp) / ABCB1 
 
In the year 1976, Juliano et al. published the discovery of a colchicine selected Chinese 
hamster ovary cell line that displayed resistance toward a wide range of amphiphilic 
drugs.30 Owing to the altered drug permeability, they named this cell surface glycoprotein 
P-glycoprotein. Among the three most important MDR-associated ABC transport 
proteins (ABCB1, ABCC1 and ABCG2), P-glycoprotein (P-gp/ABCB1/MDR1) was 
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discovered first and is probably the best studied member. It is widely expressed on the 
plasma membrane, Golgi membrane, and intracellular canaliculus of normal human 
tissues, including the liver, kidney, colon, adrenal gland, intestine, placenta, 
hematopoietic precursor cells and endothelial cells at the blood-brain, blood-testis and 
blood-placenta barriers.31 ABCB1 functions as a protective cellular unit by effluxing 
xenobiotics, including chemotherapeutic drugs. Since the transport protein is often also 
widely expressed in drug resistant tumors, a chemotherapeutic cancer treatment can result 
in failure owing to the MDR of the cancer cells toward the chemotherapeutic drugs.  
   
1.2.2.1 Structure and function 
 
ABCB1 is a 170 kDa glycoprotein, encoded by the MDR1 gene, and consists of 1280 
amino acids.32,33 The transport protein contains two symmetrical NBDs and TMDs, where 
the TMDs consist of six membrane spanning α-helical domains each (see Figure 2).8 The 
two homolog halves are joined by a linker region and the N- and C-termini are located in 
the cytoplasm.34 Rosenberg et al. suggested by cryoelectron microscopy that the two 
TMDs form a funnel-shaped aqueous “pore” in the membrane that is probably involved 
in the transport of substrates.35 
 
 
Figure 2: Topology model of ABCB1 (P-gp). 
 
As mentioned before, the transport protein is able to efflux a wide variety of substrates 
by ATP consumption. In this regard, lipophilic, uncharged or (weakly) basic species are 
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transported most efficiently and an amphophilic nature was identified as a common 
feature of many substrates.36 This finding is in accordance with the proposed transport 
mechanism for ABCB1: the “vacuum cleaner”- and the “flippase”-models, that are 
illustrated in Figure 3.  
Raviv et al. discovered in a fluorescence resonance energy transfer (FRET) study with 
the lipophilic photolabelled probe iodonaphthalene-1-azide that the substrate doxorubicin 
was located within the membrane close to ABCB1.37 Based on this and other studies as 
well, it was proposed, that ABCB1 interacts with its substrates within the membrane and 
subsequently effluxes them directly to the extracellular medium.38 This transport process 
was termed hydrophobic “vacuum cleaner” and is depicted on the left hand side in  
Figure 3.  
 
 
Figure 3: Schematic model of the “Vacuum cleaner” and “Flippase” transport mechanism of substrates 
by P-glycoprotein (P-gp/ABCB1) modified from Sharom.39 
 
Also, NMR studies revealed that (amphiphilic) substrates enter the lipid bilayer of the 
membrane and frequently accumulate in the inner or outer leaflet near to the headgroup 
of the lipid chain.40 The “Flippase” model (right hand side in Figure 3) describes the 
translocation of a substrate by the transport protein from the inner leaflet of the lipid 
bilayer to the outer leaflet. From here, the substrate exits the membrane by passive 
diffusion into the extracellular medium. Indeed, the majority of the scientific evidence 
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points to the suggestion that the efflux takes place in a flippase-like manner although both 
models could be involved in the transport process.38  
 
1.2.2.2 Substrates and inhibitors of ABCB1 
 
The spectrum of transported substrates of ABCB1 is broad and includes compounds 
preferably with lipophilic and amphiphilic properties. The molecular weight of 
transported molecules ranges from less than 200 to almost 1900 Da comprising aromatic 
groups, but also non-aromatic linear or circular molecules.36 It effluxes several 
chemotherapeutic agents, fluorescent dyes, natural products, TKIs, HIV protease 
inhibitors, steroids and other substances (compare Table 1). Fluorescent dyes like calcein 
can be co-administered with modulators to monitor the efflux activity of the transport 
protein which can be correlated to the inhibitory potency of the test compounds. Most 
notably, ABCB1 was called multidrug resistance protein 1 (MDR1) as its expression is 
associated with the cellular resistance toward several cytotoxic drugs, which can be a 
major obstacle in chemotherapy.  
In silico analysis revealed, that the number and the strength of the hydrogen bonds formed 
between a compound and ABCB1 is a crucial determinant for the distinction between 
substrates and inhibitors: compounds with a pronounced ability to form hydrogen bonds 
are more likely to be inhibitors than substrates of ABCB1.41  
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Table 1: Selection of Substrates of ABCB1.36,39 
 
Compound-class Compound 
CHEMOTHERAPEUTIC AGENTS  
  
     Anthracyclines Daunorubicin 
 Doxorubicin 
     Camptothecins Topotecan 
     Taxanes Doxotacel 
 Paclitaxel 
     Vinca alkaloides Vinblastine 
 Vincristine 
FLUORESCENT DYES  
 Calcein AM (calcein acetoxymethylester) 
 Hoechst 33342 
 Rhodamine 123 
NATURAL PRODUCTS  
 Flavonoides 
 Curcuminoides 
 Colchicine 
TYROSINE KINASE INHIBITORS  
 Imatinib  
 Gefitinib 
STEROIDS  
 Corticosterone 
 Aldosterone 
 
Inhibitors of ABCB1 were classified in three generations according to specificity, affinity 
and toxicity (see Table 2). Many of the first generation inhibitors like the calcium channel 
blocker verapamil or the immunosuppressive cyclosporine A, were found to be 
transported substrates themselves and act as competitive inhibitors. Unfortunately, 
serious toxic effects resulted owing to the high doses that were needed for an effective 
inhibition of ABCB1.42 In the first clinical trials using inhibitors of the first and partly of 
the second generation, mostly poor results were achieved which were due to the 
mentioned toxic effects, unwanted pharmacokinetic drug interactions and a poor potency 
and selectivity of the inhibitors toward the transport protein.43  
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Table 2: Selection of Inhibitors of ABCB1.44,45 
 
Inhibitors Compound 
FIRST GENERATION   
 Verapamil 
 Cyclosporine A 
 Reserpine 
 Quinidine 
 Tamoxifen 
  
SECOND GENERATION  
 Dexverapamil 
 Valspodar (PSC833) 
 Dofequidar fumarate (MS-209) 
 Biricodar (VX-710) 
  
THIRD GENERATION  
 Elacridar (GF120918) 
 Tariquidar (XR9576) 
 Zosuquidar (LY336979) 
 Mitotane (NSC-38721) 
  
  
 
The second generation inhibitors were often deduced from the structures of the first 
generation inhibitors. These derivatives frequently displayed a higher specificity and a 
reduced toxicity. However, several compounds were found to be substrates of cytochrome 
P450 3A4 (CYP450 3A4) and influenced the metabolism of co-administered anticancer 
drugs which led to unpredictable pharmacokinetics.46  
Third generation inhibitors did not exhibit the described downsides of the first two 
generations. For instance, Tariquidar or Zusoquidar were found to be potent and specific 
inhibitors of ABCB1 with a low cytotoxicity. Some of them even achieved promising 
results in clinical trials.47,48,49 Nevertheless, the transfer from successful in vitro 
experiments to in vivo led to the rise of unexpected difficulties that must to be addressed 
in future studies.43    
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1.2.3 Multidrug Resistance associated Protein 1 (MRP1) / 
ABCC1 
 
ABCC1 was first discovered in 1992 by Cole et al. and cloned from the multidrug-
resistant small cell lung cancer cell line H69AR.50 This cell line exhibited resistance 
toward the cytostatic drug doxorubicin which could be attributed to the expression of the 
multidrug resistance associated protein 1 (MRP1) later termed ABCC1. Similar to 
ABCB1 and ABCG2, ABCC1 is able to efflux a wide spectrum of molecules, including 
several anticancer drugs, highlighting ABCC1 as an important target in terms of MDR.  
Subsequent work showed, that ABCC1 performs important pharmacological and 
toxicological functions:36 a study conducted by Wijnholds et al. concluded that the 
sensitivity of mice towards treatment with the cytostatic drug Etoposide was highly 
increased in Abcc1 knockout mice.51 Other studies with Abcc1 knockout mice resulted 
in the same conclusion, correlating the expression of the transport protein to an increased 
cellular resistance toward some toxic compounds.52 ABCC1 is expressed in almost all 
human tissues, most notably in lung, spleen, testis, kidney, placenta, thyroid, bladder and 
adrenal gland.53 In contrast to the apical membrane location of other ABC transporters, 
ABCC1 is predominantly located in the basolateral membrane of polarized cells where it 
most likely effluxes its substrates into the interstitial space, rather than excreting them 
into bile, urine or gut.54  
 
1.2.3.1 Structure and function 
 
ABCC1 consists of 1531 amino acid residues and adds up to a molecular weight of 190 
kDa.55 Within the ABCC subfamily, ABCC1 exists in a „long“ form, meaning that it 
contains two TMDs with 6 membrane spanning α-helices each, two NBDs and an 
additional TMD 0 with 5 membrane spanning α-helices (see Figure 4).56 The function of 
this additional TMD 0 is not yet clear. Mutational studies in this region have shown that 
it could influence the folding of the protein.57 Other studies suggest that it can contribute 
to the ABCC1 homo-dimerization.58 However, complete removal of TMD 0 did not affect 
the transport function or its proper routing to the plasma membrane.59  
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Figure 4: Topology model of ABCC1 (MRP1). 
 
The transport is accomplished by TMD 1 and 2 forming a „pore“ through which the 
substrates are effluxed.55 A similar phenomenom was described in chapter 1.2.2.1 for 
ABCB1, that shares the same functional core (two TMDs and two NBDs) and also forms 
a „pore“ which is involved in the transport of substrates.  
 
1.2.3.2 Substrates and inhibitors of ABCC1 
 
The substrate spectrum of ABCC1 comprises several anticancer drugs such as 
anthracyclines, mitoxantrone, methotrexate or camptothecines and also Vinca alkaloids. 
This can affect the response of cancer patients toward chemotherapeutic treatment and 
may lead to failure of the therapy. Interestingly, it was found that for some substrates, 
which do not form GSS-conjugates, GSH is required for the transport. Substrates 
depending on the co-transport with GSH are for instance the Vinca alkaloid Vincristine 
or the anthracyclines Daunorubicin and Doxorubicin.60 In this regard, ABCC1 mostly 
(co-)transports amphipathic organic anions including hydrophobic drugs or other 
compounds that are conjugated or complexed to either the anionic tripeptide glutathione 
(GHS), glucuronic acid, or to sulfate.36,61 Also heavy metal ions, such as arsenite or 
antimony are subject to transport by ABCC1, most likely as a complex with GSH.62,63 A 
selection of ABCC1 substrates is illustrated in Table 3. 
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Table 3: Selection of Substrates of ABCC1.36,54  
 
Compound class Compound 
CHEMOTHERAPEUTIC AGENTS  
  
     Vinca alkaloids Vinblastine  
 Vincristine 
  
     Camptothecins Topotecan 
 Irinotecan 
 SN-38 
       
     Anthracyclines Doxorubicin 
 Daunorubicin 
 Epirubicin 
      
     Others Methotrexate 
 Mitoxantrone 
  
GLUTATHIONE CONJUGATES (-GS)  
 
Dinitrophenyl-GS, Doxorubicin-GS, 
Cyclophosphamide-GS, Hydroxynonenal-GS, 
Glutathione (GSH, GSSG) 
  
GLUCURONIDE CONJUGATES (-G)  
 Bilirubin-G, Estradiol 17βD-G, Etoposide-G, NS-38-G  
  
SULFATE CONJUGATES (-S)  
 
Estrone-3-S, Taurocholate-3-S, Sulfatolithocholyl 
taurine 
  
OTHERS  
 Curcuminoides  
 Calcein 
 
 
Owing to the affinity of the transporter toward anionic molecules, there have been 
difficulties in finding effective inhibitors that are able to permeate the lipophilic cell 
membrane and so far only few inhibitors of ABCC1 as compared to ABCB1 have been 
identified.64 The first compounds included general organic anion transport inhibitors, 
such as probenecid, sulfinpyrazole, benzbromarone or indomethacin. Unfortunately, 
these compounds modulated the activity of most of the ABC-related organic anion efflux 
transporters and also the activity of some of the pharmacological relevant solute carrier 
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family organic anion importers.55 Another problem was the low affinity and poor 
specificity of some inhibitors like cyclosporine A or PSC833.65 
Later, more specific inhibitors of ABCC1 were developed. Most notably, the quinoline 
derivative MK-571 (a LTC4 analog), which is used as a specific standard inhibitor and 
possesses a carboxyl function which is deprotonated in physiological conditions. The 
compound was originally developed as a cysteinyl leukotriene receptor 1 (CysLTR1) 
antagonist for the purpose of treating asthma.55 In the class of LTC4 derivatives the 
compound ONO-1078 was found to be potent and specific toward ABCC1. Moreover, 
the tricyclic isoxazoles LY465803 and LY475776 exhibited a considerable potency and 
selectivity toward the transport protein. Nevertheless, there is a persistent need for more 
potent and specific inhibitors displaying a low cytotoxicity.  
 
1.2.4 Breast Cancer Resistance Protein (BCRP) / ABCG2 
 
The human breast cancer resistance protein is the second member of the G subfamily of 
the ATP-binding cassette (ABC) efflux transporter superfamily, and hence also 
designated as ABCG2.66 It was first discovered in 1998 by the research group of Doyle 
et al. in MCF-7/AdrVp human breast cell carcinoma cells that displayed a resistance 
toward anticancer drugs even in the absence of known multidrug resistance transporters 
such as P-gp and MRP.67 The newly discovered transport protein was then termed breast 
cancer resistance protein (BCRP). Shortly after, Allikmets et al. reported the cloning of a 
nearly identical transporter that was widely expressed in the placenta and thus named it 
ABCP.68 Later, Miyake et al. reported multiple distinct mitoxantrone-resistant sublines, 
pointing to the existence of another major transport protein conferring drug resistance.69 
Here, the transport protein was named MXR or mitoxantrone resistance protein, due to 
its discovery in co-administration of mitoxantrone in the colon carcinoma cell line S1-
M1-80. Owing to the different terms for the newly discovered gene (BCRP, ABCP and 
MXR), the Gene Nomenclature Committee officially named it ABCG2, reflecting that it 
is the second member of the human ABCG subfamily. 2, 70  
To date, the subfamily G comprises the six members ABCG1, ABCG2, ABCG3, 
ABCG4, ABCG5 and ABCG8 which are extensively reviewed in the work of Moitra et 
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al. and Kusuhara and Sugiyama.71,72 Among those, ABCG3 has not been detected in 
humans so far. 
 
1.2.4.1 Distribution and physiological role of ABCG2 in human tissues 
 
Increased expression of ABCG2 is often found in human tissues comprising important 
physiological functions such as the protection of the organism against harmful 
xenobiotics. The research group of Doyle et al. reported high levels of ABCG2 in the 
placenta, brain, prostate, small intestine, testis, ovary, liver, adrenal gland, uterus, and 
central nervous system, using the northern blot analysis.73 ABCG2 was also found to be 
widely expressed in stem cells and is recognized as a marker in cancer stem cells.74 Some 
of these functional tissues are discussed in more detail in the following paragraph. 
Significant expression levels of ABCG2 were found in the syncitiotrophoblasts of the 
placenta, giving rise to the assumption that the transport protein is vital for the protection 
of the fetus from toxins.75 Experiments carried out by Jonker et al. substantiated this 
hypothesis as they administered the cytostatic drug topotecan, which is a substrate of 
ABCG2, together with the ABCG2-inhibitor elacridar to pregnant P-gp deficient mice. 
As a result, the relative fetal penetration of topotecan was two-fold higher than in the 
vehicle-treated control group.76 Similar results were found in a study conducted by Zhang 
et al. where the administration of the antibiotic nitrofurantoin to ABCG2 knockout mice 
and wild-type mice showed that the knockout mice lacked the protective function of the 
placenta toward the drug.77 In this regard it is not surprising that ABCG2 has been 
reported to transport substrates from the fetal to the maternal space, even against a 
concentration gradient.78,79   
A considerable induction of ABCG2 expression has also been found in the mammary 
gland in the breast of lactating mice, cows and humans. The physiological role of ABCG2 
in the lactating breast was investigated by van Hervaarden et al. in a study on ABCG2-
deficient and wild type mice. A 60-fold higher concentration of riboflavin (vitamin B2) 
was found in the milk of wild-type mice leading to the conclusion that ABCG2 can 
accumulate important nutrients into milk.80 However, the active secretion of clinically 
and toxicologically important substrates, such as PhIP (2-Amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine), the cytostatic drug topotecan or the anti-ulcerative 
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cimetidine, also led to an accumulation of the harmful substances in mouse milk.81 A 
similar outcome resulted for other dietary carcinogens and antibiotics which accumulated 
in the milk of animals with an expression of ABCG2 in the mammarial gland.82,83,84 
Hence, the diet of a breastfeeding mother plays an important role in reducing the excretion 
of harmful doses of toxins into the milk. 
The blood brain barrier (BBB) exhibits high levels of ABCG2 that are mainly located 
at the luminal cell surface of the microvessel endothelium.85,86,87 It was found that 
ABCG2 works together with ABCB1 in the BBB and is responsible for restricting the 
entry of numerous xenobiotics into the brain.6 However, many therapeutic agents are 
thereby restrained from reaching their intracerebral targets which leads to the requirement 
of higher drug doses and therefore can often result in a systemic toxicity.88 An increased 
brain uptake of chemotherapeutic drugs was achieved by inhibition of both, ABCB1 and 
ABCG2, by dual-inhibitors like Elacridar. Several results comprising different studies 
were summarized by Agarwal et al. and demonstrated, that MDR caused by ABC 
transport proteins can be overcome by direct inhibition.89  
More details regarding the expression of ABCG2 in different tissues are provided in the 
reviews of Robey et al. (2009) and Stacy et al. (2013). 4,90      
 
1.2.4.2 Structure and function of ABCG2  
 
ABCG2 is a 72 kDa integral membrane protein consisting of 655 amino acids.91 It 
comprises only one cytosolic N-terminal nucleotide-binding domain (NBD) and one C-
terminal transmembrane domain (TMD) with six transmembrane helices, as depicted in 
Figure 5.92 Unlike ABCB1 and ABCC1, ABCG2 is a half-transporter that exhibits a 
reversed TMD-NBD arrangement of which the relevance is still unknown.93 Among ABC 
transport proteins, the formation of composite ATP binding sites, based on the interaction 
of two NBDs, is postulated as the fundamental functional unit.94,95 With regard to 
ABCG2, the full function can be achieved by dimerization or the formation of higher 
oligomers.  
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Figure 5: Topology model of ABCG2 (BCRP), a). Protein 3D structure of the ABCG5/ABCG8 
heterodimer, b).  
 
Current studies revealed, that the formation of tetramers is preferred in the presence or 
absence of transported substrates. This has been demonstrated by a combination of 
fluorescence correlation spectroscopy, photon counting histogram analysis, and stepwise 
photobleaching.96,97 Moreover, it is suggested that one functional tetrameric complex is 
composed of four BCRP homodimers which could form via linkages by intermolecular 
disulfide bridges at cysteine 603.98,99,100,101 However, there is also contradicting evidence 
to this hypothesis described by some mutation studies in C603.99,102  
For a better clarity, a schematic topology of the membrane is illustrated in Figure 6, 
highlighting the residues or mutations that affect the functioning of the transport protein. 
Here, C603 is highly conserved at the extracellular loop between TMD 5 and 6 in 
proximity to C592 and C608. According to mutagenesis data, all mentioned cysteine 
residues probably provide stability to the protein by formation of intramolecular disulfide 
bonds.100 In this regard, the mutation of C592 or C608 in ABCG2 expressing Flp-In-293 
cells resulted in a significant decrease in protein levels of the transporter.  
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Figure 6: Schematic illustration of the membrane topology of ABCG2 and highlights of residues or 
mutations that affect the functioning of the transporter. The graphic was modified from Stacy et al. 
(2013).90  
 
Further mutational studies of Wakabayashi et al. and Polgar et al. identified two more 
regions that could be involved in the formation of dimers:103,104 this regards the amino 
acids T402, G406, G410, G553 and the GXXXG motif in general, comprising the amino 
acid chain G406-G410. One or several mutations at the mentioned regions could result in 
a reduced protein expression, decreased drug efflux, alterations in glycosylations and 
retention of ABCG2 in the endoplasmatic reticulum (ER). 
The glycosylation of ABCG2 was found to play a vital role in the function of ABCG2 as 
it confers stability to the protein structure. Altered glycosylation could lead to an 
increased degradation of the protein and thereby regulates the expression of the transport 
protein.105 
In this regard, the N-linked glycosylation site at amino acid 596 was found to play a 
crucial role as demonstrated by mutagenesis studies.106  
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Moreover, a so-called “gain of function” was observed in a single nucleotide 
polymorphism (SNP) at amino acid 482 where substitution of arginine by threonine or 
glycine led to a broadened substrate spectrum of ABCG2.107,108 The dye rhodamine 123, 
for instance, is transported by the R482T and R482G mutants, but not by wild-type cells. 
Also, these mutants exhibited a higher affinity to several anthracyclines such as 
doxorubicin, daunorubicin, epirubicin and also bisanthrene, fluorescene and lysotracker 
green. Some substrates of the ABCG2 wild-type and the R482G variant are depicted in 
Figure 7. Photoaffinity labelling studies with the substrate-analog 
[I125]iodoarylazidoprazosine (IAAP) and the investigation of the ATPase activity 
revealed in several of the R482 mutants that most of the variants have a high impact on 
the substrate transport and ATP turnover, but might not be necessary for substrate 
recognition and binding.109, 110   
In proximity to amino acid 482 in TM3 a P485A variant exhibited a considerable 
reduction (70%) of the efflux of BODIPY-prazosin, but had no effect on the transport of 
MX and Hoechst 33342.111 It is known that Pro residues are able to form flexible hinges 
in TM α-helices that can be accountable for dynamic conformational changes in the 
protein which can affect the binding of drugs and the transport activity of the protein.112   
 
 
 
Figure 7: Substrate specificity of the ABCG2 wild-type form and the mutant R482G isoform.113  
 
Other SNPs studies of the ABCG2 gene targeted the amino acid changes at V12M, 
Q141K and D620N.114 Regarding the Q141K ABCG2 variant, cytotoxicity assays 
revealed a considerable effect on the transport activity of substrates like MX, topotecan, 
SN-38 and diflomotecan: HEK-293 cells exhibited a significant lower transport activity 
in the Q141 variant than in wild-type cells. On the contrary, the V12M and D620N 
Topotecan
Flavopyridol
Mitoxantrone
Pheophorbide A
Hoechst 33342
TKIs
Doxorubicin
Rhodamine 123
Daunorubicin
Epirubicin
Methotrexat R482Gwild-type
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variants displayed no significant impact on the transport activity compared to ABCG2 
wild-type cells. The altered transport function in the Q141K variant needs to be 
considered in chemotherapeutic treatment, since it has important implications for the 
pharmacokinetics and drug-resistance profiles of chemotherapeutics and is one of the 
most frequently observed SNP variants of ABCG2 in the human population.90  
                                                                                                                                                                                                 
1.2.4.3 Substrates and inhibitors of ABCG2 
 
The first substrates were discovered as ABCG2 overexpressing cells exhibited resistance 
toward several chemotherapeutics, such as methotrexate, mitoxantrone, anthracyclines 
and camptothecin derivates (see Table 4). Fluorescent dyes like Hoechst 33342 were 
found to be useful tools to investigate the transport activity of the protein in functional 
assays.115 This includes the porphyrine derivative pheophorbide A that can also be used 
as a photosensitizer in photodynamic therapy.116 The flavonoid derivative quercetin for 
instance is often used as standard activator in studies of the ATPase activity of ABCG2. 
Interestingly, TKIs like gefitinib or imatinib exhibit concentration dependent properties, 
as they act as substrates at low concentrations and as inhibitors at higher concentrations. 
But also other drugs like sulfasalazine or omeprazole are transported by ABCG2 which 
should be considered to avoid possible unwanted side-effects in medicated patients since 
they are frequently prescribed. 
The selection of substrates in Table 4 illustrates that ABCG2 is able to transport a broad 
diversity of structurally unrelated compounds. Notably, single nucleotide polymorphisms 
can alter the substrate spectrum considerably. In particular mutations at amino acid 482 
were found to broaden the spectrum (gain-of-function mutation) of ABCG2. 
 
 
 
 
 
 
 
 
1 Introduction  27 
Table 4: Selection of Substrates of ABCG2. 
 
Compound-class Compound Reference 
CHEMOTHERAPY AGENTS   
  
 
     Antifolates Methotrexate**  117, 118 
 Tomudex 119 
     Anthracenes Mitoxantrone 120, 121 
 Bisantrene 121 
 Aza-anthrapyrazole 122, 123 
     Anthracyclines Daunorubicin* 120 
 Doxorubicin* 120 
 Epirubicin* 120 
 Flavopiridol 124 
     Camptothecin derivatives Topotecan 121 
 SN-38 125 
 Irinotecan 126, 127 
FLUORESCENT DYES   
 Rhodamine 123* 121 
 Lysotracker green* 121 
 BODIPY-prazosin 121 
 Hoechst 33342 115 
 6-carboxy-2´,7´-dichlorofluoresceine 128 
PORPHYRINES   
 Pheophorbide A 129 
 Protoporphyrine IX 129 
 Phytoporphyrine 130 
FLAVONOIDES   
 Genistein 131 
 Quercetin 132 
TYROSINE KINASE INHIBITORS   
 
Imatinib  90, 133 
 
Gefitinib 90, 133 
 
Nilotinib 90, 133 
OTHER DRUGS   
 Omeprazole 134 
 Pantoprazole 134 
 Prazosin 121 
 Indolocarbazole 135 
 Sulfasalazine 136 
 Abacavir 137 
 
*: Subject to transport by the ABCG2 SNP482 mutants only 
**: Subject to transport by the ABCG2 wild-type only 
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But there is also a significant overlap of substrates between ABCG2, ABCB1 and 
ABCC1, as depicted in Figure 8. Mitoxantrone for instance is tranported by all three 
transport proteins. Topotecan, Rifamipicine and Hoechst 33342 are subject to transport 
by ABCG2 and ABCB1. 
 
 
Figure 8: Substrate overlap between ABCG2, ABCB1 and ABCC1. Substrates that are marked with an “a”              
are subject to transport by the ABCG2 R482G isoform but not the wild-type form.90   
 
Further overlap in substrates was detected among ABCG2 and ABCC1, where both 
transport folic acid, methotrexate and estrone-3-sulfate. This is in particular important in 
terms of chemotherapeutic treatment of cancer by drugs that are transported by one or 
more tranport proteins. Tissues or barriers like the BBB, that is simultaneously expressing 
ABCG2 and ABCB1, can be addressed by broadband inhibitors to reduce the resistance 
of the cells toward cytostatics with overlapping substrate specificity, such as topotecan.   
Several inhibitors of ABCG2 also displayed an overlap of selectivity with ABCB1 and 
ABCC1, which indeed is more pronounced between the transport proteins ABCG2 and 
ABCB1. Like the substrates, the inhibitors of ABCG2 comprise molecules of different 
structural features that can be compared in Table 5. To date, only few selective and potent 
inhibitors, active in the submicromolar range have been reported, and further research is 
required.138  
ABCG2
ABCC1ABCB1
Lysotracker
Pheophorbide A
Riboflavin
Doxorubicina
Mitoxantrone
Etoposidea
Folic acid
Methotrexat
Estrone-3-sulfate
Topotecan
Rifamipicin
Hoechst 33342
Cisplatin
Hydroxyurea
Cyclophosphamide
Paclitaxel
Colchicine
Mitomycine
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Table 5: Selection of Inhibitors of ABCG2. 
 
Compound-class Compound Reference 
DIKETOPIPERAZINES   
 Fumitremorgin C 123 
 Ko143 139 
 Indolyl diketopiperazines 140 
STEROIDS AND STEROID-LIKE    
 Corticosterone 141 
 Digoxin 141 
 Mometasone 142 
IMMUNOREPRESSANTS   
 Cyclosporine A (CsA) 143 
 Sirolimus 143 
 
Tacrolimus 143 
TYROSINE KINASE INHIBITORS   
 Gefitinib 144 
 Imatinib 144 
 Nilotinib 144 
ABCB1/ABCG2 DUAL-INHIBITORS   
 Elacridar (GF-120918) 145 
 Tariquidar (XR-9576) 129 
 WK-X24 (XR-9577) 146 
FLAVONOIDES   
 Chrysin 147 
 Benzoflavone 148 
 Kaempferol 131 
 Genistein 131 
AZOLES   
 Pantoprazole 134 
 Omeprazole 134 
 Ketoconazole 149 
CALCIUM CHANNEL BLOCKERS   
 Dipyridamole 150 
 Nicardipine 150 
 Nitrendipine 150 
OTHER DRUGS   
 PZ compounds 151, 152 
 Curcumine 153, 154 
 Xanthine 155 
 
 
The first specific inhibitor of ABCG2 was the diketopiperazine fumitremorgin C (FTC), 
which was isolated from Aspergillus furmigatus but displayed  severe neurotoxicity. 
Later, a less toxic and 10-fold more potent FTC analog, namely Ko143, was developed. 
It exhibited a high selectivity toward ABCG2 up to 1 µM and was established as one of 
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the standard inhibitors of the transport protein.156 More inhibitors were discovered in the 
class of steroides and immunosupressants: the immunosupressant CsA for instance was 
used as standard inhibitor in the screenings with ABCB1 and ABCC1 overexpressing 
cells, to determine the selectivity toward ABCG2 of selected compounds in this work. 
The immunosupressants CsA and Sirolimus were both able to reverse the MDR of 
ABCG2 expressing HEK cells toward the cytostatic agents topotecan and MX.143 
The class of TKIs take a particular role among inhibitors of ABCG2. Several are 
inhibitors of ABCG2 and ABCB1 and some were found to have an extraordinarily high 
affinity to ABCG2.144,157,158 Imatinib for instance has already been successfully applied 
in the treatment of chronic myeloid leukemia (CML).159 Also epidermal growth factor 
receptor (EGFR)-directed TKIs, such as gefitinib, erlotinib and afatinib demonstrated to 
be approved treatments for non-small lung cancers by activating the mutations in the 
EGFR kinase.160 Lung cancers with EGFR mutations have shown to be dependent on 
EGFR signalling for survival and proliferation, making them highly sensitive to treatment 
with EGFR TKIs such as gefitinib or erlotinib.161 
The broadspectrum inhibitor elacridar (GF120918) is a potent inhibitor of both, ABCG2 
and ABCB1. It has demonstrated to increase the oral bioavailability of cytotoxic agents 
and increased brain and CNS levels of anti-HIV drugs.162,163 elacridar is particularly 
beneficial in tissues with expression of both transport proteins, ABCG2 and ABCB1, as 
found in the BBB.  
Moreover, several compounds in the class of flavonoides, azoles and calciumchannel 
blockers have been discovered to exhibit some inhibitory potency toward ABCG2. In the 
section “other drugs” of Table 5 the compound class curcumines and PZ-compounds were 
listed. Like FTC, curcumines are “static” inhibitors which only inhibit the function of 
ABCG2. The PZ-compounds contain a benzothiazol structure and  were found to be 
“dynamic” inhibitors that inhibit the ABCG2 function and induce lysosome-dependent 
degradation of ABCG2 protein.151,152 For illustration of the broad structural variety of 
different inhibitors of ABCG2 a selection is presented in Table 6. Although the list of 
inhibitors of ABCG2 is constantly growing, only a few have been found to be highly 
potent, selective and nontoxic.  
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Table 6: Structural Formulas of Selected Inhibitors of ABCG2. 
 
SPECIFIC INHIBITORS 
 
FTC 
 
Ko143 
 
 
PZ-39 
BROADSPECTRUM INHIBITORS 
 
Elacridar (GF120918) 
 
Tariquidar (XR-9576) 
 
Reserpine 
TYROSINE KINASE INHIBITORS (TKIs) 
 
  
Gefitinib 
 
 
 
Nilotinib 
 
 
Imatinib 
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Further research is necessary to develop more compounds with the desired properties that 
might be suitable for application in vivo. Moreover, it is necessary to shed some light on 
the complex interaction of inhibitors of ABCG2 with the transport protein. 
 
1.2.4.4 Drug binding in ABCG2 
 
To date, only few studies have investigated the drug binding interaction with ABCG2, 
mostly by mutational experiments (see chapter 1.2.4.2), functional kinetic assays as well 
as photoaffinity labelling and radioligand studies. The bulk of the data presented in these 
studies pointed to the existence of several binding sites in ABCG2 that could partially 
overlap. For instance, Shukla et al. performed photoaffinity labelling of ABCG2 by IAAP 
and [3H]azidopine, that were both found to be transported substrates of the protein.164 
Here, the photolabelling as well as the transport of the photoaffinity analogs could be 
inhibited by 1,4-dihydropyridines, such as nicardipine and nifedipine. A concentration 
dependent inhibition of the labelling was determined in co-administration of different 
substrates and inhibitors providing a valuable tool for distinguishing substrates from 
inhibitors and studying the drug-binding site(s) of the transporter.  
Additional information about the binding pockets that are occupied by the photo-labelling 
agents could be derived from purified photo-labelled ABCG2. Subsequent investigations 
by trypsin digestion and mass spectrometrical analysis of the peptide fragments might 
yield crucial information about the localization of binding pockets in ABCG2, but have 
not yet been carried out successfully.66  
The research group of Clark et al. performed direct binding kinetic studies with 
[3H]daunomycin leading to the assumption that the found results cannot be described by 
a simple single site binding process.165 They showed that there are at least two binding 
sites in each ABCG2 monomer unit, one for mitoxantrone and Hoechst 33342 and another 
for prazosin. Between the two protein units, negative allosteric interactions and a positive 
cooperativity were found among different bound substrates. Unfortunately, it could not 
be determined if the two Rhodamine 123 sites interact with each other as well. 
 Another study conducted by Takenaka et al. revealed different binding sites for prazosine 
(here: IAAP) and some other substrates of ABCG2 based on a purine scaffold.166 In a 
similar fashion, Giri et al. suggested different binding sites for the nucleotide analog 
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substrates zidovudine and abacavir that seem not to overlap with those of prazosine or 
imatinib.167 The inhibitor Ko143 takes a peculiar role, as it is thought to interact with both 
binding sites mentioned above. 
There have also been some in silico studies comprising homology modeling of ABCG2 
either based on a crystal structure of mouse ABCB1 or, more recently, an 
ABCG5/ABCG8 heterodimer.168,169 An atomic model for the human ABCG5/ABCG8 
heterodimer was generated by X-ray crystallography in a nucleotide-free state at a 
resolution of 3.9 Å. In docking studies with different substrates and non-substrates László 
et al. identified several binding sites. Binding site 1 allows the entry of all drugs. 
Subsequent entry to a proposed site 2 was restricted for non-substrates of ABCG2 like 
verapamil or calcein which may serve as a selectivity filter for toxic molecules from 
natural metabolites. This hypothesis is substantiated by the localization of amino acid 
R482 in this binding region which has a great impact on the substrate selectivity. The 
same applies to the mutations of T402 or P485 that have been reported to have a 
considerable impact on the transport of substrates.170 Unfortunately, the mechanism of 
the binding of substrates and inhibitors to the protein is still not clear and awaits further 
investigation.  
 
1.2.4.5 Relevance of ABCG2 in cancer therapy 
 
The role of ABCG2 in cancer therapy is controversially discussed, since early 
expectations of promising in vitro results for inhibitors of P-gp were not met by the 
subsequent in vivo studies.171 However, several clinical studies have found some 
indication that a higher expression of ABCG2 correlates with a lower survival rate in 
small cell lung cancer, non-small cell lung cancer, pancreatic cancer, mantle cell 
lymphoma, acute myeloid leukemia, ovarian cancer and breast 
cancer.172,173,174,175,176,177,178,179,180,181  
Also, it is known that overexpression of ABCG2 can be a significant obstacle in the 
chemotherapeutic treatment of cancer with cytostatic drugs, since many of the agents are 
substrates of ABCG2. Hence, an intrinsically or developed resistance in cancer cells 
toward those drugs induced by this overexpression, might be overcome by direct 
inhibition of the transport protein. Unfortunately, only a few clinical studies targeting to 
1 Introduction 34
reverse this MDR in chemotherapy by inhibition of ABCG2 via co-administration of 
inhibitors have been conducted to date. Out of five clinical studies only two completed 
the dose-finding phase and only one is currently actively running (see Table 7).  
Regarding the terminated phase II trial of the TKI lapatinib in co-administration with 
topotecan, no clinical benefit was detected in epithelial ovarian cancer in comparison to 
the use of the cytostatic agent only. Lheureux et. al suggested that the absence of 
correlation between ABCG2 expression and clinical outcome pointed to other 
mechanisms of resistance to topotecan.182  
 
Table 7: Clinical Trials with ABCG2 Inhibitors, Adapted from Ricci et al.172 
 
 
Indeed, there have also been several animal models that aimed to reverse the ABCG2 
induced MDR by inhibition of the protein. Although many first generation inhibitors such 
Clinical trials with ABCG2 inhibitors  
(clinical trial title and phase) Status Cancer 
Chemo-
therapy 
Conjunctive 
therapy 
 
Erlotinib Hydrochloride and Irinotecan 
Hydrochloride in Treating Patients With 
Advanced Solid Tumors (Phase I) 
 
Active, not 
recruiting 
 
Advanced 
Solid Tumors 
 
Irinotecan 
 
Erlotinib 
     
A Phase I Study of Oral Topotecan and 
Lapatinib in Subjects with Advanced Solid 
Tumors (Phase I) 183 
Withdrawn Advanced 
Solid Tumors 
Topotecan Lapatinib 
     
Dosage-finding and PK Study of IV 
Topotecan and Erlotinib with Refractory Solid 
Tumors (Phase I, Dose-finding) 184 
Completed Metastatic, 
Refractory 
Solid Tumors 
Topotecan Erlotinib 
 
A Phase I, Randomized Open-label, Parallel-
cohort, Dose-finding Study of elacridar 
(GF120918) and Oral Topotecan in Cancer 
Patients (Phase I, Dose-finding) 49 
 
Completed 
 
 
Cancer 
 
Topotecan 
 
Elacridar 
(GF120918) 
     
Phase II trial of Lapatinib and Topotecan 
(LapTop) in Patients with Platinum-
refractory/resistant Ovarian and Primary 
Peritoneal Carcinoma (Phase II) 182,185 
Terminated Platinum-
refractory/ 
resistant 
Ovarian and 
Primary 
Peritoneal 
Carcinoma 
Topotecan Lapatinib 
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as FTC exhibited a high in vitro efficacy, they could not meet the expectations in vivo 
owing to significant toxic effects.126,186 In the case of FTC, a severe neurotoxicity 
prevented any further clinical use and led to the development of considerably less toxic 
structural analogs like Ko143.187 This FTC analog was able to inhibit the intestinal Abcg2 
in mice which led to an increased oral availability of topotecan.139 However, Ko143 has 
not been tested in clinical trials to date.  
Other inhibitors of ABCG2 have been investigated as well: curcumines for instance 
increased the relative bioavailability of sulfasalazine by selectively inhibiting the ABCG2 
function.188 Moreover, the broadspectrum inhibitor elacridar was able to restore 
sensitivity of a doxorubicin resistant C-26 tumor toward the cytostatic agent 
doxorubicin.189 Certainly, a spotlight was put on the investigation of tyrosine kinase 
inhibitors as they were frequently used in animal models. 
The class of TKIs was found to be very promising, since several inhibitors have already 
been tested in the clinic (compare Table 7) or even found application in cancer treatment. 
Many TKIs like gefitinib, erlotinib, sunitinib or imatinib have proven to reverse the MDR 
toward cytostatic agents induced by ABCG2 expression in vitro.190 Interestingly, they act 
as substrates at low concentrations, probably competing for the same binding site as other 
substrates, such as SN-38, prazosin or topotecan, but inhibit the ABCG2 function at 
higher concentrations.191,192,193 Moreover, some TKIs could interact with the PI3K-Akt 
pathway leading to a downregulation of the ABCG2 expression in K562/BCRP-MX10 
cells.194 These properties were exploited in an animal model by co-administering the TKI 
imatinib and the photosensitizer pheophorbide A, which is a substrate of ABCG2. The 
presence of the inhibitor imatinib led to an increased accumulation of the photosensitizer 
in the ABCG2 expressing cells resulting in considerably enhanced results of the 
photodynamic therapy (PDT).195 But TKIs have also shown mixed outcomes as ABCG2 
inhibitors when co-administered with cytotoxic agents that are substrates of ABCG2.  
Unfortunately, it seems that some other mechanisms involved in vivo could contribute to 
MDR, making the transfer from in vitro more complex than expected. Inhibitors with 
little side-effects, high selectivity and potency as well as a low toxicity can increase the 
chances for a successful outcome regarding in vivo studies.  
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Since ABCG2 is one of three major transmembrane ABC transport proteins associated 
with the occurrence of multidrug resistance (MDR), several research groups have focused 
on finding potent, selective and nontoxic inhibitors as a possible way to overcome MDR. 
Although ABCG2 was discovered in the year 1998, to this date only little is known about 
the function of the transport protein and its interaction with inhibitors on a molecular 
level.     
A main objective of this work was to build a comprehensive library of different inhibitors 
of ABCG2 based on a quinazoline scaffold, including some closely related structures. 
From the data an extensive structure-activity-relationship (SAR) is targeted that could 
pave the way for the development of novel potent inhibitors. In this regard, emphasis was 
put on the inhibitory potency and selectivity of a compound toward ABCG2. Hence, 
accumulation assays were carried out using the dyes Hoechst 33342 and pheophorbide A 
and the inhibitory potencies toward ABCB1 and ABCC1, the two other major ABC 
transport proteins, were investigated in a calcein AM assay.  
Further studies concerned the intrinsic cytotoxicity of selected compounds aiming to 
gather information about the structure-toxicity-relationship and highlighting promising 
compounds for future clinical trials.  
One central objective of this study was to investigate the ability of a compound to reverse 
MDR in ABCG2 overexpressing cells toward commercial cytostatic drugs like SN-38 
and mitoxantrone that are also substrates of the transport protein. Therefore a MDR 
reversal assay was carried out investigating selected compounds in co-administration 
with cytostatic drugs and monitoring the impact on the viability of ABCG2 
overexpressing cells. Since inhibition of ABCG2 leads to a reduced efflux of the 
cytostatic drug out of the cell a stronger decrease in the cell viability results than in 
absence of an inhibitor. A reversal of MDR can be observed if the corresponding inhibitor 
is able to increase the sensitivity of an ABCG2 overexpressing cell toward the cytostatic 
agent considerably. This in vitro investigation is important for continuative in vivo studies 
with promising compounds to enhance the outcome of chemotherapeutic cancer treatment 
that is often restricted by intrinsic or acquired MDR related to overexpression of ABCG2. 
In addition, the inhibitory potencies obtained in the Hoechst 33342 accumulation assay 
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were compared to the derived potency of a compound to reverse MDR, given as an IC50 
value. 
Inhibitory enzyme kinetics were carried out for a better understanding of the interaction 
between an inhibitor and the ABCG2 substrate Hoechst 33342. Different modes of 
binding to ABCG2 could be identified with help of the obtained data and compared to 
other well-known inhibitors like Ko143, gefitinib and elacridar.  
The interaction data analysis was complemented with further studies including the 
conformation sensitive binding of the 5D3 antibody to an epitope of ABCG2. Hereby, 
the conformational impact of different inhibitors on ABCG2 was classified and compared 
to other functional assays to elucidate the interaction with the transport protein.  
Another building block was the investigation of the ATPase activity providing 
information about the consumption of ATP through hydrolysis in the presence of an 
inhibitor. The so-called vanadate sensitive ATPase activity is closely related to the 
transport activity of the protein giving further details of the interaction and binding in 
presence of an inhibitor. 
In summary, this study can contribute to the development of new potent, selective and 
nontoxic inhibitors of ABCG2, containing a scaffold based on quinazoline and related 
structures and provide a comprehensive SAR for future studies. Also, their ability to 
reverse MDR in ABCG2 overexpressing cells by restoring the sensitivity toward 
cytostatic drugs is investigated to find promising candidates for clinical trials. Finally, the 
new data collected in several functional assays can provide new insights into the function 
of ABCG2 in presence of inhibitors which is barely understood and still lacks significant 
scientific publications.  
 
2.1 Concept for synthesis of inhibitors of 
ABCG2 derived from a quinazoline scaffold 
 
Keynote for the synthesis and design of inhibitors of ABCG2 was to modify a quinazoline 
scaffold as lead-structure that has previously been used for some potent inhibitors such 
as TKIs gefitinib, PD158780 and, with small modifications, PD153035 (Figure 9). The 
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named inhibitors all contain a substituted aniline linker at position 4 as a common 
characteristic, this feature was also adopted for the compounds in this work. 
 
 
 
Figure 9: Tyrosine kinase inhibitors (TKIs) based on a quinazoline scaffold or related structures. 
 
Based on the investigations of Juvale et al. it was discovered that substitution with a 
phenyl moiety at position 2 of the quinazoline scaffold led to a considerable increase of 
the inhibitory potency toward ABCG2.196, 197, 198 Besides the basic quinazoline scaffold, 
there are several other positions that can be modified conveniently such as substitution at 
positions 2, 4, 6 and 7 as well as the introduction of nitrogen atoms at the aromatic core 
of the quinazoline scaffold. These modifications have already in part been carried out and 
investigated in other studies. The current problem is that most of the existing inhibitors 
containing a quinazoline scaffold lack inhibitory potency toward ABCG2 or comprise 
other downsides like high intrinsic cytotoxicity, low solubility or a decreased selectivity.  
The basic variations introduced in this study are grouped into projects I to VI and are 
briefly described in the following paragraphs. An overview of all modifications is 
illustrated in Figure 10. 
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Figure 10: Overview of the structural variations carried out in project I to VI. 
Project I
Project II
Project III
Project IV
Project V
Project VI
1
2
3
45
6
7
8
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In project I, the importance of a nitrogen atom at position 3 of the quinazoline scaffold 
for the inhibitory activity toward ABCG2 was investigated (R1 = C or N). Substitution 
was only carried out in meta and para position at R2
 
since earlier results exhibited low 
potencies of ortho substitution. In order to provide a distinct interpretation of the SAR, 
all derivatives were synthesized with a phenyl moiety at position 2 of the scaffold (see 
Figure 11). Herby an easy comparison with the compounds synthesized in other projects 
was possible providing a meaningful interpretation of the corresponding modifications.  
 
 
Figure 11: Substitution pattern for the compounds of Project I. 
   
In project II, the phenyl moiety at position 2 was replaced by different pyridyl residues 
to investigate the impact of ortho, meta and para pyridyl substitution at this position. 
Moreover, the importance of the non-heteroaromatic condensed core of the quinazoline 
scaffold was investigated by replacing it with a methyl residue. The small methyl residue 
was necessary due to a convenient synthetic preparation but is unlikely to have any 
considerable impact on the inhibitory properties of the compound. 
 
 
Figure 12: Substitution pattern for the compounds of Project II. 
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For project III substitution was carried out at the aniline linker at position 4 and also at 
the phenyl moiety at position 2 of the quinazoline scaffold. This allows the investigation 
of cumulative effects of R1 and R2 including the interchangeability of both functions. In 
comparison to project I a broader spectrum of substitution patterns could be covered 
adding to the SAR of this investigation.  
 
 
Figure 13: Substitution pattern for the compounds of Project III. 
 
In project IV modification was carried out at the quinazoline scaffold by introducing a 
nitrogen atom at position 8. The resulting pyrido[2,3-d]pyrimidine scaffold was further 
functionalized by a substituted aromatic function at position 2 and a substituted aniline 
linker at position 4. Hence, the compounds could easily be compared to those of project 
I-III.  
 
 
Figure 14: Substitution pattern for the compounds of Project IV. 
 
In project V a nitro group was introduced at R3 making amino and amido functions 
accessible after reduction of the nitro residue. Additionally, the quinazoline scaffold 
contains a phenyl residue at R1, which in some cases was further substituted, and also a 
substituted aniline group at position 4. This allows an easy comparison between the 
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corresponding derivatives of project I-III (R3 = H) and also among the nitro, amino and 
amido derivatives of this project. 
  
 
Figure 15: Substitution pattern for the compounds of Project V. 
 
In project VI several modifications at the quinazoline scaffold were investigated. In one 
case a 5-membered heteroaromatic residue like thiophene and pyrrole was introduced at 
position 2 (scaffold A). Another modification was the methylation of the amino function 
at the aniline linker replacing the hydrogen atom with a methyl group (scaffold B) 
investigating the importance of an H-donor function at this position. Moreover, the amino 
linker at position 4 was replaced by an amido function (scaffold C) including both, an H-
donor and H-acceptor function. In scaffold D the aromatic moiety at position 2 was 
replaced by hydrogen and is therefore closely related to TKIs like gefitinib. Additional 
substitution was carried out at R1. Finally, a dimer was synthesized containing a 4-
nitrophenyl moiety at position 2 of a quinazoline scaffold (scaffold E). Two molecules 
were then linked by two diamines of different chain length obtaining the corresponding 
dimer.  
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Figure 16: Substitution pattern for the compounds of Project VI. Different scaffolds are marked with the 
capital letters A-E. 
 
A more detailed discussion of the modifications and the corresponding results from the 
investigations is provided in the following text. 
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3 Project I: 4-Substituted-2-
phenylquinazolines and -quinolines 
Synthesis of the substituted 4-anilino-2-phenylquinazolines was performed using a fast 
and convenient method involving microwave radiation. Commercially available aniline 
derivatives and 4-chloro-2-phenylquinazoline were used to create a comprehensive 
substance library. Substitution was only carried out at the aniline linker at position 4 and 
only comprised meta and para substituted 2-phenylquinazoline derivatives since ortho 
substitution was found to be unfavorable in former studies.196 Moreover, the gaps in 
previous studies were filled and the spectrum broadened with new substituents to provide 
a meaningful discussion of the SAR. Furthermore, two fluorescent conjugates with a 4-
anilino-2-phenylquinazoline scaffold were introduced to investigate the distribution of 
the compounds between the cells and the aqueous medium.  
Additionally, the importance of the nitrogen atom at position 3 of the quinazoline scaffold 
was investigated by synthesizing several quinoline analogues for comparison. It is notable 
that the 4-anilino-2-phenylquinazoline scaffold is more planar than the 4-anilino-2-
phenylquinoline structure, since some studies presuppose that planarity of an inhibitor is 
crucial for a high inhibitory potency.112, 66 Furthermore, the nitrogen atom at position 1 of 
aforementioned structures exhibits a more basic character for the quinoline derivative 
with a calculated pKa of 8.4 vs. 5.6 of the quinazoline derivative. Due to the fact that 
membrane permeability correlates approximately with the logP value of a compound 
calculations were carried out for the unsubstituted 4-anilino-2-phenylquinazoline and -
quinoline scaffold resulting in a calculated logP of 4.08 and 5.63, respectively.  
 
3.1 Reaction mechanism  
 
The synthesis route and a detailed reaction mechanism is provided in this chapter. Scheme 
1 illustrates the reaction conditions and Scheme 2 the reaction mechanism. 
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Scheme 1: General synthesis scheme for the preparation of compounds 1-32.a 
 
 
a: Reagents and conditions for compounds 1-27 (R1 = N): (i) i-PrOH, 100 watt microwave 
irradiation, 110 °C, 30 min. Reagents and conditions for compounds 28-32 (R1 = C): (ii) 
i-PrOH, 100 watt microwave irradiation, 110 °C, 15 min. 
 
Reaction mechanism: 
Final compounds were synthesized via nucleophilic aromatic substitution of a 4-chloro-
2-phenylquinazoline or -quinoline precursor by a substituted aniline derivative. The 
reaction mechanism is illustrated below, starting with the nucleophilic attack at position 
4 of the corresponding 4-chloro derivative by the amine. 
 
Scheme 2: Reaction mechanism for compounds 1-32. 
 
 
 
Synthesis of the compounds was carried out as described in section 10.1.1.1. In the first 
step the substituted aniline performs a nucleophilic attack at the carbon atom at position 
4 due to its low electron density induced by the chlorine atom. After addition of the aniline 
derivative to the aromatic ring, the electrons of the double bond shift to position 1 since 
nitrogen is capable of stabilizing negative charges. In the last step, hydrochloric acid is 
eliminated restoring the aromatic character of the quinazoline/quinoline scaffold. In the 
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case of an incomplete reaction, triethylamine was added to the mixture to react with 
hydrochloric acid generated during the reaction. This prevents the protonation of the 
substituted aniline molecule which would result in a significantly decreased nucleophilic 
character. 
 
3.2 Investigation of the inhibitory potency 
toward ABCG2 in the Hoechst 33342 and 
Pheophorbide A accumulation assay 
 
The Hoechst 33342 accumulation assay was carried out with the MDCK II ABCG2 
overexpressing and parental cell line to investigate the inhibitory potency of the 
compounds. The principle of this assay is based on the significant increase in fluorescence 
of the Hoechst 33342 dye when embedded in a lipophilic environment like a cell 
membrane or bound to DNA. Since it is also a substrate of ABCG2 the active efflux of 
the dye by the transport protein leads to a decrease of the total fluorescence. Inhibition of 
the transport protein on the other hand leads to lower efflux of the dye. Detection of the 
fluorescence is carried out at different inhibitor concentrations over a time-period of two 
hours. Representative curves of the measured fluorescence in the presence of the standard 
inhibitor Ko143 are illustrated in Figure 17 a). Measured fluorescence values at each 
inhibitor concentration increase until a steady-state equilibrium for Hoechst 33342 is 
reached.  
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Figure 17: Plot of the fluorescence intensity over time at various concentrations of the standard inhibitor 
Ko143 in a Hoechst 33342 accumulation assay (a). Corresponding concentration-response-curve (IC50: 
226 nM) obtained at various concentrations of Ko143 in a Hoechst 33342 accumulation assay (b).  
 
At steady state only negligible changes in the fluorescence intensity can be observed and 
it is reached after approximately 100 minutes. From the average fluorescence value 
acquired in the steady-state for each Ko143 concentration a sigmoidal concentration-
response curve is fitted using the 4-parameter logistic equation or the 3-parameter logistic 
equation with a fixed Hill-slope depending on statistical preference. A representative 
concentration-response curve of Ko143 is illustrated in Figure 17 b). After a successful 
curve-fit, characteristic parameters like the inflection point of the concentration-response 
b) 
a) 
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curve (IC50) can be calculated in order to compare the inhibitory potency of the 
compounds. More details regarding the procedure are provided in chapter 10.2.2.2.   
A second method to determine IC50 values was additionally applied to confirm the results 
of the Hoechst 33342 accumulation assay. For this purpose, a pheophorbide A 
accumulation assay was carried out. Here, the fluorescence of pheophorbide A is 
measured directly in the cells on a FACSCalibur cell analyzer (see chapter 10.2.2.3). The 
advantage of this accumulation assay is that pheophorbide A is a specific substrate of 
ABCG2 whereas Hoechst 33342 is also transported by ABCB1. Therefore, a comparison 
between both assays is used to validate the obtained results, excluding substrate specific 
effects as source of error.  
The steady-state fluorescence is measured individually in selected cells and can be 
correlated to the degree of inhibition of the ABCG2 efflux transporter. Corresponding 
sigmoidal concentration-response curves are generated as described for the Hoechst 
33342 accumulation assay. Furthermore, this method allows the measurement of 
fluorescence only in healthy cells after gating them according to their size and granularity 
given by the FSC and SSC detected on the FACS (Figure 18).     
 
 
Figure 18: Cell population obtained as a dot plot from forward scatter (FSC) versus side scatter (SSC) 
measured by FACSCalibur cell analyzer. Circled subpopulation (85.5% of total population) was used for 
the measurement while non-circled cells represent unhealthy cells/debris and were excluded. For the 
evaluation the FlowJo V10 data analysis software package was used.199 
 
 
3 Project I: 4-Substituted-2-phenylquinazolines and -quinolines  49 
The results from the Hoechst 33342 accumulation assay are discussed first. A summary 
of the obtained IC50 values from the Hoechst 33342 accumulation assay and the 
pheophorbide A assay is depicted in Table 8. The substitution pattern for all compounds 
is depicted above the table. 
Table 8: Inhibitory Activities Determined in the Hoechst 33342 Accumulation Assay Using ABCG2 
Overexpressing MDCK II BCRP Cells. Molecular Formula of the Substitution Patterns are Depicted 
Above the Table. 
 
1
 
Compound R1 R2 
Hoechst 33342 
IC50 ± SD [nM]a 
Pheophorbide A  
IC50 ± SD [µM]a 
     
1c N H  882 ± 157     n.d. 
2b N 3-NO2   130 ± 30       n.d. 
3 N 3-NO2-4-OH   81.1 ± 9.1  113 ± 17 
4b N 3-CN   140 ± 40       n.d. 
5 N 4-CN  70.0 ± 10.0 84.5 ± 17.0 
6 N 4-OH   204 ± 37  304 ± 82 
7 N 4-SO2F   556 ± 68       n.d. 
8 N 3-NHCOMe   278 ± 33  224 ± 43 
9 N 4-NHCOMe  539 ± 112       n.d. 
10 N 3-SMe 1190 ± 30       n.d. 
11b N 3-OMe 1320 ± 100       n.d. 
12b N 4-OMe 1930 ± 110       n.d. 
13c N 3,4-OMe   152 ± 19       n.d. 
14 N 3,5-OMe 2500 ± 500       n.d. 
15 N 3-F-4-OMe   872 ± 200  689 ± 149 
16 N 3-OMe-4-Br   289 ± 34  202 ± 44 
17 N 3-Me-4-I 1460 ± 70       n.d. 
18 N 3-F   355 ± 53  405 ± 66 
19 N 4-F 1060 ± 170       n.d. 
20c N 3-Cl 1930 ± 280       n.d. 
21 N 4-Cl   830 ± 118       n.d. 
22 N 3-I   791 ± 199       n.d. 
23 N 4-I   612 ± 62       n.d. 
24 N 4-COOMe   944 ± 164       n.d. 
                                                 
Table continues on the next page 
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25 N 4-COOt-Bu 5650 ± 920       n.d. 
26 N 4-COOH 6380 ± 1390       n.d. 
27 N 3-CCH   672 ± 96  513 ± 136 
28 N 3-Me 1150 ± 160       n.d. 
29 N 4-Me 1480 ± 230       n.d. 
30 N 3-t-Bu 1070 ± 110       n.d. 
31 N 4-t-Bu 1060 ± 200       n.d. 
32* N e   295 ± 55       n.d. 
33* N e   654 ± 131       n.d. 
34 C 3-NO2-4-OH   712 ± 124       n.d. 
35 C 3-CN 1680 ± 283       n.d. 
36 C 4-CN   846 ± 169       n.d. 
37 C 3-NHCOMe 1630 ± 330       n.d. 
38 C 3-OMe   951 ± 296       n.d. 
39 C 3-SMe 1900 ± 130       n.d. 
40 C 3-F 2130 ± 460       n.d. 
Gefitinib   1730 ± 270       n.d. 
XR9577d       740 ± 80  718 ± 105 
Ko143d      227 ± 14       n.d. 
 
a: IC50 values are means of three independent experiments. 
b: IC50 value taken from literature. 196 
c: Compound was synthesized previously. 196 
d: Used as reference in the corresponding assay. 
e: See substitution pattern above. 
n.d.: Not determined. 
 
 
According to the results in the Hoechst 33342 accumulation assay cyano, nitro, hydroxy, 
acetamido and fluoro functions were found to be very potent single substituents at the 
aniline moiety of the 2-phenylquinazoline scaffold. Highest potency resulted for 
compound 5, containing a 4-cyano group leading to an excellent IC50 value of 70.0 nM. 
Interestingly, substantial differences in a two-fold range between the IC50 values of 
compounds containing either the same substituent in meta or a para position were 
observed (e.g. compound pairs 4/5, 8/9, 11/12, 18/19).  
The electronic effect (electron withdrawing or electron donating) of the substituent on the 
aromatic residue in general played a minor role for the inhibitory potency of a compound 
(e.g. IC50 of compounds 5-12). Indeed, the position of the substituent had a significant 
impact on the potency of a compound. Electron withdrawing groups like cyano and nitro 
were in particular beneficial in para position (e.g. compound 4/5, 2/89; see chapter 4.2 
for 89, IC50: 70 nM) whereas electron donating groups like methoxy and acetamide 
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exhibited a decreased inhibitory potency at this position (e.g. compound 8/9, 11/12). On 
the contrary most electron donating groups had a more favorable effect at meta position. 
A distinct correlation was found among the compounds containing halogen atoms: 
Halogens of lower atomic numbers like fluorine exhibited a considerably higher 
inhibitory potency in meta than in para position. Increasing atomic numbers reversed this 
trend, favoring the para substitution slightly as demonstrated by iodine (e.g. compounds 
18-23).  
Moreover, some disubstitutions in meta and para position were investigated. The potency 
of compound 2 (R1: 3-nitro) for instance could be increased from an IC50 of 130 nM to 
81.1 nM by addition of a hydroxy function in para position, obtaining compound 3. 
Concentration-response curves of the most potent compounds 3 and 5 together with 
Ko143 are depicted in Figure 19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Concentration-response curve of compound 5 (■, IC50: 70.0 nM) and 3 (▲, IC50: 81.1 nM) in 
the Hoechst 33342 accumulation assay with Ko143 (○, IC50: 227 nM) as reference, using the ABCG2 
overexpressing MDCK II BCRP cell line. 
 
Considerably high potencies were also determined for the 3,4-disubstituted compounds 
13 and 16. Compound 13 containing a 3,4-dimethoxy group (IC50: 152 nM) was 
significantly more potent in comparison to the 3,5-dimethoxy analogue 14 (IC50: 2500 
nM).  
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Although the calculated logP values of all compounds showed no correlation with the 
inhibitory potency, considerably low values may lead to inactivity due to the loss of 
membrane permeability of a compound. This is probably a reason for the low potency of 
compound 26 (IC50: 6380 nM) containing a carboxylic acid moiety which undergoes 
deprotonation at pH 7.4 and thereby exhibits a much lower logP value and possesses a 
negative charge. Formation of carboxylic acid groups from some ester functions by 
cellular esterases is not uncommon. However, cleavage of the methyl ester group in 
compound 24 is not likely due to the relatively high IC50 of 944 nM.  
Investigation of the sterical effects on the inhibitory potency comprising different 
functions of varying bulkiness exhibited no clear correlation as illustrated by the similar 
IC50 values of compounds 28-31. The sterically demanding substituents of compounds 32 
and 33 confirmed this assertion, exhibiting rather high inhibitory potencies of 295 nM 
and 654 nM, respectively. Based on these results, the potency of a compound appears 
subject to the nature and positioning of a function at the aniline moiety rather than its 
sterical effects. 
With regard to the inhibitory potency of the quinoline derivatives 34-40 a significant 
decrease was detected in comparison to their quinazoline analogues emphasizing the 
importance of a nitrogen atom at position 3 of the scaffold. Of the quinolines only 
compounds 36 and 38 possessed moderate activities in the submicromolar range 
containing a 4-cyano and 3-methoxy substituent, respectively. 
For some compounds the IC50 values were additionally determined in a pheophorbide A 
accumulation assay, described in chapter 10.2.2.3. Obtained pIC50 values led to a very 
good correlation with the pIC50 values determined in the Hoechst 33342 accumulation 
assay (r2 = 0.91). The scatterplot of the pIC50 values determined in both assays is 
illustrated in Figure 20. 
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Figure 20: Scatterplot of pIC50 values obtained in the Hoechst 33342 assay versus the pheophorbide A 
assay of selected compounds. Each dot represents the mean pIC50 value obtained from at least three 
independent experiments and is labelled accordingly by compound number. Error bars indicate the 
standard deviation of the corresponding assay. The squared correlation coefficient r2 = 0.91. 
 
 
The concentration-response curves of the most potent compounds, 3 and 5, determined in 
the pheophorbide A accumulation assay are depicted in Figure 21. XR9577 was used as 
standard inhibitor in this assay. The tariquidar analog is known to inhibit ABCG2 as well 
as ABCB1 with different potencies and has been established as an internal standard in 
our working group.  
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Figure 21: Concentration-response curve of compounds 5 (■, IC50: 0.0700 µM) and 3 (▲, IC50: 0.0800 
µM) in the pheophorbide A accumulation assay with XR9577 (○, IC50: 0.740 µM) as reference. The 
ABCG2 overexpressing MDCK II BCRP cell line was used. 
 
The Hoechst 33342 and the pheophorbide A accumulation assay both exhibited a good 
correlation giving no indication of different substrate specifities of ABCG2 toward both 
compounds. 
 
3.3 Investigation of the inhibitory potency 
toward ABCB1 and ABCC1 in the calcein 
AM assay   
 
The inhibitory potency of the compounds toward ABCB1 and ABCC1 was determined 
in a calcein AM assay (see chapter 10.2.2.4). The assay is based on the intracellular 
accumulation of calcein which is formed in the cell by unspecific esterases. After 
cleavage of the acetoxymethyl esters, negatively charged calcein molecules accumulate 
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in the cell and can be measured fluorometrically. The intracellular concentration of 
calcein AM on the other hand depends on the efflux rate by the corresponding transport 
protein which can be modulated by inhibitors of ABCB1 and ABCC1. Thus, the measured 
fluorescence can be correlated to the inhibitory potency of a compound.  
A screening was conducted with the ABCB1 overexpressing cell line A2780adr and the 
ABCC1 overexpressing cell line H69AR. The inhibitory potency in comparison to a 
standard inhibitor of both transport proteins, namely cyclosporine A (CsA), was 
determined at a concentration of 10 µM for each compound. In the case of inhibitory 
potencies of more than 25% relative to CsA, complete concentration-response curves 
were determined and the IC50 values calculated. The results of the screening with both 
cell lines are depicted in Figure 22 and the IC50 values in Table 9.   
Among the quinazoline derivatives only compounds 13, 14 und 28 exhibited more than 
25% of inhibition relative to the standard CsA with the ABCB1 overexpressing A2780adr 
cell line. In particular, substitution with methoxy groups led to increased inhibitory 
potencies whereas other substitutions resulted in only negligible activity. However, 
almost all quinoline derivatives 34-40 displayed a relatively high inhibitory potency 
toward ABCB1 mostly exceeding the 25% mark.2 
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Figure 22: Inhibitory effect of screened compounds toward P-gp overexpressing cell line A2780adr (a) and 
MRP1 overexpressing cell line H69AR (b) in the calcein AM assay at a concentration of 10 µM. 
Cyclosporine A (CsA) was used as positive control, indicating complete inhibition. The inhibitory effect of 
each compound is expressed by the length of the bars, representing the inhibition compared to the positive 
control in percent. For each compound, three independent experiments were performed and the standard 
deviation is expressed by error bars. 
 
Similar results were observed in the screening of the inhibitory potency toward ABCC1. 
Compounds 10, 14, 24, 26, 35, 37 and 39 were found to possess more than 25% 
inhibition relative to CsA. Again, the quinoline derivatives obtained higher rates of 
inhibition in comparison to the quinazoline derivatives. A possible explanation for this 
phenomenon could be the basic character of the nitrogen atom in the quinoline structure 
with a calculated pKa of 8.4 vs 5.6 for the quinazoline structure. Meaning that the 
quinoline derivatives would be mostly protonated while the quinazolines were mostly 
neutral under physiological pH.  
 
 
 
b) 
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Table 9: Inhibitory Activity of Compounds Exhibiting an Inhibition of more than 25% in Comparison to 
the Reference Cyclosporine A (CsA) in the Calcein AM Assay at a Concentration of 10 µM. 
 
 R1 R2 
Calcein AM (ABCB1) 
IC50 ± SD [µM]a,b 
Calcein AM (ABCC1)  
IC50 ± SD [µM]a,c 
10 N 3-SMe         n.d.    3.73 ± 0.51 
13d N 3,4-OMe   1.86 ± 0.30           n.d. 
14 N 3,5-OMe   2.43 ± 0.44    6.91 ± 0.97 
24 N 4- COOMe         n.d.    8.13 ± 1.40 
26 N 4- COOH         n.d.    8.77 ± 0.77 
28 N 3-Me   3.00 ± 0.26          n.d. 
35 C 3-CN   5.06 ± 0.70    6.52 ± 0.91 
36 C 4-CN   4.74 ± 0.32          n.d. 
37 C 3-NHCOMe 0.664 ± 0.17    5.80 ± 0.94 
38 C 3-OMe   2.87 ± 0.20          n.d. 
39 C 3-SMe   1.42 ± 0.14    2.98 ± 0.38 
CsAe       1.17 ± 0.17    3.77 ± 1.03 
 
a: IC50 values were determined by three independent experiments. 
b: The P-gp overexpressing cell line A2780adr was used. 
c: The MRP1 overexpressing cell line H69AR was used. 
d: Compound was synthesized previously.198 
e: CsA is used as reference for both assays. 
n.d.: Not determined, due to low effect in the initial screening. 
 
Moreover, it is known that ABCC1 is capable of transporting anionic molecules which 
have sufficient lipophilicity to enter the membrane.50  Interestingly, compound 26 
containing a carboxylic acid function demonstrates some inhibitory potency toward 
ABCC1 but not ABCB1. This could be due to deprotonation of the carboxylic acid 
function at pH 7.4, forming an anionic species. Moreover, there is evidence that 
compound 24 undergoes cleavage of the methoxy ester by intracellular esterases 
forming a carboxylate function. This theory is substantiated by the very similar IC50 
values of compounds 24 and 26 but is in contrast to the results from the Hoechst 33342 
accumulation assay. A possible explanation for this is the use of different cell lines in 
both assays.    
In comparison a higher inhibitory potency resulted toward ABCB1 than ABCC1 for the 
majority of compounds.     
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3.4 Investigation of the intrinsic cytotoxicity 
with the MDCK II cell lines in a MTT assay 
 
The intrinsic cytotoxicity of selected compounds was investigated in a MTT assay using 
MDCK II parental and ABCG2 overexpressing cells. Toxic effects were measured after 
72 h incubation of the cells in the presence of different compound concentrations using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as indicator of the 
cell viability. Due to the fact that living cells are capable of reducing MTT via 
mitochondrial and other unspecific reductases to a purple formazan species cell viability 
can be correlated with the spectrometrically measured absorption of the dye. Further 
details regarding the assay are provided in chapter 10.2.2.5.  
From the obtained absorption values a concentration-response curve could be fitted 
yielding characteristic values like the GI50. This determinant describes the corresponding 
compound concentration which reduces the cell survival to 50% of the control. Due to 
the fact that small amounts of MeOH (≤1.8%) and DMSO (≤1%) were used for the 
preparation of the compound dilutions, a control was carried out giving the toxic effect 
in the absence of a compound (GI50: 96.1 µM; BCRP). Moreover, a therapeutic ratio (TR) 
was calculated from GI50/IC50 providing information about possible benefits, for instance 
regarding application of a compound in clinical trials.  
The obtained GI50 values and the corresponding TRs are depicted in Table 10. For better 
comparison, the TR is also illustrated as bar chart in Figure 23. 
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Table 10: Intrinsic Toxicity and Therapeutic Ratio of Selected Compounds on MDCK II ABCG2 
Overexpressing and Parental Cells. 
 
Compound R1 R2 
GI50 [µM]a 
BCRP 
GI50 [µM]a 
Parental 
Therapeutic ratio 
(GI50/IC50) b 
 
     
1 N H 27   26   30 
3 N 3-NO2-4-OH 52 150 660 
5 N 4-CN   8.0   17 110 
6 N 4-OH 12   27   60 
8 N 3-NHCOMe 13   31   46 
13c N 3,4-OMe 23   17 150 
18 N 3-F 17   28   49 
19 N 4-F 29   26   27 
21 N 4-Cl   6.8   15     8.1 
22 N 3-I 15   17   19 
23 N 4-I   9.3     8.9   15 
28 N 3-Me 13   24   11 
Gefitinib     1.4     2.1     0.80  
Ko143     11   11   49 
Quercetin   46   33  
MeOH/DMSO     96d 140d  
 
a: Concentration leading to 50% of cell survival of MDCK II BCRP and parental cells. The data was 
   obtained from at least two independent experiments as mean values. 
b: The therapeutic ratio of selected compounds is calculated from the ratio of GI50 to IC50 values, derived  
from MTT viability assay and Hoechst 33342 accumulation assay with ABCG2 overexpressing MDCK II  
BCRP cells. 
c: Compound was previously synthesized.198 
d: Positive control of the cytotoxicity from dilution with DMSO/MeOH without compound. 
 
Among all test compounds a moderate intrinsic cytotoxicity was found which was mostly 
lower than that of Ko143 (GI50: 11.1 µM). To ponder the benefit of a compound for 
further studies, its IC50 value must also be taken into account yielding a TR. In this regard 
the potent standard inhibitor Ko143, often described in literature as “nontoxic”, obtained 
a TR of 49 with MDCK II ABCG2 overexpressing cells.  
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Figure 23: Therapeutic ratio of selected compounds, calculated from the ratio of GI50 to IC50-values, 
derived from MTT viability assay and Hoechst 33342 accumulation assay with ABCG2 overexpressing 
MDCK II BCRP cells. The highest score was obtained with compound 3 (GI50/IC50 = 655), while the 
reference compound Ko143 yielded GI50/IC50 = 48.9.  
 
Interestingly, the most potent compounds from the Hoechst 33342 accumulation assay, 
namely 3 and 5, exhibited significant differences in their toxicities obtaining GI50 values 
of 52.4 µM and 7.96 µM, respectively. Corresponding concentration-response curves of 
both compounds including the determined toxicity of MeOH/DMSO without compound 
are illustrated in Figure 24.  
The disubstitution with 3-nitro and 4-hydroxy carried out for compound 3 led to the 
highest TR of 655 in this subset. This finding is particularly startling, since compound 6, 
containing a monosubstitution with 4-hydroxy, exhibited a considerably higher 
cytotoxicity (GI50: 12.2 µM). Although it is known that nitro and cyano functions can 
contribute to increased toxic effects, this is not the case for the disubstituted  
compound 3.       
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Figure 24: MTT viability assay of compound 3 (▲, GI50 = 52.4 µM) and 5 (■, GI50 = 7.96 µM) using the 
ABCG2 overexpressing cell line MDCK II BCRP. A control with the same concentration of MeOH and 
DMSO (○, GI50 = 71.5 µM), analogue to the dilution of the compounds, was carried out for comparison. 
The amount of MeOH and DMSO used for the dilution was ≤ 1.8% and ≤ 1.0%, respectively. 
 
Regarding meta and para substituents, distinct differences in cytotoxicity were observed 
for some compound pairs like 18/19 or 22/23. Similar differences between the meta and 
para derivatives have already been discussed in terms of the inhibitory potency 
investigated in the Hoechst 33342 accumulation assay. It is likely that these derivatives 
occupy different binding pockets at ABCG2 or exhibit a different interaction with the 
transport protein. More evidence to this suggestion is provided in the following chapters.  
 
3.5 Investigation of the reversal of multidrug 
resistance  
 
Multidrug resistance toward cytostatic drugs like SN-38 or MX is often related to an 
overexpression of ABCG2, which facilitates the active efflux of the drugs out of the cell. 
3 Project I: 4-Substituted-2-phenylquinazolines and -quinolines 62
Since some cytostatic drugs are substrates of ABCG2 the cellular resistance to these drugs 
can be overcome by co-administration with potent inhibitors. Inhibition of the transport 
protein leads to a reduced efflux of cytostatic drugs resulting in an increased intracellular 
accumulation and lower cell viability. The measured cell viability can then be correlated 
to the inhibitory efficacy of the co-administered compound.  
For this subset the cytostatic agents Hoechst 33342 and SN-38 were investigated, since 
they are both substrates of ABCG2. The assay was carried out with the ABCG2 
overexpressing MDCK II BCRP and parental cell line. Due to the lack of transport 
proteins, parental cells show no resistance toward the cytostatic drugs and were used as 
control indicating “total inhibition” of ABCG2. In contrast the ABCG2 overexpressing 
MDCK II BCRP cell line exhibits resistance toward the drugs, which can be reduced by 
co-administering different concentrations of an inhibitor. More details regarding the 
execution of the assay are provided in chapter 10.2.2.6. The investigation was carried out 
with the most potent compounds, 3 and 5. Both compounds were able to achieve a full 
reversal of the MDR in MDCK II BCRP cells toward SN-38 and Hoechst 33342 at low 
concentrations of about 5 µM. Corresponding concentration-cell viability curves for 
compound 3 and 5 in the presence of Hoechst 33342 and SN-38 are depicted in  
Figure 25. 3 
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Figure 25: MDR reversal assay of compound 3 (a, b) and 5 (c, d), demonstrating the ability to reverse the 
MDR toward the cytostatic drugs Hoechst 33342 (a, c) and SN-38 (b, d), using parental MDCK II and 
ABCG2 overexpressing cell lines. The grey arrows indicate the increasing sensitization of the ABCG2 
overexpressing cells with higher compound concentrations (see legend). At a compound concentration of 
5 µM, full reversal is achieved, indicated by a similar IC50 value as the parental cells.  
a: parental MDCK II cells.  
 
A full reversal of MDR is indicated by the concentration-response curves with similar 
GI50 values of the parental cells and the ABCG2 overexpressing cells in the presence of 
the corresponding inhibitor. The grey arrows indicate the increased sensitization toward 
the corresponding cytostatic drug with increasing compound concentration. This can also 
be visualized by plotting the pGI50 values from the concentration-effect curves obtained 
in the MDR reversal assay against the logarithm of the compound concentration. Hereby, 
concentration-efficacy curves can be fitted with the logistic equation yielding EC50 values 
that characterize the extent of MDR reversal by a compound. The resulting sigmoidal 
curves are depicted in Figure 26.  
According to the plot, a very similar efficacy was obtained for both inhibitors in the 
presence of Hoechst 33342 and also SN-38. For compound 3 an EC50 value of 132 nM 
for Hoechst 33342 and 161 nM for SN-38 were calculated. In comparison to the Hoechst 
33342 accumulation assay (IC50: 81.1 nM) the derived EC50 values obtained from the 
MDR reversal assay are slightly higher. Compound 5 on the other hand obtained IC50 
values of 52.9 nM and 46.5 nM in the MDR reversal assay in co-administration of 
c) d) 
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Hoechst 33342 and SN-38, respectively. Hence, the efficacy of compound 5 is estimated 
slightly higher than suggested by the Hoechst 33342 accumulation assay (IC50: 70.0 nM). 
 
 
 
 
 
 
 
 
Figure 26: Plot of the pGI50 values, determined in the MDR reversal assay (Figure 25), against the 
corresponding concentration of compound 3 and 5, respectively. The efficacy of sensitization toward the 
corresponding cytostatic is indicated by the pEC50 value corresponding to a reversal of MDR by 50%. 
The pGI50 of the parental cells defines “total sensitization” of ABCG2, while the pGI50 of the resistant 
cell line defines “no sensitization”, depicted in the figure by –∞ and -3, respectively. For compound 3 (a) 
IC50 values of 132 nM (● Hoechst 33342) and 161 nM (□ SN-38) were determined. Compound 5 (b) 
yielded IC50 values of 52.9 nM (● Hoechst 33342) and 46.5 nM (□ SN-38). 
 
Investigation of the factor of resistance (Fr), given by the ratio of the GI50 in the resistant 
cell line to the GI50 of the sensitive cells in the presence of a cytostatic drug, obtained a 
mean value of 6.40 for Hoechst 33342 and 7.95 for SN-38. Hence, the ABCG2 expressing 
cell line exhibits a slightly decreased sensitivity toward SN-38 compared to Hoechst 
33342.   
Additionally, the sensitization of the ABCG2 overexpressing MDCK II BCRP cell line 
toward the cytostatic drug MX, which is also a substrate of ABCG2, was investigated in 
the presence of compound 3 and 5. Similar to SN-38, co-administration of an inhibitor of 
ABCG2 leads to increased intracellular concentrations of MX owing to a reduced efflux 
out of the cell. As a result a greater decrease in cell viability is observed than in absence 
of an inhibitor. The assay was carried out at different compound concentrations in the 
presence and absence of 0.5 µM MX. Further details of the assay are provided in chapter 
10.2.2.7.  
a) b) 
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The bar charts in Figure 27 illustrate that both compounds were able to reverse the 
resistance of the ABCG2 overexpressing cells toward MX.  
 
 
 
 
 
 
 
Figure 27: MDR reversal assay of compounds 3 (a) and 5 (b), demonstrating their ability to reverse MDR 
toward the cytostatic mitoxantrone (MX), in the ABCG2 overexpressing cell line MDCK II BCRP. The 
bars represent the cell viability at a given modulator concentration in the presence (light grey) and 
absence (dark grey) of 0.5 µM mitoxantrone. Control shows viability of cells without modulator. The 
standard deviation is expressed by error bars.   
 
Half-maximal growth inhibition (GI50) was achieved for compound 3 at 68.4 nM and for 
5 at 4.41 nM. Due to few measurements, the determined values in the MDR reversal assay 
with MX are more susceptible to error than with SN-38, but still provide a good 
estimation of the efficacy of a compound.  
Overall, compound 5 demonstrated a considerably high potency in MDR reversal assays 
using SN-38, Hoechst 33342 and MX, suggesting a somewhat higher inhibitory potency 
than determined in the Hoechst 33342 accumulation assay. The inhibitory potency of 
compound 3 in the MDR reversal assays concurs very well with the results of the Hoechst 
33342 accumulation assay. Also, the differences between the calculated IC50 values 
obtained with Hoechst 33342 and SN-38 exhibit a good correlation for both compounds, 
meaning there is probably no significant difference regarding the substrate specificity of 
ABCG2 toward both cytostatic drugs.  
 
a) b) 
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3.6 Investigation of the interaction with Hoechst 
33342 
 
The interaction of selected compounds with Hoechst 33342 was investigated using 
ABCG2 overexpressing MDCK II BCRP cells. Varying compound concentrations were 
combined with varying concentrations of Hoechst 33342 and the interaction type could 
be determined using the Lineweaver-Burk double reciprocal plot, described in chapter 
10.2.2.8. This method provides information about the compound interacting with Hoechst 
33342 either in a competitive, non-competitive or uncompetitive manner using a 
relatively simple graphical method.  
Although the Lineweaver-Burk method can be susceptible to experimental errors due to 
the double reciprocal plot, it provides preliminary results that can be compared to other 
methods like the Cornish-Bowden direct linear plot.  A summary of the results obtained 
with the Lineweaver-Burk method is presented in Table 11 listing the intersection of the 
straight lines together with the corresponding interpretation. A selection of the 
corresponding plots is depicted in Figure 28. 
 
 Table 11: Interaction with Hoechst 33342 According to the Lineweaver-Burk Double Reciprocal Plot. 
 
Compound 
Substituent R2 
(R1 = N) Intersection  
type of interaction  
with Hoechst 33342 
3 3-NO2-4-OH 2. Quadrant Non-competitive mixed type 
4 3-CN X-axis Non-competitive 
5 4-CN 2. Quadrant Non-competitive mixed-type 
17 3-Me-4-I Y-axis Competitive 
18 3-F 2. Quadrant Non-competitive mixed-type 
19 4-F X-axis Non-competitive 
20 3-Cl 2. Quadrant Non-competitive mixed-type 
21 4-Cl Y-axis Competitive 
22 3-I X-axis Non-competitive 
23 4-I 3. Quadrant Non-competitive mixed-type 
Ko143  3. Quadrant Non-competitive mixed-type 
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Since a non-competitive interaction with Hoechst 33342, mostly of the “mixed type”, was 
found to be the predominant mechanism, compounds 17 and 21 take a peculiar role due 
to their competitive interaction. It is likely that both compounds bind to the same pocket 
or at least have a high impact on the binding of Hoechst 33342. Further studies with the 
conformational sensitive 5D3 antibody binding (see chapter 3.7) and the ATPase activity 
assay (see chapter 3.8) substantiated the differences that were observed in the interaction 
type investigation, distinguishing non-competitive inhibitors from those of the “mixed 
type” and the competitive inhibitors.  
Another striking point is the distinction of compounds by the position of their substituent 
(meta or para) according to their interaction with Hoechst 33342 (e.g. compounds 4 and 
5; 18 and 19; 20 and 21; 22 and 23). The same observation was mostly made for the IC50 
values in the Hoechst 33342 accumulation assay resulting in different inhibitory potencies 
of the meta and para derivatives.  4 
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Figure 28: Double-reciprocal plot according to Lineweaver-Burk for selected compounds 17 (a), 18 (b), 
19 (c), 20 (d), 21 (e), 22 (f), 23 (g) and Ko143 (h). Compound concentrations are specified in the legend.  
 
In order to validate the results from the Lineweaver-Burk double reciprocal plot, the 
Cornish-Bowden method was applied (see chapter 10.2.2.8). A direct linear plot of the 
data produces the corresponding Vmax and KM values for each inhibitor concentration. By 
means of the trend regarding the values toward increasing compound concentration a non-
competitive (Vmax ↓, KM ↔), competitive (Vmax ↔, KM ↑) or “mixed-type”  
(Vmax ↓, KM ↑) interaction with Hoechst 33342 is suggested. For better comparison, linear 
regression of the Vmax and KM values was performed and the obtained slopes summarized 
as scatter plot in Figure 29. 
 
e) f) 
g) h) 
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Figure 29: Scatter plot of the calculated slopes obtained from the linear regression of KM (○) and Vmax 
(■) values according to the Cornish-Bowden direct linear plot. 
 
Obtained results are in accordance with the type of interaction determined from the 
Lineweaver-Burk double reciprocal plot. Corresponding Cornish-Bowden plots of 
selected compounds are depicted in Figure 30. Compounds with considerably high 
competitive character like 3, 17, 21 and 23 obtained high positive slopes for KM. On the 
other hand, compound 18, 19, 20, 22, 23 possess a high negative slope for Vmax which is 
characteristic for compounds with a non-competitive interaction. Interestingly, all of the 
compounds showing a high portion of competitive interaction contain a para substitution, 
mostly with lipophilic halogen atoms of a high atomic number like chlorine and iodine. 
In contrary, an increased non-competitive character was frequently observed for meta 
substituted derivatives. 
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Figure 30: Direct linear plot for compound17 (a), 18 (b), 19 (c), 20 (d), 21 (e), 22 (f), 23 (g) and Ko143 
(h) according to Cornish-Bowden. For better visualization of the slopes linear regression of the Vmax (■) 
and KM (●) values was performed. Excluded values are depicted as open symbols of the corresponding 
shape. 
 
a) b) 
c) d) 
e) f) 
g) h) 
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The change of the interaction type observed for several compounds like the 3-chloro and 
4-chloro derivatives 20 and 21 is particularly interesting, as it suggests different binding 
pockets for those derivatives. According to the Lineweaver-Burk plot and the Cornish-
Bowden plot, the phenomenon of different types of interaction of meta and para 
derivatives containing the same substituent was observed for most of the investigated 
compounds.   
 
3.7 Investigation of the conformation sensitive 
5D3 antibody binding to an epitope of ABCG2 
 
The investigations of the conformational impact of a compound on ABCG2 was carried 
out with the conformation sensitive 5D3 antibody using the ABCG2 overexpressing PLB-
985 cell line. This antibody binds specifically to an epitope of ABCG2 indicating 
intramolecular changes. The fluorescence measured by a FACSCalibur flow cytometer 
originating from the bound 5D3 antibody-fluorophore conjugate correlates with the 
conformational change of ABCG2. A shift in fluorescence, called a “5D3-shift”, is 
observed when the co-administration of a compound produces a different rate of labelling 
in ABCG2 than without compound. Additional information about the assay is provided 
in chapter 10.2.2.9.  
Prior studies suggested that the monoclonal antibody can serve as a sensitive tool to study 
intramolecular changes but also reflects ATP binding, the formation of a catalytic 
intermediate, or substrate inhibition within the transport cycle of the ABCG2 protein.200 
It was found that substrates often induced a smaller shift than inhibitors of ABCG2.201  
Some compounds exhibit concentration dependent properties, they can act as substrates 
at low concentrations and as inhibitors at high concentrations as asserted for ABCB1.202 
Hence, this assay can also be used to detect a change in a concentration dependent binding 
mode (e.g. binding pocket, substrate/inhibitor) of a compound indicated by a significant 
change in the 5D3-shift.  
Some 5D3-shifts of selected commercially available drugs are depicted as a bar chart in 
Figure 31 (black bars). The amount of labelling obtained by the standard inhibitor of 
ABCG2, namely Ko143, was set to 100%. Both concentrations of 10 µM and 25 µM 
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yielded a comparable degree of labelling with 5D3 antibody. A considerably lower shift 
was found for Hoechst 33342 at 10 µM which is known to be a substrate of ABCG2. The 
flavonoid quercetin, which is also a substrate of ABCG2, gives comparable results to 
Hoechst 33342, and exhibits only a small shift at the concentrations of 10 and 25 µM, 
which was also found in other studies.203, 204 In contrast, the TKIs and inhibitors of 
ABCG2 gefitinib and elacridar show an increased shift at 10 µM. Interestingly, the shift 
caused by elacridar is very similar to Ko143.  
For better comparison, a dotted line was introduced in the bar chart (Figure 31) indicating 
the amount labelling obtained by Hoechst 33342 at 10 µM.  
Highest shifts were obtained with compounds 17 (1 µM: 88%) and 23 (10 µM: 82%) both 
containing a 4-iodo substituent. Notably, both compounds exhibited an exclusively 
competitive interaction with Hoechst 33342. In contrary, compounds with a high non-
competitive character (3, 4, 18, 19, 20, 22) predominantly resulted in shifts lower than 
the average of 61% at a concentration of 10 µM. Noticeable differences for instance 
between a meta iodo (22) and para iodo (23) derivatives that have already been observed 
in the interaction type investigation (see chapter 3.6), were also found in the 5D3 antibody 
binding assay: both compounds exhibit an increasing shift toward higher compound 
concentrations. However, this effect is much more pronounced for compound 23, 
resulting in increasingly higher shifts than 22 at equivalent concentrations. This indicates 
that both compounds bind to a different site on ABCG2 or possibly to several binding 
pockets of different affinities, which could depend on the compound concentration. The 
substantially different effects of both compounds, including other meta/para derivatives, 
on the ATPase activity is discussed in chapter 3.8.   
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Figure 31: 5D3 immunoreactivity modulation of ABCG2 by commercial compounds (black bars) and 
various compounds at different concentrations (grey bars). Fluorescence detected by the 5D3-labeling of 
ABCG2 in the presence of 10 µM Ko143 was set to 100% and the fluorescence measured in the absence of 
any compound taken as 0%. The dotted line represents the labelling obtained with 10 µM of Hoechst 33342.   
 
Compound 3 with the second highest inhibitory potency among all compounds yielded 
only a moderate shift of 51% with regard to Ko143. However, the majority of the 
compounds exhibited a rate of labelling far above that of the substrate Hoechst 33342 
(35%, dotted line) or quercetin (40%). According to the results, there was no correlation 
between the observed 5D3-shifts and the IC50 values determined in the Hoechst 33342 
accumulation assay. Representative histograms of compound 3, 17 and Ko143 at 10 µM 
are illustrated in Figure 32.  
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Figure 32: Histogram of the measured fluorescence at the FL3-H detector (X-axis) and the cell-count 
gated according to the fluorescence. Depicted is the fluorescence of the isotype-control (dotted curve) as 
well as of 5D3 antibody in the absence of a compound (dashed curve) and in the presence of a compound 
(continuous curve). Investigated compounds with the highest and lowest 5D3 shifts: Ko143 (a), 3 (b) and 
17 (c) at a concentration of 10 µM.   
 
Fluorescence of the isotype-control in presence of the corresponding compound is given 
as a dotted line. This is necessary to exclude an unspecific staining, which was 
considerably low for all compounds. Also, the obtained fluorescence with 5D3 antibody 
in the absence (dashed curve) and presence (continuous curve) of a compound is 
illustrated in the figure. High shifts were found for Ko143 and 17, whereas 3 resulted in 
a minor shift. 
 
3.8 Investigation of the ATPase activity 
 
The study of the ATPase activity in presence of a compound provides important 
information about the transport activity or related processes in ABCG2 leading to 
hydrolysis of ATP. In the simplest instance ATP consumption is associated with an active 
transport of substrates by ABCG2. Cleavage of ATP forms inorganic phosphate (Pi) that 
can be measured colorimetrically giving an estimation of the transport activity of the 
protein. But first, the transport unspecific ATP hydrolysis must be taken into account by 
adding orthovanadate that is able to efficiently inhibit the activity of ABC transport 
proteins. Subtraction of this so-called insensitive vanadate ATPase activity from the total 
ATPase activity yields the specific ATPase activity that is solely associated with the 
a) b) c) 
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transport protein. Moreover, the basal activity detected for the basic function of the 
protein in the absence of a compound was measured. For the assay Ko143 was used as 
the standard ATPase inhibitor and quercetin as the standard stimulator using High Five 
insect cell membrane preparations. The ATPase activity assays were performed by 
Jennifer Gallus. Further details are provided in chapter 10.2.2.10.  
The investigation was carried out with selected compounds, including the most potent 
ones, at three concentrations (0.1, 1 and 10 µM). A clear relation between the substitution 
pattern and the ATPase activity was observed for most compounds. The obtained results 
are presented as a bar chart in Figure 33.  
Stimulation was found for the unsubstituted compound 1 and most of the meta substituted 
derivatives like 4, 18, 20 and 22. All compounds containing a para substituent exhibited 
an ATPase activity at the basal level or below, except for compound 6 containing a para 
hydroxy substituent. It is particularly striking that the observed differences between meta 
and para derivatives with the same substituent have such a substantial impact on the 
ATPase activity, as illustrated by the meta/para compound pairs 4/5, 18/19, 20/21 and 
22/23. It is very likely that a different mode of binding to ABCG2 is responsible for this 
result. This suggestion is also in accordance with the results of other assays presented 
above.  
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Figure 33: Screening of ATPase activity of selected compounds at three different concentrations. From 
left to right the bars correspond to 0.1, 1 and 10 µM final concentration of compound. Quercetin was 
used as a standard for activation of ABCG2 ATPase activity. All values are relative vanadate-sensitive 
ATPase activities in relation to the basal activity, which is set to 100%. 
 
Concentration-response curves using several compound concentrations are depicted in 
Figure 34. Regarding the meta and para iodo derivatives 22 and 23 a very different effect 
on the ATPase activity was found: Compound 22 showed a strong stimulation whereas 
23 inhibited the ATPase activity with increasing compound concentrations below basal 
level.  
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Figure 34: Concentration-response curves for compounds 22 (a, EC50: 2350 nM), 23 (b, EC50: 8270 nM), 
Hoechst 33342 (c, EC50: 295 nM), Quercetin (d, EC50: 302 nM) and Ko143 (e, EC50: 69 nM) in the 
ATPase assay. All values are relative vanadate-sensitive ATPase activities in relation to the basal 
activity, which is set to 100%.   
 
 
e) 
d) c) 
a) b) 
3 Project I: 4-Substituted-2-phenylquinazolines and -quinolines 78
As mentioned before, this finding is not very surprising, since considerable differences 
between meta and para substituted derivatives have already been noticed in the 
investigation of the inhibitory potency toward ABCG2, the type of interaction with 
Hoechst 33342 and the binding studies with the conformation sensitive 5D3 antibody.  
A biphasic trend of the concentration dependent ATPase activity was found for the 
substrate Hoechst 33342. Although most substrates are expected to stimulate the ATPase 
activity due to an active transport by ABCG2, relatively strong deactivation was found in 
the case of Hoechst 33342. Similar results for Hoechst 33342 were also reported in other 
studies.214 As expected, highest inhibition was achieved with the standard inhibitor 
Ko143 whereas the standard stimulator quercetin exhibited a substantially increased 
stimulation of the ATPase activity with increasing compound concentrations. 
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4 Project II: 4-Substituted-2-
pyridylquinazolines and -pyrimidines 
Synthesis of the 4-substituted-2-pyridylquinazolines and –pyrimidines was carried out in 
a similar fashion as described for the compounds of project I. In comparison to project I, 
the phenyl moiety at position 2 was replaced by a pyridyl group. Since ortho, meta and 
para pyridyl substitutions were carried out in the final compounds, three different 4-
chloro-2-pyridylquinazoline precursors were synthesized. Further modification was 
achieved by introducing a substituted anilino linker at position 4 via a nucleophilic 
aromatic substitution under microwave radiation. This enables an easy comparison 
between the different ortho, meta and para pyridyl derivatives and also to the 
corresponding phenyl derivatives of project I.  
Calculation of the mean logP of all three unsubstituted 4-anilio-2-pyridyl derivatives 
resulted in a value of 2.94 that is about 1 log unit lower than with phenyl at position 2. 
Low logP values are in particular beneficial for a good watersolubility but need to be high 
enough to ensure a sufficient membrane permeability. 
Another approach was to remove the non-heteroaromatic core of the quinazoline scaffold 
in order to evaluate the molecular building blocks that are crucial for the inhibitory 
potency toward ABCG2. Consequently, the quinazoline scaffold was reduced to a 4-
methylpyrimidine structure. The small methyl residue was necessary due to a convenient 
synthetic preparation and is unlikely to impact the properties of the compound 
considerably. Substitution was carried out at position 2 with phenyl and para pyridyl. 
Further modification was achieved by introducing a substituted aniline moiety at position 
4. The logP value with the unsubstituted 4-anilino linker was calculated for both 
structures to be 3.53 (2-phenyl) and 2.27 (2-pyridyl).  
It was observed that a few compounds like 89, containing a para nitro substituent at 
position 4, exhibited a decreased solubility. This phenomenon was investigated by 
detecting the change in absorbance of a compound solution over time. An absorbance 
spectrum of compound 89 at a final concentration of 10 µM is illustrated in Figure 35. 
According to the result, no precipitation was observed within a time period of 2 h, using 
the highest final concentration applied in the Hoechst 33342 accumulation assay.  
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Figure 35: Absorption spectrum measured at the excitation maximum of compound 89 for a time period 
of 2h. The compound was diluted to 10 µM in KHB and the measurement carried out at room 
temperature. 
 
Hence, precipitation is most likely to occur during the preparation of the dilution series, 
since they contain higher concentrations than used for the measurement of the plates. This 
problem could be overcome by heating the KHB used for the dilution series to 37 °C 
and/or adjusting the methanol content to ≤1.8% in the final concentration. Hereby three 
IC50 values determined in a prior study by Juvale et al. were corrected by this method and 
are marked accordingly in the tables.198  
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4.1 Reaction mechanism  
 
A schematic synthesis route and a detailed reaction mechanism is provided above. 
Scheme 3: General synthesis scheme for the preparation of compounds 41-88. a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: Reagents and conditions: (i) DMF, I2, K2CO3, 70-90 °C, 4-8 h. (ii) MeOH, NaOMe, 60 
watt microwave irradiation, 70 °C, 4 h. (iii) POCl3, reflux, 4-12 h. (iv) Substituted aniline, 
100 watt microwave irradiation, 110 °C, 15 - 30 min.  
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Reaction mechanism A: 
In the first step, anthranilamide attacks the carbonyl function of the aldehyde derivative 
with its amino function via a nucleophilic addition followed by elimination of H2O. Ring-
closure is achieved via a nucleophilic addition of the amido-nitrogen atom at the initially 
formed imine double bond depicted below. In the last step, a double bond between 
position 1 and 2 is formed by oxidation with elemental iodine.  
 
 
 
Reaction mechanism B/E: 
The carbonyl function at position 4 is substituted by chlorine via a chlorination reaction 
using POCl3. The reaction mechanism for B is illustrated below and applies analogously 
to E.  
 
 
 
Reaction mechanism C/F: 
A nucleophilic aromatic substitution of the corresponding 4-chloro precursor by a 
substituted aniline derivative was carried out to obtain the final compounds. The reaction 
mechanism is analogous to that used for the compounds in project I and can be reviewed 
in chapter 3.1. If the reaction was not complete, triethylamine was added to the mixture 
to react with hydrochloric acid generated during the reaction to prevent the protonation 
of the substituted aniline molecule. 
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Reaction mechanism D:  
Initially, the amino function performs a nucleophilic attack at the carbonyl group 
eliminating H2O, illustrated below. Ring-closure is achieved via an addition-elimination 
mechanism; releasing methanol. In the last step a re-arrangement of H+ occurs leading to 
the desired precursor.  
    
 
 
4.2 Investigation of the inhibitory potency 
toward ABCG2 in the Hoechst 33342 
accumulation assay 
 
Investigation of the inhibitory potency of the compounds was carried out in a Hoechst 
33342 accumulation assay using the ABCG2 overexpressing MDCK II BCRP and 
parental cell line. More information to the Hoechst 33342 accumulation assay as is 
provided in chapter 3.2 and 10.2.2.2. A summary of the associated activity data is given 
in Table 12.  
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Table 12: Inhibitory Activities Determined in the Hoechst 33342 Accumulation Assay Using ABCG2 
Overexpressing MDCK II BCRP Cells. Structural Formulas of the Substitution patterns of Scaffold A and 
B are Depicted Above the Table.5 
    
 
 
Compound R1 R2 Scaffold 
Hoechst 33342 
IC50 ± SD [nM]a 
     
51 2-Pyr 3-NO2 A       376 ± 91 
52 3-Pyr 3-NO2 A       105 ± 35 
53 4-Pyr 3-NO2 A       117 ± 29 
54 3-Pyr 4-NO2 A      64.1 ± 8.5 
55 2-Pyr 3-CN A       507 ± 61 
56 3-Pyr 3-CN A       108 ± 21 
57 4-Pyr 3-CN A       134 ± 10 
58 3-Pyr 4-CN A       166 ± 29 
59 2-Pyr 3-OMe A     1630 ± 320 
60 3-Pyr 3-OMe A     1020 ± 180 
61 4-Pyr 3-OMe A       558 ± 111 
62 4-Pyr 4-OMe A       742 ± 21 
63 2-Pyr 3,4-OMe A     1060 ± 80 
64 3-Pyr 3,4-OMe A       753 ± 151 
65 4-Pyr 3,4-OMe A       545 ± 113 
66 4-Pyr 3-CF3 A       216 ± 40 
67 4-Pyr 4-CF3 A       488 ± 38 
68 4-Pyr 3-CF3,4-OMe A       146 ± 23 
69 3-Pyr 3-F A       156 ± 37 
70 4-Pyr 3-SO2F A     1380 ± 184 
71 3-Pyr 3-N(Me)2 A     1200 ± 210 
72 4-Pyr 3-OH A     1070 ± 190 
73 4-Pyr 4-OH A     4260 ± 1220 
74 3-Pyr 3-CH2OH A       810 ± 239 
75 4-Pyr 3-CH2OH A       921 ± 216 
                                                 
Table continues on the next page 
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76 3-Pyr 3-NO2,4-OH A       245 ± 21 
77 3-Pyr 3-CO2Me A       362 ± 74 
78 4-Pyr 3-CO2Me A       405 ± 98 
79 4-Pyr 3-CO2tBu A       299 ± 97 
80 4-Pyr 3-CO2H A   60000 ± 14800 
81 4-Pyr 4-CO2H A     9640 ± 2 
82 4-Pyr 3-CN B       132 ± 24 
83 4-Pyr 3-OMe B       271 ± 28 
84 4-Pyr 4-OMe B       874 ± 181 
85 Ph 3-CN B       122 ± 24 
86 Ph 4-CN B       128 ± 32 
87 Ph 3-NO2,4-OH B      98.8 ± 17.4 
88 Ph H B       648 ± 149 
3 Ph 3-NO2,4-OH A      81.1 ± 9.2 
2b Ph 3-NO2 A       130 ± 30 
89c Ph 4-NO2 A      69.6 ± 8.2 
4b Ph 3-CN A       140 ± 40 
5 Ph 4-CN A      71.4 ± 10.1 
90 b Ph 3-OH A       150 ± 30 
6 Ph 4-OH A       211 ± 38 
18 Ph 3-F A       363 ± 54 
1 Ph H A       882 ± 157 
Ko143d             227 ± 14 
 
 a: IC50 values are means of three independent experiments. 
 b: IC50 value taken from literature.198  
 c: Compounds synthesized in earlier study.198 
 d: Used as reference in the assay. 
 
First, the inhibitory potency of ortho, meta and para pyridyl residues was compared at R1 
together with different substituents at R2 such as nitro, cyano, methoxy or 3,4-dimethoxy. 
The evidence that was gathered pointed to a low inhibitory potency of the compounds 
substituted with an ortho pyridyl moiety. In contrast, meta and para pyridyl residues 
yielded compounds of considerably higher potency, both at a comparable level. The 
relation between ortho, meta and para pyridyl is exemplified in compounds 51-53, 55-
57, 59-61 and 63-65. These results led to the synthesis of only meta and para pyridyl 
derivatives in the following compounds.  
Interestingly, a significant similarity regarding the IC50 values was found for most of the 
meta and para pyridyl derivatives and their phenyl analogues discussed in project I. 
Hence it is not surprising that the combination with nitro, cyano, trifluoromethyl and 
fluoro at R2 resulted in high inhibitory potencies. Only a few instances like the 3- and 4-
4 Project II: 4-Substituted-2-pyridylquinazolines and -pyrimidines 86
hydroxy derivatives 72 and 73 exhibited a pronounced difference in comparison to their 
corresponding phenyl analogues 90 and 6.  
The highest inhibitory potency was obtained by compound 54 with an IC50 of 64 nM, 
containing a 3-pyridyl group at R1 and 4-nitro at R2. The compound is about 4-fold more 
potent than one of the most potent inhibitors of ABCG2, namely Ko143. The 
corresponding 2-phenyl analogue 89 possessed a very similar IC50 of 70 nM containing 
4-nitro at R2. Again, the para nitro substitution at R2 in compound 54 turned out to be 
more potent than the meta nitro substitution present in compound 52 (IC50: 105 nM). 
Moreover, a few compounds containing methoxy and butoxy esters were investigated and 
resulted in increased inhibitory potency (see compound 77-79).  
Subsequently, several compounds containing a considerably smaller 4-methyl pyrimidine 
scaffold were investigated using pyridyl or phenyl groups as substituents at position 2. In 
comparison to their quinazoline analogues, very similar IC50 values were obtained for the 
4-methyl pyrimidine derivatives (see compounds 82/57, 83/61, 84/62, 85/4, 86/5, 87/3 
and 88/1). Concentration-response curves of the most potent compounds containing a 
quinazoline (compound 54) or a 4-methyl pyrimidine scaffold (compound 87) together 
with the standard inhibitor Ko143 is depicted in Figure 36.  
 
 
 
 
 
 
 
 
 
Figure 36: Concentration-response curve of compound 54 (■, IC50: 64.1 nM) and 87 (▲, IC50: 98.8 nM) 
in a Hoechst 33342 accumulation assay with Ko143 (○, IC50: 227 nM) as reference, using the ABCG2 
overexpressing MDCK II BCRP cell line. 
   
The substituted 4-methyl pyrimidine scaffold is particular interesting since it represents 
a very small molecule consisting of only three aromatic moieties but reveals significantly 
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high inhibitory potencies similar to a quinazoline scaffold. Besides the high ligand 
efficiency in comparison to the quinazoline derivatives, it also exhibits a decreased 
calculated logP value in the range of half a log unit. This is interesting since a certain 
degree of lipophilicity is required for membrane permeability but must also not be too 
high due to a reduced solubility of the compound under physiological conditions. 
However, a rather poor correlation (r2 = 0.21) between the pIC50 value and the calculated 
logP value was observed for the compounds of this subset (Figure 37). Here the two 
carboxyl groups containing compounds 80 and 81 were omitted, as the logP is calculated 
for the neutral form, which is not present under the assay conditions.  
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Correlation of calculated logP values with the corresponding pIC50 values. For the 
calculation of the logP values a software package from ACD/Labs was used (see experimental section). 
 
4.3 Investigation of the inhibitory potency 
toward ABCB1 and ABCC1 in the calcein 
AM assay   
 
A calcein AM assay was conducted to screen the selectivity of several compounds toward 
ABCG2. Therefor the ABCB1 overexpressing cell line A2780 adr and the ABCC1 
overexpressing cell line H69 AR were used and the assay was carried out as described in 
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chapters 3.3 and 10.2.2.4. The corresponding screenings were carried out at a compound 
concentration of 10 µM and CsA was used as positive control, indicating total inhibition 
of both transporters. In the cases where compounds exhibited an inhibitory potency of 
more than 25% relative to the control, additional tests were carried out with more dilutions 
to generate concentration-response curves allowing calculation of IC50 values. A 
summary of the calculated IC50 values of the compounds showing more than 25% of 
inhibition in the screening is given in Table 13. Screening results for the inhibitory 
activity toward ABCB1 and ABCC1 are depicted as bar charts in Figure 38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Inhibitory effect of screened compounds toward ABCB1 overexpressing cell line A2780 adr 
(a) and ABCC1 overexpressing cell line H69 AR (b) in a calcein AM assay at a concentration of 10 µM. 
Cyclosporine A (CsA) was used as positive control, indicating complete inhibition. The height of the bars 
represents the inhibition compared to the positive control in percent. For each compound, three 
independent experiments were performed and the standard deviation expressed as error bars.  
 
a) 
b) 
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Compounds with nitro and cyano functions at R2 exhibited a high selectivity toward 
ABCG2 which is advantageous with respect to their significantly high inhibitory potency 
in the Hoechst 33342 accumulation assay. Increased potencies toward ABCB1 and, to a 
lesser extent, toward ABCC1 was observed in the presence of methoxy and ester 
functions. These observations were in good accordance with the results of project I and 
prior studies.198, 205  
Interestingly, compound 79 containing a 4-pyridyl residue at R1 and tert-butyl 3-
aminobenzoate at R2 obtained a higher inhibitory potency toward ABCB1 than the 
standard CsA (IC50: 1.21 µM) with an excellent IC50 of 0.334 µM. Because compound 79 
also has a high inhibitory potency toward ABCG2, it could be used as an interesting drug 
for inhibiting both, ABCB1 and ABCG2 which are simultaneously expressed in some 
important tissues like the BBB.  
Table 13: Inhibitory Activity of Compounds Exhibiting an Inhibition of more than 25% in Comparison to 
the Reference CsA in a Calcein AM Assay at 10 µM. 
 
Compound R1 R2 Scaffold 
Calcein AM 
(ABCB1) 
IC50 ± SD [µM]a 
Calcein AM 
(ABCC1) 
IC50 ± SD [µM]b 
            
59 2-Pyr 3-OMe A   12.7 ± 1.83           n.t. 
60 3-Pyr 3-OMe A   4.78 ± 0.57           n.t. 
61 4-Pyr 3-OMe A   5.43 ± 0.83           n.t. 
62 4-Pyr 4-OMe A         n.d.     17.9 ± 2.1 
63 2-Pyr 3,4-OMe A   6.30 ± 0.36           n.t. 
64 3-Pyr 3,4-OMe A   3.11 ± 0.21           n.t. 
65 4-Pyr 3,4-OMe A   2.08 ± 0.36           n.t. 
68 4-Pyr 3-CF3,4-OMe A   2.78 ± 0.50           n.d. 
78 4-Pyr 3-CO2Me A   6.37 ± 0.12           n.t. 
79 4-Pyr 3-CO2tBu A 0.334 ± 0.056           n.t. 
81 4-Pyr 4-CO2H A   3.67 ± 0.10           n.t. 
87 Ph 3-NO2,4-OH B         n.d.     15.9 ± 2.9 
CsAc       1.21 ± 0.16     2.97 ± 0.38  
 
a: The ABCB1 overexpressing cell line A2780 adr was used. 
b: The ABCC1 overexpressing cell line H69 AR was used. 
c: Cyclosporine A is used as reference for both assays. 
n.d.: Not determined, due to low effect in the initial screening. 
n.t.: Not tested 
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A concentration-response curve of compound 79 including the positive control CsA is 
depicted in Figure 39.  
Moreover, the inhibitory potency toward ABCB1 was found to correlate with the position 
of the nitrogen atom at the pyridyl moiety in R1, showing increasing activities from ortho 
to meta to para (see compound 51-53, 55-57, 59-61 and 63-65).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Concentration-response curve of compound 79 (●, IC50: 0.334 µM) in a calcein AM assay 
with cyclosporine A (○, IC50: 1.21 µM) as reference, using the ABCB1 overexpressing cell line A2780 
adr. Results were obtained in at least three independent experiments and the standard deviation is 
expressed by error bars.   
 
The screening of the inhibitory potency of selected compounds toward ABCC1 resulted 
in only two compounds giving slightly more than 25% of inhibition relative to the positive 
control CsA (IC50: 2.97 µM). Only compounds 62 and 87 obtained an increased inhibitory 
potency but resulted in poor IC50 values of 18 and 16 µM when tested with several 
compound dilutions. Although the selection included the most potent compounds, the test 
set was smaller than in the screening performed with ABCB1 overexpressing cells. This 
was due to prior results from project I identifying the inhibition of ABCC1 as less 
important. 
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4.4 Investigation of the intrinsic cytotoxicity 
with the MDCK II cell lines in a MTT assay 
 
The intrinsic cytotoxicity of selected compounds was investigated in a MTT assay with 
MDCK II parental and ABCG2 overexpressing cells. Toxic effects were measured after 
72 h incubation of the cells in the presence of different compound concentrations using 
MTT as indicator of the cell viability. Further details of the procedure are provided in 
chapters 3.4 and 10.2.2.5. A summary of the obtained GI50 values and the corresponding 
therapeutic ratios is depicted in Table 14. 
 
Table 14: Intrinsic Toxicity of Selected Compounds toward MDCK II ABCG2 Overexpressing and 
Parental Cells.6 
 
Compound R1 R2 Scaffold 
GI50 [µM]a 
BCRP 
GI50 
[µM]a 
Parental 
Therapeutic 
ratio 
(GI50/IC50) b 
 
      
52 3-Pyr 3- NO2 A   71   65   620 
54 3-Pyr 4- NO2 A   73   74 1100 
56 3-Pyr 3-CN A   75   91   700 
57 4-Pyr 3-CN A   88 110   660 
58 3-Pyr 4-CN A   79 100   240 
66 4-Pyr 3-CF3 A   13   12     58 
67 4-Pyr 4-CF3 A 120 170   240 
68 4-Pyr 3-CF3,4-OMe A     2.9     2.5     20 
69 3-Pyr 3-F A   47 130   300 
71 3-Pyr 3-N(Me)2 A   10   14      8.3 
72 4-Pyr 3-OH A     9.2   12      8.6 
73 4-Pyr 4-OH A   55 120     13 
82 4-Pyr 3-CN B     6.9     9.3     52 
86 Ph 4-CN B   18   28   140 
87 Ph 3-NO2,4-OH B   49   58   500 
88 Ph H B 110 140   170 
3 Ph 3-NO2,4-OH A   52 150   650 
4 Ph 4-CN A   10   14   150 
6 Ph 4-OH A   15   23     69 
                                                 
Table continues on the next page 
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16 Ph 3-F A   18   28     50 
1c Ph H A   27   26     30 
Ko143         13   13     49 
MeOH/DMSO         96d 140d  
 
a: Concentration leading to 50% of cell survival of MDCK II BCRP and parental cells. The data was 
    obtained from at least two independent experiments as mean values. 
b: The therapeutic ratio of selected compounds is calculated from the ratio of GI50 to IC50-values, derived 
from MTT viability assay and Hoechst 33342 accumulation assay with ABCG2 overexpressing MDCK 
II BCRP cells. 
c: Compound was previously synthesized. 197, 198 
d: Positive control of the cytotoxicity from dilution with DMSO/MeOH without compound. 
 
Resulting GI50 values of the quinazoline derivatives (scaffold A) 52, 54, 56-58, 66-69 and 
71-73 containing a pyridyl moiety illustrate a substantial benefit of this group regarding 
their intrinsic cytotoxicity. Only compounds containing meta substitutions with 
trifluoromethyl, dimethylamino or hydroxy exhibited increased toxic effects (see 
compound 66, 68, 71 and 72). A possible mechanism for increased toxic effects could be 
associated with ATP depletion in the cell due to increased stimulation of the ATPase 
activity by a compound. For several instances, high stimulation of the ATPase activity 
was found in meta substituted compounds at the anilino linker and deactivation in case of 
para substitution. Moreover, for several compounds significant differences in the GI50 
values between the meta and para derivatives at R2, were observed, as for instance in 
compounds 72/73 and 66/67. 
Numerous pyridyl derivatives led to negligible or low cytotoxic effects in comparison to 
their phenyl analogues, including compounds with substitution at R2 by either 4-cyano 
(compounds 58/4: GI50 = 79.4/10.4 µM), 4-hydroxy (compounds 73/6: GI50 = 55.0/14.6 
µM) or 3-fluoro (compounds 69/16: GI50 = 46.8/18.0 µM).  
Concentration-response curves of highly potent compounds (IC50 < 140 nM) containing 
scaffold A or B (compound 54, 56, 57, 82 and 87) and a control (only DMSO/MeOH) are 
depicted in Figure 40.  
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Figure 40: MTT viability assay of compounds 54, 56, 57, 82 and 87 using the ABCG2 overexpressing 
MDCK II BCRP(closed circle) and parental MDCK II cell line (open circle). The following GI50-values 
were determined in the ABCG2 overexpressing cell line:
 
compound 54 GI50: 73.3 µM, 56: 75.3 µM, 57: 
88.1 µM, 82: 6.92 µM and 87: 49.0 µM. A control with the same concentration of MeOH and DMSO 
used in the dilution of the compounds, was carried out for comparison (■, GI50 = 96.1 µM). The final 
concentration of MeOH and DMSO used for the dilution was ≤ 1.8% and ≤ 1.0%, respectively.  
 
a) b) 
c) d) 
e) f) 
0
50
100
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-
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Derivatives containing a 4-methyl pyridyl scaffold yielded varying GI50 values. Besides 
the 4-pyridyl derivative 82, all other investigated derivatives containing phenyl at R1 
exhibited similar or lower cytotoxic effects than their analogues with a quinazoline 
scaffold. Due to the limited amount of investigated compounds, further derivatives have 
to be synthesized and investigated in order to provide a more comprehensive conclusion.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: MTT viability assay of compounds 54 (a), 56 (b), 57 (c), 87 (d) and a control (e) was carried 
out using the MDCK II ABCG2 overexpressing (closed circle) and parental MDCK II cell line (open 
circle). The control contains the same concentration of MeOH used in the dilution of the compounds. The 
final concentration of MeOH used for the dilution was ≤ 1.0%. No DMSO was used in this assay.  
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Since a few compounds such as 54, 56, 57 and 87 exhibited no cytotoxic effects, a 
modified MTT viability assay was carried out without DMSO and less than 1% MeOH 
in the highest concentration and the remaining parameters in the MTT assay were kept 
the same. This modification was possible due to the increased water solubility of the 
compounds. Corresponding concentration-response curves of the cell viability are 
depicted in Figure 41.  
Stimulation of the cell proliferation was often observed at low concentrations which is 
probably accounted to a defensive cellular mechanism. Further increase of the 
concentration eventually reversed this effect leading to a decreasing cell viability.  
All tested compounds showed no significant cytotoxic effects in the range of 0.1 to 30 
µM. On the contrary, stimulation of the cell proliferation is observed within a certain 
concentration range for compounds 54, 57 and 87. Only 87 exhibited a negative trend in 
the cell viability at a concentration of roughly 100 µM or higher. Compound 56 and the 
control, containing only MeOH, exhibited a constant cell viability at all concentrations.  
Due to a restricted solubility, higher compound concentrations could not be used. Thus it 
was not possible to create sigmoidal concentration-viability curves and determining a 
GI50 value. In comparison to the first method using DMSO together with an increased 
amount of MeOH, the GI50 of the nontoxic compounds is very likely higher than 96 µM, 
resulting from the cytotoxic effects of the solvents only. 
 
Figure 42: Therapeutic ratios of selected compounds, calculated from the ratio of GI50 to IC50 derived 
from MTT cytotoxicity assay and Hoechst 33342 accumulation assay, respectively. The highest score was 
obtained for compound 54 (GI50/IC50 = 1143), while the reference compound Ko143 yielded GI50/IC50 = 
48.9.  
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The highest TR of 1140 resulted for compound 54 containing a substitution with 3-pyridyl 
at R1 and 4-nitro at R2. In comparison the potent inhibitor Ko143 obtained a TR of only 
48.9. The benefit of the high inhibitory potency together with the low intrinsic 
cytotoxicity within this class of compounds leads to considerably high TRs that 
summarized in Figure 42. In particular, substitution with pyridyl at R1 and nitro or cyano 
at R2 resulted in selective compounds with extraordinarily high TRs that are promising 
candidates for in vivo studies. 
 
4.5 Investigation of the reversal of multidrug 
resistance 
 
The ability to reverse MDR in ABCG2 overexpressing MDCK II BCRP cell line toward 
SN-38 by co-administration of potent inhibitors 54, 56 and 87 was investigated in a MDR 
reversal assay. Further details are provided in chapters 3.5 and 10.2.2.6. 
Concentration-viability curves obtained with parental and ABCG2 expressing MDCK II 
cell lines are depicted in Figure 43. 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
Figure continues on the next page 
a) b) 
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Figure 43: MDR reversal assay of compound 54 (a, b), 56 (c, d) and 87 (e, f) demonstrating the ability to 
reverse the MDR toward the cytostatic SN-38, using parental MDCK II and ABCG2 overexpressing cell 
lines. The grey arrows indicate the increasing sensitization of the ABCG2 overexpressing cells with 
higher compound concentrations (see legend). At a compound concentration of 5 µM, full reversal is 
achieved, indicated by a similar IC50 value as the parental cells.  
a: Parental MDCK II cells.  
 
The investigated compounds all led to a full reversal of the cell-resistance toward SN-38 
at a concentration of 5 µM or less, indicated by similar pGI50 values of the parental cells 
and the ABCG2 expressing cells. Reversal of MDR due to increasing inhibition of 
ABCG2 is indicated by the grey arrow in Figure 43 a), c) and e). Repetition of the assay 
using parental cells resulted in comparable pGI50 values demonstrating no compound 
c) d) 
e) f) 
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concentration dependent effects on the viability of the cells, as can be seen from the 
concentration-viability curves presented in Figure 43 b), d) and f). Additionally, the pGI50 
values from the MDR reversal assay were plotted against the logarithm of the 
corresponding compound concentration for a better visualization of the obtained results. 
Hereby, a sigmoidal concentration-effect curve could be fitted using the logistic equation 
to yield EC50 values that characterize the extent of MDR reversal by a compound 
(illustrated in Figure 44). 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Nonlinear regression of the pGI50 values determined in the efficacy assay (Figure 43 a, c and 
e) against the corresponding concentrations of compounds 54, 56 and 87. pEC50 is the concentration that 
reduces resistance of the ABCG2 overexpressing cells to 50 percent. The following EC50 values were 
calculated: 21.2 nM (54), 85.0 nM (56) and 62.3 nM (87). The pGI50 values of the parental cells 
determined in an analogous efficacy assay (Figure 43 b, d and f) are depicted by open circles. The point 
in parenthesis at 0.1 µM in (c) was excluded. 
  
Thereby EC50 values of 21.2, 85.0 and 62.3 nM were determined for compound 54, 56 
and 87, respectively. According to the results in the MTT assay, the efficacy of the most 
potent compound 54 is about three-fold higher than the calculated IC50 value obtained in 
a) b) 
c) 
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the Hoechst 33342 accumulation assay. Regarding compound 56 and 87, a good 
correlation was found in the determined EC50 values derived from the efficacy assay and 
the results from the Hoechst 33342 accumulation assay (IC50: 108 nM, 56; and 98.8 nM, 
87).   
An additional MDR reversal assay with compound 54 and 87 was carried out to 
investigate the sensitization of the MDCK II ABCG2 overexpressing cell line toward the 
cytostatic drug MX. The assay was carried out with different compound concentrations 
in the presence and absence of 0.5 µM MX. Further details to the assay are provided in 
chapters 3.5 and 10.2.2.7. Both compounds were able to fully reverse the resistance of 
the cells toward MX at a concentration of about 0.1 µM as illustrated in Figure 45.  
 
 
 
 
 
 
 
 
 
Figure 45: MDR reversal assay of compound 54 (a, EC50: 12.6 nM) and 87 (b, EC50: 22.0 nM), 
demonstrating the ability to reverse the MDR toward the cytostatic MX, using ABCG2 overexpressing 
cell line MDCK II BCRP. The bars represent the cell viability at a given modulator concentration in the 
presence (light grey) and absence (dark grey) of 0.5 µM MX. The control shows cell viability of cells 
without modulator in the presence and absence of 0.5 µM MX. Standard deviation is expressed by error 
bars. 
 
Half-maximal growth inhibition was calculated for compound 54 as 12.6 nM and for 87 
as 22.0 nM. The most potent compound, 54, exhibited a high potency in both MDR 
reversal assays with SN-38 and MX, suggesting a somewhat higher inhibitory potency 
than determined in the Hoechst 33342 accumulation assay. A possible reason for this 
could be different affinities of the substrates to ABCG2 accounting for this result.  
 
  
a) b) 
4 Project II: 4-Substituted-2-pyridylquinazolines and -pyrimidines 100
4.6 Investigation of the interaction with Hoechst 
33342 
 
The interaction of selected compounds with Hoechst 33342 was investigated using 
ABCG2 overexpressing MDCK II BCRP cells. Varying compound concentrations were 
combined with varying concentrations of Hoechst 33342 and the interaction type could 
be determined by employing the Lineweaver-Burk double reciprocal plot, described in 
chapters 4.6 and 10.2.2.8. A summary of the results obtained with the Lineweaver-Burk 
method is presented in Table 15 listing the intersection of the straight lines together with 
the corresponding interpretation. A selection of the corresponding plots is depicted in 
Figure 46. 
Table 15: Interaction with Hoechst 33342 According to the Lineweaver-Burk Double Reciprocal Plot. 
 
Compound R1 R2 Scaffold Intersection  
type of interaction  
with Hoechst 33342 
54 3-Pyr 4-NO2 A X-axis Non-competitive 
58 3-Pyr 4-CN A 3. Quadrant Non-competitive mixed type 
61 4-Pyr 3-OMe A Y-axis competitive 
66 4-Pyr 3-CF3 A 2. Quadrant Non-competitive mixed type 
67 4-Pyr 4-CF3 A 3. Quadrant Non-competitive mixed type 
82 4-Pyr 3-CN B 2. Quadrant Non-competitive mixed type 
84 4-Pyr 4-OMe B 3. Quadrant Non-competitive mixed type 
Ko143    3. Quadrant Non-competitive mixed-type 
 
 
According to the Lineweaver-Burk double reciprocal plot the selected compounds mostly 
exhibited a non-competitive interaction of the “mixed type” with the substrate Hoechst 
33342. The most potent compound 54 led to a clear non-competitive interaction, 
indicating that it binds differently from Hoechst 33342. Solely compound 61 exhibited a 
competitive interaction suggesting that it occupies the same binding pocket as Hoechst 
33342.  
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Figure 46: Double-reciprocal plot according to Lineweaver-Burk for selected compounds 54 (a), 61 (b), 
66 (c), 67 (d), 82 (e), 84 (f).Compound concentrations are specified in the legend.  
 
 
a) b) 
c) d) 
e) f) 
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In order to validate the results from the Lineweaver-Burk double reciprocal plot, the 
Cornish-Bowden method was applied. Additional information is provided in chapters 3.6 
and 10.2.2.8. Additionally a linear regression of the Vmax and KM values was performed 
and the obtained slopes summarized as scatter plot in Figure 47. Corresponding linear 
regression are depicted in Figure 48 (for Ko143 see chapter 3.6).   
 
Figure 47: Scatter plot of the slopes obtained from the linear regression of KM (○) and Vmax (■) values 
calculated from the Cornish-Bowden direct linear plot.  
 
The non-competitive interaction of compound 54 was confirmed by the Cornish-Bowden 
method showing decreasing Vmax and the constant KM values. Compound 61 on the other 
hand yielded a high positive slope for KM and a roughly constant, slightly negative slope 
for Vmax which is characteristic for a competitive interaction.   
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Figure 48: Direct linear plot of 54 (a), 61 (b), 66 (c), 67 (d), 82 (e) and 84 (f) according to Cornish-
Bowden resulting in compound-concentration dependent lines after linear regression of the Vmax (■) and 
KM (●) values. Excluded values are depicted as open symbols of the corresponding shape. 
 
a) b) 
c) d) 
e) f) 
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For the compounds that were classified as non-competitive of the “mixed type” in the 
Lineweaver Burk plot, the Cornish-Bowden plot suggests a pronounced non-competitive 
character for compounds 66, 67 and 84. On the contrary, a considerably high competitive 
character was found for compound 82. Overall a non-competitive interaction, mostly of 
the “mixed type”, resulted for the majority of the investigated compounds. Similar 
findings were made for the 4-substituted-2-phenylquinazolines of project I. Moreover, no 
contradiction in the kinetic interpretation was found between the Lineweaver-Burk and 
the Cornish-Bowden method.  
 
4.7 Investigation of the conformation sensitive 
5D3 antibody binding to an epitope of ABCG2 
 
The conformational impact of selected compounds on ABCG2 was investigated with the 
conformation sensitive 5D3 antibody which binds specifically to an epitope of the 
transport protein. Measurement of the fluorescence emitted by the bound antibody was 
carried out with a FACSCalibur flow cytometer using ABCG2 overexpressing PLB-985 
cells. Additional information about the assay is provided in chapters 3.7 and 10.2.2.9. The 
results from this assay are summarized as a bar-chart in Figure 49 using Ko143 as positive 
control representing 100% labelling with the antibody.  
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Figure 49: 5D3 immunoreactivity modulation of ABCG2 by various compounds at a concentration of 1 and 
10 µM. Fluorescence detected by the 5D3-labeling of ABCG2 in the presence of 10 µM Ko143 was set to 
100% and the fluorescence measured in the absence of any compound taken as 0%. The dotted line 
represents the labelling obtained with Hoechst 33342.   
 
Highest labelling with the antibody was observed for the most potent compound 54 (80%) 
followed by 82 (77%) and 66 (70%) at a compound concentration of 10 µM. Although 
all three compounds exhibited a high inhibitory potency in the Hoechst 33342 
accumulation assay, the IC50 does not necessarily correlate with the rate of staining. This 
is illustrated by the compounds 57 and 85 possessing high inhibitory potencies but 
showing low labelling with the 5D3 antibody. Moreover, some compounds presented in 
chapter 3.7 with relatively low inhibitory potencies (e.g. 17 and 19) gave a high rate of 
labelling with the antibody. 
 A significant difference in the degree of labeling was found among the meta and para 
trifluoromethyl derivatives 66 and 67. Here, an increased rate of labelling (70%) resulted 
for the meta derivative whereas the para derivative yielded a lower rate (48%). Both 
compounds had shown a mixed interaction type with Hoechst 33342, whereas only 
compound 66 exhibited a notable increase of KM with increasing concentration in the 
Cornish-Bowden plot, which is characteristic for a competitive interaction. 
An increase of the compound concentration from 1 µM to 10 µM led to a higher labelling 
with the antibody in case of compounds 54 and 58, where the increase of labelling was 
considerably higher for compound 54.  
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Representative histograms of the compounds Ko143, 54 and 85 at 10 µM are illustrated 
in Figure 50.  
 
 
   
Figure 50: Histogram of the measured fluorescence at the FL3-H detector (X-axis) and the cell-count 
gated according to the fluorescence. Depicted is the fluorescence of the isotype-control (dotted curve) as 
well as of 5D3 antibody in the absence of a compound (dashed curve) and in the presence of a compound 
(continuous curve). Compounds with the highest and lowest 5D3 shifts: Ko143 (a), 54 (b) and 85 (c) at a 
concentration of 10 µM.   
 
Fluorescence of the isotype-control in presence of the corresponding compound is shown 
as a dotted line. This is necessary to exclude any unspecific staining. Also, the obtained 
fluorescence with 5D3 antibody in the absence (dashed curve) and presence (continuous 
curve) of a compound is provided. Here, high shifts were observed with Ko143 and 
compound 54, while 85 results in a minor shift comparable to the fluorescence obtained 
with the antibody alone.  
 
4.8 Investigation of the ATPase activity 
 
Again Ko143 was used as the standard ATPase inhibitor and quercetin as the standard 
stimulator. The ATPase activity assays were performed by Jennifer Gallus. Further details 
are provided in chapters 3.8 and 10.2.2.10.  
The screening was conducted at three different concentrations (1, 10 and 25 µM) 
including only the most potent compounds. A summary of the results is provided as bar 
chart in Figure 51.  
a) b) c) 
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The majority of the compounds showed high stimulation of the ATPase activity and only 
few a moderate stimulation near basal level. Indeed, the substitution pattern of the pyridyl 
at R1 had a measurable impact on the ATPase activity. For instance, a considerably greater 
increase of the stimulatory effect resulted for the para pyridyl derivatives in comparison 
to their meta pyridyl analogues. This is exemplified in the meta/para compound pair 
52/53 and 56/57. Interestingly, compound 57 containing a 3-cyano function at R2 led to a 
higher ATPase stimulation than the standard stimulator quercetin. This is in accordance 
with the results of project I where the 2-phenylquinazoline analogue 4 containing 3-cyano 
caused a considerably high activation. Almost no stimulation was found for compound 
58 with a 4-cyano substituent. A similar result had already been observed for its 2-
phenylquinazoline analogue 5 (see chapter 3.8). The different impact between a meta and 
a para substitution at the aniline linker at position 4 of the quinazoline scaffold confirmed 
the results of previous assays. 
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Figure 51: Screening of ATPase activity of selected compounds at three different concentrations. From left to right the bars correspond to 1, 10 and 25 µM final 
concentration of compound. Quercetin was used as a standard for activation of ABCG2 ATPase activity. All values are relative vanadate-sensitive ATPase activities in 
relation to the basal activity, which is set to 100%. 
 
4 Project II: 4-Substituted-2-pyridylquinazolines and -pyrimidines  109
Only low stimulation near the basal level was observed for compounds 60-62 containing 
a meta or para methoxy group at R2. In the previous enzyme kinetic investigation 
compound 61 was found to possess a distinct competitive interaction with Hoechst 33342 
(see chapter 4.6). According to the collected data, a connection between a near basal or 
even subbasal ATPase activity and a pronounced competitive kinetic interaction with 
Hoechst 33342 can be drawn. Moreover, compounds with a decreased ATPase activity 
frequently caused high conformational changes in ABCG2 like the standard Ko143, as 
investigated in the 5D3 antibody binding assays.  
Regarding the 4-methyl pyrimidine derivatives 82-88, the trends of the ATPase activity 
were quite similar to their quinazoline analogues. In Figure 52 the concentration-response 
curves of selected compounds 54, 61, 66 and 79 are depicted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: Concentration-response curves for compounds 54 (a, EC50: 26.7 nM), 61 (b), 66 (c) and 79 
(d) in the ATPase assay. All values are relative vanadate-sensitive ATPase activities in relation to the 
basal activity, which is set to 100%.  
 
a) b) 
c) d) 
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Most potent compound 54 caused a considerable stimulation of the ATPase activity, 
resulting in a sigmoidal concentration-response curve. The maximum value of the curve 
was similar to the standard activator quercetin obtaining an EC50 value of 26.7 nM in 
comparison to 302 nM of quercetin. Almost no stimulation was found for compound 61. 
Interestingly a bell-shaped curve resulted for compound 66. This is presumed to be due 
to an activating high-affinity and a deactivating low-affinity binding site. At low 
compound concentration predominantly the activating binding site is occupied whereas 
high concentrations lead to binding to the deactivating site triggering a reversal of the 
ATPase activity.206 A strong inhibition of the ATPase activity resulted for compound 79 
containing a bulky 3-tert-butyl ester group.  
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5 Project III: 2,4-Substituted 
quinazolines 
 
In this project substitution was carried out on corresponding aromatic cores at position 2 
and 4 of the quinazoline scaffold. Hence, precursors of differently substituted 4-chloro-
2-phenylquinazoline derivatives were synthesized and reacted with differently substituted 
aniline derivatives via nucleophilic substitution under microwave radiation. In 
comparison to the compounds of project I this modification increased the number of 
possible substituent combinations and provides additional information on the reciprocal 
effects among the functions at positions 2 and 4 of the quinazoline scaffold. This is in 
particular interesting in terms of cumulative effects and also the interchangeability of 
substituents at positions 2 and 4 with respect to the inhibitory potency of a compound.  
Decreased solubility, which was observed in only a few para nitro derivatives like 
compound 89 (see chapter 4) and 144 was reviewed by measuring the absorption over a 
period of 2 h. 
 
 
 
 
 
 
 
 
 
Figure 53: Absorption spectrum measured at the excitation maximum of compound 144 over a time 
period of 2 h. The compound was diluted in KHB to 10 µM and the measurement carried out at room 
temperature. 
 
According to Figure 53 no precipitation occurs at a final concentration of 10 µM of 
compound 144. Questionable IC50 values published in former work of Juvale et al. were 
re-determined and corrected.198  
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5.1 Reaction mechanism  
 
A schematic synthesis route and a detailed reaction mechanism is provided in this chapter. 
Scheme 4: General synthesis scheme for the preparation of compounds 91-152.a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: Reagents and conditions: (i) DMF, I2, K2CO3, 70-90 °C, 4-8 h. (ii) POCl3, reflux, 4-12 
h. (iii) Substituted aniline, 100 watt microwave irradiation, 110 °C, 15 - 30 min.  
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91: R1 = 3-NO2
92: R1 = 4-NO2
93: R1 = 3-CN
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Reaction mechanism A: 
The reaction mechanism is analogue to that used for the compounds in project II and can 
be reviewed in chapter 4.1 (reaction mechanism A).  
 
 
 
Reaction mechanism B: 
The carbonyl function at position 4 is substituted by chlorine via a chlorination reaction 
using POCl3. The mechanism is analogously to that presented in chapter 4.1. 
  
 
 
Reaction mechanism C: 
Synthesis of the final compounds follows the mechanism explained in chapter 3.1 and 
can be reviewed there.  
 
5.2 Investigation of the inhibitory potency 
toward ABCG2 in the Hoechst 33342 
accumulation assay 
 
The inhibitory potency of the compounds was investigated in a Hoechst 33342 
accumulation assay using the ABCG2 overexpressing MDCK II BCRP and parental cell 
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line. Additional information to the Hoechst 33342 accumulation assay as is presented in 
chapter 3.2 and 10.2.2.2. The associated activity data is summarized in Table 16.  
 
 
 
Table 16: Inhibitory Activities Determined in the Hoechst 33342 Accumulations Assay Using ABCG2 
Overexpressing MDCK II BCRP Cells. Structural Formulas of the Substitution Pattern are Depicted 
Above the Table.8 
 
Compound R1 R2 
Hoechst 33342 
IC50 ± SD [nM]a 
 
  
 
105 3-NO2 H     108 ± 21 
106 3-NO2 d   2780 ± 660 
107 3-NO2 3-NO2     236 ± 16 
108 3-NO2 3-NO2,4-OH     151 ± 7 
109 3-NO2 3-CN     120 ± 27 
110 3-NO2 3-OCH3     121 ± 14 
111 3-NO2 3,4-OCH3    55.6 ± 3.1 
112 3-NO2 3-OCH3,4-Br     801 ± 257 
113 3-NO2 3,4-Oet     210 ± 41 
114 3-NO2 d     263 ± 53 
115 3-NO2 3-SCH3    94.8 ± 17.2 
116 3-NO2 4-SCH3    88.6 ± 15.9 
117 3-NO2 3-NH2     284 ± 40 
118 3-NO2 3-N(-CH3)2     221 ± 15 
119 3-NO2 3-N(-CH2CH3)2     230 ± 43 
120 3-NO2 3-NHCOCH3     127 ± 7 
121 3-NO2 3-CF3 10700 ± 900  
122 3-NO2 3-CF3,4-OCH3 16200 ± 4900 
123 3-NO2 4-I   1770 ± 380 
124 4-NO2 3-NO2     166 ± 19 
125 4-NO2 3-CN     336 ± 20 
126 4-NO2 3-OCH3     107 ± 17 
                                                 
Table continues on the next page 
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127 4-NO2 3,4-OCH3    86.7 ± 8.0 
128 3-CN 3-OH,4-OCH3     297 ± 53 
129 3-CN 3-NHCOCH3     225 ± 18 
130 2-OCH3 3-NO2     642 ± 134 
131 3-OCH3 3-NO2     139 ± 34 
132 3-OCH3 4-NO2       68 ± 13 
133 3-OCH3 3,5-NO2     291 ± 54 
134 3-OCH3 3-NO2,4-F   1190 ± 340 
135 3-OCH3 3-CN     359 ± 66 
136 3-OCH3 3-F   1640 ± 310 
137 3-OCH3 3-OCH3     811 ± 178 
138 3-OCH3 3,4-OCH3     480 ± 29 
139 4-OCH3 3-NO2     183 ± 19 
140 4-OCH3 3-CN   2120 ± 310 
141 4-OCH3 3-OCH3   2140 ± 380 
142 4-OCH3 3,4-OCH3     418 ± 13 
143b 3,4-OCH3 3-NO2    82.5 ± 6.2 
144b 3,4-OCH3 4-NO2    44.2 ± 8.6 
145 3,4-OCH3 3,5-NO2     610 ± 54 
146 3,4-OCH3 3-NO2,4-OH     305 ± 21 
147 3,4-OCH3 3-CN     136 ± 16 
148 3,4-OCH3 3-CF3,4-OCH3     795 ± 190 
149 3,4-OCH3 3-OCH3     365 ± 57 
150 3,4-OCH3 3-OCH3,4-Br    47.5 ± 7.1 
151 3,4-OCH3 3-F     462 ± 93 
152 3,4-OCH3 3-SO2F     570 ± 116 
Ko143c       227 ± 14 
Elacridar       361 ± 48 
 
a: IC50 values are means of three independent experiments. 
b: Compounds synthesized in earlier study.198  
c: Used as reference in the assay. 
d: See substitution pattern above. 
 
According to the results of project I and II compounds with nitro in meta or para position 
at the anilino linker exhibit an excellent inhibitory potency (e.g. compounds 2 and 90) 
often favouring the para substitution as more beneficial. As little was known about the 
effects of substitutions at the aromatic core in position 2 of the quinazoline scaffold the 
interchangeability of several different functions between R1 and R2 was investigated. In 
the case of 3-nitro only a negligible difference was found after interchange of the 
substituents leading to comparable IC50 values of 130 nM and 108 nM for the 
corresponding compound 2 and 105. The phenomenon of interchangeability of 
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substituents between R1 and R2 was also observed for several other compounds which are 
summarized in Figure 54.  
 
 
Figure 54: Comparison of the pIC50 values of structurally related compounds with interchanged 
substituents at R1 and R2.    
 
Also the importance of an aromatic residue at position 4 of the quinazoline scaffold was 
investigated. Hence, the potent compound 105 containing 3-nitro at R1 and an anilino 
moiety at position 4, was compared to compound 106 with a cyclohexylamino function 
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at position 4 instead of anilino. Interestingly, the loss of the aromaticity resulted in a 
considerable decrease of inhibitory potency of more than 25-fold.   
Extraordinarily potent compounds resulted from combination of a nitro group together 
with a methoxy or 3,4-dimethoxy substitution at R1 and R2. The highest inhibitory 
potency was determined for compound 144, containing a 3,4-dimethoxy group at R1 and 
4-nitro at R2 with an IC50 of 44.2 nM. It was found that disubstitution with 3,4-dimethoxy 
led to higher potencies than a mono-methoxy function in combination with nitro groups. 
Examples are compounds 111, 127, 143 and 144, all of which are highly potent inhibitors 
possessing an IC50 value below 100 nM.  
Also the combination of 3,4-dimethoxy at R1 and 3-methoxy,4-bromo at R2 in compound 
150 yielded a rather low IC50 of 47.5 nM. The 3-methoxy,4-bromo substitution had 
already proven its benefit in project I exhibiting a high inhibitory potency in the 4-
substituted 2-phenylquinazoline derivative 16 (IC50: 289 nM). Concentration-response 
curves of the three most potent compounds 111, 144 and 150 in the Hoechst 33342 
accumulation assay are depicted in Figure 55.   
 
 
 
 
 
 
 
 
 
 
Figure 55: Concentration-response curve of compound 111 (○, IC50: 55.6 nM), 144 (□, IC50: 44.2 nM) 
and 150 (∆, IC50: 47.5 nM) in the Hoechst 33342 accumulation assay with Ko143 (■, IC50 : 227 nM) as 
reference, using the ABCG2 overexpressing MDCK II BCRP cell line. 
 
Since the combination of 3,4-dimethoxy groups and nitro functions yielded 
extraordinarily high inhibitory potencies, further modifications at the methoxy functions 
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were carried out. Unfortunately, replacement of the 3,4-dimethoxy group by a 3,4-
diethoxy or a 1,4-dioxane function resulted in a decreased inhibitory potency of about 4-
fold illustrated in the 3-nitro (R1) derivatives 111, 113 and 114. This could be due to the 
increased sterical demand of the ethoxy function and the restrained flexibility in the 
dioxane derivative.  
Although some evidence was found that substituents like nitro and cyano which exhibit 
a negative mesomeric effect (-M) on the aromatic rings at position 2 and 4, led to high 
inhibitory potencies, other groups like dimethoxy with a positive mesomeric effect on the 
aromatic moiety also led to increased inhibitory potencies.  
More important could be the formation of H-bonds by functions like nitro, cyano or 
methoxy that could be pivotal for interaction with the transport protein. Hydrogen bond 
donor functions in meta position of the anilino linker (R2) are most likely not crucial for 
the potency of a compound as demonstrated by 117, 118 and 119: here, the free amine 
yielded a very similar IC50 as the dimethylamino and the diethylamino derivative, 
indicating that the free electron pair of the nitrogen is important for activity. 
Regarding ortho substitutions at R2, that have been found to lead to low inhibitory 
activities, one compound was synthesized with an ortho substitution at R1 for comparison. 
As expected, it possessed the lowest inhibitory potency as illustrated by the three methoxy 
derivatives 130, 131 and 139. Again, this might be due to steric requirements of the 
substituent as mentioned in chapter 3. 
 
5.3 Investigation of the inhibitory potency toward 
ABCB1 and ABCC1 in the calcein AM assay   
 
The selectivity of several compounds toward ABCG2 was screened in a calcein AM. For 
this purpose, the ABCB1 overexpressing cell line A2780 adr and the ABCC1 
overexpressing cell line H69 AR were used and the assay carried out as described in 
chapters 3.3 and 10.2.2.4. For the screenings a compound concentration of 10 µM was 
chosen and CsA was used as positive control, indicating total inhibition of both 
transporters. For compounds showing an inhibitory potency of more than 25% relative to 
the control, additional dilutions were prepared to generate a concentration-response curve 
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resulting in an IC50 value. A summary of the calculated IC50 values of the compounds 
showing more than 25% of inhibition in the screening is given in Table 17. Screening 
results for the inhibitory activity toward ABCB1 and ABCC1 are depicted as bar charts 
in Figure 56. A clear correlation was observed between the number of methoxy functions 
present in a compound and the inhibitory potency toward ABCB1 and, although to a lower 
extent, also toward ABCC1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Inhibitory effect of screened compounds toward ABCB1 overexpressing cell line A2780 adr 
(a) and MRP1 overexpressing cell line H69 AR (b) in the calcein AM assay at a concentration of 10 µM. 
Cyclosporine A (CsA) was used as positive control, indicating complete inhibition. The inhibitory effect of 
each compound is expressed by the length of the bars, representing the inhibition compared to the 
positive control in percent. For each compound, three independent experiments were performed and the 
standard deviation is expressed by error bars. 
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Among the compounds that exceed the 25% mark in the calcein AM assay solely 
compound 120 with an amido group and the amino-derivatives 117-119 contain no 
methoxy group. Compounds capable of inhibiting more than one target transport protein 
are of particular interest with regard to tissues that express several different ABC transport 
proteins like ABCG2 and ABCB1 that are for instance overexpressed in the BBB.    
In this context, broadspectrum inhibitors like elacridar have been successfully tested in 
vivo in tissues showing an overexpression of ABCG2 and ABCB1. Promising candidates 
of broadspectrum inhibitors are for instance compound 138, 142, 144 and 149 that were 
found to be highly potent inhibitors of ABCG2 and also ABCB1, some possessing 
comparable or even better inhibitory activities toward ABCB1 than the standard CsA.  
 
Table 17: Inhibitory Activity of Compounds Showing an Inhibition of more than 25% in Comparison to 
the Reference Cyclosporine A (CsA) in the calcein AM Assay at a Concentration of 10 µM. 
 
Compound R1 R2 
Calcein AM (ABCB1) 
IC50 ± SD [µM]a,b 
Calcein AM (ABCC1)  
IC50 ± SD [µM]a,c 
 
        
117 3-NO2 3-NH2 13.10 ± 1.02       n.t. 
118 3-NO2 3-N(CH3)2   6.30 ± 0.71       n.t. 
119 3-NO2 3-N(CH2CH3)2   9.36 ± 1.28       n.t. 
120 3-NO2 3-NHCOCH3   1.81 ± 0.58       n.d. 
137 3-OCH3 3-OCH3   1.87 ± 0.36       n.t. 
138 3-OCH3 3,4-OCH3   1.10 ± 0.22       n.t. 
141 4-OCH3 3-OCH3   2.46 ± 0.23       n.t. 
142 4-OCH3 3,4-OCH3   1.22 ± 0.17 7.72 ± 0.99 
144d 3,4-OCH3 4-NO2   2.45 ± 0.42 40.6 ± 12.9 
148 3,4-OCH3 3-CF3,4-OCH3   1.67 ± 0.46       n.t. 
149 3,4-OCH3 3-OCH3   1.04 ± 0.09       n.t. 
150 3,4-OCH3 3-OCH3,4-Br   3.15 ± 0.66 44.2 ± 4.4 
152 3,4-OCH3 3-SO2F   3.26 ± 0.06       n.t. 
Cyclosporine Ae       1.21 ± 0.17 3.53 ± 0.61  
 
a: IC50 values were determined by at least three independent experiments. 
b: The ABCB1 overexpressing cell line A2780 adr was used. 
c: The ABCC1 overexpressing cell line H69 AR was used. 
d: Compound was synthesized previously.198 
e: Cyclosporine A is used as reference for both assays. 
n.d.: Not determined, due to low effect in the initial screening. 
n.t.: Not tested 
 
5 Project III: 2,4-Substituted quinazolines  121
Representative concentration-response curves of compound 149 and CsA are depicted in 
Figure 57.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57: Concentration-response curve of compound 149 (■, IC50: 1.04 µM) in a calcein AM assay 
with CsA (○, IC50: 1.21 µM) as reference, using the ABCB1 overexpressing cell line A2780 adr. 
 
The inhibitory potency toward ABCC1 was screened with fewer compounds since 
compounds from project I and II exhibited a lower activity. This was substantiated by the 
compounds of project III. One compound (142) was similar active against ABCB1 and 
ABCC1.  
Only three compounds in the test set, including the most potent, barely exceeded the 25% 
mark in the CsA assay with ABCC1 overexpressing cells. This resulted in considerably 
high IC50 values derived from the corresponding dose response curves that had to be fitted 
to the top fluorescence value of CsA. 
Indeed, it has to be pointed out that the majority of the substances, in particular those 
containing nitro functions, exhibited an excellent selectivity toward ABCG2. Some 
examples are the highly potent compounds 105, 108, 111, 124, 126, 127, 131, 132, 139, 
and 147. 
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5.4 Investigation of the intrinsic cytotoxicity 
with the MDCK II cell lines in a MTT assay 
 
The determination of the intrinsic cytotoxicity of selected compounds was performed in 
a MTT assay using MDCK II parental and ABCG2 overexpressing cells. For this purpose, 
the toxic effects were measured after 72 h incubation of the cells in the presence of 
different compound concentrations using MTT as indicator of the cell viability. More 
details regarding the assay are provided in chapters 3.4 and 10.2.2.5. The obtained GI50 
values and the corresponding therapeutic ratios are depicted in Table 18. 
Table 18: Intrinsic Toxicity of Selected Compounds on MDCK II ABCG2 Overexpressing and Parental 
Cells. 
 
a: Concentration leading to 50% of cell survival of MDCK II BCRP and parental cells. The data was 
    obtained from at least two independent experiments as mean values. 
b: Compound was synthesized previously.198  
c: Positive control of the cytotoxicity from dilution with DMSO/MeOH without compound. 
 
Compound R1 R2 
 
 
GI50 [µM]a 
BCRP 
GI50 [µM]a 
Parental 
 
 
Therapeutic 
ratio (GI50/IC50) 
 
  
 
 
 
107 3-NO2 3-NO2   4.6     4.9   19 
109 3-NO2 3-CN   4.9     4.3   41 
110 3-NO2 3-OCH3   7.3     9.1   60 
111 3-NO2 3,4-OCH3 15   16 270 
120 3-NO2 3-NHCOCH3 26   84 210 
121 3-NO2 3-CF3   8.5     9.8     0.80 
122 3-NO2 3-CF3,4-OCH3   1.5     0.92     0.094 
123 3-NO2 4-I   3.2     4.4     1.8 
127 4-NO2 3,4-OCH3   8.7   13   49 
131 3-OCH3 3-NO2 20.9   33 150 
132 3-OCH3 4-NO2   8.0   11 120 
134 3-OCH3 3-NO2,4-F 99   78   83 
138 3-OCH3 3,4-OCH3   8.7     9.3   18 
143b 3,4-OCH3 3-NO2 23   17 150 
144b 3,4-OCH3 4-NO2   6.4     6.9 140 
147 3,4-OCH3 3-CN 20   73 150 
149 3,4-OCH3 3-OCH3 15   14   33 
150 3,4-OCH3 3-OCH3,4-Br 10   11 210 
Ko143     13   13   49 
MeOH/DMSO     96c 140c  
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Investigation of the intrinsic cytotoxicity of selected compounds showed that GI50 values 
were either comparable or slightly worse than those in project I. This could be due to the 
presence of more functional groups leading to an accumulation of toxic effects. However, 
this suggestion does not apply to every substitution pattern. For instance the disubstitution 
with 3-nitro-4-hydroxy at the anilino linker was found to be considerably beneficial (see 
project I, compound 3). Corresponding monosubstitutions in compound 6 and 131 often 
led to increased cytotoxic effects.  
Another crucial factor for the cytotoxicity of a compound was found to be the position of 
the substitution at the aromatic ring as shown by comparing the meta and para derivatives 
131/132 and 143/144.  
 
 
 
 
 
 
 
 
 
Figure 58: MTT viability assay of compounds 111 (○), 144 (□), and 150 (∆) using the MDCK II ABCG2 
overexpressing cell line. The GI50 values were determined as 15.1 µM (○), 6.40 µM (□) and 10.0 µM (∆), 
respectively. A control with the same concentration of MeOH and DMSO as used for the dilution of the 
compounds, was carried out for comparison (●, GI50 = 96.1 µM). The amount of MeOH and DMSO used 
for the dilution was ≤ 1.8% and ≤ 1.0%, respectively. 
 
The highest TR among the investigated compounds was found for compound 111 with a 
GI50/IC50 ratio of 270. As a comparison, Ko143 had a TR of only 48.9.  
Concentration-cell-viability curves for compounds 111, 144 and 150, which possessed 
the highest inhibitory potencies in the Hoechst 33342 accumulation assay, are illustrated 
in Figure 58. Despite their increased intrinsic cytotoxicity, the compounds yielded 
relatively high TRs owing to their high potency.  
An overview of the TRs of selected compounds is provided as a bar chart in Figure 59. 
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Figure 59: Therapeutic ratios of selected compounds, calculated from the ratio of GI50 and IC50 values 
determined in MTT viability assay and Hoechst 33342 accumulation assay, respectively. The highest 
value was calculated for compound 111 (GI50/IC50 = 270), while the reference compound Ko143 yielded 
GI50/IC50 = 48.9.  
 
5.5 Investigation of the reversal of multidrug 
resistance 
 
The Reversal of the MDR in ABCG2 overexpressing MDCK II BCRP cell line toward 
SN-38 was investigated by co-administration of the most potent compounds 144 and 150. 
Further details are provided in chapters 3.5 and 10.2.2.6. Concentration-viability curves 
obtained by parental and ABCG2 expressing MDCK II cell lines are depicted in Figure 
60. 9 
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Figure 60: MDR reversal assay of compound 144 and 150 demonstrating the ability to reverse the MDR 
toward the cytostatic SN-38, using parental MDCK II and ABCG2 overexpressing cell lines (a, c). The 
grey arrow indicates the increasing sensitization of the ABCG2 overexpressing cells with higher 
compound concentrations (see legend). At a compound concentration of 1 µM, full reversal is achieved, 
indicated by a similar pGI50 as the parental cells. For comparison an analogue assay was performed 
using only parental MDCK II cells (b, d).  
a: Parental MDCK II cells.   
 
Compounds 144 and 150 both produce a full reversal of the resistance toward SN-38 at a 
concentration of 1 µM, as indicated by comparable GI50 values of the parental cells and 
the ABCG2 expressing cells in the presence of a compound. Reversal of MDR is 
illustrated by the grey arrow in Figure 60 a) and c) and shows the shift of the GI50 values 
toward higher compound concentration.  
An analogous assay was carried out with only parental cells leading to comparable pGI50 
values for each compound concentration (Figure 60 b) and c)). Hence, the shift in the 
ABCG2 overexpressing cells is caused by the inhibition of the transporter but not due to 
cytotoxic or other unspecific effects.  
For a clear visualization of the obtained results, the pGI50 values from the MDR reversal 
assay were plotted against the logarithm of the corresponding compound concentration. 
And a sigmoidal concentration-effect curve was fitted with the logistic equation yielding 
EC50 values characterizing the extent of MDR reversal by a compound as depicted in 
Figure 61. Hereby, EC50 values of 12.7 and 15.6 nM were determined for compound 144 
and 150, respectively. According to the results, the efficacy of both compounds is about 
3 to 3.5-fold higher than the calculated IC50 value obtained in the Hoechst 33342 
c) d) 
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accumulation assay. This result is similar to the most potent compounds of project I and 
II, namely 5 and 54 that also possessed a higher efficacy than the result of the Hoechst 
33342 accumulation assay suggested.   
 
 
 
 
 
 
 
 
Figure 61: Nonlinear regression of the pGI50 values determined in the MDR reversal assay Figure 60 a) 
and c) with the corresponding concentration of compound 144 and 150. The EC50 value characterising 
half-maximal sensitization toward SN-38, was calculated as 12.7 nM (144) and 15.6 nM for compound 
150 (●). For compounds 144 and 150 IC50 values of 44.2 nM and 47.5 nM in the Hoechst 33342 
accumulation assay were obtained, respectively. A nonlinear regression of the pGI50 values determined in 
an analogous reversal assay (Fig. 7 b and d), but using only parental MDCK II cells, is depicted with 
open circles (○).  
 
Moreover, the sensitization of the ABCG2 overexpressing MDCK II BCRP cell line 
toward the cytostatic drug MX was investigated by co-administration of compound 144 
and 150. The assay was carried out at different compound concentrations in the presence 
and absence of 0.5 µM MX. Further details to the assay are provided in chapters 3.5 and 
10.2.2.7. Both compounds were able to reverse the resistance of the cells toward MX as 
illustrated in Figure 62.  
 
 
 
 
 
 
b) a) 
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Figure 62: MDR reversal assay of compounds 144 (a) and 150 (b), demonstrating their ability to reverse 
MDR toward the cytostatic drug mitoxantrone, in the ABCG2 overexpressing cell line MDCK II BCRP. 
The bars represent the cell viability at a given modulator concentration in the presence (light grey) and 
absence (dark grey) of 0.5 µM mitoxantrone. Control shows viability of cells without modulator. The 
standard deviation is expressed by error bars.   
 
Both compounds produced full reversal of the MDR at a concentration of about 1 µM. 
Half-maximal growth inhibition was reached for compound 144 at 7.4 nM and for 150 at 
9.7 nM. The EC50 values determined in the MDR reversal assay with MX reflect the 
results of the MDR reversal assay with SN-38 very well. 
 
5.6 Investigation of the interaction with Hoechst 
33342 
 
The interaction of selected compounds with Hoechst 33342 was investigated with 
ABCG2 overexpressing MDCK II BCRP cells using varying compound concentrations 
combined with varying concentrations of Hoechst 33342. The Lineweaver-Burk double 
reciprocal plot was used to determine the interaction type, described in chapters 4.6 and 
10.2.2.8.  
A summary of the results obtained with the Lineweaver-Burk method can be found in 
Table 19 listing the intersection of the straight lines with the corresponding interpretation.  
a) b) 
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Table 19: Interaction with Hoechst 33342 According to the Lineweaver-Burk Double Reciprocal Plot. 
 
Compound R1 R2 Intersection  
type of interaction  
with Hoechst 33342 
111 3-NO2 3,4-OCH3 2. Quadrant Non-competitive mixed type 
130 2-OCH3 3-NO2 2. Quadrant Non-competitive mixed type 
139 4-OCH3 3-NO2 Y-axis competitive 
144 3,4-OCH3 4-NO2 Y-axis competitive 
149 3,4-OCH3 3-OCH3 3. Quadrant Non-competitive mixed type 
150 3,4-OCH3 3-OCH3, 4-Br 3. Quadrant Non-competitive mixed type 
Ko143   3. Quadrant Non-competitive mixed-type 
 
Corresponding plots obtained according to the Lineweaver-Burk method are depicted in 
Figure 63. Evaluation of the intersections by the straight lines resulted in a non-
competitive “mixed type” interaction with Hoechst 33342 for compound 111, 130, 149 
and 150 and a competitive interaction for 139 and 144. Interestingly, the competitive 
compounds both contain a single para substitution which was frequently found as a 
common pattern in previous chapters. 10 
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Figure 63: Lineweaver–Burk plot for compounds 111 (a), 130 (b), 139 (c), 144 (d) and 149 (e) using 
various concentrations together with the ABCG2 substrate Hoechst 33342. Compound concentrations are 
specified in the legend.  
 
The results from the Lineweaver-Burk double reciprocal plot were validated using the 
Cornish-Bowden method, which is described in chapters 3.6 and 10.2.2.8. By linear 
regression of the Vmax and KM values the obtained slopes were summarized as scatter plot 
in Figure 64. Corresponding linear regression plots are illustrated in Figure 65 (for Ko143 
see chapter 3.6).   
 
   
e) 
d) c) 
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Figure 64: Scatter plot of the slopes obtained from the linear regression of KM (○) and Vmax (■) values 
calculated from the Cornish-Bowden direct linear plot.  
 
 
The results from the Lineweaver-Burk plot were found to be in good accordance with the 
Cornish-Bowden plot: A high competitive character was found for compounds 130, 139 
and 144 indicated by the pronounced increase of the KM values with increasing compound 
concentration. Compounds 130 and 144 also showed decreasing Vmax values indicating a 
non-competitive interaction of the “mixed type”. For compound 111, 149 and 150 on the 
other hand a considerable decrease of the Vmax values with increasing compound 
concentration was found that is typical for a non-competitive inhibitor. In summary, a 
clear competitive interaction was found for compound 139 (Vmax ↔, KM ↑), a purely non-
competitive interaction for 111, 149 and 150 (Vmax ↓, KM ↔) and a non-competitive 
interaction of the “mixed-type” for compounds 130 and 144. 
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 Figure 65: Linear regression of the Vmax (■) and KM (●) values determined from the direct linear plot 
according to Cornish-Bowden for compounds 111 (a), 130 (b), 139 (c), 144 (d) and 149 (e). Excluded 
values are depicted as open symbols of the corresponding shape. 
 
Interestingly, the findings from the kinetic investigation are in agreement with those from 
5D3 antibody assay (chapters 5.7) and even more pronounced from the ATPase assay 
(chapter 5.8). 
 
 
a) b) 
c) d) 
e) 
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5.7 Investigation of the conformation sensitive 
5D3 antibody binding to an epitope of ABCG2 
 
Selected compounds were investigated with the conformation sensitive 5D3 antibody, 
which binds specifically to an epitope of the transport protein, to explore their 
conformational impact on ABCG2. Emitted fluorescence by the bound antibody was 
measured with a FACSCalibur flow cytometer using ABCG2 overexpressing PLB-985 
cells. More information about the assay is provided in chapters 3.7 and 10.2.2.9. The 
results are presented as a bar-chart depicted in Figure 66 including Ko143 as positive 
control representing 100% labelling with the antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: 5D3 immunoreactivity modulation of ABCG2 by various compounds at different concentrations. 
Fluorescence detected by the 5D3-labeling of ABCG2 in the presence of 10 µM Ko143 was set to 100% 
and the fluorescence measured in the absence of any compound taken as 0%. The dotted line represents 
the labelling obtained with Hoechst 33342.  
 
Highest staining with 5D3 antibody was obtained for compound 139 at 10 µM resulting 
in 94% of the labelling of Ko143 at the same concentration. As presented in the previous 
chapter, 139 exhibited a clear competitive interaction with Hoechst 33342. A correlation 
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between a competitive interaction with Hoechst 33342 and the observation of high 
conformational change in the 5D3 antibody assay has already been found for several other 
compounds like 17 which was discussed in chapter 3. However, also few non-competitive 
compounds showed a similarly high amount of labelling by the antibody like 54 which 
was discussed in chapter 4. 
Moreover, compounds 130 and 131 led to an increased immunostaining with 5D3 
antibody obtaining 87% and 80% respective labelling with in comparison to Ko143. In 
the interaction investigation a highly competitive character was found for compound 130.   
Further differences were identified for the meta and para derivatives 143 and 144 
obtaining considerably different 5D3 shifts at 10 µM.  
Additionally, several dilutions of compound 144, 149 and 150 were prepared to 
investigate the concentration dependency of the rate of the bound 5D3 antibody. All three 
compounds gave an undulating rate of labelling with increasing concentrations. This 
might point toward the existence of more than one binding pocket with different affinities 
for those compounds. This hypothesis is substantiated by the results of the ATPase 
investigation discussed in the following chapter.  
Representative histograms of compounds yielding the highest and the lowest 5D3 shift in 
the assay as well as the standard Ko143 are depicted in Figure 67. Histograms of 
compounds Ko143, 139 and 150 were obtained at a compound concentration of 10, 10 
and 1 µM, respectively.   
 
   
Figure 67: Histogram of the measured fluorescence at the FL3-H detector (X-axis) and the cell-count 
gated according to the fluorescence. Depicted is the fluorescence of the isotype-control (dotted curve) as 
well as of 5D3 antibody in the absence of a compound (dashed curve) and in the presence of a compound 
(continuous curve).Compounds with the highest and lowest 5D3 shifts: Ko143 (a), 139 (b) and 150 (c) at 
a concentration of 10, 10 and 1 µM, respectively.   
 
a) b) c) 
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5.8 Investigation of the ATPase activity 
 
The assay was performed with Ko143 as standard ATPase inhibitor and quercetin as 
standard stimulator using High Five insect cell membrane preparations. The ATPase 
activity assays were carried out by Jennifer Gallus. Further details are provided in 
chapters 3.8 and 10.2.2.10.  
For the screening three different concentrations (1, 10 and 25 µM) were used and only 
the most potent compounds were selected. A summary of the results is depicted as bar 
chart in Figure 68.  
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Figure 68: Screening of ATPase activity of selected compounds at three different concentrations. From left to right the bars correspond to 1, 10 and 25 µM final 
concentration of compound. All values are relative vanadate-sensitive ATPase activities in relation to the basal activity, which is set to 100%. *Compounds 113 -119 
were investigated at a final concentration of 1 and 10 µM. Quercetin was used as a standard for activation of ABCG2 ATPase activity. 
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Investigated compounds were able to activate and also inhibit ATPase activity depending 
on the substitution pattern. The ATPase activity was modulated by meta and para nitro 
derivatives like 111/127, 131/132 and 143/144 very differently: A strong activation was 
detected for the meta derivatives comparable to quercetin. The para derivatives on the 
other hand showed increasing deactivation with higher compound concentration leading 
to a biphasic progression in the screening (see compound 112, 126, 132, 144 and 150). 
Similar effects regarding meta and para derivatives have already been observed in the 
compounds of project I and II. Additionally it was found that ether and amino functions 
containing larger alkyl residues shift the ATPase activity considerably to the deactivating 
phase. This was observed for compounds 113, 114, 116, 118 and 119 that yielded between 
80 and 25% of the basal activity at a concentration of 10 µM. The corresponding 
analogues containing smaller alkyl chains exhibited high stimulation (compound 111) or 
no effect in the case of 117, which contains a free amine group. It is possible that 
lipophilic properties of the substituents at R2 are responsible for the deactivating effect in 
the ATPase assay. 
A more detailed investigation of compounds 144, 149 and 150 at several different 
concentrations resulted in bell-shaped concentration-effect curves (see Figure 69). As 
mentioned before, this is an indication for distinct high affinity and low-affinity binding 
sites. A biphasic concentration-effect curve resulted for compound 130 (EC50: 1.03 µM), 
showing ATPase stimulation at low concentration and strong inhibition at higher 
concentration as depicted in Figure 69 a).  11 
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Figure 69: Concentration-response curves for compounds 130 (a, EC50: 1030 nM), 144 (b), 149 (c) and 
150 (d) in the ATPase assay. All values are relative vanadate-sensitive ATPase activities in relation to the 
basal activity, which is set to 100%.  
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6 Project IV: 2,4-Substituted 
pyrido[2,3-d]pyrimidines 
 
In this project the quinazoline scaffold was modified by replacing the carbon atom at 
position 8 with nitrogen resulting in a pyrido[2,3-d]pyrimidine scaffold. Substitution was 
carried out at position 2 by introducing different aromatic functions and also at position 
4 using a substituted anilino moiety. These derivatives can easily be compared to the 
compounds investigated in projects I, II and III, since they differ only in the basic scaffold 
but not in most of the substitution patterns used at the aromatic cores.  
This class of compounds was prepared by a convenient synthesis presented in the 
following chapter. It includes several substituted acid chlorides and anilines that are 
readily available, facilitating a broad variety of quick modifications of the scaffold.  
For the unsubstituted basic scaffold a logP value of 2.48 was calculated which is 1.60 log 
units lower than the quinazoline analogue. This increases the watersolubility of the 2,4-
substituted pyrido[2,3-d]pyrimidines and renders precipitation under assay conditions 
less likely.  
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6.1 Reaction mechanism  
 
A schematic synthesis route and a detailed reaction mechanism is provided below. 
Scheme 5: General synthesis scheme for the preparation of compounds 153-197.a 
 
 
a: Reagents and conditions: (i) R1COCl, Et3N, THF. (ii) 28% aq NH3, MeOH. (iii) POCl3, 
reflux, 4-12 h. (iv) Substituted aniline, 100 watt microwave irradiation, 110 °C, 2 - 10 
min.  
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Reaction mechanism A:  
In the first step methyl 2-aminonicotinate performs a nucleophilic attack at the carbonyl 
function of the substituted acid chloride using the electron pair of the nitrogen atom. 
Nucleophilic addition is followed by elimination of hydrochloric acid restoring the 
carbonyl function and also compensating the formal positive charge at the nitrogen atom. 
After formation of the amide function, hydrochloric acid is precipitated with 
triethylamine as salt to prevent protonation of the amino group in the 2-aminonicotinate 
and thereby preserve its nucleophilic character. 
 
 
 
Reaction mechanism B:  
The methoxy residue of the ester function is then substituted by ammonia, attacking the 
carbonyl function. Subsequently, ring closure is accomplished by an intramolecular 
condensation reaction: The electron pair of the previously formed amide nitrogen attacks 
the carbonyl function releasing water under formation of a N-C double bond at position 
1.  
 
 
Reaction mechanism C: 
The carbonyl function at position 4 is substituted in the presence of POCl3 via a 
chlorination reaction. The corresponding reaction mechanism follows that of chapter 4.1 
and is illustrated below. 
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Reaction mechanism D: 
Synthesis of the final compounds was conducted via nucleophilic aromatic substitution 
of the corresponding 4-chloropyrido[2,3-d]pyrimidine precursor by a substituted aniline 
derivative. The reaction mechanism is analogous to that used for the compounds in project 
I and can be reviewed in chapter 3.1.  
 
6.2 Investigation of the inhibitory potency 
toward ABCG2 in the Hoechst 33342 
accumulation assay 
 
Inhibitory potency of the compounds was investigated in a Hoechst 33342 accumulation 
assay using the ABCG2 overexpressing MDCK II BCRP and parental cell line. More 
detailed information to the Hoechst 33342 accumulation assay as is given in chapter 3.2 
and 10.2.2.2. A summary of the activity data can be reviewed in Table 20.  
In the first series a phenyl moiety was introduced at R1 in combination with different 
substituted anilines at R2 yielding compounds 162 – 177. The obtained IC50 values were 
compared to their 2-penylquinazoline analogues of project I providing information about 
the influence of the nitrogen atom at position 8.  
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Table 20: Inhibitory Activities Derived from the Hoechst 33342 Accumulations Assay Toward ABCG2 
Overexpressing MDCK II BCRP Cell Line. The Substitution Pattern is Illustrated Above the Table.12 
 
 
Compound R1 R2 Scaffold 
Hoechst 33342 
IC50 ± SD [nM]a 
 
    
162 Ph H A     149 ± 13 
163 Ph 3-NO2 A     519 ± 90 
164 Ph 3-NO2-4-OH A     528 ± 94 
165 Ph 4-NO2 A 19500 ± 4200 
166 Ph 3-CN A     400 ± 56 
167 Ph 4-CN A   1210 ± 80 
168 Ph 3-OMe A     150 ± 20 
169 Ph 4-OMe A     238 ± 18  
170 Ph 3,4-OMe A     343 ± 28 
171 Ph 3-SMe A     206 ± 36 
172 Ph 3-OH A   1230 ± 58 
173 Ph 4-OH A   2040 ± 160 
174 Ph 3-NHCOCH3 A   5270 ± 940 
175 Ph 3-CF3 A     177 ± 18 
176 Ph 3-F A     164 ± 19 
177 Ph 3-Cl A     454 ± 149 
178 3-OMe-Ph 3-NO2 A     747 ± 168 
179 3-OMe-Ph 3-NO2-4-OH A   1260 ± 140 
180 3-OMe-Ph 3-CN A     348 ± 51.6 
181 3-OMe-Ph 4-CN A     876 ± 172 
182 3-OMe-Ph 3-OH A     963 ± 220  
183 3-OMe-Ph 4-OH A   1300 ± 20 
184 3-OMe-Ph 3,4-OMe A     572 ± 8 
185 3-OMe-Ph 4-SMe A     910 ± 135 
186 3-OMe-Ph 3-NHCOCH3 A   6400 ± 2120 
187 3-OMe-Ph 3-CF3 A     264 ± 48 
188 3-OMe-Ph 4-CF3 A     425 ± 35 
189 3-OMe-Ph 3-F A     163 ± 30 
190 3-OMe-Ph 4-F A     539 ± 99 
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191 3-OMe-Ph 3,4-F A     621 ± 80 
192 3-OMe-Ph 3-Cl A     628 ± 58 
193 3-OMe-Ph 3-Br A   1530 ± 240 
194 3-Pyr 3-NO2 A          n.a. 
195 3-Pyr 4-NO2 A          n.a. 
196 3-Pyr 3-F A   1230 ± 50 
197 3-Pyr 3-OH A 16900 ± 3470 
1c Ph H B     882 ± 157  
2b Ph 3-NO2 B     130 ± 30 
3c Ph 3-NO2-4-OH B    80.0 ± 9.2 
89c Ph 4-NO2 B    69.6 ± 8.2 
4b Ph 3-CN B     140 ± 40 
5 Ph 4-CN B    71.4 ± 10.1 
11 b Ph 3-OMe B   1320 ± 100 
12 b Ph 4-OMe B   1930 ± 110 
6 Ph 4-OH B     204 ± 37 
8 Ph 3-NHCOCH3 B     278 ± 33 
20 b Ph 3-Cl B   1930 ± 280 
Ko143d        227 ± 14 
 
a: IC50 values are means of three independent experiments. 
b: IC50 value taken from literature.198  
c: Compounds synthesized in earlier study.198  
d: Used as reference in the assay. 
n.a.: not active 
 
Among the first series, the most potent compound 162 yielded an IC50 of 149 nM 
containing a phenyl group at R1 and hydrogen at R2. In contrast, the corresponding 
quinazoline analogue 1 possessed a relatively low inhibitory potency with an IC50 of 882 
nM. Interestingly, substitution patterns that had resulted in poor IC50 values at a 
quinazoline scaffold turned out to be beneficial at the pyrido[2,3-d]pyrimidine scaffold. 
Examples are compounds 168 and 169 containing a meta and para methoxy substitution 
at R2 with high inhibitory potencies of 150 and 238 nM, respectively. In comparison their 
quinazoline analogues 11 and 12 had IC50 values of only 1320 and 1930 nM. 
Concentration-response curves of highly potent compound 162 and 169 together with the 
standard inhibitor Ko143 are depicted in Figure 70.  
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Figure 70: Concentration-response curve of compound 162 (▲, IC50: 149 nM) and 169 (■, IC50: 238 
nM) in a Hoechst 33342 accumulation assay with Ko143 (○, IC50: 227 nM) as reference, using the 
ABCG2 overexpressing MDCK II BCRP cell line. 
 
Further potent compounds resulted from substitution with 3-trifluoro and 3-
trifluoromethyl groups, yielding compounds 175 and 176 which had IC50 values of 177 
and 164 nM, respectively.  
On the other hand nitro, cyano and hydroxy functions that resulted in high potencies using 
a quinazoline scaffold (see compound 2, 3, 89, 4, 5 and 6) decreased the inhibitory 
potency considerably for the 2-phenylpyrido[2,3-d]pyrimidine analogues. The observed 
inverse correlation of the inhibitory activity between most of the 2-phenylquinazoline and 
2-phenylpyrido[2,3-d]pyrimidine derivatives is illustrated in Figure 71.        
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Figure 71: Linear regression of pIC50 values determined in the Hoechst 33342 accumulation assay for 
derivatives containing the 2-phenylpyrido[2,3-d]pyrimidine scaffold A and the corresponding analogue 
containing the 2-phenylquinazoline scaffold B.a  
a: The values of some 4-substituted-2-phenylquinazolines were taken from literature, at which the IC50 
value of the 4-nitroanilino-2-phenylquinazoline derivative was re-determined and corrected.198    
 
In the next series a 3-methoxyphenyl moiety was introduced at R1. Among those, the 
highest potencies were achieved by substitution with 3-trifluoro and 3-trifluoromethyl 
groups at R2 leading to compound 187 (IC50: 264 nM) and 189 (IC50: 163 nM). A great 
resemblance in potency was found between the subsets using phenyl and the 3-
methoxyphenyl groups at R1, yielding very similar IC50 values for the corresponding 
analogues.  
A significantly decreased inhibitory potency resulted in derivatives containing 3-pyridyl 
residues at R1. Even substitution with 3-fluoro at R2, which had proven to be very 
beneficial in the previous series, led to a rather poor IC50 of 1230 nM in compound 196.     
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6.3 Investigation of the inhibitory potency toward 
ABCB1 and ABCC1 in the calcein AM assay   
 
The selectivity toward ABCG2 was screened for several compounds in a calcein AM 
assay. For this purpose, the ABCB1 overexpressing cell line A2780 adr and the ABCC1 
overexpressing cell line H69 AR were used and the assay carried out according to the 
description in chapters 3.3 and 10.2.2.4. Screening results for the inhibitory activity 
toward ABCB1 and ABCC1 are illustrated as bar charts in Figure 72.  
 
 
 
 
 
 
 
 
 
Figure 72: Inhibitory effect of screened compounds toward P-gp overexpressing cell line A2780adr (a) 
and MRP1 overexpressing cell line H69AR (b) in a calcein AM assay at a concentration of 10 µM. 
Cyclosporine A (CsA) was used as positive control, indicating complete inhibition. The inhibitory effect of 
each compound is expressed by the height of the bars, representing the inhibition compared to the 
positive control in percent. For each compound, 3 independent experiments were performed and the 
standard deviation expressed by error bars. 
 
The screening of a selection of compounds, including the most potent ones, exhibited no 
activity toward ABCB1 and ABCC1. With regard to projects I-III the presence of one or 
more methoxy functions was found to correlate with increased inhibitory potency toward 
ABCB1 and ABCC1. Although some compounds of this test set contain methoxy 
functions at R1 and R2 the selectivity toward ABCG2 was not affected. Also a slightly 
higher activity toward ABCB1 was found in comparison to ABCC1. Nevertheless, none 
a) b) 
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of the selected compounds exceeded the 25% inhibition-mark using both cell lines with 
respect to the standard inhibitor CsA. 
6.4 Investigation of the intrinsic cytotoxicity 
with the MDCK II cell lines in a MTT assay 
 
A MTT assay was conducted with MDCK II parental and ABCG2 overexpressing cells 
to investigate the intrinsic cytotoxicity of selected compounds. Measurement of the toxic 
effects was performed after 72 h incubation of the cells in the presence of different 
compound concentrations utilizing MTT as indicator of the cell viability. The procedure 
is described in more detail in chapters 3.4 and 10.2.2.5. A summary of the obtained GI50 
values together with the corresponding therapeutic ratios is depicted in Table 21. 
 
Table 21: Intrinsic Toxicity of Selected Compounds on MDCK II ABCG2 Overexpressing and Parental 
Cells 
Compound R1 R2 Scaffold 
GI50 [µM]a 
BCRP 
GI50 [µM]a 
Parental 
Therapeutic 
ratio(GI50/IC50) 
 
  
  
 
 
162 Ph H A 92   67 620 
167 Ph 4-CN A 75 140   62 
168 Ph 3-OMe A 84 120 590 
169 Ph  4-OMe A 47   47 200 
170 Ph 3-SMe A 86 110 420 
173 Ph 4-OH A 46   61   22 
175 Ph 3-CF3 A 97 120 680 
177 Ph 3-Cl A 62   98 360 
187 3-OMe-Ph 3-CF3 A 99   92 560 
189 3-OMe-Ph 3-F A 97 110 600 
1b Ph H B 27   26   30 
5 Ph 4-CN B   8.0   17 110 
6 Ph 4-OH B 12   27   60 
Ko143       13   13   49 
MeOH/DMSO       96c 140c  
 
a: Concentration leading to 50% of cell survival of MDCK II BCRP and parental cells. The data was 
    obtained from at least two independent experiments as mean values. 
b: Compound was first synthesized elsewhere.198  
c: Positive control of the cytotoxicity from dilution with DMSO/MeOH without compound. 
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The cytotoxic investigation made clear the advantage of the compounds containing a 2,4-
substituted pyrido[2,3-d]pyrimidine scaffold. They exhibited a considerably lower 
intrinsic cytotoxicity than compounds with a quinazoline scaffold as illustrated by the 
compound pairs 162/1, 167/5 and 173/6. Interestingly, some para substituents at R2 led 
to slightly decreased GI50 values in scaffold A as observed in compounds 169 and 173. 
Almost no toxic effects were detected for the meta derivatives 168, 170, 175 and 177.  
According to the high GI50 values of the compounds, which were very similar to the 
control containing only MeOH and DMSO, the observed toxic effects must mostly be due 
to the toxic effects of the solvents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 73: MTT viability assay of compound 162, 167, 169 and 173 using the ABCG2 overexpressing 
MDCK II BCRP (■) and parental MDCK II cell line (∆). For ■ a GI50 of 91.6 µM (a), 75.3 µM (b), 46.7 
µM (c) and 45.5 µM (d) was determined. A control with the same concentration of MeOH and DMSO 
analogous to the dilution of the compounds, was carried out for comparison (■, GI50 = 96.1 µM). The 
amount of MeOH and DMSO used for the dilution was ≤ 1.8% and ≤ 1.0%, respectively. 
 
a) b) 
c) d) 
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Therefore, the GI50 can probably be increased even further by reducing the amount of 
solvents which has already been demonstrated for some compounds of project II (see 
chapter 4.4). Concentration-viability curves of selected compounds 162, 167, 169 and 
173 are depicted in Figure 73. Owing to the low cytotoxic effects of compound 175, 
significantly high TRs were calculated resulting in the highest ratio of 676. A similarly 
high TR of 615 was determined for the unsubstituted compound 162. Seven out of ten 
investigated compounds based on scaffold A resulted in TRs higher than 250 making 
them promising compounds for in vivo studies. On the contrary the standard inhibitor 
Ko143 has a TR of only 48.9. An overview of the TRs is given in Figure 74. 
 
 
Figure 74: Therapeutic ratio of selected compounds, calculated from the ratio of GI50 to IC50 derived 
from MTT viability assay and Hoechst 33342 accumulation assay, respectively. The highest value was 
calculated for compound 175 (GI50/IC50 = 676), while the reference compound Ko143 yielded GI50/IC50 = 
48.9.  
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6.5 Investigation of the reversal of multidrug 
resistance  
 
The ability to reverse MDR in ABCG2 overexpressing MDCK II BCRP cell line against 
SN-38 by co-administration of the potent compounds 162, 167 and 169 was investigated 
in a MDR reversal assay. Further details are provided in chapters 3.5 and 10.2.2.6. 
Concentration-viability curves obtained for parental and ABCG2 expressing MDCK II 
cell lines are depicted in Figure 75.  13 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
                                                 
Figure continues on the next page 
a)  b) 
d) c) 
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Figure 75: MDR reversal assay of compound 162, 167 and 169 demonstrating the ability to reverse the 
MDR toward the cytostatic SN-38, using parental MDCK II and ABCG2 overexpressing cell lines (a, c 
and e). The grey arrow indicates the increasing sensitization of the ABCG2 overexpressing cells with 
higher compound concentrations (see legend). At a compound concentration of 1 µM, full reversal is 
achieved, indicated by a similar pEC50 as the parental cells. For comparison an analogous assay was 
performed using only parental MDCK II cells (b, d and f).  
a: Parental MDCK II cells.   
 
Full reversal of the resistance toward SN-38 was produced by selected compounds 162, 
167 and 169 at a concentration below 10 µM, indicated by comparable EC50 values of the 
parental cells and the ABCG2 expressing cells. The increasing sensitization of the 
ABCG2 expressing cells is visualized by the grey arrow in Figure 75 a), c) and e).  
An analogous assay using only parental cells was carried out to consider possible side 
effects that might influence the reversal of MDR. Indeed, no such effects could be 
observed in the parental cell line obtaining comparable EC50 values from the 
concentration-viability curves in Figure 75 b), d) and f).  
Determination of the extent of reversal by the compounds was carried out by plotting the 
pGI50 values from the MDR reversal assay against the logarithm of the corresponding 
compound concentration. Hereby, sigmoidal curves were fitted with the logistic equation 
and the EC50 calculated for each compound. Maximum inhibition is given by the top value 
of the parental cells which should be comparable to the top value obtained with the 
ABCG2 expressing cells indicating the state “total inhibition”. The corresponding plot is 
illustrated in Figure 76.  
e) f) 
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Figure 76: Nonlinear regression of the pGI50 values determined in the viability assay (Figure 75 a), c) 
and e)) and the corresponding concentration of compound 162, 167 and 169. Correlation of the degree of 
sensitization toward SN-38, indicated by the pEC50 value, an EC50 of 42.9 nM (162), 319 nM (167) and 
53.8 nM (169) was determined (●). Compound 162, 167 and 169 yielded IC50 values of 149 nM, 1206 
nM and 238 nM in the Hoechst 33342 accumulation assay, respectively. A nonlinear regression of the 
pEC50 values determined in an analogous efficacy assay Figure 75 b), d) and f)), but using only parental 
MDCK II cells, is depicted with open circles (○).  
 
According to the plot EC50 values of 42.9, 319 and 53.8 nM resulted for compound 162, 
167 and 169, respectively. Indeed, the inhibitory potency derived from the MDR reversal 
is about 4-fold higher than determined in the Hoechst 33342 accumulation assay. Yet, the 
tendency of the inhibitory potency obtained in both assays is in excellent accordance. 
Higher inhibitory activities in the MDR reversal assay in comparison to the Hoechst 
33342 accumulation assay have also been observed for other compounds discussed in 
project I-III and could be due to a lower affinity of SN-38 to ABCG2. 
a) b) 
c) 
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Moreover, the sensitization of ABCG2 overexpressing MDCK II BCRP cell line toward 
the cytostatic drug MX was investigated in co-administration of compound 144 and 150. 
The assay was carried out at different compound concentrations in the presence and 
absence of 0.5 µM MX. Further details of the assay are provided in chapters 3.5 and 
10.2.2.7. Both compounds were able to reverse the resistance of the cells toward MX, as 
illustrated in Figure 77. 
 
 
 
 
 
Figure 77: MDR reversal assay of compounds 162 (a) and 169 (b), demonstrating their ability to reverse 
MDR toward the cytostatic mitoxantrone (MX), in the ABCG2 overexpressing cell line MDCK II BCRP. 
The bars represent the cell viability at a given modulator concentration in the presence (light grey) and 
absence (dark grey) of 0.5 µM mitoxantrone. Control shows viability of cells without modulator. The 
standard deviation is expressed by error bars.   
 
Full reversal of the resistance toward MX was resulted with both compounds at a 
concentration between 0.1 and 1 µM. The half-maximal growth inhibition was obtained 
by compound 162 and 169 at a concentration of 8.61 and 20.9 nM, respectively. Due to 
fewer measurements, the determined values in the MDR reversal assay with MX are more 
susceptible to error than with SN-38, but still provide a good estimation of the efficacy 
of a compound. Compound 162 was distinguished as more potent than 169, which is in 
agreement to the Hoechst 33342 accumulation assay and the MDR reversal assay with 
SN-38. 
a) b) 
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6.6 Investigation of the interaction with Hoechst 
33342 
 
Investigation of the interaction of selected compounds with Hoechst 33342 was carried 
out with ABCG2 overexpressing MDCK II BCRP cells. For this purpose, varying 
compound concentrations were combined with varying concentrations of Hoechst 33342 
and the interaction type could be determined by using the Lineweaver-Burk double 
reciprocal plot, described in chapters 4.6 and 10.2.2.8.  
The results obtained with the Lineweaver-Burk method is depicted in Table 22, providing 
the intersection of the straight lines together with the corresponding interpretation. 
Corresponding plots obtained according to the Lineweaver-Burk method are depicted in  
Figure 78.   
 
 Table 22: Interaction with Hoechst 33342 According to the Lineweaver-Burk Double Reciprocal Plot. 
 
Compound R1 R2 Intersection  
type of interaction  
with Hoechst 33342 
162 Ph H X-axis Non-competitive 
166 Ph 3-CN 3. Quadrant Non-competitive mixed type 
167 Ph 4-CN 3. Quadrant Non-competitive mixed type 
168 Ph 3-OMe X-axis Non-competitive 
169 Ph 4-OMe Y-axis Competitive 
178 3-OMe-Ph 3-NO2 X-axis Non-competitive 
181 3-OMe-Ph 4-CN 2. Quadrant Non-competitive mixed type 
188 3-OMe-Ph 4-CF3 2. Quadrant Non-competitive mixed type 
Ko143   3. Quadrant Non-competitive mixed-type 
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By evaluation of the intersections of the straight lines a non-competitive “mixed type” 
interaction with Hoechst 33342 was determined for compounds 166, 167, 181 and 188. 
A pure non-competitive interaction was found for compounds 162, 168 and 178 and a 
competitive interaction exclusively for compound 169. According to the results 
obtained for the test set, this class of compounds, except one compound, does not 
compete for the same binding pocket with Hoechst 33342. Indeed, the majority exhibits 
a non-competitive of the “mixed-type” meaning that they are able to influence the active 
site but bind apart from Hoechst 33342. 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
Figure continues on the next page 
a) b) 
c) d) 
6 Project IV: 2,4-Substituted pyrido[2,3-d]pyrimidines 156
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 78: Lineweaver–Burk plot for compounds 162 (a), 166 (b), 167 (c), 168 (d), 169 (e), 178 (f), 181 
(g) and 188 (h) using various concentrations together with the ABCG2 substrate Hoechst 33342. 
Compound concentrations are specified in the legend.  
 
Additionally, the results from the Lineweaver-Burk double reciprocal plot were validated 
using the Cornish-Bowden method. Information regarding this procedure is provided in 
chapters 3.6 and 10.2.2.8. The linear regression of the Vmax and KM values resulted in 
slopes that were summarized as scatter plot in Figure 79. Corresponding linear regression 
plots are illustrated in Figure 80 (for Ko143 see chapter 3.6). 
e) f) 
g) h) 
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Figure 79: Scatter plot of the slopes obtained from the linear regression of KM (○) and Vmax (■) values 
calculated from the Cornish-Bowden direct linear plot.  
 
Results obtained with the Cornish-Bowden method are consistent with the corresponding 
Lineweaver-Burk plots. Thus, compound 162, 166, 168, 178, 181 exhibit a more 
pronounced non-competitive interaction (Vmax ↓) and 167, 169 and 188 a rather 
competitive interaction (KM ↑), as indicated by the slopes of the regression of the KM and 
Vmax values in the Cornish-Bowden plot. 15 
 
 
 
 
 
 
                                                 
Figure continues on the next page 
a) b) 
6 Project IV: 2,4-Substituted pyrido[2,3-d]pyrimidines 158
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80: Linear regression of the Vmax (■) and KM (●) values determined from direct linear plot for 
compounds 162 (a), 166 (b), 167 (c), 168 (d), 169 (e), 178 (f), 181 (g), and 188 (h). Excluded values are 
depicted as open symbols of the corresponding shape. 
 
 
c) d) 
e) f) 
g) h) 
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The para cyano analogues 167 and 5 (see chapter 3.6) contain different scaffolds but both 
exhibited a noticeable competitive portion whereas the corresponding meta derivatives 
166 and 4 showed a rather non-competitive interaction with Hoechst 33342. Another 
example is compound pair 168 and 169 containing 3-OMe and 4-OMe at R1. Here the 
meta derivative shows a non-competitive and the para derivative a competitive 
interaction with Hoechst 33342. This points to the extraordinary impact of the choice of 
substitution and position at R1 (meta vs. para) influencing the inhibitory potency, the 
binding to ABCG2, and other aspects as well. 
 
6.7 Investigation of the conformation sensitive 
5D3 antibody binding to an epitope of ABCG2 
 
The conformational impact on ABCG2 of selected compounds was investigated using the 
conformation sensitive 5D3 antibody. The antibody binds specifically to an epitope of the 
transport protein and the emitted fluorescence by the bound antibody was measured with 
a FACSCalibur flow cytometer utilizing ABCG2 overexpressing PLB-985 cells. Further 
information is provided in chapters 3.7 and 10.2.2.9. A bar-chart summarizes the results 
of this assay using Ko143 as positive control representing 100% labelling with the 
antibody, as depicted in Figure 81.  
Among selected compounds the highest labelling was observed for compound 167 
containing 4-cyano at R1 with a labelling-rate of 93% compared to the standard Ko143. 
In contrast, the 3-cyano derivative 166 possesses a labelling of 63% with the 5D3 
antibody pointing out the distinction between meta and para derivatives. Also, a high 
labelling resulted for compound 181, another 4-cyano derivative. This is in accordance to 
the observations in project I where compound 5 exhibited a high rate of labelling 
containing a 4-cyano substituent on a 2-phenylquinazoline scaffold. 
 
 
 
6 Project IV: 2,4-Substituted pyrido[2,3-d]pyrimidines 160
 
Figure 81: 5D3 immunoreactivity modulation of ABCG2 at a compound concentration of 10 µM. 
Fluorescence detected by the 5D3-labeling of ABCG2 in the presence of 10 µM Ko143 was set to 100% 
and the fluorescence measured in the absence of any compound taken as 0%. The dotted line represents 
the labelling obtained with Hoechst 33342.  
 
However, only a minor difference was observed for the meta and para methoxy 
derivatives 168 and 169. Interestingly, the difference in the Hoechst 33342 accumulation 
assay was also less pronounced, although both compounds showed different interactions 
with Hoechst 33342. 
Very little labeling of only 41% was found for compound 178 containing 3-methoxy at 
R1 and 3-nitro at R2. Due to the fact that the obtained labelling is similar to that of 
Quercetin and Hoechst 33342 it is possible that compound 178 could be transported by 
ABCG2, at least to some extent. To substantiate this claim some more data would have 
to be collected from different assays. According to the cytotoxicity data and the conducted 
fluorescence experiments, no indication was found that the compounds are substrates of 
ABCG2.     
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Furthermore, representative histograms of compounds with the highest and the lowest 
5D3 shift in the assay as well as the standard Ko143 are depicted in Figure 82. Histograms 
of compounds Ko143, 166 and 167 were obtained at a compound concentration of 10 
µM, respectively.   
 
 
Figure 82: Histogram of the measured fluorescence at the FL3-H detector (X-axis) and the cell-count 
gated according to the fluorescence. Depicted is the fluorescence of the isotype-control (dotted curve) as 
well as of 5D3 antibody in the absence of a compound (dashed curve) and in the presence of a compound 
(continuous curve).Compounds with the highest and lowest 5D3 shifts: Ko143 (a), 166 (b) and 167 (c) at 
a concentration of 10 µM.   
 
6.8 Investigation of the ATPase activity 
 
For this purpose Ko143 was used as standard ATPase inhibitor and quercetin as standard 
stimulator using High Five insect cell membrane preparations. The ATPase activity 
assays were performed by Jennifer Gallus. Further details are provided in chapters 3.8 
and 10.2.2.10. Three different compound concentrations (1, 10 and 25 µM) were used in 
the screening, including the most potent compounds. A summary of the results is 
illustrated as bar chart in Figure 83.  
 
 
a) b) c) 
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Figure 83: Screening of ATPase activity of selected compounds at three different concentrations. From 
left to right the bars correspond to 1, 10 and 25 µM final concentration of compound. Quercetin was used 
as a standard for activation of ABCG2 ATPase activity. All values are relative vanadate-sensitive ATPase 
activities in relation to the basal activity, which is set to 100%. 
 
All investigated compounds led to either medium or strong activation of the ATPase 
activity. Differences were in particular noticeable for the meta and para compound pairs 
containing the same substituent. This is illustrated by compound 166/167 and 168/169 
containing either a cyano or methoxy group at R2. Both substituents led to a considerably 
higher ATPase stimulation when present in meta position compared to the para 
substitution.  
Considerably higher rates of ATPase stimulation resulted for substitution with 3-methoxy 
than with hydrogen at R1, as illustrated in the compound pairs 163/178, 180/166, 167/181 
and 176/189. Among those, compound 178 and 189 led to an extraordinary strong 
stimulation of the ATPase activity, in part even stronger than the standard stimulator 
quercetin. Corresponding concentration-response curves of compound 168, 169 and 178 
carried out with more concentrations each led to a sigmoidal curve progression illustrated 
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in Figure 84. Here, EC50 values for compound 168, 169 and 178 were calculated as 118, 
9.28 and 18.0 nM where the standard stimulator quercetin obtained an EC50 of only 302 
nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 84: Concentration-response curves for compounds 168 (a, EC50: 118 nM), 169 (b, EC50: 9 nM) 
and 178 (c, EC50: 18 nM) in the ATPase assay. All values are relative vanadate-sensitive ATPase 
activities in relation to the basal activity, which is set to 100%.  
 
Compound 167, 181 and 184 on the other hand exhibited a strong decrease of the activity 
with higher compound concentrations. Previous investigation of the conformation 
sensitive 5D3 antibody binding resulted in the highest labelling for compounds 167 and 
181 (see chapter 6.7). Moreover, these two compounds were also found to possess high 
portions of competitive interaction with Hoechst 33342 (see chapter 6.6). In many cases, 
low ATPase activity levels correlated with a high rate of labelling by 5D3 antibody and 
a pronounced competitive character of interaction with Hoechst 33342.  
b) a) 
c) 
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7 Project V: 2,4-Substituted 6-
nitroquinazolines 
 
In this project a nitro function was introduced at position 6 of a 2,4-substituted 
quinazoline scaffold. The impact of this modification can easily be compared to the 
previously discussed compounds of project I-III. The introduced nitro group is a HBA 
function and decreases the electron density at the quinazoline moiety. For better insights 
into the SAR, reduction of the nitro moiety was carried out yielding an amino function at 
position 6. This aromatic amine on the other hand is a HBD function and increases the 
electron density at the quinazoline scaffold. Due to the large conjugated pi-system a 
strong fluorescence could be observed in some amino derivatives after excitation. In 
contrary, compounds containing nitro functions showed no fluorescence owing to 
quenching effects. Fluorescence measurements of compound 244 are provided in chapter 
8.10, discussing the possibility of a substrate character. Further modification was 
achieved by reacting the amino function with aromatic acid chlorides. Formed amides 
contain both, a HBD and HBA function and also a bulky aromatic residue. 
Although a relatively low logP value of 3.81 was calculated for the unsubstituted 6-nitro 
derivative 211, some compounds showed a reduced solubility during preparation of the 
dilution series. Hence, the amount of MeOH was increased for some compounds, but kept 
below 5% in the final concentration to prevent damage of the cells.  
 
7.1 Reaction mechanism  
 
A schematic synthesis route and a detailed reaction mechanism is provided on the 
following page. 
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Scheme 6. General synthesis scheme for the preparation of compounds 198-248.a 
 
 
a: Reagents and conditions: (i) Triphosgene, THF, reflux, 3h. (ii) NH3, 50 °C, 30 min.  
(iii) I2, K2CO3, DMF, 90-110 °C, 8-12 h (iv) POCl3, reflux, 4-12 h. (v) Substituted aniline, 
100 watt microwave irradiation, 110 °C, 20-40 min. (vi) BBr3, DCM, -60°C → RT, 12 h. 
(vii) THF, 4 bar H2, Pd/C, RT, 24 h. (viii) RCOCl, THF, 0 °C → RT, 6-12 h. 
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Reaction mechanism A:  
Initially, triphosgene dissociates in phosgene molecules at high temperature that react as 
electrophiles. The amino and the hydroxy function of the 2-amino-5-nitrobenzoic acid 
perform a nucleophilic attack at the positively polarized carbon atom of the phosgene 
molecule performing an intramolecular ring-closure and releasing hydrochloric acid. The 
underlying mechanism is an addition-elimination reaction.  
 
 
Reaction mechanism B: 
The cyclic organic acid anhydride reacts in situ with ammonium gas opening the ring by 
nucleophilic attack at the carbonyl function at position 4. Due to the instability of the N-
substituted carbamic acid group it reverts to carbon dioxide forming an amino function 
and yielding 2-amino-5-nitrobenzamide. 
 
 
Reaction mechanism C:  
In the first step, 2-amino-5-nitrobenzamide attacks the carbonyl function of the aldehyde 
derivative with its amino function via nucleophilic addition followed by elimination of 
H2O. Ring-closure is achieved via nucleophilic addition by the amide nitrogen atom at 
the initially formed imine double bond depicted below. In the last step, a double bond 
between position 1 and 2 is inserted by oxidation with elemental iodine.  
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Reaction mechanism D: 
The carbonyl function at position 4 undergoes chlorination in the presence of POCl3. The 
corresponding reaction mechanism is illustrated below and can be reviewed in chapter 
4.1. 
 
 
 
Reaction mechanism E: 
Final compounds were synthesized via nucleophilic aromatic substitution of the 
corresponding 4-chloro-6-nitroquinazoline precursor by a substituted aniline derivative. 
The reaction mechanism is analogous to that used for the compounds in project I and can 
be reviewed in chapter 3.1.  
 
Reaction mechanism F:  
Boron tribromide reacts with the methyl ether functions of compound 20 as an 
electrophile which is attacked by the free nucleophilic electron pairs of the oxygen atom 
leading to an elimination of a bromine atom. The released bromide ions attack the methyl 
residues of the ether functions in a nucleophilic substitution reaction forming 
bromomethane and O-dibromoborane. Work up with water results in the formation of an 
aromatic hydroxy function.     
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Reaction mechanism G: 
The nitro function at position 6 can be reduced using palladium on carbon as a catalyst in 
the presence of hydrogen gas in a catalytic hydrogenation reaction. Hereby, the nitro 
function is reduced to an amino function. 
 
Reaction mechanism H:  
Previously formed amino function at position 6 performs a nucleophilic attack at the 
carbonyl function of the substituted acid chloride. Nucleophilic addition is followed by 
elimination of hydrochloric acid to restore the carbonyl function and compensate formal 
charges at the nitrogen atom to obtain an amide function. In the case of compound 245 a 
second addition-elimination reaction occurred yielding an iminoethyl acetate function. 
Hydrochloric acid was precipitated as salt formed with triethylamine. 
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7.2 Investigation of the inhibitory potency 
toward ABCG2 in the Hoechst 33342 
accumulation assay 
 
Investigation of the inhibitory potency of the compounds was carried out in a Hoechst 
33342 accumulation assay using the ABCG2 overexpressing MDCK II BCRP and 
parental cell line. Additional information to the Hoechst 33342 accumulation assay as is 
provided in chapter 3.2 and 10.2.2.2. The resulting activity data is given in Table 23.  
Table 23: Inhibitory Activities Derived from the Hoechst 33342 Accumulations Assay Toward ABCG2 
Overexpressing MDCK II BCRP Cell Line. The Substitution Pattern is Illustrated Above the Table.16 
 
  
Compound R1 R2 
 
 
R3 
Hoechst 33342 
IC50 ± SD [nM]a 
     
211 Ph H NO2   106 ± 15 
212 Ph 3-NO2-4-OH NO2  37.4 ± 5.0 
213 Ph 3-CN NO2  48.2 ± 7.7 
214 Ph 4-CN NO2  48.1 ± 9.2 
215 Ph 3-OH NO2  65.3 ± 9.7 
216 Ph 3,4-OH NO2   119 ± 17 
217 Ph 3-OMe NO2  33.1 ± 5.6 
218 Ph 3,4-OMe NO2  37.0 ± 5 
219 Ph 3-NHCOCH3 NO2  78.7 ± 13.5 
220 Ph 3-F NO2  51.5 ± 9.8 
221 Ph 3-CF3 NO2  49.1 ± 5.8 
222 Ph 3-CO2H NO2   904 ± 17 
223 4-Pyr 3-CN NO2  63.8 ± 13.2 
224 3-Pyr 3-OMe NO2  47.0 ± 4.0 
225 3-Pyr 4-OMe NO2  57.7 ± 7.0 
226 4-Pyr 4-OMe NO2  75.5 ± 14.4 
227 3-CF3-Ph H NO2  59.6 ± 8.00 
                                                 
Table continues on the next page 
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228 3-CF3-Ph 3-NO2-4-OH NO2  33.0 ± 4.7 
229 3-CF3-Ph 3-NO2 NO2  66.3 ± 13.3 
230 3-CF3-Ph 4-NO2 NO2  61.4 ± 5.7 
231 3-CF3-Ph 3-OH NO2  27.6 ± 2.4 
232 3-CF3-Ph 3-OMe NO2  59.0 ± 5.9 
233 3-CF3-Ph 3,4-OMe NO2  30.2 ± 4.3 
234 3-CF3-Ph 3-SMe NO2   101 ± 16 
235 3-CF3-Ph 3-F NO2  44.8 ± 6.2 
236 3-CF3-Ph 3-NHCOCH3 NO2  44.8 ± 4.4 
237 3-OMe-Ph 4-CN NO2  27.8 ± 3.8 
238 3-OMe-Ph 3-F NO2  23.4 ± 3.4 
239 3,4-OMe-Ph 3-CF3 NO2  57.2 ± 7.9 
240 3-Pyr 3-OMe NH2    369 ± 54 
241 3-Pyr 4-OMe NH2   646 ± 69 
242 3-CF3-Ph H NH2   726 ± 49 
243 3-CF3-Ph 3-OH NH2   799 ± 159 
244 3-CF3-Ph 3-OMe NH2   835 ± 113 
245 3-Pyr 3-OMe N-1-Iminoethyl acetate 5310 ± 240 
246 3-Pyr 3-OMe N-3-Nitrobenzamide 1150 ± 190 
247 3-Pyr 4-OMe N-3-Nitrobenzamide 1620 ± 70 
248 3-Pyr 3-OMe N-Nicotinamide 1040 ± 80 
1b Ph H H   882 ± 157 
3 Ph 3-NO2-4-OH H  80.0 ± 9.1 
5 Ph 4-CN H  69.9 ± 10 
13b Ph 3,4-OMe H   152 ± 19 
18 Ph 3-F H   355 ± 53 
8 Ph 3-NHCOCH3 H   278 ± 33 
Ko143c      227 ± 14 
     
 
a: IC50 values are means of three independent experiments. 
b: Compounds synthesized in earlier study.198  
c: Used as reference in the assay. 
 
The significant impact of the 6-nitro function on the inhibitory activity toward ABCG2 
becomes evident by comparison of the unsubstituted compounds 211 and 1. A 
considerable increase in potency was obtained in the presence of a 6-nitro group resulting 
in an IC50 of 106 nM whereas the unsubstituted scaffold without 6-nitro obtained an IC50 
of 882 nM.  
In the first series of compounds containing a phenyl moiety at R1 and 6-nitro were 
investigated with different substituents at R2. All compounds showed a considerable 
increase in potency in comparison to the corresponding analogues lacking a 6-nitro group 
which is illustrated in the compound pairs 211/1, 212/3, 214/5, 218/13, 219/8 and 220/18.  
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Substitution with 3-nitro-4-hydroxy, 3-methoxy and 3,4 methoxy at R2 led to 
corresponding compounds 212, 217 and 218 which all obtained excellent IC50 values 
below 40 nM. The lowest potency among this subset resulted for compound 222 (IC50: 
904 nM) containing a carboxylic acid function. This is probably due to a decreased 
membrane permeability of the anionic species due to deprotonation under physiological 
conditions.  
Replacement of the phenyl residue with 3- and 4-pyridyl functions yielded the highly 
potent compounds 223-226 with IC50 values in the range of 47 to 76 nM. Owing to the 
pyridyl function this modification decreased the logP value considerably in comparison 
to a phenyl moiety resulting in an enhanced solubility.  
Subsequently, a trifluoromethyl substituent was introduced at R2. Again, increased 
inhibitory activities were observed in the highly potent compounds 228 (R2: 3-nitro-4-
hydroxy), 231 (R2: 3-hydroxy) and 233 (R2: 3,4-dimethoxy) which possessed rather low 
IC50 values of roughly 30 nM.  
Since substitution with methoxy and fluoro groups turned out to be beneficial for high 
potencies, 3-methoxy and 3,4-dimethoxy functions were subsequently introduced at R1. 
A substitution with 3-methoxy at R1 and 3-fluoro at R2 was found to lead to the highest 
inhibitory potency among the whole test set. The calculated IC50 value of 23 nM for 
compound 238 is approximately 10-fold lower than that of Ko143. Corresponding 
concentration-response curves of the two most potent compounds 237 and 238 together 
with the reference Ko143 are illustrated in Figure 85. Overall, 29 different compounds 
containing a 6-nitro function were synthesized possessing an extraordinary low average 
IC50 value of roughly 85 nM.  
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Figure 85: Concentration-response curve of compound 237 (□, IC50: 27.8 nM) and 238 (▲, IC50: 23.4 
nM) in a Hoechst 33342 accumulation assay with Ko143 (■, IC50: 227 nM) as reference, using the 
ABCG2 overexpressing MDCK II BCRP cell line. 
 
The reduction of the nitro function at position 6 yielded the corresponding amino 
derivatives 240-244 that led to a considerable decrease in the inhibitory potency of about 
10-fold or higher which is illustrated in the compound pairs 240/224, 241/225, 242/227, 
243/231 and 244/232. It is reasonable that HBA functions like nitro are significantly more 
beneficial than HBD functions like amino. Also, differences in the IC50 values were 
noticeable for the meta/para methoxy compound pair 240/241 which is a common 
phenomenon throughout all projects.  
Following, the reaction of the 6-amino functions with substituted acid chlorides yielded 
an amido function mostly linked to a bulky aromatic residue. Unfortunately, the inhibitory 
potency decreased further in comparison to their amine analogues.  
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7.3 Investigation of the inhibitory potency 
toward ABCB1 and ABCC1 in the calcein 
AM assay   
 
A calcein AM assay was performed to screen the selectivity of several compounds toward 
ABCG2. For the assay the ABCB1 overexpressing cell line A2780 adr and the ABCC1 
overexpressing cell line H69 AR were used. Further details regarding the assay are 
described in chapters 3.3 and 10.2.2.4. Screening results regarding the inhibitory activity 
toward ABCB1 and ABCC1 are depicted as bar charts in Figure 86. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 86 Inhibitory effect of screened compounds toward ABCB1 overexpressing cell line A2780adr (a) 
and MRP1 overexpressing cell line H69AR (b) in the calcein AM assay at a concentration of 10 µM. 
Cyclosporine A (CsA) was used as positive control, indicating complete inhibition. The inhibitory effect of 
each compound is expressed by the length of the bars, representing the inhibition compared to the 
positive control in percent. For each compound, three independent experiments were performed and the 
standard deviation is expressed by error bars. 
 
a) 
b) 
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The screening comprises several of the most potent compounds including some 6-amino 
derivatives and only negligible inhibitory activity less than 25% was found in comparison 
to CsA. This is surprising since some activity was found for compounds of project I-III 
containing one or more methoxy groups. Even compound 233 containing a substitution 
with 3,4-dimethoxy showed no measurable inhibitory activity toward ABCB1 and 
ABCC1. 
 
7.4 Investigation of the intrinsic cytotoxicity with 
the MDCK II cell lines in a MTT assay 
 
The intrinsic cytotoxicity of selected compounds was studied in a MTT assay using 
MDCK II parental and ABCG2 overexpressing cells. Toxic effects were determined after 
72 h incubation of the cells in the presence of different compound concentrations and the 
cell viability was detected using MTT as indicator. Additional details of the procedure 
are provided in chapters 3.4 and 10.2.2.5 and a summary of the obtained GI50 values and 
the corresponding therapeutic ratios is depicted in Table 24. 
In the development of medicinal drugs nitro functions have frequently been found to 
increase cytotoxicity. The same applies to the 6-nitro derivatives that were investigated 
in this project. Distinctive differences regarding the toxic effects were observed in 
compounds bearing a 6-nitro function and the corresponding analogues lacking that 
function. This is illustrated in the compound pairs 211/1, 212/3 and 218/13 resulting in 
GI50 values of 18/27, 13/52 and 8/23 µM, respectively. Nevertheless, relatively high TRs 
were calculated owing to the extraordinarily high inhibitory potency of the majority of 
compounds. For instance, most potent compound 238 obtained a very poor GI50 of 4.38 
µM but resulted in a TR of 187 which is still significantly better than Ko143 (TR: 48.9).  
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Table 24: Intrinsic Toxicity of Selected Compounds on MDCK II ABCG2 Overexpressing and Parental 
Cells. 
 
Compound R1 R2 
 
 
 
R3 
 
 
GI50 [µM]a 
BCRP 
GI50 [µM]a 
Parental 
 
 
Therapeutic 
ratio 
(GI50/IC50)b 
 
      
211 Ph H NO2 18   36   170 
212 Ph 3-NO2-4-OH NO2 13     9.8   350 
217 Ph 3-OMe NO2   5.5     6.9   170 
218 Ph 3,4-OMe NO2   8.1     8.5   220 
223 4-Pyr 3-CN NO2 77 100 1200 
226 4-Pyr 4-OMe NO2 85 130 1100 
228 3-CF3-Ph 3-NO2-4-OH NO2 27   24   830 
231 3-CF3-Ph 3-OH NO2   3.4    3.0   120 
233 3-CF3-Ph 3,4-OMe NO2   3.6    3.2   120 
237 3-OMe-Ph 4-CN NO2 11    9.1   400 
238 3-OMe-Ph 3-F NO2   4.4   11   190 
241 3-Pyr 4-OMe NH2 19   28     31 
1 Ph H H 27   26     30 
3 Ph 3-NO2-4-OH H 52 150   660 
13 Ph 3,4-OMe H   23 17   150 
Ko143        13 13     49 
MeOH/DMSO        96c 140c  
 
 
a: Concentration leading to 50% of cell survival of MDCK II BCRP and parental cells. The data was   
obtained from at least two independent experiments as mean values. 
b: Therapeutic ratio was calculated from the ratio of the GI50 [µM] obtained with BCRP expressing cells 
and the IC50 [µM] obtained from the Hoechst 33342 assay. 
c: Positive control of the cytotoxicity from dilution with DMSO/MeOH without compound. 
 
Among the 6-nitro derivatives only substitution with 4-pyridyl at R1 yielded compounds 
demonstrating a significantly low intrinsic cytotoxicity. Examples are compound 223 
(GI50: 77 µM) and 226 (GI50: 85 µM) leading to the highest TR in this project with ratios 
of 1212 and 1119, respectively. Similar effects were observed in project II where the 
replacement of phenyl at position 2 with a pyridyl moiety led to a substantial decrease of 
the intrinsic cytotoxicity (see chapter 3.4 and 4.4).  
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A concentration-cell viability curve of compound 223, 226, 238 and a dilution series 
without compound is presented in Figure 87. 
 
Figure 87: MTT viability assay of compounds 223 (○), 226 (□), and 238 (∆) using the ABCG2 
overexpressing MDCK II BCRP cell line. The GI50 values were determined as 84.5 µM (□), 77.3 µM (○) 
and 9.46 µM (∆), respectively. A control with the same concentration of MeOH and DMSO analogues to 
the dilution of the compounds, was carried out for comparison (■, GI50 = 96.1 µM). The amount of 
MeOH and DMSO used for the dilution was ≤ 1.8% and ≤ 1.0%, respectively. 
 
An overview of the TRs obtained by selected compounds is given in Figure 88, 
summarizing that the majority of the investigated compounds yielded values higher than 
100. Indeed, this is more than two-fold higher with respect to the standard inhibitor Ko143 
which is often labelled as “nontoxic” at effective concentrations in literature. Although 
the compounds of project V exhibited a relatively high cytotoxicity in comparison to other 
projects, they still obtain good TRs owing to their high inhibitory potency. 
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Figure 88: Therapeutic ratio of selected compounds, calculated from the ratio of GI50 to IC50 derived 
from MTT viability assay and Hoechst 33342 accumulation assay, respectively. The highest value was 
calculated for compound 223 (GI50/IC50 = 1212), while the reference compound Ko143 yielded GI50/IC50 
= 48.9.  
 
Besides 223 and 226, also compound 228 yielded a good TR containing a disubstitution 
with 3-nitro-4-hydroxy at R2 which has proven to be beneficial regarding a high inhibitory 
potency toward ABCG2 and low cytotoxicity. Similar results have already been detected 
for compound 3 which contained the same substitution and was one of the most attractive 
candidates among the compounds of project I.  
In particular compounds 223 and 226 that contain a 4-pyridyl residue are promising 
candidates for in vivo investigations due to a low cytotoxicity, enhanced watersolubility 
and high inhibitory potency toward ABCG2.   
 
7.5 Investigation of the reversal of multidrug 
resistance  
 
The ability to reverse MDR in ABCG2 overexpressing MDCK II BCRP cell line toward 
SN-38 by co-administration of the potent compounds 212, 228 and 238 was investigated 
in a MDR reversal assay. Further details are provided in chapters 3.5 and 10.2.2.6. 
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Corresponding concentration-viability curves obtained for parental and ABCG2 
expressing MDCK II cell lines are depicted in Figure 89. Full reversal of the resistance 
of the ABCG2 overexpressing MCDK II BCRP cells toward SN-38 was observed for 
compounds 212, 228 and 238 at concentrations less than 1 µM. A full sensitization of the 
ABCG2 overexpressing cells is indicated by comparable GI50 values in the resistant and 
parental cell line. The increasing sensitization with increasing compound concentrations 
is marked by the grey arrow in Figure 89 a), c) and d). 17 
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Figure 89: MDR reversal assay of compound 212, 228 and 238 demonstrating the ability to reverse the 
MDR toward the cytostatic drug SN-38, using parental MDCK II and ABCG2 overexpressing cell lines 
(a, c, e). The dashed arrow indicates the increasing sensitization of the BCRP overexpressing cells with 
higher compound concentrations (see legend). At a compound concentration of 1 µM, full reversal is 
achieved, indicated by a similar pGI50 as the parental cells. For comparison an analogous assay was 
performed using only parental MDCK II cells (b, d and f). a: Parental MDCK II cells.   
 
An analogous assay using only parental cells was carried out to evaluate possible effects 
between cells, inhibitor and SN-38 that could affect the pGI50 value. The obtained 
concentration-viability curves of the corresponding compounds exhibited no shift in the 
pGI50 values as illustrated in Figure 89 b), d) and f) indicating no side-effects.  
For a clear visualization of the obtained results, the pGI50 values from the MDR reversal 
assay were plotted against the logarithm of the corresponding compound concentration. 
Herby, a sigmoidal concentration-effect curve can be fitted with the logistic equation 
yielding EC50 values characterizing the extent of MDR reversal by a compound as 
depicted in Figure 90.  
 
 
 
 
 
e) f) 
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Figure 90: Nonlinear regression of the pGI50 values determined in the viability assay Figure 89 a), c) and 
e) in presence of different concentrations of compound 212, 228 and 238. Correlation of the degree of 
sensitization toward the corresponding cytostatic drug, indicated by the pEC50 value, an EC50 of 34.0 nM 
(212) 57.0 nM (228) and 51.5 nM (238) was determined (●). Compound 212, 228 and 238 yielded IC50 
values of 37.4 nM, 33.0 nM and 23.4 nM in the Hoechst 33342 accumulation assay, respectively. A 
nonlinear regression of the pGI50 values determined in an analogous efficacy assay (Figure 89 b), d) and 
f)), but using only parental MDCK II cells, is depicted with open circles (○).  
 
From the sigmoidal curves EC50 values of 34 nM, 57 nM and 52 nM were calculated for 
compounds 212, 228 and 238, respectively. Those IC50 values were slightly higher in 
compounds 228 and 238 compared to the Hoechst 33342 accumulation assay, whereas 
212 exhibited only negligible differences in both assays. A possible reason for the lower 
potency in the MDR reversal assay could be solubility problems that could lead to 
precipitation over the long period of time (72 h).  
a) b) 
c) 
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Additionally, the sensitization of the ABCG2 overexpressing MDCK II BCRP cell line 
toward the cytostatic drug MX was investigated in the presence of compound 231 and 
238. Further details to the assay are provided in chapters 3.5 and 10.2.2.7.  
Full reversal of the resistance toward MX was observed for both compounds at a 
concentration between 0.1 and 1 µM as illustrated in Figure 91. 
 
 
 
  
 
Figure 91: MDR reversal assay of compounds 231 (a) and 238 (b), demonstrating their ability to reverse 
MDR toward the cytostatic mitoxantrone, in the ABCG2 overexpressing cell line MDCK II BCRP. The 
bars represent the cell viability at a given modulator concentration in the presence (light grey) and 
absence (dark grey) of 0.5 µM mitoxantrone. Control shows viability of cells without modulator. The 
standard deviation is expressed by error bars.  
 
Half-maximal growth inhibition was calculated for compound 231 as 21.8 nM and for 
238 as 19.5 nM. The calculated IC50 values were in excellent accordance to the results of 
the Hoechst 33342 accumulation assay. Also, the increased cytotoxic effects of both 
compounds reflect by the decreasing cell viability in the absence of MX (grey bars). 
 
 
 
 
 
a) b) 
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7.6 Investigation of the interaction with Hoechst 
33342 
 
Selected compounds were investigated regarding their interaction with Hoechst 33342, 
using ABCG2 overexpressing MDCK II BCRP cells. Therefore, varying compound 
concentrations were combined with varying concentrations of Hoechst 33342 and the 
interaction type could be determined using the Lineweaver-Burk double reciprocal plot, 
described in chapters 4.6 and 10.2.2.8. The results obtained with the Lineweaver-Burk 
method are presented in Table 25 listing the intersection of the straight lines together with 
the corresponding interpretation. Corresponding plots obtained according to the 
Lineweaver-Burk method are depicted in Figure 92.   
 
Table 25: Interaction with Hoechst 33342 According to the Lineweaver-Burk Double Reciprocal Plot. 
 
Compound R1 R2 R3 Intersection  
type of interaction  
with Hoechst 33342 
217 Ph 3-OMe NO2 2. Quadrant Non-competitive mixed-type 
225 3-Pyr 4-OMe NO2 2. Quadrant Non-competitive mixed-type 
231 3-CF3-Ph 3-OH NO2 Y-axis competitive 
237 3-OMe-Ph 4-CN NO2 2. Quadrant Non-competitive mixed-type 
238 3-OMe-Ph 3-F NO2 3. Quadrant Non-competitive mixed-type 
240 3-Pyr 3-OMe NH2 2. Quadrant Non-competitive mixed-type 
241 3-Pyr 4-OMe NH2 3. Quadrant Non-competitive mixed-type 
244 3-CF3-Ph 3-OMe NH2 2. Quadrant Non-competitive mixed-type 
Ko143    3. Quadrant Non-competitive mixed-type 
 
 
In this project non-competitive mixed-type interactions were found to be the predominant 
interaction type for the selected compounds with the substrate Hoechst 33342. “Mixed-
type” inhibitors bind differently from Hoechst 33342 but are able to influence the active 
site and thus the turnover rate. It is possible that they bind nearby to the Hoechst 33342 
binding pocket or could induce substantial conformational change in the protein which 
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has an impact on the binding of Hoechst 33342. Only compound 231 showed a 
competitive interaction suggesting the same binding pocket as Hoechst 33342. Indeed, 
the results are similar to other projects where in the majority of cases a non-competitive 
interaction was observed. 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
Figure continues on the next page 
a) b) 
c) d) 
7 Project V: 2,4-Substituted 6-nitroquinazolines 184
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 92: Lineweaver–Burk plot for compounds 217 (a), 225 (b), 231 (c), 237 (d), 238 (e), 240 (f), 241 
(g) and 244 (h) using various concentrations together with the ABCG2 substrate Hoechst 33342. 
Compound concentrations are specified in the legend. 
 
In order to validate the results from the Lineweaver-Burk double reciprocal plot, the 
Cornish-Bowden method was applied which is described in chapters 3.6 and 10.2.2.8. By 
linear regression of the Vmax and KM values slopes were obtained and summarized as a 
scatter plot in Figure 93. Corresponding linear regression plots are illustrated in Figure 
94 (for Ko143 see chapter 3.6). 
 
 
e) f) 
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Figure 93: Scatter plot of the slopes obtained from the linear regression of KM (○) and Vmax (■) values 
calculated from the Cornish-Bowden direct linear plot. 
 
Obtained slopes from the linear regression of the KM and Vmax values resulting from the 
Cornish-Bowden plot exhibited a good correlation with the data of the Lineweaver-Burk 
method. As expected a high positive slope for KM resulted for compound 231 indicating 
a competitive interaction with Hoechst 33342. Since the slope of Vmax was considerably 
low the data concludes a pure competitive character for 231, which is in accordance with 
the result of the Lineweaver-Burk method.  
High non-competitive portions were found for compounds 217, 225, 237, 238 and 241. 
Compound 240 and 244 showed strong characteristics of both, a non-competitive 
interaction and a distinct competitive portion, which is typical for a “mixed-type” 
inhibitor.  
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Figure 94: Direct linear plot of 217 (a), 225 (b), 231 (c), 237 (d), 238 (e), 240 (f), 241 (g), and 244 (h) 
according to Cornish-Bowden resulting in compound-concentration dependent lines after linear 
regression of the Vmax (■) and KM (●) values. Excluded values are depicted as open symbols of the 
corresponding shape. 
 
Again, a significant difference was displayed by the meta and para analogues 240 and 
241 bearing a 3-methoxy or 4-methoxy function at R2, respectively. According to the 
Cornish-Bowden method a notable competitive character was determined for 240 and a 
pronounced non-competitive interaction for 241.  
Also, it is likely that the position of a methoxy group at R2 has an impact on the interaction 
with Hoechst 33342. This is illustrated by the 3-methoxy derivatives 217, 240 and 244 
with pronounced competitive characteristics and the 4-methoxy derivatives 241 and 225 
that display a rather non-competitive interaction.  
 
7.7 Investigation of the conformation sensitive 
5D3 antibody binding to an epitope of 
ABCG2 
 
The conformation sensitive 5D3 antibody was used to investigate the conformational 
effect of selected compounds on ABCG2 as it binds specifically to an epitope of the 
transport protein. The bound antibody emits fluorescence, which was measured with a 
FACSCalibur flow cytometer using ABCG2 overexpressing PLB-985 cells. Additional 
g) h) 
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information about the procedure is provided in chapters 3.7 and 10.2.2.9. A summary of 
the results from this assay is presented as a bar-chart in Figure 95 using Ko143 as positive 
control representing 100% labelling with the antibody.  
Highest conformational sensitive labelling with the antibody was found for compounds 
217 and 241 at a concentration of 10 µM. Both compounds resulted in a labelling of 88 
and 84% in comparison to Ko143 (10 µM), respectively. Also, the highly potent 
compound 231 resulted in a high percentage of 66% labelling, even at a concentration of 
only 1 µM.  
 
 
 
 
 
 
 
 
 
 
 
Figure 95: 5D3 immunoreactivity modulation of ABCG2 by various compounds at a concentration of 1 
and 10 µM. Fluorescence detected by the 5D3-labeling of ABCG2 in the presence of 10 µM Ko143 was 
set to 100% and the fluorescence measured in the absence of any compound taken as 0%. The dotted line 
represents the labelling obtained with Hoechst 33342.   
 
A decreased labelling resulted for compound 244 yielding 47% as compared to Ko143. 
However, the results obtained in the interaction type investigation are not satisfyingly 
reflected in the 5D3 shift assay. In previous projects high percentages of conformation 
dependent labelling were frequently found in compounds displaying a pronounced 
competitive character. Moreover, marked differences resulted for the majority of the 
meta/para compound pairs like 240/241. Here, the labelling rate was 72 and 84%, 
respectively, exhibiting a slight but still notable difference.    
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Furthermore, representative histograms of compounds with the highest and the lowest 
5D3 shift in the assay as well as the standard Ko143 are depicted in Figure 96. Histograms 
of compounds Ko143, 217 and 244 were obtained at a compound concentration of 10 
µM, respectively.   
 
 
Figure 96: Histogram of the measured fluorescence at the FL3-H detector (X-axis) and the cell-count 
gated according to the fluorescence. Depicted is the fluorescence of the isotype-control (dotted curve) as 
well as of 5D3 antibody in the absence of a compound (dashed curve) and in the presence of a compound 
(continuous curve).Compounds with the highest and lowest 5D3 shifts: Ko143 (a), 217 (b) and 244 (c) at 
a concentration of 10 µM.   
 
7.8 Investigation of the ATPase activity 
 
The investigation was carried out with Ko143 as standard ATPase inhibitor and quercetin 
as standard stimulator. The ATPase activity assays were performed by Jennifer Gallus. 
Further details are described in chapters 3.8 and 10.2.2.10.  
For the screening the most potent compounds were investigated at three different 
concentrations (1, 10 and 25 µM) and a summary of the results is provided as bar chart 
in Figure 97. 
 Stimulation of the ATPase activity was found in the majority of the selected compounds. 
Among those, compound 218, 224, 227, 242 and 244 were identified as strong stimulators 
of ATPase activity. Compound 244 in particular yielded an extraordinarily strong 
stimulation exceeding the activating effect of the standard Quercetin. 
Reduced stimulation was found for compounds 211, 220 and 240. Almost no effect on 
the ATPase activity was detected for compounds 230, 231 and 232. This was often 
a) b) c) 
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observed in compounds that showed a competitive interaction like compound 231. A 
notable deactivation of the ATPase activity was found for compound 233 at high 
concentrations. According to the screening it showed a bi-phasic trend of ATPase activity 
changing from activation at a concentration of 1 µM to deactivation at higher 
concentrations.  
Pronounced activation of the ATPase activity was often observed after reduction of the 
nitro function at position 6 to an amino group. This is illustrated by compounds 232 and 
244 where the 6-amino species yielded a significantly higher stimulation of activity than 
the corresponding 6-nitro species.  
 
 
 
 
 
 
 
 
 
 
Figure 97: Screening of ATPase activity of selected compounds at three different concentrations. From 
left to right the bars correspond to 1, 10 and 25 µM final concentration of compound. Quercetin was used 
as a standard for activation of ABCG2 ATPase activity. All values are relative vanadate-sensitive ATPase 
activities in relation to the basal activity, which is set to 100%. *Compound 217 was investigated at a 
final concentration of 1 and 10 µM. 
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A concentration-response curve of the most potent compound 238 is depicted in Figure 
98 yielding an EC50 of 38 nM which was calculated by using the four-parameter logistic 
equation. However, the curve reaches a top value of only 126% stimulation in comparison 
to the basal activity (100 %). Compound 238 resulted roughly in a two-fold lower 
stimulation of the ATPase activity in comparison to the standard activator quercetin 
(EC50: 302 nM).  
 
 
Figure 98: Concentration-response curve for compound 238 in the ATPase assay. All values are relative 
vanadate-sensitive ATPase activities in relation to the basal activity, which is set to 100%. High Five 
insect cell ABCG2 membrane preparations were used for carrying out ATPase activity measurements. An 
EC50 of 38 nM was calculated for this compound. 
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8 Project VI: Different modifications 
at the quinazoline scaffold     
 
In this chapter several modifications at the quinazoline scaffold are described that were 
investigated. First, 5-membered heteroaromatic functions, namely thiophene and pyrrole, 
were introduced at position 2 of a substituted 4-anilinoquinazoline derivative. Hereby, 
similarities and differences in comparison to substitution with a 2-phenyl function were 
examined. Subsequently, different 4-anilino-2-phenylquinazolines were methylated at the 
aniline linker to investigate the importance of an H-donor function for the inhibitory 
activity of a compound. In the next step, a primary amino function was synthesized at 
position 4 of a 2-phenylquinazoline scaffold. The amine group was then reacted with 
differently substituted aromatic acid chlorides obtaining amido functions at position 4 and 
were compared to the corresponding precursors containing an amino linker. Then, 
substituted 4-anilinoquinazoline derivatives without substitution at position 2 were 
synthesized to investigate the importance of an aromatic function at this position. Finally, 
synthesis of two different dimers was carried out reacting a 2-substituted-4-
chloroquinazoline derivative with ethylendiamine or 1,3-diaminopropane. Hence, the 
impact of the different length of the linkers on the inhibition of ABCG2 could be 
investigated. Further details regarding the reaction mechanisms for the preparation of the 
compounds are illustrated below.  
The calculated logP values correspond to the unsubstituted species, named by scaffold B-
D (see chapter 8.1) and are given as 5.01 (scaffold B; R1 = Ph, R2 = Me), 3.73 (scaffold 
C; R1 = H) and 3.14 (scaffold D; R1 = H).   
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8.1 Reaction mechanism 
 
A schematic synthesis route and a detailed reaction mechanism is provided in this chapter. 
Scheme 7: General synthesis scheme for the preparation of compounds 253-280.a20 
 
 
 
 
                                                 
Scheme continues on the next page 
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a: Reagents and conditions: (i) DMF, I2, K2CO3, 70-90 °C, 4-8 h. (ii) POCl3, reflux, 4-12 
h.  (iii) Substituted aniline, isopropanol, 100 watt microwave irradiation, 110 °C, 15 - 30 
min. (iv) Substituted amine, isopropanol, 100 watt microwave irradiation, 110 °C, 15 - 
30 min. (v) 4-Substituted-2-phenylquinazoline, MeI, NaH, DMF, 0 °C 1h, RT 2-6 h. (vi) 
t-BuOK, 150 watt microwave irradiation, 180 °C, 2 min. (vii) substituted benzoyl 
chloride, THF, TAM, RT, 12 h. (viii) 4-chloro-2-(4-nitrophenyl)quinazoline, TAM, 
isopropanol, reflux, 4-6 h. 
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Reaction mechanism A: 
The reaction mechanism is analogues to that used for the compounds in project II and can 
be reviewed in chapter 4.1 (reaction mechanism A).  
 
N
H
NH
O
N
NH
O
[I2]
N
NH2
O
+/- H+
R2
R2 R2
 
 
Reaction mechanism B: 
Substitution of the carbonyl function at position 4 takes place in the presence of POCl3 in 
a chlorination reaction. The reaction mechanism is described in chapter 4.1 and also 
illustrated below. 
 
 
 
Reaction mechanism C: 
Final compounds were synthesized by a nucleophilic aromatic substitution of the 
corresponding 4-chloroquinazoline precursor by reaction with a substituted aniline 
derivative. The reaction mechanism is analogous to that used for the compounds in project 
I and can be reviewed in chapter 3.1 
 
Reaction mechanism D:  
Reaction follows the mechanisms described above for C. 
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Reaction mechanism E:  
Methylation of the aniline linker is carried out with methyl iodide after deprotonation of 
the amino function. Therefor, sodium hydride is used as a base which forms hydrogen 
gas. Subsequently, the deprotonated nitrogen atom performs a nucleophilic substitution 
reaction at methyl iodide yielding the product and sodium iodide salt.     
 
 
 
 
Reaction mechanism F: 
In the first step the amino function of 2-aminobenzonitrile performs a nucleophilic attack 
at the carbon of the cyano group. After addition, the imine function achieves 
intramolecular ring closure by nucleophilic attack at the second cyano group followed by 
exchange of protons and rearrangement of the electron pairs and doublebonds within the 
molecule leading to a quinazoline derivative.   
 
 
 
Reaction mechanism G: 
Formation of the amide is carried out by a nucleophilic attack of the amino function at 
the carbonyl group of the substituted acid chloride. Nucleophilic addition is followed by 
elimination of hydrochloric acid to restore the carbonyl function and compensate formal 
charges at the nitrogen atom leading to an amide function. Hydrochloric acid is 
precipitated with triethyl amine as a salt. 
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Reaction mechanism H: 
Reaction follows the mechanisms described above for C. 
 
Reaction mechanism I: 
Reaction follows the mechanism described above for C, except that the corresponding 
diamino species is used as nucleophile. Both amino functions of the corresponding 
diamine react in a nucleophilic substitution reaction each with one 4-chloroquinazoline 
derivative forming a dimer. 
 
8.2 Investigation of the inhibitory potency 
toward ABCG2 in the Hoechst 33342 
accumulation assay 
 
A Hoechst 33342 accumulation assay was carried out using the ABCG2 overexpressing 
MDCK II BCRP and parental cell line to determine the inhibitory potency of the 
compounds. The Hoechst 33342 accumulation assay as is also described in chapter 3.2 
and 10.2.2.2. A summary of the associated activity data is shown in Table 26.  
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Table 26: Inhibitory Activities Derived from the Hoechst 33342 Accumulations Assay Toward ABCG2 
Overexpressing MDCK II BCRP Cell Line. The Corresponding Substitution Pattern is Illustrated Above 
the Table.21 
 
 
Compound R1 R2 
 
 
Scaffold 
Hoechst 33342 
IC50 ± SD [µM]a Inhibition [%]e 
 
  
   
253 3-NO2 S A     300 ± 47   92 
254 4-NO2 S A     335 ± 42   84 
255 3-CN S A     178 ± 19   92 
256 3,4-OMe S A     202 ±  21 102 
257 3-F S A     953 ± 176   86 
258 3-NHCOCH3 S A     360 ± 20   90 
259 3-CN NH A     156 ± 10 104 
260 4-OMe NH A   2570 ± 1560 103 
261 3,4-OMe NH A     652 ± 137   98 
262 H H B          n.a.    n.a. 
263 H 
 
C     424 ± 32   59 
264 2-NO2  C     994 ± 99   64 
265 3-NO2  C    54.5 ± 9.4   70 
266 4-NO2  C    93.1 ± 8.4   61 
267 H  D 10700 ± 2070       f 
268 3-NO2-4-OH  D   2900 ± 490      f 
269 4-OH  D   2630 ± 844   55 
270 4-CN  D   1270 ± 460   75 
271 3-OMe  D     645 ± 68   67 
272 3-SMe  D   1350 ± 320   60 
273 3-F  D   8120 ± 2190       f 
274 3-NHCOCH3  D 28900 ± 4600      f 
275 -CH2-CH2-  E     619 ± 134   90 
                                                 
Table continues on the next page 
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276 -CH2-CH2-CH2-                                                                                        E     229 ± 26   95 
277 3-NO2-Ph Me B   20305 ± 190      f 
278 4-NO2-Ph Me B   3670 ± 390      f 
279 4-CN-Ph Me B 10100 ± 2000      f 
280 3-F-Ph Me B   3950 ± 350        f 
1b Ph H B     882 ± 157   96 
2b, c 3-NO2-Ph H B     130 ± 30 n.d.a. 
90b 4-NO2-Ph H B    69.6 ± 8.2   84 
3 3-NO2-4-OH-Ph H B    81.1 ± 9.1   81 
6 4-OH-Ph H B     204 ± 37   87 
4c 3-CN-Ph H B     140 ± 40 n.d.a 
5 4-CN-Ph H B    69.9 ± 10   87 
11c 3-OMe-Ph H B   1320 ± 100 n.d.a. 
12c 4-OMe-Ph H B   1930 ± 110 n.d.a. 
13b 3,4-OMe-Ph H B     152 ± 19   97 
10 3-SMe-Ph H B   1190 ± 31   86 
18 3-F-Ph H B     355 ± 53   84 
8 3-NHCOCH3-Ph H B     278 ± 33   98 
Ko143d  
 
     227 ± 14 100 
Gefitinib      1730 ± 270   88 
Elacridar        361 ± 48   85 
 
a: IC50 values are means of three independent experiments. 
b: Compounds synthesized in earlier study.198  
c: IC50 value taken from literature. .198 
d: Used as reference in the assay. 
e: Percentage of inhibition with regard to Ko143 
f: Top value fixed to top of Ko143 
n.a.: Not active 
n.d.a.: No data available 
 
 
In the first series a thienyl or pyrrolyl moiety was investigated at position 2 of the 
quinazoline scaffold. High inhibitory potencies toward ABCG2 in the range of 180-360 
nM resulted for thiophene in combination with the following substituents at R2, 3- and 4-
nitro, 3-cyano, 3,4-dimethoxy or 3-acetamido. In the case of the pyrrolyl moiety at R1 a 
3-cyano function at R2 was identified as the best substituent obtaining an excellent IC50 
of 156 nM. However, both five-membered heteroaromatic residues led to a somewhat 
lower or at best similar inhibitory potency compared to phenyl at position 2.  
The conversion of the anilino-linker into an amido-linker required the synthesis of 
precursor 262, containing solely a free amine without aromatic groups at position 4 of the 
quinazoline scaffold. Interestingly, the precursor exhibited no inhibitory activity leading 
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to the conclusion that aniline functions at position 4 are crucial for a potent inhibition of 
ABCG2. Further synthesis was carried out by reacting compound 262 with substituted 
acid chlorides yielding the 4-amido derivatives 263-266 that contain hydrogen or nitro 
groups as substituents at R1 of scaffold C. In comparison to the corresponding 4-anilino 
analogues 1, 2 and 92, the amido derivatives showed a significantly increased inhibitory 
potency. Compound 265 containing a 3-nitro function at R1 was the most potent one 
among the compounds of project VI with an excellent IC50 value of 55 nM. Unfortunately, 
the reduced solubility and the lower maximum inhibition in comparison to Ko143 posed 
a clear disadvantage of this class of compounds. Representative concentration-response 
curves of the most potent compounds 259 (scaffold A) and 265 (scaffold C) are illustrated 
in Figure 99. 
  
 
 
 
 
 
 
Figure 99: Concentration-response curve of compound 259 (●; IC50: 156 nM; a)) and 265 (●; IC50: 54.5 
nM; b)) in a Hoechst 33342 accumulation assay with Ko143 (○, IC50: 227 nM) as reference, using the 
ABCG2 overexpressing MDCK II BCRP cell line. Compound 265 reaches an Imax of about 70% of the 
standard Ko143. 
 
Subsequently, the aromatic moiety at position 2 was replaced by hydrogen and 
substitution was only carried out on the aniline function at position 4 of the quinazoline 
scaffold. Apart from the missing modification at position 6 and 7, the resulting 
compounds 267-274 are closely related to the TKI gefitinib. Hereby relatively poor IC50 
values similar to gefitinib were obtained, and it was concluded that an aromatic residue 
at position 2 is crucial for high inhibitory potencies toward ABCG2. Only compound 271 
with 3-methoxy substitution at R1 had an IC50 value in the high nanomolar range of 645 
a) b) 
concentration log [M]
1000
1500
2000
2500
3000
-9 -8 -7 -6 -5-
8 Project VI: Different modifications at the quinazoline scaffold  201
nM. Also, the percentage of maximal inhibition with regard to Ko143 was reduced in this 
subset to about 60%.  
Following, the dimers 275 and 276 were synthesized by an aromatic nucleophilic 
substitution between the corresponding diamine derivative and two equivalents of 4-
chloro-2-(4-nitrophenyl)quinazoline. A roughly three-fold higher inhibitory potency 
resulted in the Hoechst 33342 accumulation assay for compound 276 containing a propyl 
alkyl chain. Its IC50 of 229 nM is very similar to the potent inhibitor Ko143 and about 
three-fold more potent than its analogue 275 that contains a shorter ethyl alkyl chain.  
In addition, some substituted 4-anilino-2-phenylquinazolines were synthesized in order 
to carry out methylation at the anilino-linker. Hence, the H-donor function of the 
substituted aniline at position 4 was removed and replaced by a methyl group. As a result 
significant reduction of the inhibitory potency was detected after the methylation, 
illustrated by the increased IC50 values of compound 277-280. These findings substantiate 
the importance of an HBD function at this position and provide an explanation regarding 
the findings in the work of A. Spindler. Here, 2-phenylquinazolines were investigated 
where the amino linker of the substituted aniline at position 4 was replaced by ether or 
thioether linker.207 It is not surprising that those groups led to poor inhibitory potencies 
since both linkers have no HBD functions. 
 
8.3 Investigation of the inhibitory potency 
toward ABCB1 and ABCC1 in the calcein 
AM assay   
 
A calcein AM assay was conducted to investigate the selectivity of several compounds 
toward ABCG2 using the ABCB1 overexpressing cell line A2780 adr and the ABCC1 
overexpressing cell line H69 AR. More details regarding the assay are provided in 
chapters 3.3 and 10.2.2.4. The results of the calculated IC50 values of the compounds 
showing more than 25% of inhibition in the screening is depicted in Table 27. Screening 
results for the inhibitory activity toward ABCB1 and ABCC1 are illustrated as bar charts 
given in Figure 100. The screening includes the most potent compounds. 
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Figure 100: Inhibitory effect of screened compounds toward ABCB1 overexpressing cell line A2780adr 
(a) and MRP1 overexpressing cell line H69AR (b) in the calcein AM assay at a concentration of 10 µM. 
Cyclosporine A (CsA) was used as positive control, indicating complete inhibition. The inhibitory effect of 
each compound is expressed by the length of the bars, representing the inhibition compared to the 
positive control in percent. For each compound, three independent experiments were performed and the 
standard deviation is expressed by error bars. 
 
First the inhibitory potencies of compounds 253-261 toward ABCB1 were investigated 
containing substitution with thienyl or pyrrolyl at position 2. The highest potency was 
found for compounds with 3,4-dimethoxy substitution at R1. This observation has already 
been made in previous projects, in which the inhibitory potency toward ABCB1 has been 
correlated to the presence of methoxy groups. It was not surprising that compounds 256 
and 261, containing a 3,4-dimethoxy function at R1, reached the highest inhibition in the 
screening and yielded IC50 values of 1.88 and 1.81 µM, respectively.  
a) 
b) 
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Table 27: Inhibitory Activity of Compounds Exhibiting an Inhibition of more than 25% in Comparison to 
the Reference Cyclosporine A (CsA) in the Calcein AM Assay at a Concentration of 10 µM. 
 
Compound R1 R2 
 
 
Scaffold 
Calcein AM 
(ABCB1) 
IC50 ± SD [µM]a,b 
Calcein AM 
(ABCC1)  
IC50 ± SD [µM]a,c 
      
 
    
256 3,4-OMe S A   1.88 ± 0.71   9.68 ± 0.26 
258 3-NHCOCH3 S A   14.7 ± 4.42         n.d. 
259 3-CN NH A   18.8 ± 0.87   85.1 ± 7.9 
260 4-OMe NH A   8.03 ± 0.96         n.d. 
261 3,4-OMe NH A   1.81 ± 0.21   17.3 ± 1.9 
Cyclosporine Ad        1.17 ± 0.17   3.53 ± 0.61  
 
a: IC50 values were determined by at least three independent experiments. 
b: The P-gp overexpressing cell line A2780adr was used. 
c: The MRP1 overexpressing cell line H69AR was used. 
d: Cyclosporine A is used as reference for both assays. 
n.d.: Not determined, due to low effect in the initial screening. 
 
A concentration-response curve of the potent compound 261 using the ABCB1 
overexpressing cell line A2780adr is depicted in Figure 101. Low or only negligible 
potencies resulted for the remainder of substituents at R1. Indeed, a moderately increased 
inhibitory potency toward ABCB1 was observed for substitution at R2 with pyrrolyl in 
comparison to thienyl, which is illustrated by compound pairs 255/259 and 256/261. 
Overall, the compounds exhibited higher potencies toward ABCB1 in comparison to 
ABCC1. The highest potency toward ABCC1 showed compound 256 that yielded a poor 
IC50 value of 9.68 µM. Interestingly, the 2-pyrrolyl derivative 261 and the 2-phenyl 
derivative 13 (project I), which both contain a substitution with 3,4-dimethoxy at the 
anilino moiety, showed a similar trend in potency toward ABCB1 and ABCC1, with 
higher inhibitory potency toward ABCB1. 
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Figure 101: Concentration-response curve of compound 261 (■, IC50: 1.81 µM) in a calcein AM assay 
with Cyclosporine A (○, IC50: 1.17 µM) as reference, using the ABCB1 overexpressing cell line 
A2780adr. 
 
Moreover, the most potent amide derivatives 265 and 266 as well as the dimers 275 and 
276 were investigated but were not active against ABCB1 and ABCC1. It is likely that 
the presence of a nitro function increases the selectivity toward ABCG2 which was also 
found in several nitro derivatives of other projects.  
 
8.4 Investigation of the intrinsic cytotoxicity 
with the MDCK II cell lines in a MTT assay 
 
The intrinsic cytotoxicity of selected compounds was investigated in a MTT assay with 
MDCK II parental and ABCG2 overexpressing cells. Further details of the assay are 
provided in chapters 3.4 and 10.2.2.5. A summary of the obtained GI50 values and the 
corresponding therapeutic ratios is given in Table 28. 
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Table 28: Intrinsic Toxicity of Selected Compounds on MDCK II ABCG2 Overexpressing and Parental 
Cells. 
 
Compound R1 R2 
 
 
 
Scaffold 
 
 
GI50 [µM]a 
BCRP 
GI50 [µM]a 
Parental 
 
 
Therapeutic 
ratio (GI50/IC50) 
 
      
253 3-NO2 S A 14   15   46 
254 4-NO2 S A 83 110 250 
255 3-CN S A 59   63 330 
259 3-CN NH A 39   55 250 
263 H  C 72 130 170 
265 3-NO2  C   1.4     4.5   25 
266 4-NO2  C   0.90     1.8     9.7 
271 3-OMe  D 14     8.9     6.3 
276 -CH2-CH2-CH2-  E 53 132 230 
Ko143      13   13   56 
Gefitinib      1.4     2.1     0.80 
MeOH/DMSO      96b 140b  
 
a: Concentration leading to 50% of cell survival of MDCK II BCRP and parental cells. The data was 
   obtained from at least two independent experiments as mean values. 
b: Positive control of the cytotoxicity from dilution with DMSO/MeOH without compound. 
 
First the intrinsic cytotoxicity was investigated for compounds 253-259 containing a 2-
thienyl or 2-pyrrolyl moiety. Here, quite different GI50 values resulted for the meta/para 
compound pair. Cytotoxicity of the derivatives with thienyl at position 2 and 3-nitro 
(compound 253) or 4-nitro (compound 254) at R2 resulted in GI50 values of 14 and 83 
µM, respectively. In comparison substitution with pyrrolyl a slightly reduced intrinsic 
cytotoxicity was observed for thienyl, illustrated by compounds 255 and 259.  
Concentration-response curves of both compounds are provided in Figure 102. The 
highest TR of 331 among the selected compounds was calculated for compound 255 
containing a substitution with thienyl at position 2 and 3-cyano at R2 of scaffold A.  
Moreover, marked differences in cytotoxicity of selected amido-derivatives based on 
scaffold C were found for different substitution patterns. A hydrogen function at R1 led 
to an almost nontoxic compound whereas substitution with 3-nitro or 4-nitro yielded 
considerably decreased GI50 values in the range of 1 µM (see compounds 263, 265 and 
266).  
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Figure 102: MTT viability assay of compounds 259 (○) and 265 (□) using the ABCG2 overexpressing 
MDCK II BCRP cell line. The GI50 values were determined as 38.8 µM (○) and 1.35 µM (□), respectively. 
A control with the same concentration of MeOH and DMSO analogous to the dilution of the compounds, 
was carried out for comparison (■, GI50 = 96.1 µM). The amount of MeOH and DMSO used for the dilution 
was ≤ 1.8% and ≤ 1.0%, respectively. 
 
Regarding scaffold D, compound 271, with a 3-methoxy substituent at R1, possessed a 
relatively high cytotoxicity with a GI50 value of 14 µM. Due to the lack of substitution at 
position 2 it shows the highest structural similarity to the TKI gefitinib which was found 
to be even more cytotoxic resulting in an IC50 of 1.36 µM.    
Although it was found that the presence of nitro functions may increase the cytotoxic 
effects, the dimer 276 possessed a high GI50 value of 53 µM benefiting its TR. An 
overview of the TRs of selected compounds is depicted in Figure 103. 
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Figure 103: Therapeutic ratios of selected compounds, calculated from the ratio of GI50 to IC50 derived 
from MTT viability assay and Hoechst 33342 accumulation assay, respectively. The highest value was 
calculated for compound 21 (GI50/IC50 = 270), while the reference compound Ko143 yielded GI50/IC50 = 
55.5.  
 
Owing to a high inhibitory potency in the Hoechst 33342 accumulation assay, high 
therapeutic ratios between 250 and 330 resulted for the moderately cytotoxic compounds 
254, 255, 259 and 276. The best TR value calculated for compound 255 is about 6-fold 
higher than for the standard inhibitor Ko143.  
 
8.5 Investigation of the reversal of multidrug 
resistance 
 
Sensitization of ABCG2 overexpressing MDCK II BCRP cell line toward the cytostatic 
drug MX was investigated for selected compounds. The assay was carried out at different 
compound concentrations in the presence and absence of 0.5 µM MX. Further details of 
the assay are provided in chapters 3.5 and 10.2.2.7.  
Here the most potent compounds 255, 259, 265 and 266 were investigated in co-
administration with MX. Sensitivity of the ABCG2 overexpressing cells was restored by 
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all four compounds. Full reversal of the resistance toward MX was observed for all 
compounds at a concentration of about 1 µM, and is illustrated in Figure 104. 
Regarding the amido-derivatives 265 and 266 a higher cytotoxic effect was observed in 
the absence of MX indicated by the decrease in cell viability of MDCK II BCRP cells 
(dark grey bars) with increasing compound concentrations. No toxic effects were detected 
for compound 255 and 259 which is in accordance with the results from the MTT 
cytotoxicity assay described above.  
 
 
 
 
 
 
 
    
 
Figure 104: MDR reversal assay of compounds 255 (a), 259 (b), 265 (c) and 266 (d) demonstrating their 
ability to reverse MDR toward the cytostatic mitoxantrone, in the ABCG2 overexpressing cell lines 
MDCK II BCRP. The bars represent the cell viability at a given modulator concentration in the presence 
(light grey) and absence (dark grey) of 0.5 µM mitoxantrone. Control shows viability of cells without 
modulator. The standard deviation is expressed by error bars.   
 
 
a) b) 
c) d) 
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However, a significant decrease of the cell viability was observed in all compounds due 
to increasing sensitization of the resistant cells toward MX by the corresponding inhibitor 
(light grey bars). This effect was considerably more pronounced in comparison to the 
intrinsic cytotoxicity of the compounds. 
The half-maximal growth inhibition was calculated from the data using the four-
parameter logistic equation. Here, EC50 values of 45, 8, 47 and 77 nM were calculated for 
compounds 255, 259, 265 and 266, respectively. The EC50 of compound 255 was about 
four-fold lower than the IC50 determined in the Hoechst 33342 accumulation assay. 
Although the determined EC50 values in the MDR reversal assay with MX are more 
susceptible to error than with SN-38, due to fewer measuring points, they still provide a 
good estimation of the efficacy of a compound. 
Compounds 265 and 266 yielded EC50 values that were in good agreement to those from 
the Hoechst 33342 accumulation assay. According to the data of the MDR reversal assay, 
compound 266 could be distinguished as less potent than 265 which agreed with the 
Hoechst 33342 results. An extraordinarily potent EC50 value in the low nanomolar range 
resulted for compound 259. This is interesting, since the 3-cyano derivatives 255 and 259 
both yielded similar IC50 values in the Hoechst 33342 accumulation assay. The exact 
mechanism that is responsible for this difference is unclear but could be due to the 
different substituents thienyl and pyrrolyl at position 2 of the quinazoline scaffold. 
 
8.6 Investigation of the interaction with Hoechst 
33342 
 
The interaction of selected compounds with Hoechst 33342 was investigated using 
ABCG2 overexpressing MDCK II BCRP cells. Varying compound concentrations were 
combined with varying concentrations of Hoechst 33342 and the interaction type could 
be determined from the Lineweaver-Burk double reciprocal plot, described in chapters 
4.6 and 10.2.2.8.  
A summary of the results obtained with the Lineweaver-Burk method is presented in 
Table 29, listing the intersection of the straight lines together with the corresponding 
interpretation.  
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Table 29: Interaction with Hoechst 33342 According to the Lineweaver-Burk Double Reciprocal Plot. 
 
Compound R1 R2 Intersection  
type of interaction  
with Hoechst 33342 
253 3- NO2 S 2. Quadrant Non-competitive mixed-type 
254 4- NO2 S 2. Quadrant Non-competitive mixed-type 
255 3-CN S 2. Quadrant Non-competitive mixed-type 
259 3-CN NH 2. Quadrant Non-competitive mixed-type 
265 3- NO2  2. Quadrant Non-competitive mixed-type 
266 4- NO2  2. Quadrant Non-competitive mixed-type 
Gefitinib   3. Quadrant Non-competitive mixed-type 
Elacridar   X-axis Non-competitive 
Ko143   3. Quadrant Non-competitive mixed-type 
 
 
According to the Lineweaver-Burk plots depicted in Figure 105 a non-competitive 
interaction with Hoechst 33342 resulted for all compounds. Except for elacridar the 
remainder of the compounds showed an interaction of the “mixed-type”. This was also 
found for the majority of the compounds of projects I-IV and occurs when the inhibitor 
binds different from Hoechst 33342 but is still able to influence the turnover rate at the 
active site.22  
 
 
 
 
 
 
 
                                                 
Figure continues on the next page 
a) b) 
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Figure 105: Lineweaver–Burk plots for compounds 253 (a), 254 (b), 255 (c), 259 (d), 265 (e), 266 (f), 
gefitinib (g) and elacridar (h) using various concentrations together with the ABCG2 substrate Hoechst 
33342. Compound concentrations are specified in the legend. 
 
 
c) d) 
e) f) 
g) h) 
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Additionally the results from the Lineweaver-Burk double reciprocal plot were reassured 
using the direct linear method according to Cornish-Bowden. Additional information is 
provided in chapters 3.6 and 10.2.2.8. A summary of the obtained slopes by linear 
regression of the results according to the Cornish-Bowden method, is depicted in Figure 
106. Corresponding linear regression plots are illustrated in Figure 107.  
 
 
Figure 106: Scatter plot of the slopes obtained from the linear regression of KM (○) and Vmax (■) values 
calculated from the Cornish-Bowden direct linear plot. 
 
 
The summary of the slopes derived from linear regression of the Vmax and KM values of 
the Cornish-Bowden plot confirmed the results obtained by the Lineweaver-Burk method. 
All compounds exhibit a significant decrease of the Vmax values and roughly constant KM 
values with increasing compound concentrations, which is characteristic for a non-
competitive interaction with Hoechst 33342. The same results were observed for elacridar 
and the TKI gefitinib. 
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Figure 107: Direct linear plot of 253 (a), 254 (b), 255 (c), 259 (d), 265 (e), 266 (f), gefitinib (g) and 
elacridar (h) according to Cornish-Bowden resulting in compound-concentration dependent lines after 
linear regression of the Vmax (■) and KM (●) values. Excluded values are depicted as open symbols of the 
corresponding shape. 
 
According to the results, a non-competitive interaction was observed for the selected 
compounds which included different modifications. Thus, the compounds bind different 
from the substrate binding site of Hoechst 33342 to ABCG2 but are able to influence the 
turnover rate at the active site. Moreover, none of the investigated compounds exhibited 
a significant competitive portion, as indicated by the constant KM values independent of 
compound concentrations.   
 
8.7 Investigation of the conformation sensitive 
5D3 antibody binding to an epitope of ABCG2 
 
The conformational effect of selected compounds on ABCG2 was studied with the 
conformation sensitive 5D3 antibody which binds specifically to an epitope of the 
transport protein. Measurement of the fluorescence emitted by the bound antibody was 
performed with a FACSCalibur flow cytometer using PLB-985 ABCG2 overexpressing 
cells. Additional information about the assay is provided in chapters 3.7 and 10.2.2.9. The 
results from this assay are summarized as a bar-chart in Figure 108 using Ko143 as 
positive control representing 100% labelling with the antibody. 
g) h) 
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Figure 108: 5D3 immunoreactivity modulation of ABCG2 by various compounds at a concentration of 1 
and 10 µM. Fluorescence detected by the 5D3-labeling of ABCG2 in the presence of 10 µM Ko143 was 
set to 100% and the fluorescence measured in the absence of any compound taken as 0%. The dotted line 
represents the labelling obtained with Hoechst 33342.   
 
The highest conformational change resulted for compound 255 at a concentration of 10 
µM resulting in a labelling by the 5D3 antibody of 81% in comparison to Ko143. The 2-
pyrrolyl analog 259, which also contained a 3-cyano group at R1, led to a lower labelling 
of 60% as compared to the thienyl derivative 255.    
Also, the dimer 275 yielded high rates of labelling of around 78% at a concentration of 1 
and 10 µM. In many cases a high labelling with the conformation sensitive antibody 
correlated with a decreased ATPase activity and a high portion of competitive interaction 
with Hoechst 33342.  
Compounds 265 and 266 with an amide linker possessed low IC50 values in the Hoechst 
33342 accumulation assay but with decreased Imax values, and led to a low labelling of 
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approximately 54% at 10 µM. In comparison, Hoechst 33342, which is a substrate of 
ABCG2, reached only 35% labelling with the antibody.  
Representative histograms of the compounds yielding the highest and the lowest 5D3 
shift in the assay as well as the standard Ko143 are depicted in Figure 109. The histograms 
of compounds Ko143, 255 and 266 were obtained at a compound concentration of 10 
µM.   
 
 
Figure 109: Histogram of the measured fluorescence at the FL3-H detector (X-axis) and the cell-count 
gated according to the fluorescence. Depicted is the fluorescence of the isotype-control (dotted curve) as 
well as of 5D3 antibody in the absence of a compound (dashed curve) and in the presence of a compound 
(continuous curve). Shown are the compounds with the highest and lowest 5D3 shifts at 10 µM namely 
Ko143 (a), 255 (b) and 266 (c).   
 
 
8.8 Investigation of the ATPase activity 
 
Ko143 was used as standard ATPase inhibitor and quercetin as standard stimulator. The 
ATPase activity assays were performed by Jennifer Gallus. Further details are provided 
in chapters 3.8 and 10.2.2.10.  
The screening was conducted at three different concentrations (1, 10 and 25 µM) for the 
most potent compounds in the Hoechst 33342 assay. A summary of the results is provided 
as bar chart in Figure 110. 
A high stimulation of ATPase activity was observed for compounds 254, 255, 257 and 
259 based on scaffold A containing substitutions with thienyl or pyrrolyl at position 2 as 
c) a) b) 
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well as 3-cyano, 3,4-dimethoxy or 3-fluoro at R1. In contrast, the derivatives 263 and 266 
containing an amido-linker (scaffold C), had negligible effect on the ATPase activity as 
the measured values were in the range of the basal activity.  
 
Figure 110: Screening of ATPase activity of selected compounds at three different concentrations. From 
left to right the bars correspond to 1, 10 and 25 µM final concentration of compound. Quercetin was used 
as a standard for activation of ABCG2 ATPase activity. All values are relative vanadate-sensitive ATPase 
activities in relation to the basal activity, which is set to 100%. *Compound elacridar was investigated at 
a final concentration of 1 and 10 µM. 
 
Moreover, a slight increase in ATPase activity was detected for the derivatives 267, 270, 
271 and 273 that lack aromatic substitution at position 2 (scaffold D). The derivatives 
showed similar stimulation of nearly half of the activation caused by the compounds 
based on scaffold A. The TKI gefitinib which is related closest to those compounds also 
yielded negligible stimulation around the basal level (see chapter 3.8). A strong inhibition 
of the ATPase activity was detected for the dimer 276. The observed deactivation was 
even stronger than in case of Ko143, the standard inhibitor of ATPase activity. This led 
to a more detailed investigation using several concentrations of 276 in co-administration 
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with quercetin and Ko143 that were kept at 1 µM. Additionally, an analogues assay was 
carried out with the strongly stimulating compound 259. The concentration of 259 and 
276 was varied between 1 nM and 10 µM and the obtained concentration-response curves 
are illustrated in Figure 111 a) and b). 
 
 
 
 
 
 
 
Figure 111: Concentration-response curves for compounds 259 (a, ■) and 276 (b, ●) in the ATPase 
assay. Additionally, concentration-response curves of the corresponding compound in the presence of 1 
µM Ko143 (□) or 1 µM Quercetin (○) were carried out. All values are relative vanadate-sensitive 
ATPase activities in relation to the basal activity, which is set to 0%.  
 
Owing to the strong stimulation effect, compound 259 fully reversed the deactivating 
effect of 1 µM Ko143 at a concentration of roughly 3 µM. The effect on stimulation by 
quercetin was rather low, although the compound reduced the stimulation slightly so that 
both ATPase activities aligned toward higher concentrations.  
In contrast, only 4.7 nM of the deactivating compound 276 was needed to reduce the 
stimulating effect of 1 µM quercetin to basal level. This equals a 213-fold lower dose of 
compound 276 to produce a full reversal of stimulation by 1 µM Quercetin. In 
comparison, an equimolar amount of Ko143 was needed to reverse the stimulating effect 
of quercetin (data not shown). Indeed, the effect on Ko143 was rather low but exhibited 
a slight increase of the activity values with higher compound concentrations.  
 
  
 
 
a) b) 
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8.9 Confocal laser scanning microscopy 
 
Due to the strong fluorescence of compound 244 inside a cell membrane further 
investigation with ABCG2 expressing MCF-7 MX and parental MCF-7 cells were carried 
out. Differences in the fluorescence between both cell lines can give further insights if 
the compound is transported by ABCG2. This cell line was preferred, since the MDCK 
II ABCG2 expressing cell line is transfected with GFP (green fluorescent protein), which 
is linked to cDNA of ABCG2 and might interfere with the fluorescence of the compound. 
Compound 244 exhibits a very strong fluorescence at a maximum emission wavelength 
of 444 nm after excitation at a wavelength of 405 nm.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 112: Fluorescence obtained with Nikon A1 R confocal laser scanning microscope for compound 
244 at 1 µM using MCF-7 MX ABCG2 overexpressing (a) and parental MCF-7 (b) cell lines. The cells 
were incubated fur 20 min and washed with KHB and the washed cells were then measured after 45 
minutes. An excitation wavelength of 405 nm was used and the fluorescence emission detected after 
passing a DAPI bandpass filter.  
 
The MCF-7 cell lines were incubated at a compound concentration of 1 µM for a period 
of 20 min. Subsequently, the cells were washed and the cellular fluorescence measured 
after 45 min using a Nikon A1 R confocal laser scanning microscope. An excitation 
wavelength of 405 nm was used and the emission detected with a DAPI bandpass filter 
(478-495 nm). The pictures above show the cellular fluorescence of compound 244, 
a) b) 
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recorded 45 min after the washing procedure. According to the similar fluorescence 
intensity in the MCF-7 MX (a) and parental MCF-7 cells (b), it is unlikely that the 
compound is a transported substrate of ABCG2. The confocal microscopic pictures were 
taken by Thomas Ross. 
 
8.10 Investigation of substrate properties of 
selected compounds by fluorescence 
measurements 
 
Additionally, the substrate properties of compounds 32 and 33 of project I, containing a 
phthalimide or coumarin moiety in position 4 of a 2-phenylquinazoline scaffold, were 
investigated. Due to their interesting properties described in the following text, the 
compounds could be used in expulsion experiments or functionalized as a fluorescent 
antibody conjugate. 
They exhibited different emission maxima at 10 µM in KHB, illustrated in Figure 113. 
Further measurements of the fluorescence in ABCG2 expressing and parental cells using 
a FACSCalibur resulted in a comparable intensity, giving no indication that the 
compounds are transported substrates (data not shown). Moreover, the fluorescence-
spectrum of compound 244 of project V was measured on a Luminescence Spectrometer 
LS55 using KHB or MDCK II parental and ABCG2 overexpressing cells in KHB. The 6-
amino derivative 244 showed almost no fluorescence in KHB whereas the fluorescence 
increased significantly in the lipophilic environment of cells. 
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Figure 113: Fluorescence spectrum obtained with compound 32 (a) and 33 (b) at a concentration of 10 
µM using an excitation wavelength of 355 nm. Emission peaks were determined at 443 nm (a) and 508 
nm (b). 
 
A representative fluorescence spectrum of compound 244 in the presence of MDCK II 
ABCG2 overexpressing, parental cells and KHB at a compound concentration of only 1 
µM is depicted in Figure 114.  
 
 
Figure 114: Fluorescence spectrum obtained with compound 244 at a concentration of 1 µM using an 
excitation wavelength of 405 nm. Curves show the fluorescence obtained after 1 h of incubation with the 
compound using MDCK II ABCG2 overexpressing cells (continuous curve), parental cells (dashed curve) 
and KHB (dotted curve) exhibiting an emission maximum at a wavelength of 444 nm. 
 
The observed difference in fluorescence between both cell lines is negligibly small, 
indicating that compound 244 is not a substrate of ABCG2. Additionally, this was 
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confirmed in a flow cytometric investigation using ABCG2 overexpressing and parental 
MDCK II cells (data not shown) and also by confocal microscopy (see chapter 8.9).  
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9 Conclusion 
9.1 Summary of the results  
 
The investigation of inhibitors of ABCG2 based on a quinazoline scaffold was divided 
into 6 projects. Different modifications were synthesized in each project and the 
compounds examined by several functional assays. Here, the same methodology was 
applied throughout the investigation in order to provide a meaningful comparison 
between the different projects. Overall, this work led to a diverse substance library of 219 
novel final compounds. A brief summary of the results in each project is provided and 
discussed in the following chapters.    
 
9.1.1 Project I 
 
The first project focused on 2-phenylquinazolines containing a substituted aniline linker 
at position 4. Substitution was only carried out in meta and para position since ortho 
substitution led to low inhibitory potencies toward ABCG2. This served as a starting 
point, so that the obtained results could easily be compared to other projects. Additionally, 
2-phenylquinolines were synthesized analogously to the 2-phenylquinazolines to 
investigate the importance of the nitrogen atom in position 3 which was replaced by a 
carbon atom. 
Regarding the quinazoline scaffold, considerably high inhibitory potencies resulted in the 
Hoechst 33342 accumulation assay by monosubstitution with cyano, nitro and hydroxy 
residues. Moreover, it turned out that disubstitution with 3-nitro,4-hydroxy and 3,4-
dimethoxy led to highly potent compounds. The highest activity in this subset was found 
for compound 5 containing a 4-cyano substituent and yielding an excellent IC50 of 70 nM. 
The standard inhibitor Ko143, which is one of the most potent inhibitors of ABCG2 
known in literature, possessed a considerably higher IC50 value of 227 nM. In most cases, 
significant differences between meta and para substitution were observed which was 
often also reflected in other assays and is discussed in the following paragraph. For some 
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compounds the IC50 was additionally determined by flow cytometric measurement using 
pheophorbide A in order to exclude substrate specific effects. A good correlation of the 
pIC50 values (r2 = 0.91) for both assays was found, validating the obtained results with 
both methods. Regarding the compounds based on a quinoline structure, a significant 
decrease of the inhibitory potency was observed in comparison to their quinazoline 
analogues. Hence, the nitrogen atom at position 3 of the quinazoline structure is a vital 
feature for potent inhibitors of ABCG2. An explanation for this finding could be the 
decreased planarity of the molecule owing to the sterical hindrance between the hydrogen 
atom at position 3 and the aromatic core in position 2 leading to a twist. Calculations 
using the MMFF94x force field showed an torsion angle of roughly 3 degree for the 2-
phenylquinazoline and about 33 degree for the 2-phenylquinoline. Several studies 
concluded that the planarity of an inhibitor of ABCG2 is crucial for its potency.66,90,112  
The screening against the two other major MDR transport proteins ABCB1 and ABCC1 
in a calcein AM assay showed a high selectivity toward ABCG2 for the majority of the 
compounds. In comparison to a quinazoline scaffold the selectivity toward ABCG2 was 
considerably lower in the quinoline derivatives. Particularly the presence of methoxy, 
thiomethyl, ester and carboxylic acid functions increased the potency toward ABCB1 and 
ABCC1. Here, the non-selective compounds exhibited a slightly higher potency against 
ABCB1 than ABCC1.  
Investigation of the intrinsic cytotoxicity of the compounds yielded moderate GI50 values 
for the quinazoline derivatives that were slightly better than the potent standard inhibitor 
Ko143 (GI50: 11.1 µM). An excellent GI50 of 52 µM was determined for compound 3 
containing a disubstitution with 3-nitro,4-hydroxy. Due to its high inhibitory potency the 
compound had the highest therapeutic ratio (TR: 655) in the subset which is more than 
13-fold higher than Ko143. According to the results, a comparable or higher cytotoxicity 
resulted for ABCG2 overexpressing cells with respect to the parental MDCK II cell line. 
This is a strong indication that the substances are inhibitors and not substrates of ABCG2. 
Similar results were observed in the broad majority of compounds from the other projects. 
One key point of this work was the investigation of the ability of a compound to reverse 
the multidrug resistance in ABCG2 overexpressing cells. For that purpose a MDR 
reversal assay was carried out with co-administration of the cytostatic drugs SN-38 and 
Hoechst 33342. The most potent compounds, 3 and 5, led to a full reversal of the MDR 
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and the derived EC50 values from the MTT data of both cytostatic drugs were in a good 
agreement. In contrast to compound 3, the 4-cyano derivative 5 was significantly more 
potent in the MTT assay than in the Hoechst 33342 accumulation assay. A similar MTT 
assay was carried out with compound 3 and 5 in co-administration with the cytostatic 
drug MX. Once again, compound 5 demonstrated a significantly higher efficacy than 3 
and resulted in a full reversal of the MDR at a concentration of 0.1 µM.   
Investigation of the interaction with Hoechst 33342 was carried out utilizing the methods 
according to Lineweaver-Burk and Cornish-Bowden. Predominantly, a non-competitive 
interaction with Hoechst 33342 was found for the compounds. Also, the majority of the 
compounds exhibited a non-competitive interaction of the “mixed type”, meaning that 
they bind distant from the Hoechst 33342 binding pocket but still influence the active site 
for instance by conformational changes of the protein. Compounds competing with 
Hoechst 33342 for the active site were found to contain para substitutions with lipophilic 
halogen atoms like chlorine and iodine. On the contrary, the standard inhibitor Ko143 
exhibited a non-competitive interaction which has already been found in a previous 
study.208 Moreover, it was striking that significant differences between meta and para 
substitution were observed in the interaction type investigation. Examples are the 
meta/para compound pairs 4/5, 18/19 and 20/22 where this modification led to an altered 
binding to ABCG2. 
Conformation sensitive binding studies with the monoclonal 5D3 antibody confirmed the 
before mentioned differences between meta and para substitution. Compound 4 and 5 
containing a 3-cyano and a 4-cynao function, respectively, exhibited a considerable 
difference regarding the labelling with the 5D3 antibody. Particularly high rates of 
labelling resulted for compounds that showed a significant competitive interaction with 
Hoechst 33342 (e.g. 17 and 23). One of the exceptions to this is the standard inhibitor 
Ko143 which was used as control for this assay resulting in the highest rate of labelling 
which was set to 100%.  
Further investigations of the modulation of the ABCG2 related ATPase activity by 
different inhibitors led to interesting results: In this subset different effects on the ATPase 
activity were observed ranging from deactivation to strong stimulation, including 
compounds that had no effect on the ATPase activity. Again, strong differences were 
found for meta/para derivatives like 4/5, 18/19, 20/21, 22/23. Activities at or below the 
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basal level were in particular observed for para derivatives. In contrast, the majority of 
the meta derivatives led to increased ATPase activity. A high stimulation of the ATPase 
activity can for instance be exploited in targeting selective cell death of ABCG2 
overexpressing cells by ATP depletion. Based on the results the existence of several 
binding sites occupied by differently substituted inhibitors is highly likely and will be 
discussed in more detail in chapter 9.3.   
 
9.1.2 Project II 
 
In this project the phenyl moiety at position 2 of the quinazoline scaffold was exchanged 
by pyridyl. This led to a lower logP value which can be beneficial in terms of an enhanced 
bioavailability of a compound. Furthermore, the aromatic quinazoline system was 
reduced by removing the unsubstituted aromatic core. Due to the convenient preparation 
a 4-methylpyrimidine scaffold was synthesized and substituted at position 2 by a phenyl 
or pyridyl moiety. Further substitution was carried out at position 4 bearing substituted 
anilines. Likewise, the logP value was calculated and proved to be even lower than for 
the 2-pyridylquinazolines. 
Several compounds exhibited high inhibitory potencies in the Hoechst 33342 
accumulation assay. The best IC50 value of 64 nM was determined for compound 54 
containing a 4-nitro function at the aniline linker and 3-pyridyl at position 2. Substitutions 
with nitro and cyano substituents led to high potencies and the SAR showed similar trends 
as in project I, but only for meta and para pyridyl groups at position 2. In general, the 
substitution in ortho position resulted in reduced potencies for all investigated compounds 
in this work. This could be due to sterical issues leading to unfavorable conformational 
changes of the residues at position 2 or 4. Also, very similar activities were found for the 
pyrimidine derivatives in comparison to their quinazoline analogues. Since they consist 
of only 3 aromatic cores, this class of compounds exhibits an extraordinary high ligand 
efficiency.  
In terms of selectivity toward ABCG2, comparable results as for the compounds in project 
I were obtained. The presence of methoxy, ester and carboxylic acid functions led to 
increased inhibitory potencies toward ABCB1 and, to a lesser extent, also toward 
ABCC1.  
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A major difference between project I and II was observable in the MTT cytotoxicity 
assay. Replacement of the phenyl moiety at position 2 of the quinazoline scaffold by 
pyridyl decreased the cytotoxicity considerably. Some of the pyridyl derivatives exhibited 
no toxic effect even at concentrations up to 100 µM, including the most potent compound. 
Since the inhibitory potency was comparable to the analogues of project I, extraordinarily 
high TRs of more than 1130 were obtained. Hence, the compounds of project II excel as 
promising candidates for in vivo experiments combining low cytotoxicity, high selectivity 
and potency toward ABCG2 as well as an enhanced watersolubility due to the low logP 
value. 
Moreover, all selected compounds were able to reverse MDR toward SN-38 in the 
ABCG2 overexpressing MDCK II BCRP cell line at very low doses. According to the 
MTT data the most potent compound 54 possessed an EC50 of 21 nM which was about 
three-fold lower than determined in the Hoechst 33342 accumulation assay. Also the 
calculated EC50 values of compounds 56 and 87 were slightly lower, but still in good 
accordance to the IC50 value obtained in the Hoechst 33342 accumulation assay. Co-
administration of compound 54 and 87 with MX resulted in a high efficacy leading to a 
full reversal of the MDR at concentrations between 0.1 and 1 µM. 
In investigations of the type of interaction according to Lineweaver-Burk essentially all 
compounds showed non-competitive interactions with Hoechst 33342 that were mostly 
of the “mixed type”. A closer investigation utilizing the Cornish-Bowden method then 
revealed strong competitive portions for some compounds. A possible reason for this 
could be an allosteric interaction with the protein influencing the turn-over rate at the 
active site. 
The conformation sensitive labelling with the monoclonal 5D3 antibody yielded a high 
amount of staining for the most potent compound 54. Also the competitive inhibitor 61 
obtained a high amount of labelling with the antibody which was also observed for 
compounds with a pronounced competitive interaction in Project I. Most notably, 
significant differences between meta and para derivatives resulted as illustrated by 
compounds 66 and 67. But, high rates of labelling were not exclusive to inhibitors with a 
high competitive portion (see compound 54). 
In the study of the ATPase activity solely stimulating effects were observed for the 
selected compounds. Only a few compounds showed low stimulation near the basal level, 
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including the competitive compound 61. Interestingly, a strong competitive interaction 
often led to low stimulation or even deactivation of the ATPase activity. Although it is 
still a widespread claim that stimulation of ATPase activity is linked exclusively to 
substrates, the current work and other studies prove the contrary.209 High stimulation by 
the compounds may also be exploited to target ABCG2 expressing cells selectively by 
depleting the cellular ATP.   
 
9.1.3 Project III 
 
In this project 2,4-substituted quinazoline derivatives were synthesized. Substitution at 
both aromatic cores resulted in an increased amount of possibilities and enabled the 
investigation of more complex SAR studies including cumulative effects among the 
functional groups. In this context the interchangeability of the residues at both aromatic 
moieties was investigated. 
According to the Hoechst 33342 accumulation assay, the presence of an aromatic residue 
at position 4 of the quinazoline scaffold is crucial for the inhibitory potency. This was 
confirmed by a cyclohexylamino residue at position 4 leading to a considerably decreased 
potency in comparison to phenyl. Interestingly, the exchange of the substituents between 
the aromatic moieties at position 2 and 4 led to comparable IC50 values. The highest 
potency resulted for compound 144 (IC50: 44.2 nM) containing a combination of 3,4-
dimethoxy at position 2 and 4-nitro at position 4. In general, excellent potencies were 
obtained by combination of methoxy groups, particularly 3,4-methoxy, together with 
nitro functions. This combination led to compounds with IC50 values even below 100 nM 
(e.g. 111, 127, 143 and 144). In many cases, higher inhibitory activities were obtained by 
para substitution with nitro or cyano groups (e.g. 131/132 or 143/144).  
The screening of the selectivity of several compounds toward ABCG2 was carried out in 
a calcein AM assay, substantiating the results of previous projects: a noticeable decrease 
of selectivity was observed in most compounds containing two or more methoxy groups. 
Here, higher inhibitory potencies were detected toward ABCB1 than ABCC1. Since 
several compounds contained a combination of methoxy and nitro groups, a few potent 
broadspectrum inhibitors resulted comprising extraordinary high potencies toward 
ABCG2, ABCB1 and some even toward ABCC1. These compounds could be used to 
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circumvent the cellular resistance in barrier tissues like the BBB, which contains a high 
expression of ABCG2 and ABCB1, in order to increase the efficacy of certain drugs. In 
this regard, broadspectrum inhibitors like elacridar have already been successfully 
tested.210  
The intrinsic cytotoxicity of selected compounds was investigated in a MTT assay with 
MDCK II parental and ABCG2 overexpressing cells. Selected compounds of project III 
exhibited a similar cytotoxicity in comparison to project I. Although the mean GI50 in this 
subset was in the range of Ko143, most of the TRs were still considerably higher owing 
to the significantly greater inhibitory potencies toward ABCG2. The highest TR of 270 
resulted for compound 111 containing a substitution with 3-nitro at R1 and 3,4-dimethoxy 
at R2. Moreover, it was found that two or more nitro and/or cyano functions led to 
increased toxic effects in the corresponding compound (e.g. 107 and 109).    
The reversal of the MDR in the ABCG2 overexpressing MDCK II BCRP cell line toward 
the cytostatic drugs SN-38 and MX was investigated in a MDR reversal assay. Here, the 
most potent compounds 144 and 150 resulted in a roughly three-fold lower EC50 value in 
co-administration with SN-38 than observed in the Hoechst 33342 accumulation assay. 
Likewise, considerably increased inhibitory potencies have already been observed in 
some of the most potent compounds in other projects (e.g. compound 5 and 54). With 
regard to SN-38, a very similar potency was observed for compounds 144 and 150 by co-
administration of cytostatic drug MX.  
Interaction type investigations using the Lineweaver-Burk and Cornish-Bowden method 
showed that only compound 139 displayed a clear competitive interaction with Hoechst 
33342. For the remaining compounds a non-competitive interaction was found, for some 
with a pronounced competitive portion, which is typical for non-competitive “mixed 
type” inhibitors. For instance, high competitive portions were found for compounds 130 
and 144 that could be due to substitution in ortho or para position.  
The results from this investigation were also reflected in the conformation sensitive 5D3 
antibody labelling assay. High shifts were frequently observed for inhibitors with a 
pronounced competitive portion with regard to the interaction with Hoechst 33342. 
Hence, the highest shift of 94% with in comparison to Ko143 was found for compound 
139, followed by compound 130 that yielded a labelling of 80%. Besides a few 
exceptions, certain patterns were noticeable such as the significantly different rate of 
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labelling between meta and para derivatives (e.g. 143 and 144) or the correlation of the 
interaction with the observed 5D3 shift.  
Similar patterns were also found in the screening of the ATPase activity of selected 
compounds. Compound 130 for instance, that showed a competitive interaction with 
Hoechst 33342 and also a high 5D3 shift in the immunostaining assay resulted in a strong 
deactivation of the ATPase activity. In general, inhibitors that had a pronounced 
competitive interaction and/or a high labelling with the 5D3 antibody were frequently 
found to deactivate the ATPase activity, mostly at higher concentrations, and often 
contained a para substitution. A more detailed investigation of selected compounds 132, 
144, 149 and 150 revealed a concentration dependent effect on the ATPase activity with 
stimulation at low concentrations and inhibition at high concentrations. This is suggested 
to be due to a concentration dependent activating high affinity and a deactivating low 
affinity binding site yielding bell-shaped concentration-effect curves.206 Also, the 
addition of alkyl groups to amino or ether functions resulted in compounds which 
inhibited the ATPase activity (compare compounds 113, 114, 116, 118 and 119). An 
interpretation of this effect is given in chapter 9.3. 
 
9.1.4 Project IV 
 
In this project the carbon atom at position 8 of the quinazoline scaffold was replaced by 
nitrogen resulting in a pyrido[2,3-d]pyrimidine scaffold. Substitution was carried out 
analogously to the quinazoline derivatives of projects I-III on the aniline linker at position 
4 and at position 2 by introducing different aromatic moieties. Notably, a very low logP 
value resulted from this modification probably enhancing the watersolubility in this class 
of compounds. 
The inhibitory potency of all test-compounds toward ABCG2 was determined in a 
Hoechst 33342 accumulation assay. Surprisingly, all 2-phenyl derivatives exhibited an 
enantiotopic inhibitory potency toward their quinazoline analogues. Therefore, the lowest 
IC50 value of 149 nM was observed for the unsubstituted compound 162, whereas the 
unsubstituted quinazoline analogue 1 led to a poor IC50 of only 882 nM. Similarly high 
inhibitory potencies resulted for compounds with meta methoxy and meta fluorine 
substituents at either phenyl ring. Nitro, cyano and hydroxy substituents that previously 
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led to high inhibitory potencies in the quinazoline derivatives resulted in poor inhibitory 
potencies in the pyrido[2,3-d]pyrimidine derivatives. Again, significant differences 
between the meta and para derivatives were noticeable, for instance illustrated by 
compounds 166 and 167.  
A great advantage of this class of inhibitors was the selectivity for ABCG2. The screening 
of selected compounds in the calcein AM assay yielded no noteworthy inhibitory potency 
toward ABCB1 or ABCC1 emphasizing their benefit for specific investigations involving 
ABCG2.  
The investigation of the intrinsic cytotoxicity of selected compounds in a MTT assay 
revealed another advantage of the pyrido[2,3-d]pyrimidine scaffold. Most of the 
compounds possessed intrinsic cytotoxic effects that were either very low or not 
measurable, similar to the substituted 2-pyridylquinazolines of project II. The cell 
viability was often restricted by the toxic effects of the solvents (MeOH/DMSO) resulting 
in a similar GI50 as the control. The highest TR of 676 was calculated for compound 175 
containing a substitution with 3-trifluoromethyl at the anilino linker at position 4 and a 
phenyl residue at position 2. Like in other assays, the meta and para analogues frequently 
showed considerable toxicity differences, as observed for the meta/para derivatives 168 
and 169 that yielded GI50 values differing about two-fold.  
A MDR reversal assay was carried out with compounds 162, 167 and 169 in order to 
investigate their ability to revert MDR in ABCG2 overexpressing cells toward the 
cytostatic drug SN-38. According to the MDR reversal data, they all possessed a four-
fold higher inhibitory potency than in the Hoechst 33342 assay and the tendencies of the 
calculated IC50 values were very well reflected. The phenomenon of lower IC50 values 
resulting from the MDR reversal assay was also observed for most of the compounds 
investigated in other projects and is discussed in chapter 9.3. A full reversal of MDR was 
also obtained in a similar assay using the cytostatic drug MX in co-administration with 
compound 162 and 169. Again, the potencies obtained in the MTT assay exhibited similar 
trends compared to the Hoechst 33342 accumulation assay, but were considerably higher. 
The investigation of the type of interaction using the Lineweaver-Burk and Cornish-
Bowden methods led to mostly non-competitive or non-competitive interactions of the 
“mixed type” with Hoechst 33342. Among the selected compounds of project IV the three 
derivatives 167, 169 and 188 exhibited strong evidence for a high portion of competitive 
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interaction. All three of them contain a para substitution at the aniline linker in position 
4 which was a frequent pattern in inhibitors showing a pronounced competitive 
interaction with Hoechst 33342. On the contrary, many meta derivatives resulted in a 
more pronounced non-competitive interaction.  
The conformation sensitive 5D3 antibody binding study resulted in some familiar 
patterns: Major differences were found between the meta and para cyano derivatives 166 
and 167, leading to a labelling of 63 and 93%, respectively. Also the 4-cyano derivative 
181 yielded a high staining of 79% with respect to Ko143. This is in accordance to the 
finding for the 4-cyano derivative 5, containing a quinazoline scaffold, which has been 
investigated in project I. In general, compounds showing a pronounced competitive 
interaction with Hoechst 33342 often yielded a higher amount of labelling by the 
conformation sensitive 5D3 antibody.   
Screening of the ATPase activity resulted solely in stimulating effects. However, 
increasing concentrations led to a strong decrease of the stimulating effect in some 
compounds like 167, 181 and 184. In A more detailed investigation of compound 178 an 
even higher stimulation than the standard Quercetin (EC50: 302 nM) was determined with 
a rather low EC50 of 18.0 nM. For compounds 167 and 181 high competitive portions 
were detected in the interaction type investigation. They also showed the highest amount 
of labelling with the conformation sensitive 5D3 antibody. This pattern was frequently 
found in inhibitors with a low stimulating or even deactivating effects on the ATPase 
activity. Again, a clear distinction between meta and para derivatives was observed in 
the ATPase activity assay (e.g. compound 166/167 and 168/169). 
  
9.1.5 Project V 
 
In this project a nitro function was introduced at position 6 of the 2,4-substituted 
quinazoline scaffold. Although the calculated logP values was relatively low, a reduced 
solubility was observed in some of the compounds requiring higher amounts of methanol 
in the final concentration (MeOH < 5%) for the dilution series. Reduction of the nitro 
function yielded the corresponding 6-amino derivatives which were further modified by 
reacting them with different acid chlorides leading to the corresponding amide 
derivatives.  
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In most instances, the presence of a 6-nitro function led to extraordinary high inhibitory 
potencies in the Hoechst 33342 accumulation assay. The clear advantage of this 
modification is noticeable by comparison of the corresponding quinazoline derivatives 
211 and 1. Here, the 6-nitro derivative 211 was roughly 9-fold more potent than the 
analogue 1, which lacks the 6-nitro group. It was discovered that further substitution of 
the aromatic moieties at position 2 and 4 of the quinazoline scaffold increased the 
inhibitory potency even more. Beneficial substituents were for instance methoxy and 
fluorine groups that led to the most potent compound 238 with a superb IC50 of 23 nM. 
Overall 29 different compounds were synthesized containing a 6-nitro function and 
yielded an average IC50 of 85 nM. Reduction of the 6-nitro group yielded 6-amino 
functions that decreased the inhibitory activity of the corresponding analogues 
considerably. Even lower potencies resulted for the corresponding amides.  
In the investigation of the selectivity toward ABCG2 no noticeable inhibitory potency 
toward ABCB1 and ABCC1 was observed for the tested compounds. In this regard, a 
high selectivity has often been observed in the presence of nitro functions, making this 
class of compounds favorable for further specific investigations of ABCG2.  
The study of the intrinsic cytotoxicity in an MTT assay showed increased toxic effects 
among the investigated compounds. In comparison to their analogues, lacking 
substitution at position 6, an about three-fold decreased GI50 resulted (see compound pairs 
211/1, 212/3 and 218/13). However substitution with pyridyl in position 2 of the 
quinazoline scaffold resulted in a significantly decreased cytotoxicity. Almost no toxic 
effect was detected for compounds 223 and 226, similar to the 2-pyridyl derivatives of 
project II. Owing to the high inhibitory potency and the low cytotoxicity, extraordinarily 
high TRs of roughly 1200 and 1100 were calculated for both compounds. Due to the 
enhanced watersolubility of the 2-pyridyl derivatives, these are promising candidates for 
in vivo studies.   
Selected compounds, including the most potent compound 238, were additionally 
investigated for their ability to reverse MDR in ABCG2 overexpressing cells toward SN-
38 and MX. All compounds led to a full reversal when co-administered with SN-38 with 
EC50 values that were for some compounds negligibly higher compared to the IC50 values 
of the Hoechst 33342 accumulation assay. In general, the derived EC50 values were either 
comparable or even lower than observed for the compounds of other projects. A possible 
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reason could be some degree of precipitation over the time period of 72 h. However, in 
the MDR reversal assay in co-administration of MX, the EC50 values were in excellent 
accordance to the IC50 values obtained in the Hoechst 33342 accumulation assay. 
In the interaction type investigation a pronounced competitive interaction with Hoechst 
33342 was found only for compound 231. For the remaining compounds a non-
competitive interaction of the “mixed type” resulted. Among these, many exhibited 
considerable competitive portions, indicating a binding site nearby Hoechst 33342 or 
strong allosteric interactions with the active site.  
Unfortunately, the results of the interaction type investigation did not agree as well as in 
other projects with the data determined in the conformation sensitive 5D3 antibody 
binding assay. Notably, the competitive compound 231 led to a high labelling of 66% 
using a concentration of only 1 µM. In comparison to other projects the overall labelling 
was somewhat increased which could be due to the higher competitive portions observed 
in the corresponding interaction type investigation. In particular, a high percentage of 
labelling of 84 and 88% was found for compounds 241 and 217 containing a 6-amino or 
6-nitro group, respectively.  
The investigation of the ATPase activity illustrated that the substituent in position 6 had 
a strong impact on the modulation of ATPase. This could be seen from the analog 
compounds 232 and 244 with a 6-nitro or 6-amino substituent, respectively. Overall most 
of the compounds had a stimulating effect on the ATPase activity, some even in the range 
of quercetin (e.g. compounds 218, 227, 242 and 244). A deactivation was detected solely 
for compound 233. Like in other projects, some compounds had no effect on the ATPase 
activity yielding values in the basal range (e.g. compounds 230, 231 and 232). Among 
them was compound 231, which had shown a competitive interaction with Hoechst 
33342. In this regard, compounds with high competitive portions were often found to 
exhibit either none or a deactivating effect on the ATPase activity.  
 
9.1.6 Project VI   
 
In this project, several modifications at position 2 and 4 of the quinazoline scaffold were 
investigated. These comprised substitution with 5-membered heteroaromatic residues at 
position 2 (scaffold A), methylation of the aniline linker at position 4 (scaffold B), 
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exchange of the aniline linker at position 4 by an amide linker (scaffold C), exchange of 
the aromatic moiety at position 2 by hydrogen (scaffold D), and the formation of two 
different dimers (scaffold E).  
The investigation of the inhibitory potency toward ABCG2 in the Hoechst 33342 
accumulation assay resulted in good IC50 values for substitution with thienyl and pyrrolyl 
in position 2 (scaffold A). Both residues led to low IC50 values of 178 and 156 nM in 
combination with a 3-cyano function at the aniline linker in position 4 (see compounds 
255 and 259). Although several potent compounds resulted from both heteroaromatic 
residues they led to comparable or somewhat higher IC50 values in comparison to a 
substitution with phenyl. A considerable decrease in potency was determined for the 
compounds based on scaffold B after methylation of the aniline linker. Hence, the H-
donor function at position 4 is crucial for a potent inhibition of ABCG2. Also, the inactive 
compound 262 which contained a free amine in position 4 demonstrated the importance 
of an aromatic moiety linked to the amine. The exchange of the aniline linker in position 
4 by an amido linker (scaffold C) increased the inhibitory potency significantly. Among 
those, the best derivative 265 led to an excellent IC50 value of 55 nM containing a 3-nitro 
substituent at the aromatic core on position 4. However, this class resulted in lower Imax 
values in the range of about 60% in comparison to Ko143. Removal of the aromatic 
function at position 2 (scaffold D) led to increased IC50 values and also lower Imax values 
in comparison to their 2-phenylquinazoline analogues. Among the synthesized dimers 
(scaffold E) it was found that a longer alkyl chain enhanced the solubility and also the 
inhibitory potency. The dimers 275 and 276 containing a 4-nitro substituent at position 2 
and the quinazoline scaffold was linked at position 4 by the corresponding diamine to 
achieve dimerization. Hereby, an IC50 of 229 nM which is very similar to Ko143 resulted 
for 276 containing a propyl chain.   
In the calcein AM assay selected compounds including the most potent ones were 
screened to determine their inhibitory potency toward ABCB1 and ABCC1. Increased 
potencies resulted only for compounds based on scaffold A that contained methoxy 
functions. In general, a higher activity was detected toward ABCB1 than ABCC1. Similar 
results have also been observed for several compounds in other projects.    
The investigation of the intrinsic cytotoxicity included several of the most potent 
compounds and exhibited further interesting SAR. Significant differences were observed 
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in the GI50 values of the nitro meta/para derivatives 253 and 254 bearing thienyl at 
position 2. Those differences between meta and para substituents were also found in other 
projects and could be an indication of a different interaction with ABCG2. The highest 
TR of 331 resulted for compound 255 containing a 3-cyano substituent at position 4 and 
thienyl at position 2. For the most part, the compounds containing scaffold A led to good 
GI50 values and beneficial TRs. Regarding the highly potent compounds 265 and 266 
containing an amido linker at position 4 (scaffold B), considerably increased cytotoxic 
effects were observed for the nitro derivatives and could be a criterion for the exclusion 
from in vivo studies. 
The four most potent compounds 255, 259, 265 and 266 were additionally investigated 
in a MDR reversal assay to examine their ability to reverse the MDR toward the cytostatic 
drug MX. A full reversal was produced by all compounds at a concentration of about 1 
µM. Determined EC50 values were in very good accordance to the Hoechst 33342 
accumulation assay for the derivatives 265 and 266 containing an amido linker at position 
4. On the contrary, significantly lower EC50 values resulted for the 3-cyano derivatives 
255 and 259 which contained a thienyl or pyrrolyl moiety at position 2, respectively. 
Indeed, the pyrrolyl derivative 259 showed a considerably higher efficacy in comparison 
to compound 255.  
The interaction type investigation utilizing the Lineweaver-Burk method detected for all 
of the selected compounds a non-competitive interaction with Hoechst 33342, primarily 
of the “mixed type”. This interaction-type was also most frequently observed in all 
projects including the commercial inhibitors Ko143, elacridar and gefitinib. The 
pronounced non-competitive character of all compounds was supported by an additional 
analysis using the method of Cornish-Bowden. 
In the conformation sensitive 5D3 antibody binding assay a different labelling was 
determined for the 3-cyano derivatives 255 and 259: Substitution with thienyl at position 
2 led to a high labelling of 81% whereas the corresponding pyrrolyl substitution yielded 
60%. Most notably, the dimer 276, containing a propyl linker, and the dual-inhibitor 
elacridar showed very high rates of labelling. Interestingly, an increased labelling with 
the antibody often correlated to high competitive characteristic and a decreased ATPase 
activity. This relationship is further discussed in the following paragraph.  
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In the investigation of the ATPase activity the derivatives 254, 255, 257 and 259 
containing a 5-membered heteroaromatic moiety in position 2 (scaffold A) displayed a 
strong stimulating effect of around 150% of the basal activity. In contrast, the 4-amide 
derivatives 263 and 266 (scaffold C) had no effect on the ATPase activity resulting in 
values near the basal activity. Only low stimulation was found for the derivatives 267, 
270, 271 and 273 (scaffold D) which lack an aromatic function at position 2. Solely the 
dimer 276 (scaffold E) inhibited the ATPase activity. A more detailed investigation with 
several concentrations of the stimulating compound 259 or the deactivating compound 
276 in co-administration of 1 µM Ko143 or 1 µM Quercetin illustrated the strong 
potencies of both compounds: Compound 259 reversed the deactivating effect of 1 µM 
Ko143 at a concentration of 3 µM whereas compound 276 reversed the stimulating effect 
of 1 µM Quercetin even at a concentration of only 5 nM. 
 
9.2 SAR of inhibitors of ABCG2  
 
In this paragraph the structural features of a potent inhibitor of ABCG2 based on a 
quinazoline scaffold are briefly discussed and summarized. First, the SAR of derivatives 
with 2-phenyl-4-anilinoquinazoline scaffold and substitution at the aromatic moieties at 
position 2 and 4 will be discussed (Figure 115). These modifications have been performed 
in compounds discussed in project I and III. The derived patterns were found to be valid 
to compounds of some other projects as well.  
In general, substitution at ortho position led to decreased inhibitory potencies throughout 
this study and confirmed the results of previous research.196,198 A possible reason for this 
finding could be the reduced planarity of the molecule caused by an increased sterical 
hindrance arising from an ortho substituent leading to a stronger twist among the 
corresponding aromatic cores. In this regard, several studies have found that planarity is 
required for potent inhibitors of ABCG2.66,112,90 Other studies suggested that π-π 
stacking of aromatic cores could increase the binding to ABCG2, which is most effective 
in a planar molecule.211  
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Figure 115: Substitution pattern of a substituted 2-phenyl-4-anilinoquinazoline scaffold. Most 
substitutions were carried out at R2 but very similar potencies resulted when swapping substituents 
between the aromatic cores. 
 
In particular, for the majority of the compounds large differences of IC50 values between 
meta and para derivatives with the same substituent were found. The substituent position 
not only had a great impact on the inhibitory potency but also on the interaction/binding 
of a compound with/to ABCG2. This will be discussed in more detail in chapter 9.3.  
Electron withdrawing groups like nitro and cyano have proven to lead to considerably 
higher potencies in para position than in meta (e.g. compound 2/89, 4/5). This effect was 
more pronounced on the aniline moiety at R2 than at R1 (e.g. compound pairs 126/132 and 
127/144) and led to excellent IC50 values below 100 nM for the before mentioned 
derivatives 2, 89, 4 and 5. In contrary, electron donating groups like methoxy often 
exhibited a decreased inhibitory potency at para position (e.g. compound 11 and 12). 
Hence, the potency of a compound is dependent on the position at the corresponding 
aromatic residue and also the electronic properties of the used substituent. Substituents 
containing HBA or HBD functions both led to potent compounds, regardless of their 
positions. Examples are for instance substitutions with nitro and hydroxy (see chapter 
3.2). High inhibitory potencies were in particular observed in meta or para 
monosubstitution with nitro, cyano, hydroxy, or fluoro groups as well as disubstitution 
with 3,4-dimethoxy, 3-NO2,4-OH and 3-OMe,4-Br functions. Regarding the substitution 
at R1 and R2, the collected data indicates an interchangeability of the substituents between 
the aromatic moieties, leading to mostly comparable inhibitory potencies (see chapter 
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3.2). Notably, the combination of nitro functions and 3,4-dimethoxy resulted in several 
highly potent inhibitors (see compound 111, 127, 143 and 144) with IC50 values below 
100 nM. 
An overview of the most important modifications in the projects I-VI is illustrated in 
Figure 116. Firstly, it was found that the lack of aromatic substitution at R1 decreased the 
inhibitory activity significantly. Examples are the compounds 267-274 (see chapter 8.2) 
that exhibited the greatest resemblance to the TKI gefitinib and yielded IC50 values that 
were mostly above 1 µM. Considering substitution at R1, high inhibitory potencies were 
found for compounds with phenyl or pyridyl residues. However, the pyridyl group 
possessed an additional advantage over the phenyl group by leading to low cytotoxic 
effects and an improved solubility.   
Secondly, the presence of a nitrogen atom at R2 is highly preferable over a carbon atom. 
The resulting decrease in potency and loss of selectivity that was observed in the 
quinoline derivatives could be due to the higher basicity of the nitrogen atom at position 
1 of the scaffold. Another reason could be the decreased planarity in the 2,4-substituted 
quinoline caused by the steric hindrance between the hydrogen atom at position 3 and the 
hydrogen atom on the aromatic moiety at R1. As discussed above, planarity is one of the 
characteristics that is frequently found in potent inhibitors of ABCG2.  
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 Figure 116: Structural features that are crucial for a potent inhibitor of ABCG2 containing a 
quinazoline scaffold. Good and poor substituents regarding the inhibitory potency toward ABCG2 are 
illustrated in the corresponding textbox. 
 
Since most of the compounds contained an aniline linker at position 4 of the quinazoline 
scaffold (R3: H; R4: subst. Ph) the importance of this HBD function was investigated. The 
replacement of the hydrogen atom at R3 by a methyl group decreased the inhibitory 
potency drastically. Hence, it was concluded that the HBD function of the aniline function 
in position 4 is crucial.  
Further modification was carried out at R5 introducing functions with different electronic 
and steric properties. Very high inhibitory potencies were determined for 6-nitro 
derivatives yielding the most active compounds of this work. Here, 29 derivatives were 
synthesized and almost all of them possessed IC50 values well below of 100 nM. On the 
one hand, the nitro function decreases the electron density at the aromatic core by negative 
mesomeric effects. On the other hand, it provides HBA functions via its oxygen atoms 
which could play a decisive factor for its high potency. On the contrary, decreased 
inhibitory potencies resulted from 6-amino functions. This group increases the electron 
density at the aromatic core and is able to interact via HBD functions with its 
environment. Although, they were significantly less potent than their 6-nitro analogues, 
the IC50 values were still below 1 µM. Structurally related drugs based on a quinazoline 
scaffold frequently contained ether functions at position 6 and/or 7, like the TKI gefitinib. 
1
2
3
45
6
7
8
Good: Ph (if R3 = H) 
Poor:  Cyclohexyl,  H (if R3 = H) 
Good: H (if R4 = Ph) 
Poor:  Me (if R4 = Ph) 
Good: NO2 > H
Poor:  NH2, NHCOR
Good: Ph ~ Pyr > Thienyl ~ Pyrrolyl
Poor:  HGood: quinazoline ~ 6-methylpyrimidine
Good: N
Poor:  C
Good: N ~ C
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It is probable that HBAs at this region are beneficial for potent inhibition which is 
substantiated by the results of the 6-nitro derivatives in this work. 
The introduction of a nitrogen atom at R6 resulted in some interesting effects regarding 
the potency of the resulting pyrido[2,3-d]pyrimidine derivatives. In the case of 
substitution with a 2-phenyl moiety and a substituted aniline linker at position 4 an 
enantiotopic activity in relation to the corresponding quinazoline analogues was 
observed. Here, the inhibitory potency in a pyrido[2,3-d]pyrimidine derivative could be 
altered by exchanging nitrogen at R6 with a carbon atom, meaning that the inhibitory 
potency was reversed after the exchange. In this subset several highly potent compounds 
were found which were superior to Ko143 and exhibited IC50 values below 200 nM. 
Beneficial substituents were methoxy, fluoro, trifluoromethyl and 3-cyano functions. 
Notably, the highest potency was determined for the unsubstituted derivative 162 (IC50: 
149 nM, see chapter 6.2) which previously resulted in a low potency for the quinazoline 
derivative (compound 1, IC50: 882 nM). Additionally, a high selectivity toward ABCG2, 
a low intrinsic cytotoxicity and an enhanced watersolubility compared to a quinazoline 
scaffold was found for this class of compounds.      
Investigations of the importance of the left aromatic condensed core in the quinazoline 
scaffold highlighted some more interesting SAR regarding its contribution to inhibitory 
potency toward ABCG2. It was observed that the replacement of the left aromatic ring by 
a methyl function had only negligible effect on the inhibitory potency. Thus, the resulting 
2,4-substituted 6-methylpyrimidine derivatives possessed an extraordinarily high ligand 
efficiency containing only 3 aromatic cores. This comes with a considerably low 
calculated logP value and a comparable inhibitory potency toward ABCG2 in comparison 
to their quinazoline analogues.  
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9.3 Interaction of inhibitors with ABCG2 
 
Since the discovery of ABCG2 in 1998 some effort has been undertaken to collect 
information regarding the function of the transport protein. One approach was to utilize 
homology models based on related X-ray resolution structures, like the recently published 
ABCG5-ABCG8 heterodimer, which can help to validate experimental data and develop 
new ideas. 170,178 Here, a possible explanation for the broadened substrate spectrum in the 
mutant ABCG2 R482G isoform was given by an in silico docking study that aimed to 
identify possible substrate binding pockets in the transport protein. According to several 
experimental studies, it is known that ABCG2 possesses multiple binding sites for 
substrates and inhibitors. 66,112,167,209,212 Although the binding of substrates to ABCG2 is 
comparatively well explored, for instance by mutagenesis, photo-affinity labelling and a 
few binding studies, little is known about the binding of inhibitors.93,109,117,120,165,213  
Indeed, the need for new studies investigating the polyspecificity and drug binding in 
ABCG2, in particular in the presence of inhibitors, persists and needs to attract more 
notice in the future.  
This study aimed to find patterns in different cell based assays that will help to draw 
conclusions regarding the binding and interaction of inhibitors with ABCG2. Also, the 
collected data can be utilized to develop new inhibitors with the desired properties for 
further studies.  
The investigation of the interaction between selected inhibitors and ABCG2 was carried 
out in several functional cell based assays including the MDR reversal and cytotoxicity 
assay, enzyme kinetic studies, conformation sensitive 5D3 antibody binding and an 
investigation of the ATPase activity. The compounds were picked by criteria like a high 
inhibitory potency, which was determined in the Hoechst 33342 accumulation assay, or 
according to the results of previous functional assays.  
First and foremost, it is very likely that most of the investigated compounds are inhibitors 
of ABCG2 and not substrates. This assertion was substantiated by fluorescence 
spectrometric investigations of some potent fluorophores containing a quinazoline 
scaffold (see chapter 8.10) and also by means of a flow cytometric analysis on a FACS 
(data not shown) and confocal microscopy (see chapter 8.9). Moreover, the MTT 
cytotoxicity data showed for most compounds a very similar half maximal growth 
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inhibition (GI50) in the ABCG2 overexpressing and parental cells. If the compounds were 
subject to transport by ABCG2, a considerably lower cytotoxicity would be expected for 
the ABCG2 overexpressing cells. Also, a large portion of test-compounds reached a 
maximum inhibition between 80 and 110% in comparison to standard inhibitor Ko143, 
which suggests that they are no “partial inhibitors”.  
Regarding the selectivity toward ABCG2 it was found that the presence of methoxy 
groups led to an increase of the inhibition toward ABCB1 and ABCC1, the other two 
major MDR transport proteins. Here, the potency toward ABCB1 was more pronounced 
than toward ABCC1. Moreover, a higher selectivity toward ABCG2 resulted from the 
presence of nitro functions that were found to lead to potent inhibitors of ABCG2. 
Notably, some compound classes like the 2,4-substituted pyrido[2,3-d]pyrimidines in 
project IV and the 2,4-substituted 6-nitroquinazolines of project V were extraordinarily 
high selective for ABCG2. 
One key point in this study was the investigation of several compounds regarding their 
ability to reverse the MDR in a MDR reversal assay. The assay was carried out by co-
administration of the compounds with the cytostatic drugs Hoechst 33342, SN-38 and 
MX leading to full sensitization of the ABCG2 overexpressing cells toward the 
corresponding drugs for each compound. Due to several different concentrations that 
were used for SN-38 as well as for the corresponding compound, an EC50 value could be 
calculated characterizing the potency of a compound. In comparison to the IC50 values 
obtained from the Hoechst 33342 accumulation assay, the calculated EC50 values were 
either similar or frequently even lower, suggesting a higher potency of the compounds. 
An explanation for the difference in both types of assays could be different affinities of 
the substrates SN-38 and Hoechst 33342. Indeed, this is probably not the only reason 
since very similar IC50 values have been obtained with both cytostatic drugs as presented 
in chapter 3.5, which points to other factors like a different passive diffusion coefficient 
of the substrates. Indeed, the tendencies of the inhibitory potencies in the Hoechst 33342 
assay were well reflected in the results of the MDR reversal assay, illustrated for instance 
by compounds 162, 167 and 169 (see chapter 6.5). The pEC50 values obtained with SN-
38 showed a good correlation with those of MX (r2 = 0.96; outliers, namely compound 5 
and 162, were excluded). However, the EC50 values resulting with SN-38 were roughly 
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2.6 times higher, which can be attributed to the previously mentioned factors like a 
different passive diffusion coefficient. 
The enzyme kinetic investigation of the interaction between different compounds and the 
substrate Hoechst 33342 shed some light on the binding modes at ABCG2. By utilizing 
the kinetic methods according to Cornish-Bowden and Lineweaver-Burk it was 
concluded that most compounds exhibited a non-competitive interaction with Hoechst 
33342, including the drugs Ko143, gefitinib and elacridar. Hence, the binding sites of the 
compounds are different from that of the substrate Hoechst 33342. Among these, many 
compounds showed non-competitive interaction of the “mixed type”, meaning that they 
are able to influence the active site, probably via a conformational allosteric interaction. 
Also, it is possible that they bind near the Hoechst 33342 binding pocket, which would 
explain the strong impact of some “mixed-type”-inhibitors on the active site. Another 
reasonable mechanism could be a concentration depended binding of a compound to 
different high- and low-affinity binding sites as suggested by Pozza et al. who 
investigated the quenching of the intrinsic fluorescence of purified ABCG2.110 This 
theory is substantiated by some compounds giving bell-shaped curves in the ATPase 
assay which is discussed below. High portions of competitive interaction with Hoechst 
33342 were frequently found in compounds bearing para substituents, in particular for 
those containing lipophilic substituents like iodine, bromine and chlorine atoms (see 
compounds 17, 21 and 23, chapter 3.6 and compounds 112 and 150, chapter 5.6). 
According to the kinetic data, some of them could bind at the same binding pocket as 
Hoechst 33342. In large part, the obtained results are in agreement with those of other 
functional assays described below. 
Yet another possibility to distinguish the interactions of different inhibitors with ABCG2 
is by studying the conformational change they induce when binding to the protein. For 
this purpose the conformation sensitive 5D3 antibody was used and Ko143 set as control 
inhibitor resulting in 100% labelling. A high conformational change is expected for 
inhibitors of ABCG2 whereas substrates like Hoechst 33342 or Quercetin lead to a lower 
amount of labelling with the antibody.201 As expected, a low labelling was found for the 
substrates Hoechst 33342 (35%) and quercetin (40%) but a high labelling for the 
inhibitors elacridar (89%) and gefitinib (66%). For most of the investigated compounds 
of this study a labelling of more than 50% was observed. A high rate of labelling with 
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5D3 antibody between 70-90% resulted particularly for compounds that exhibited a high 
competitive portion in the interaction type investigation (e.g. compound 5, 17, 23, 54, 82 
and 139). Among these, a strong correlation between a high degree of labelling and a 
para substitution with higher halogen atoms or other functions like nitro and cyano was 
found. Moreover, no apparent relationship between the IC50 value of a compound and the 
degree of labelling was observed at 10 µM. Hence, the 5D3 assay may be utilized to 
provide information of the interaction of an inhibitor with ABCG2 and possibly to 
identify binding pockets. The collected data was mostly in accordance to the patterns that 
were found in the other functional assays that are discussed in this chapter.  
Further studies of the vanadate sensitive ATPase activity, which is associated with the 
transport activity of an ABC transport protein, provided some more insights into the 
interaction of different inhibitors with ABCG2. For instance, the investigation of the 
ATPase activity can help to distinguish between substrates and inhibitors of ABCG2. A 
high stimulation of the ATPase activity is expected for substrates like quercetin whereas 
inhibitors often led to deactivation, like Ko143. However, this distinction is 
oversimplified and has been proven not to apply to every inhibitor/substrate. The well-
known substrate Hoechst 33342 for instance showed a concentration dependent biphasic 
trend of the ATPase activity leading to deactivation at higher concentration (see chapter 
3.8) and substantiated the results from another research group.214 Regarding inhibitors of 
ABCG2 several compounds have been reported to stimulate the ATPase activity, some 
even to a considerable extent.209,215 In this study, different effects on ATPase activity 
could be observed for the investigated compounds. They contained deactivating 
compounds like Ko143 (e.g. 17, 23, 130 and 276), strongly stimulating compounds (e.g. 
4, 57, 131, 170, 178 and 244) and compounds that had negligible effect on the ATPase 
activity (e.g. 5, 19, 21, 58, 61, 105, 162, 167, 230, 263 and 266). A closer look at the 
substitution patterns showed that in many cases deactivation or only a low impact on 
ATPase activity was obtained by para substituted and strong stimulation by meta 
substituted derivatives. This phenomenon is for instance clearly seen by the meta/para 
compound pairs 130/131 and 143/144 (see chapter 5.8). Compounds containing a 3,4-
dimethoxy group like 144, 149 and 150 (see chapter 5.8) did frequently stimulate the 
ATPase activity at low concentration and deactivate it at high concentrations which led 
to bell-shaped concentration-activity curves. As explained previously, it is suggested that 
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those compounds bind in a concentration dependent matter to an activating high affinity 
and a deactivating low affinity binding pocket.110,206 The data also suggests that the 
lipophilicity of a substituent can influence the ATPase activity. Bulky alkyl substituents 
were for instance found to result in a sub-basal activity (compared in chapter 5.8 for 
compounds 113, 114, 117, 118 and 119). This is in accordance with a study of Egido et. 
al. where lipophilic compounds led to inhibition of ATPase activity and hydrophilic ones 
stimulated the ATPase activity.216 Similar observations were made for the less lipophilic 
compounds of project II and IV, which mostly stimulated the ATPase activity.217 More 
lipophilic scaffolds (e.g. project I and III) or functions like iodo and tert-butyl esters, as 
well as substitution in para position, frequently resulted in low stimulation or 
deactivation. 
Interestingly, most of the data collected in the kinetic investigation and the 5D3 binding 
study showed a good correlation with the ATPase activity. In the case of high competitive 
portions toward Hoechst 33342, an increased labelling by the conformation sensitive 5D3 
antibody was frequently observed leading to an ATPase activity at the basal level or 
lower.   
It is surprising, that the interaction of an inhibitor with ABCG2 can be altered 
considerably by minor modifications of the substitution pattern, as shown by the meta 
and para derivatives. Possible reasons for this could be due to the different 
physicochemical properties (e.g. lipophilicity), a differing sterical demand or changed 
interactions of the inhibitor with the protein at the binding pocket(s).      
In this comprehensive study of inhibitors of ABCG2 that are based on a quinazoline 
scaffold, a large amount of interesting data was collected about the SAR and also the 
interaction of the inhibitors with the transport protein. In six different projects several 
classes of compounds with systematic varied substitution patterns were investigated and 
the results categorized to find patterns among the functional assays. Hereby, some more 
light can be shed on the yet unclear function and complex mechanisms of ABCG2. The 
collected data can also help to develop further highly potent, nontoxic and selective 
inhibitors of ABCG2 that are promising candidates for clinical trials.    
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10.1 Chemistry 
10.1.1 Synthesis procedures and affiliated data  
10.1.1.1 Synthesis of 4-Substituted-2-phenylquinazolines and -
quinolines 
 
General procedure for the preparation of 4-anilino-2-phenylquinazoline derivatives 
4-chloro-2-phenylquinazoline (1 mmol) and a substituted aniline (1 mmol) were added to 
a 50 mL microwave tube and suspended in 25 mL isopropanol. The tube was sealed and 
the reaction mixture stirred under 100 watt microwave irradiation at 110 °C for 30 min. 
Completion of the reaction was monitored by TLC. After cooling, a precipitate was 
formed and filtered off by suction. If no precipitate was formed, the solvent was removed 
by rotary evaporation and the obtained solids recrystallized from 75% EtOH. In the case 
of incomplete reaction, triethylamine (1 mmol) was added to the mixture to react with 
HCl generated after the nucleophilic substitution. 
 
2-nitro-4-((2-phenylquinazolin-4-yl)amino)phenol (3)  
 
Molecular weight: 358.36 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-amino-2-nitrophenol (154 mg, 1 mmol) as described in the general 
procedure above to yield 3 as yellow solid (229 mg, 60%), mp 283-284 °C (decomp.). 
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1H NMR (500 MHz, DMSO-d6) δ 11.63 (s, 1H), 11.30 (s, 1H), 8.89 (d, J = 8.3 Hz, 1H), 
8.62 (d, J = 2.6 Hz, 1H), 8.42 (dt, J = 8.2, 1.1 Hz, 2H), 8.31 (d, J = 8.4 Hz, 1H), 8.13 – 
7.96 (m, 2H), 7.86 – 7.76 (m, 1H), 7.76 – 7.66 (m, 1H), 7.67 – 7.56 (m, 2H), 7.34 (dd, J 
= 9.0, 0.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.89, 157.56, 150.36, 141.61, 
136.02, 135.84, 133.23, 132.33, 131.32, 129.25, 129.08, 128.71, 128.11, 124.45, 121.52, 
120.67, 119.37, 112.95. Anal. Calcd. for C20H14N4O3: C, 67.03; H, 3.94; N, 15.63. 
Found: C, 66.85; H, 4.30; N, 15.52. 
 
4-((2-phenylquinazolin-4-yl)amino)benzonitrile (5).   
 
Molecular weight: 322.37 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-cyanoaniline (118 mg, 1 mmol) as described in the general procedure above 
to yield 5 as pale yellow solid (235 mg, 73%), mp 299-302 °C (decomp.).  
1H NMR (500 MHz, DMSO-d6) δ 11.57 (s, 1H), 8.95 (d, J = 8.3 Hz, 1H), 8.45 – 8.36 (m, 
2H), 8.30 (d, J = 8.4 Hz, 1H), 8.21 – 8.12 (m, 2H), 8.12 – 8.03 (m, 1H), 8.02 – 7.92 (m, 
2H), 7.86 – 7.76 (m, 1H), 7.72 – 7.65 (m, 1H), 7.65 – 7.57 (m, 2H). 13C NMR (126 MHz, 
DMSO) δ 159.08, 157.80, 143.23, 142.14, 135.84, 133.07, 132.94, 129.21, 129.12, 
128.06, 124.66, 124.12, 122.56, 118.98, 113.37, 107.45. Anal. Calcd for C21H14N4: C, 
78.24; H, 4.38; N, 17.38. Found: C, 78.03; H, 4.61; N, 17.56. 
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4-((2-phenylquinazolin-4-yl)amino)phenol (6). 
 
Molecular weight: 313.36 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-aminophenol (109 mg, 1 mmol) as described in the general procedure above 
to yield 6 as bright yellow solid (255 mg, 81%), mp 335-336 °C (decomp.). 
1H NMR (500 MHz, DMSO-d6) δ 11.53 (s, 1H), 9.77 (s, 1H), 8.87 (d, J = 8.3 Hz, 1H), 
8.42 – 8.28 (m, 3H), 8.10 – 8.00 (m, 1H), 7.83 – 7.75 (m, 1H), 7.74 – 7.66 (m, 1H), 7.66 
– 7.53 (m, 4H), 6.96 – 6.88 (m, 2H). 13C NMR (126 MHz, DMSO) δ 158.74, 157.21, 
156.19, 135.81, 133.41, 131.69, 129.30, 129.10, 128.13, 128.09, 126.17, 124.57, 120.45, 
115.35, 112.73. Anal. Calcd for C20H15N3O: C, 76.66; H, 4.83; N, 13.41; Found: C, 
76.72; H, 4.97; N, 13.34.  
 
4-((2-phenylquinazolin-4-yl)amino)benzenesulfonyl fluoride (7).  
 
Molecular weight: 379.41 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-aminobenzenesulfonyl fluoride (175 mg, 1 mmol) as described in the 
general procedure above to yield 7 as white solid (245 mg, 76%), mp 278-279 °C 
(decomp.). 
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1H NMR (500 MHz, DMSO-d6) δ 11.68 (s, 1H), 9.02 (t, J = 2.0 Hz, 1H), 8.95 (d, J = 8.3 
Hz, 1H), 8.49 – 8.38 (m, 3H), 8.28 (d, J = 8.4 Hz, 1H), 8.14 – 8.04 (m, 1H), 8.05 – 7.98 
(m, 1H), 7.92 (t, J = 8.1 Hz, 1H), 7.87 – 7.76 (m, 1H), 7.72 – 7.62 (m, 1H), 7.63 – 7.51 
(m, 2H). 13C NMR (126 MHz, DMSO) δ 159.00, 157.86, 139.62, 135.69, 132.80, 131.97, 
131.78, 131.09, 130.78, 129.07, 128.98, 127.96, 124.59, 124.43, 123.10, 122.71, 113.34. 
Anal. Calcd for C20H14FN3O2S: C, 63.31; H, 3.72; N, 11.08. Found: C, 63.68; H, 3.86; 
N, 10.99. 
 
N-(3-((2-phenylquinazolin-4-yl)amino)phenyl)acetamide (8).  
 
Molecular weight: 354.41 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and N-(3-aminophenyl)acetamide (150 mg, 1 mmol) as described in the general 
procedure above to yield 8 as white solid (135 mg, 38%), mp 291-293 °C. 1H NMR (500 
MHz, DMSO-d6) δ 11.46 (s, 1H), 10.22 (s, 1H), 8.88 (d, J = 8.3 Hz, 1H), 8.42 (dt, J = 
8.3, 1.2 Hz, 2H), 8.32 (d, J = 8.3 Hz, 1H), 8.28 (t, J = 2.0 Hz, 1H), 8.13 – 8.02 (m, 1H), 
7.87 – 7.76 (m, 1H), 7.75 – 7.65 (m, 1H), 7.61 (dd, J = 8.4, 7.0 Hz, 2H), 7.53 (dt, J = 7.5, 
1.9 Hz, 1H), 7.48 – 7.36 (m, 2H), 2.09 (s, 3H). 13C NMR (126 MHz, DMSO) δ 168.64, 
159.13, 157.46, 140.83, 139.88, 137.30, 135.85, 133.25, 131.89, 129.46, 129.01, 128.82, 
128.10, 124.60, 121.01, 119.37, 117.08, 115.22, 112.87, 24.15. Anal. Calcd. for 
C22H18N4O: C, 74.56; H, 5.12; N, 15.81. Found: C, 74.31; H, 5.26; N, 15.48. 
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N-(4-((2-phenylquinazolin-4-yl)amino)phenyl)acetamide (9). 
 
Molecular weight: 354.41 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and N-(4-aminophenyl)acetamide (150 mg, 1 mmol) as described in the general 
procedure above to yield 9 as white solid (163 mg, 46%), mp 238-240 °C. 1H NMR (500 
MHz, DMSO-d6) δ 11.40 (s, 1H), 10.18 (s, 1H), 8.84 (d, J = 8.3 Hz, 1H), 8.39 – 8.32 (m, 
2H), 8.26 (d, J = 8.4 Hz, 1H), 8.06 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.83 – 7.71 (m, 5H), 
7.71 – 7.66 (m, 1H), 7.63 (dd, J = 8.3, 6.7 Hz, 2H), 2.08 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 168.51, 158.80, 157.52, 137.64, 135.73, 133.14, 131.95, 129.15, 129.08, 
128.02, 124.85, 124.43, 123.56, 119.96, 119.07, 112.91, 24.14. Anal. Calcd. for 
C22H18N4O: C, 74.56; H, 5.12 N, 15.81. Found: C, 74.69; H, 5.33; N, 15.78. 
 
N-(3-(methylthio)phenyl)-2-phenylquinazolin-4-amine (10).  
 
Molecular weight: 343.45 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-(methylthio)aniline (139 mg, 1 mmol) as described in the general procedure 
above to yield 10 as pale yellow solid (243 mg, 71%), mp 138-139 °C. 1H NMR (600 
MHz, DMSO-d6) δ 10.56 (s, 1H), 8.71 (d, J = 8.1 Hz, 1H), 8.40 (d, J = 7.2 Hz, 2H), 8.04 
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(d, J = 8.1 Hz, 1H), 7.96 (d, J = 11.5 Hz, 2H), 7.70 (s, 2H), 7.56 (q, J = 6.9, 5.3 Hz, 3H), 
7.42 (t, J = 7.9 Hz, 1H), 7.12 (d, J = 7.6 Hz, 1H), 2.54 (s, 3H). 13C NMR (151 MHz, 
DMSO) δ 158.47, 139.13, 138.59, 129.22, 128.81, 128.54, 127.08, 123.80, 122.30, 
120.28, 119.57, 113.64, 99.68, 14.91. Anal. Calcd. for C21H17N3S: C, 73.44; H, 4.99; N, 
12.24. Found: C, 73.56; H, 4.84; N, 11.91 
 
N-(3,4-dimethoxyphenyl)-2-phenylquinazolin-4-amine (13)  
 
 
Molecular weight: 357.41 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3,4-dimethoxyaniline (153 mg, 1 mmol) as described in the general procedure 
above to yield 13 as bright yellow solid (171 mg, 48%), mp 135-137 °C. 1H NMR (500 
MHz, DMSO-d6) δ 11.46 (s, 1H), 8.90 (d, J = 8.3 Hz, 1H), 8.48 – 8.38 (m, 2H), 8.34 (d, 
J = 8.4 Hz, 1H), 8.16 – 7.94 (m, 1H), 7.80 (s, 1H), 7.75 – 7.67 (m, 1H), 7.67 – 7.54 (m, 
3H), 7.39 (dd, J = 8.7, 2.5 Hz, 1H), 7.09 (d, J = 8.7 Hz, 1H), 3.81 (d, J = 10.7 Hz, 6H). 
13C NMR (126 MHz, DMSO) δ 158.67, 158.14, 148.49, 146.02, 134.00, 132.05, 131.27, 
128.66, 128.33, 126.59, 123.46, 114.91, 113.75, 111.89, 108.00, 55.92, 55.67. Anal. 
Calcd. for C22H19N3O2: C, 73.93; H, 5.36; N, 11.76. Found: C, 73.63; H, 5.52; N, 11.77. 
 
 
 
 
 
 
 
10 Experimental section  253
N-(3,5-dimethoxyphenyl)-2-phenylquinazolin-4-amine (14) 
 
 
Molecular weight: 357.41 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3,5-dimethoxyaniline (153 mg, 1 mmol) as described in the general procedure 
above to yield 14 as yellow solid (279 mg, 78%),.mp 230-231 °C. 1H NMR (600 MHz, 
DMSO-d6) δ 11.25 (s, 1H), 8.90 (d, J = 8.3 Hz, 1H), 8.48 – 8.39 (m, 2H), 8.31 (d, J = 8.4 
Hz, 1H), 8.06 (t, J = 7.7 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1H), 7.69 (t, J = 7.3 Hz, 1H), 7.63 
(t, J = 7.6 Hz, 2H), 7.21 (d, J = 2.2 Hz, 2H), 6.46 (t, J = 2.2 Hz, 1H), 3.79 (s, 6H). 13C 
NMR (151 MHz, DMSO) δ 160.78, 159.29, 157.88, 139.45, 136.04, 133.41, 129.52, 
129.39, 128.39, 124.85, 114.98, 113.42, 102.67, 98.90, 55.89. Anal. Calcd. for 
C22H19N3O2: C, 73.93; H, 5.36 N, 11.76. Found: C, 74.02; H, 5.57; N, 11.51. 
 
N-(3-fluoro-4-methoxyphenyl)-2-phenylquinazolin-4-amine (15). 
 
Molecular weight: 345.38 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-fluoro-4-methoxyaniline (141 mg, 1 mmol) as described in the general 
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procedure above to yield 15 as light yellow solid (192 mg, 56%), mp 262-263 °C 
(decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.65 (s, 1H), 8.95 (d, J = 8.3 Hz, 1H), 8.43 
– 8.29 (m, 3H), 8.11 – 8.02 (m, 1H), 7.83 (dd, J = 13.1, 2.5 Hz, 1H), 7.82 – 7.77 (m, 1H), 
7.73 – 7.67 (m, 1H), 7.67 – 7.60 (m, 3H), 7.31 (t, J = 9.3 Hz, 1H), 3.90 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 158.93, 157.59, 151.75, 149.81, 145.45 (d, J = 10.4 Hz), 141.44, 
135.86, 133.23, 132.40, 130.17 (d, J = 9.5 Hz), 129.15, 128.13, 124.52, 121.38, 120.65, 
113.77 – 113.76 (d), 112.91, 112.75 (d, J = 21.9 Hz), 56.41. Anal. Calcd. for 
C21H16FN3O: C, 73.03; H, 4.67; N, 12.17. Found: C, 72.70; H, 4.84; N, 12.38. 
 
N-(4-bromo-3-methoxyphenyl)-2-phenylquinazolin-4-amine (16).  
 
Molecular weight: 406.28 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-bromo-3-methoxyaniline (202 mg, 1 mmol) as described in the general 
procedure above to yield 16 as yellow solid (280 mg, 69%), mp 276-278 °C (decomp.). 
1H NMR (500 MHz, DMSO-d6) δ 11.20 (s, 1H), 8.85 (d, J = 8.3 Hz, 1H), 8.52 – 8.31 (m, 
2H), 8.22 (d, J = 8.4 Hz, 1H), 8.06 (t, J = 7.8 Hz, 1H), 7.89 – 7.75 (m, 2H), 7.74 – 7.54 
(m, 4H), 3.90 (s, 3H). 13C NMR (151 MHz, DMSO) δ 158.90, 157.69, 155.42, 138.56, 
135.72, 132.78, 129.16, 129.09, 128.06, 124.47, 117.43, 114.66, 113.16, 108.65, 56.44. 
Anal. Calcd. for C21H16BrN3O: C, 62.08; H, 3.97; N, 10.34. Found: C, 61.81; H, 4.23; 
N, 10.29. 
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N-(4-iodo-3-methylphenyl)-2-phenylquinazolin-4-amine (17). 
 
Molecular weight: 437.28 g/mol 
 
 The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-iodo-3-methylaniline (233 mg, 1 mmol) as described in the general 
procedure above to yield 17 as beige solid (224 mg, 51%), mp 274-276 °C (decomp.). 1H 
NMR (500 MHz, DMSO-d6) δ 11.48 (s, 1H), 8.91 (d, J = 8.4 Hz, 1H), 8.43 – 8.36 (m, 
2H), 8.33 (d, J = 8.5 Hz, 1H), 8.12 – 8.01 (m, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 
2.5 Hz, 1H), 7.83 – 7.75 (m, 1H), 7.74 – 7.66 (m, 1H), 7.66 – 7.58 (m, 2H), 7.52 (dd, J = 
8.5, 2.6 Hz, 1H), 2.44 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.85, 157.54, 141.24, 
138.74, 137.69, 135.78, 133.12, 129.19, 129.11, 128.06, 125.38, 124.49, 123.57, 121.67, 
113.07, 97.31, 27.76. Anal. Calcd. for C21H16IN3: C, 57.68; H, 3.69; N, 9.61. Found: C, 
57.96; H, 3.82; N, 9.51. 
 
N-(3-fluorophenyl)-2-phenylquinazolin-4-amine (18). 
 
Molecular weight: 315.35 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-fluoroaniline (111 mg, 1 mmol) as described in the general procedure above 
to yield 18 as pale yellow solid (269 mg, 85%), mp 298-299 °C (decomp.). 1H NMR (500 
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MHz, DMSO-d6) δ 11.59 (s, 1H), 8.96 (d, J = 8.6 Hz, 1H), 8.39 (dq, J = 7.1, 1.5 Hz, 2H), 
8.35 (d, J = 8.9 Hz, 1H), 8.12 – 8.01 (m, 1H), 7.90 – 7.77 (m, 2H), 7.77 – 7.72 (m, 1H), 
7.72 – 7.66 (m, 1H), 7.63 (t, J = 7.5 Hz, 2H), 7.56 (td, J = 8.2, 6.7 Hz, 1H), 7.16 (td, J = 
8.5, 2.6 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.92, 160.99, 159.15, 157.59, 139.08 
(d, J = 6.3 Hz), 135.87, 133.14, 130.38 (d, J = 9.2 Hz), 129.19, 129.08, 128.10, 124.65, 
120.17, 113.03, 112.74 (d, J = 16.3 Hz), 111.29 (d, J = 24.3 Hz).Anal. Calcd. for 
C20H14FN3: C, 76.18; H, 4.48; N, 13.33. Found: C, 76.54; H, 4.60; N, 13.08. 
 
N-(4-fluorophenyl)-2-phenylquinazolin-4-amine (19). 
 
 
Molecular weight: 315.35 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-fluoroaniline (111 mg, 1 mmol) as described in the general procedure above 
to yield 19 as beige solid (213 mg, 68%), mp 271-272 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 11.52 (s, 1H), 8.89 (d, J = 8.3 Hz, 1H), 8.43 – 8.34 (m, 2H), 8.30 (d, J = 8.7 
Hz, 1H), 8.13 – 7.99 (m, 1H), 7.97 – 7.84 (m, 2H), 7.85 – 7.75 (m, 1H), 7.74 – 7.65 (m, 
1H), 7.64 – 7.54 (m, 2H), 7.44 – 7.32 (m, 2H). 13C NMR (126 MHz, DMSO) δ 161.01 – 
159.08 (J = 233 Hz) , 159.15, 157.51, 141.64, 135.80, 133.53, 133.16, 132.26, 129.24 – 
129.06 (J = 21,7 Hz), 128.04, 126.68 – 126.62 (J = 7,9 Hz), 124.62, 121.35, 115.66 – 
115.48 (22,6 Hz), 112.90. Anal. Calcd. for C20H14FN3: C, 76.18; H, 4.48; N, 13.33. 
Found: C, 76.32; H, 4.87; N, 13.12. 
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N-(4-chlorophenyl)-2-phenylquinazolin-4-amine (21)  
 
 
Molecular weight: 331.80 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-chloroaniline (128 mg, 1 mmol) as described in the general procedure above 
to yield 21 as pale yellow solid (227 mg, 69%), mp 288-289 °C (decomp.). 1H NMR (500 
MHz, DMSO-d6) δ 11.54 (s, 1H), 8.91 (d, J = 8.4 Hz, 1H), 8.45 – 8.34 (m, 2H), 8.31 (d, 
J = 8.5 Hz, 1H), 8.15 – 8.01 (m, 1H), 7.99 – 7.86 (m, 2H), 7.87 – 7.75 (m, 1H), 7.77 – 
7.66 (m, 1H), 7.66 – 7.47 (m, 4H). 13C NMR (126 MHz, DMSO) δ 159.08, 157.93, 
150.63, 138.44, 138.32, 133.47, 130.45, 128.59, 128.52, 128.29, 128.04, 127.32, 126.17, 
123.84, 123.14, 114.10. Anal. Calcd. for C20H14ClN3: C, 72.40; H, 4.25; N, 12.66. 
Found: C, 72.17; H, 4.39; N, 12.58. 
 
N-(3-iodophenyl)-2-phenylquinazolin-4-amine (22).  
 
Molecular weight: 423.26 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-iodoaniline (219 mg, 1 mmol) as described in the general procedure above 
to yield 22 as pale yellow solid (145 mg, 34%), mp 226-227 °C. 1H NMR (500 MHz, 
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DMSO-d6) δ 11.51 (s, 1H), 8.91 (d, J = 8.3 Hz, 1H), 8.49 – 8.38 (m, 3H), 8.32 (d, J = 8.4 
Hz, 1H), 8.12 – 8.02 (m, 1H), 7.93 – 7.84 (m, 1H), 7.84 – 7.76 (m, 1H), 7.73 – 7.65 (m, 
2H), 7.65 – 7.57 (m, 2H), 7.32 (t, J = 8.0 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.96, 
157.42, 142.00, 138.74, 135.81, 134.41, 133.16, 132.70, 130.71, 129.20, 129.03, 128.06, 
124.55, 123.36, 121.70, 113.02, 94.03. Anal. Calcd. for C20H14IN3: C, 56.76; H, 3.33; 
N, 9.93. Found: C, 56.38; H, 3.68; N, 10.04. 
 
N-(4-iodophenyl)-2-phenylquinazolin-4-amine (23).  
 
Molecular weight: 423.26 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-iodoaniline (219 mg, 1 mmol) as described in the general procedure above 
to yield 23 as pale yellow solid (166 mg, 39%), mp 271-272 °C (decomp.). 1H NMR (500 
MHz, DMSO-d6) δ 11.50 (s, 1H), 8.91 (d, J = 8.4 Hz, 1H), 8.47 – 8.35 (m, 2H), 8.31 (d, 
J = 8.4 Hz, 1H), 8.11 – 8.00 (m, 1H), 7.94 – 7.83 (m, 2H), 7.83 – 7.75 (m, 1H), 7.76 – 
7.66 (m, 3H), 7.66 – 7.56 (m, 2H). 13C NMR (126 MHz, DMSO) δ 159.17, 158.03, 
142.34, 137.83, 137.43, 136.14, 133.33, 132.90, 129.43, 129.29, 128.41, 126.57, 124.50, 
122.06, 113.26, 91.09. Anal. Calcd. for C20H14IN3: C, 56.76; H, 3.33; N, 9.93. Found: 
C, 56.65; H, 3.62; N, 9.91. 
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methyl 4-((2-phenylquinazolin-4-yl)amino)benzoate (24).  
 
Molecular weight: 355.40 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and methyl 3-aminobenzoate (193 mg, 1 mmol) as described in the general 
procedure above to yield 24 as white solid (195 mg, 55%), mp 273-275 °C (decomp.). 1H 
NMR (500 MHz, DMSO-d6) δ 10.11 (s, 1H), 8.61 (d, J = 8.4 Hz, 1H), 8.47 (d, J = 7.3 
Hz, 2H), 8.20 (d, J = 8.4 Hz, 2H), 8.07 (d, J = 8.3 Hz, 2H), 7.90 (d, J = 4.1 Hz, 2H), 7.65 
(t, J = 5.8 Hz, 1H), 7.54 (q, J = 8.9, 7.9 Hz, 3H), 3.86 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 166.06, 159.04, 157.86, 150.78, 144.26, 138.21, 133.63, 130.53, 130.08, 
128.66, 128.35, 128.08, 126.34, 123.95, 123.27, 121.12, 114.29, 52.01, 40.20. Anal. 
Calcd. for C22H17N3O2: C, 74.35; H, 4.82; N, 11.82. Found: C, 74.29; H, 5.13 N, 11.43. 
 
tert-butyl 4-((2-phenylquinazolin-4-yl)amino)benzoate (25).  
 
Molecular weight: 397.48 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and tert-butyl 3-aminobenzoate (193 mg, 1 mmol) as described in the general 
procedure above to yield 25 as pale yellow solid (302 mg,76%), mp 328- 330 °C 
(decomp.). 1H NMR (600 MHz, DMSO-d6) δ 11.44 (s, 1H), 8.91 (t, J = 7.8 Hz, 1H), 8.47 
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– 8.35 (m, 2H), 8.28 (d, J = 7.9 Hz, 1H), 8.12 – 7.98 (m, 5H), 7.81 (dd, J = 9.2, 6.2 Hz, 
1H), 7.68 (t, J = 7.2 Hz, 1H), 7.64 (dd, J = 8.2, 6.5 Hz, 2H), 1.57 (s, 9H). 13C NMR (126 
MHz, DMSO) δ 166.91, 164.61, 158.99, 157.78, 141.68, 135.74, 132.92, 130.08, 129.81, 
129.18, 129.10, 128.13, 127.99, 124.52, 123.43, 122.20, 113.25, 80.86, 27.98. Anal. 
Calcd. for C25H23N3O2: C, 75.55; H, 5.83; N, 10.57. Found: C, 75.43; H, 5.89 N, 10.87. 
 
4-((2-phenylquinazolin-4-yl)amino)benzoic acid (26).  
 
Molecular weight: 341.37 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-aminobenzoic acid (137 mg, 1 mmol) as described in the general procedure 
above to yield 26 as light yellow solid (254 mg, 74%), mp 336-337 °C (decomp.). 1H 
NMR (600 MHz, DMSO-d6) δ 11.98 (s, 1H), 11.79 (s, 1H), 9.03 (d, J = 8.3 Hz, 1H), 8.43 
(d, J = 7.6 Hz, 3H), 8.25 – 7.93 (m, 5H), 7.81 (t, J = 7.7 Hz, 1H), 7.66 (dt, J = 36.7, 7.5 
Hz, 3H). 13C NMR (151 MHz, DMSO) δ 166.92, 159.17, 157.47, 141.35, 136.03, 133.33, 
130.05, 129.45, 129.14, 128.22, 128.04, 124.89, 123.95, 113.11. Anal. Calcd. for 
C21H15N3O2: C, 73.89; H, 4.43; N, 12.31. Found: C, 74.26; H, 4.64 N, 12.10. 
 
N-(3-ethynylphenyl)-2-phenylquinazolin-4-amine (27). 
 
Molecular weight: 321.38 g/mol 
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 The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-ethynylaniline (117 mg, 1 mmol) as described in the general procedure 
above to yield 27 as pale yellow solid (213 mg, 66%), mp 222-224 °C. 1H NMR (500 
MHz, DMSO-d6) δ 11.77 (s, 1H), 9.01 (d, J = 8.3 Hz, 1H), 8.49 – 8.31 (m, 3H), 8.14 – 
8.00 (m, 2H), 7.98 – 7.87 (m, 1H), 7.86 – 7.75 (m, 1H), 7.74 – 7.65 (m, 1H), 7.61 (t, J = 
7.6 Hz, 2H), 7.54 (t, J = 7.9 Hz, 1H), 7.43 (dt, J = 7.6, 1.2 Hz, 1H), 4.27 (s, 1H). 13C 
NMR (126 MHz, DMSO) δ 157.23, 141.16, 137.44, 135.91, 133.31, 131.87, 129.33, 
129.27, 129.18, 128.99, 128.12, 127.57, 125.09, 124.78, 122.07, 121.00, 112.88, 82.95, 
81.23. Anal. Calcd. for C22H15N3: C, 82.22; H, 4.70; N, 13.08. Found: C, 82.14; H, 5.05 
N, 12.83. 
 
2-phenyl-N-(m-tolyl)quinazolin-4-amine (28).  
 
Molecular weight: 311.39 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-methylaniline (107 mg, 1 mmol) as described in the general procedure above 
to yield 28 as pale yellow solid (247 mg, 79%), mp >300 °C. 1H NMR (500 MHz, DMSO-
d6) δ 11.58 (s, 1H), 8.95 (d, J = 8.3 Hz, 1H), 8.51 – 8.28 (m, 3H), 8.15 – 7.97 (m, 1H), 
7.87 – 7.76 (m, 1H), 7.75 – 7.55 (m, 5H), 7.41 (t, J = 7.8 Hz, 1H), 7.22 – 7.10 (m, 1H), 
2.40 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.01, 157.35, 141.16, 138.12, 137.07, 
135.82, 133.26, 132.18, 129.25, 129.07, 128.63, 128.09, 127.05, 124.96, 124.59, 121.62, 
121.19, 112.91, 21.20. Anal. Calcd. for C21H17N3: C, 81.00; H, 5.50; N, 13.49. Found: 
C, 80.84; H, 5.79; N, 13.55. 
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2-phenyl-N-(p-tolyl)quinazolin-4-amine. (29)  
 
Molecular weight: 311.39 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-methylaniline (107 mg, 1 mmol) as described in the general procedure above 
to yield 29 as pale yellow solid (256 mg, 82%), mp 254-256 °C (decomp.). 1H NMR (500 
MHz, DMSO-d6) δ 11.56 (s, 1H), 8.92 (d, J = 8.3 Hz, 1H), 8.45 – 8.28 (m, 3H), 8.14 – 
8.00 (m, 1H), 7.87 – 7.76 (m, 1H), 7.76 – 7.66 (m, 3H), 7.65 – 7.55 (m, 2H), 7.39 – 7.26 
(m, 2H), 2.37 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.98, 157.39, 140.84, 135.90, 
134.49, 133.36, 131.93, 129.31, 129.29, 129.12, 128.17, 124.65, 124.46, 120.85, 112.87, 
20.86. Anal. Calcd. for C21H17N3: C, 81.00; H, 5.50; N, 13.49. Found: C, 81.37; H, 5.58; 
N, 13.23. 
 
N-(3-(tert-butyl)phenyl)-2-phenylquinazolin-4-amine (30).  
 
Molecular weight: 353.47 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 3-(tert-butyl)aniline (149 mg, 1 mmol) as described in the general procedure 
above to yield 30 as pale yellow solid (263 mg, 74%), mp 223-224 °C. 1H NMR (500 
MHz, DMSO-d6) δ 11.63 (s, 1H), 8.98 (d, J = 8.3 Hz, 1H), 8.52 – 8.33 (m, 3H), 8.13 – 
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8.02 (m, 1H), 7.94 (t, J = 2.0 Hz, 1H), 7.81 (td, J = 7.7, 7.2, 1.2 Hz, 1H), 7.69 (td, J = 7.3, 
1.2 Hz, 1H), 7.66 – 7.62 (m, 1H), 7.62 – 7.55 (m, 2H), 7.45 (t, J = 7.9 Hz, 1H), 7.40 – 
7.35 (m, 1H), 1.34 (d, J = 0.9 Hz, 9H). 13C NMR (126 MHz, DMSO) δ 158.99, 157.24, 
151.37, 140.98, 136.81, 135.83, 133.34, 131.86, 129.31, 128.91, 128.45, 128.08, 124.65, 
123.37, 121.69, 121.62, 120.89, 112.89, 34.72, 31.22. Anal. Calcd. for C24H23N3: C, 
81.55; H, 6.56; N, 11.89. Found: C, 81.47; H, 6.89; N, 11.70. 
 
N-(4-(tert-butyl)phenyl)-2-phenylquinazolin-4-amine (31).  
 
Molecular weight: 353.47 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 4-(tert-butyl)aniline (149 mg, 1 mmol) as described in the general procedure 
above to yield 31 as pale yellow solid (233 mg, 66%), mp 287-289 °C (decomp.). 1H 
NMR (500 MHz, DMSO-d6) δ 11.66 (s, 1H), 9.02 (d, J = 8.3 Hz, 1H), 8.53 – 8.29 (m, 
3H), 8.11 – 7.99 (m, 1H), 7.89 – 7.73 (m, 3H), 7.70 (td, J = 7.1, 6.7, 1.4 Hz, 1H), 7.62 
(td, J = 7.2, 6.6, 1.3 Hz, 2H), 7.57 – 7.45 (m, 2H), 1.33 (d, J = 1.1 Hz, 9H). 13C NMR 
(126 MHz, DMSO) δ 158.82, 157.46, 148.93, 140.82, 135.83, 134.56, 133.25, 131.92, 
129.32, 129.07, 128.08, 125.45, 124.70, 123.87, 120.84, 112.86, 34.48, 31.27. Anal. 
Calcd. for C24H23N3: C, 81.55; H, 6.56; N, 11.89. Found: C, 81.68; H, 6.62; N, 11.89. 
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5-((2-phenylquinazolin-4-yl)amino)isoindoline-1,3-dione (32). 
 
 
Molecular weight: 366.38 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 5-aminoisoindoline-1,3-dione (162 mg, 1 mmol) as described in the general 
procedure above to yield 32 as slightly yellow solid (227 mg, 62%), mp >300 °C. 1H 
NMR (500 MHz, DMSO-d6) δ 11.44 (s, 1H), 11.33 (s, 1H), 8.90 (d, J = 8.4 Hz, 1H), 8.52 
(d, J = 1.8 Hz, 1H), 8.46 – 8.39 (m, 2H), 8.35 (dd, J = 8.2, 1.9 Hz, 1H), 8.22 (d, J = 8.4 
Hz, 1H), 8.05 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.79 (ddd, J = 8.3, 
7.0, 1.2 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.60 (dd, J = 8.2, 6.6 Hz, 2H). 13C NMR (126 
MHz, DMSO) δ 168.98, 168.89, 158.93, 157.90, 143.48, 135.59, 133.79, 132.66, 129.03, 
128.41, 128.08, 127.87, 124.47, 123.81, 117.37, 113.47. Anal. Calcd. for C22H14N4O2: 
C, 72.12; H, 3.85 N, 15.29. Found: C, 72.31; H, 4.06; N, 15.21. 
 
4-methyl-7-((2-phenylquinazolin-4-yl)amino)-2H-chromen-2-one (33). 
 
Molecular weight: 379.42 g/mol 
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The title compound was synthesized from 4-chloro-2-phenylquinazoline (241 mg, 1 
mmol) and 7-amino-4-methyl-2H-chromen-2-one (175 mg, 1 mmol) as described in the 
general procedure above to yield 33 as a yellow solid (292 mg, 77%), mp >300 °C. 1H 
NMR (500 MHz, DMSO-d6) δ 11.37 (s, 1H), 8.91 (d, J = 8.3 Hz, 1H), 8.44 – 8.36 (m, 
2H), 8.24 (d, J = 8.3 Hz, 1H), 8.11 – 8.03 (m, 2H), 8.00 (dd, J = 8.6, 2.1 Hz, 1H), 7.88 
(d, J = 8.6 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.67 (dd, J = 8.2, 6.1 Hz, 1H), 7.62 (dd, J = 
8.2, 6.4 Hz, 2H), 6.36 (d, J = 1.4 Hz, 1H), 2.47 (d, J = 1.2 Hz, 3H). 13C NMR (126 MHz, 
DMSO) δ 160.00, 158.88, 157.93, 153.34, 153.11, 141.17, 135.61, 132.72, 129.05, 
127.89, 125.71, 124.42, 119.30, 116.82, 113.47, 113.40, 110.34, 18.19. Anal. Calcd. for 
C24H17N3O2: C, 75.98; H, 4.52 N, 11.08. Found: C, 75.94; H, 4.78; N, 11.06. 
 
General Procedure for the preparation of 4-anilino-2-phenylquinoline derivatives 
4-chloro-2-phenylquinoline (1 mmol) and a substituted aniline (1 mmol) were added to a 
50 mL microwave tube and suspended in 25 mL isopropanol. The tube was sealed and 
the reaction mixture stirred under 100 watt microwave irradiation at 110 °C for 15 min. 
Reaction control was performed by TLC. Workup of the compounds was analogous to 4-
anilino-quinazoline compounds. For some quinoline derivatives it was necessary to 
recrystallize from acetone. In the case of incomplete reaction, triethylamine (1 mmol) was 
added to the mixture to react with HCl generated by the nucleophilic substitution. 
 
2-nitro-4-((2-phenylquinolin-4-yl)amino)phenol (34). 
 
Molecular weight: 357.37 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinoline (240 mg, 1 mmol) 
and 4-amino-2-nitrophenol (154 mg, 1 mmol) as described in the general procedure above 
to yield 34 as a yellow solid (218 mg, 61%), mp 238-239 °C. 1H NMR (500 MHz, 
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DMSO-d6) δ 11.50 (s, 1H), 11.05 (s, 1H), 8.82 (dd, J = 8.7, 1.3 Hz, 1H), 8.34 (dd, J = 
8.5, 1.1 Hz, 1H), 8.11 – 7.98 (m, 2H), 7.97 – 7.86 (m, 2H), 7.80 (ddd, J = 8.3, 7.0, 1.2 
Hz, 1H), 7.75 (dd, J = 8.8, 2.7 Hz, 1H), 7.70 – 7.57 (m, 3H), 7.39 (d, J = 8.9 Hz, 1H), 
6.95 (s, 1H). 13C NMR (126 MHz, DMSO) δ 155.10, 153.13, 151.34, 139.26, 137.21, 
134.13, 132.67, 132.32, 132.02, 129.33, 128.74, 128.32, 127.14, 123.59, 122.61, 120.90, 
120.60, 116.63, 99.01. Anal. Calcd. for C21H15N3O3: C, 70.58; H, 4.23 N, 11.76. Found: 
C, 70.93; H, 4.49; N, 11.71. 
 
3-((2-phenylquinolin-4-yl)amino)benzonitrile (35). 
 
Molecular weight: 321.38 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinoline (240 mg, 1 mmol) 
and 3-aminobenzonitrile (118 mg, 1 mmol) as described in the general procedure above 
to yield 35 as a yellow solid (273 mg, 85%), mp 267-269 °C. 1H NMR (500 MHz, 
DMSO-d6) δ 11.33 (s, 1H), 8.98 – 8.90 (m, 1H), 8.45 – 8.37 (m, 1H), 8.09 (t, J = 1.8 Hz, 
1H), 8.05 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.99 – 7.93 (m, 3H), 7.87 – 7.78 (m, 2H), 7.75 
(t, J = 7.9 Hz, 1H), 7.69 – 7.58 (m, 3H), 7.09 (s, 1H). 13C NMR (126 MHz, DMSO) δ 
154.38, 153.40, 139.46, 138.75, 134.16, 132.30, 132.04, 131.33, 130.74, 130.11, 129.30, 
128.85, 128.63, 127.24, 123.93, 121.06, 118.33, 117.02, 112.89, 99.65. Anal. Calcd. for 
C22H15N3: C, 82.22; H, 4.70 N, 13.08. Found: C, 82.34; H, 5.02; N, 12.70. 
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4-((2-phenylquinolin-4-yl)amino)benzonitrile (36). 
N
HN
CN
 
Molecular weight: 321.38 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinoline (240 mg, 1 mmol) 
and 4-aminobenzonitrile (118 mg, 1 mmol) to yield 36 as pale yellow solid (170 mg, 
53%), mp 290 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 14.53 (s, 1H), 11.21 (s, 
1H), 8.87 (d, J = 8.6 Hz, 1H), 8.38 (d, J = 8.5 Hz, 1H), 8.06 (t, J = 7.7 Hz, 1H), 8.02 – 
7.93 (m, 4H), 7.82 (t, J = 9.0 Hz, 3H), 7.74 – 7.58 (m, 3H), 7.33 (s, 1H). 13C NMR (126 
MHz, DMSO) δ 156.48, 148.43, 142.42, 137.61, 131.24, 130.26, 129.83, 129.02, 128.05, 
127.50, 124.69, 123.66, 118.99. 13C NMR (126 MHz, DMSO) δ 153.65, 142.62, 134.14, 
132.05, 129.33, 128.85, 127.34, 124.58, 123.89, 118.78, 117.58, 100.74. Anal. Calcd. 
for C22H16N3: C, 81.96; H, 5.00; N, 13.03. Found: C, 81.73; H, 5.39; N, 12.82. 
 
N-(3-((2-phenylquinolin-4-yl)amino)phenyl)acetamide (37).  
 
Molecular weight: 353.43 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinoline (240 mg, 1 mmol) 
and N-(3-aminophenyl)acetamide (150 mg, 1 mmol) to yield 37 as pale yellow solid (136 
mg, 38%), mp 281 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 14.25 (s, 1H), 11.05 
(s, 1H), 10.38 (s, 1H), 8.85 (dd, J = 8.6, 1.3 Hz, 1H), 8.35 (dd, J = 8.6, 1.1 Hz, 1H), 8.08 
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– 8.01 (m, 1H), 7.98 (d, J = 2.1 Hz, 1H), 7.96 – 7.91 (m, 2H), 7.82 – 7.76 (m, 1H), 7.68 
– 7.58 (m, 3H), 7.52 – 7.43 (m, 2H), 7.23 (dt, J = 7.2, 1.9 Hz, 1H), 7.05 (s, 1H), 2.08 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 168.89, 154.61, 153.04, 140.80, 139.35, 137.52, 
134.10, 132.39, 132.00, 130.23, 129.38, 128.67, 127.09, 123.66, 120.89, 119.61, 117.85, 
116.73, 115.58, 99.01, 24.17. Anal. Calcd. for C23H20N3O: C, 77.94; H, 5.69; N, 11.86. 
Found: C, 78.20; H, 5.65; N, 11.97. 
 
N-(3-methoxyphenyl)-2-phenylquinolin-4-amine (38).  
 
Molecular weight: 326.40 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinoline (240 mg, 1 mmol) 
and 3-methoxyaniline (123 mg, 1 mmol) to yield 38 as yellow solid (76 mg, 23%), mp 
279 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 14.41 (s, 1H), 11.17 (s, 1H), 8.93 
(dd, J = 8.6, 1.2 Hz, 1H), 8.44 (dd, J = 8.6, 1.2 Hz, 1H), 8.07 – 7.97 (m, 1H), 7.95 – 7.83 
(m, 2H), 7.82 – 7.71 (m, 1H), 7.69 – 7.52 (m, 3H), 7.51 – 7.38 (m, 1H), 7.22 – 7.07 (m, 
2H), 7.05 – 6.90 (m, 2H), 3.80 (d, J = 0.9 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
160.51, 154.74, 152.96, 139.40, 138.61, 134.02, 132.37, 131.94, 130.84, 129.35, 128.63, 
127.00, 123.83, 120.90, 117.30, 116.74, 113.15, 111.14, 99.23, 55.58. Anal. Calcd. for 
C22H19N2O: C, 80.71; H, 5.85; N, 8.56. Found: C, 80.74; H, 5.81; N, 8.86. 
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N-(3-(methylthio)phenyl)-2-phenylquinolin-4-amine (39).   
 
Molecular weight: 342.46 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinoline (240 mg, 1 mmol) 
and 3-(methylthio)aniline (139 mg, 1 mmol) to yield 39 as pale yellow solid (243 mg, 
71%), mp 238-240 °C. 1H NMR (600 MHz, DMSO-d6) δ 14.42 (s, 1H), 11.22 (s, 1H), 
8.93 (dd, J = 8.5, 3.1 Hz, 1H), 8.43 (dd, J = 8.6, 3.1 Hz, 1H), 8.03 (td, J = 7.9, 3.1 Hz, 
1H), 7.90 (dd, J = 7.8, 3.0 Hz, 2H), 7.78 (td, J = 7.9, 3.1 Hz, 1H), 7.72 – 7.54 (m, 3H), 
7.54 – 7.42 (m, 2H), 7.42 – 7.32 (m, 1H), 7.27 (t, J = 5.4 Hz, 1H), 6.98 (d, J = 3.2 Hz, 
1H). 13C NMR (151 MHz, DMSO) δ 154.68, 152.99, 140.47, 139.37, 138.15, 134.10, 
132.35, 132.01, 130.36, 129.38, 128.68, 127.08, 124.58, 123.89, 122.29, 121.45, 120.89, 
116.80, 99.27, 14.71. Anal. Calcd. for C22H19N2S: C, 76.93; H, 5.58; N, 8.16. Found: C, 
77.31; H, 5.48; N, 7.99. 
 
N-(3-fluorophenyl)-2-phenylquinolin-4-amine (40). 
 
Molecular weight: 342.46 g/mol 
 
The title compound was synthesized from 4-chloro-2-phenylquinoline (240 mg, 1mmol) 
and 3-fluoroaniline (111 mg, 1 mmol) to yield 40 as yellow solid (188 mg, 60%), mp 283 
°C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 14.44 (s, 1H), 11.22 (s, 1H), 8.92 (dd, 
J = 8.5, 1.4 Hz, 1H), 8.41 (dd, J = 8.5, 1.1 Hz, 1H), 8.13 – 8.00 (m, 1H), 8.00 – 7.89 (m, 
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2H), 7.85 – 7.75 (m, 1H), 7.72 – 7.55 (m, 4H), 7.56 – 7.43 (m, 2H), 7.31 – 7.19 (m, 1H), 
7.08 (s, 1H). 13C NMR (126 MHz, DMSO) δ 163.72, 161.78, 154.50, 153.24, 139.34 (d, 
J = 10.4 Hz), 134.15, 132.32, 132.02, 131.68 (d, J = 9.3 Hz), 129.35, 128.75, 127.18, 
123.85, 121.25, 120.96, 116.89, 114.10 (d, J = 20.7 Hz), 112.48 (d, J = 23.7 Hz), 99.52. 
Anal. Calcd. for C22H16N2O: C, 79.98; H, 5.11; N, 8.88. Found: C, 80.24; H, 4.81; N, 
8.91. 
10.1.1.2 Synthesis of 4-Substituted-2-pyridylquinazolines and –
pyrimidines 
 
 
General Procedure for the Preparation of the 2-pyridylquinazolin-4(3H)-one 
derivatives 41-43. A mixture of anthranilamide (2.72 g, 20 mmol), the corresponding 
pyridinecarboxaldehyde (20 mmol), iodine (3.17 g, 25 mmol), anhydrous potassium 
carbonate (2.76 g, 20 mmol) and 20 ml DMF was stirred at 70-90 °C for 4-8 h. The end 
of the reaction was monitored by TLC and the mixture poured on crushed ice to form a 
precipitate. Incomplete precipitation was prevented by adjusting the pH with concentrated 
HCl solution to about 7. After filtering off the precipitate, it was thoroughly washed with 
100 mL of a 20% sodium thiosulfate solution followed by 100 mL of hot distilled water. 
Purification was performed by recrystallization from ethanol.    
 
2-(pyridin-2-yl)quinazolin-4(3H)-one (41).  
 
Molecular weight: 223.24 g/mol 
 
The compound was synthesized from picolinaldehyde (2.14 g, 20 mmol) as described in 
the general procedure for 41-43 to yield 41 as a white solid (3,84 g, 86%). 1H NMR (500 
MHz, DMSO-d6) δ 11.77 (s, 1H), 8.76 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 8.46 (dt, J = 7.9, 
1.1 Hz, 1H), 8.18 (dd, J = 7.9, 1.5 Hz, 1H), 8.07 (td, J = 7.7, 1.7 Hz, 1H), 7.87 (ddd, J = 
8.5, 7.0, 1.6 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.66 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.57 
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(ddd, J = 8.1, 7.0, 1.2 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 149.10, 148.82, 138.11, 
134.80, 127.82, 127.37, 126.70, 126.23, 122.29, 122.13. 
 
2-(pyridin-3-yl)quinazolin-4(3H)-one (42).  
 
Molecular weight: 223.24 g/mol 
 
The compound was synthesized from nicotinaldehyde (2.14 g, 20 mmol) as described in 
the general procedure for 41-43 to yield 42 as a white solid (3,34 g, 75%). 1H NMR (500 
MHz, DMSO-d6) δ 12.70 (s, 1H), 9.30 (d, J = 2.3 Hz, 1H), 8.76 (dd, J = 4.8, 1.6 Hz, 1H), 
8.51 (dt, J = 8.1, 1.9 Hz, 1H), 8.17 (dd, J = 7.9, 1.5 Hz, 1H), 7.85 (ddd, J = 8.5, 7.0, 1.6 
Hz, 1H), 7.76 (dd, J = 8.2, 1.1 Hz, 1H), 7.60 (ddd, J = 8.0, 4.9, 0.8 Hz, 1H), 7.55 (ddd, J 
= 8.1, 7.1, 1.2 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.22, 151.71, 150.84, 148.68, 
148.57, 135.75, 134.82, 128.95, 127.64, 127.09, 126.01, 123.74, 121.27. 
 
2-(pyridin-4-yl)quinazolin-4(3H)-one (43).  
 
Molecular weight: 223.24 g/mol 
 
The compound was synthesized from isonicotinaldehyde (2.14 g, 20 mmol) as described 
in the general procedure for 41-43 to yield 43 as a white solid (3,04 g, 68%). 1H NMR 
(500 MHz, DMSO-d6) δ 12.73 (s, 1H), 8.83 – 8.74 (m, 2H), 8.18 (dd, J = 7.9, 1.5 Hz, 
1H), 8.14 – 8.08 (m, 2H), 7.87 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.79 (dd, J = 8.2, 1.1 Hz, 
1H), 7.58 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.13, 150.65, 
150.30, 148.36, 140.14, 134.88, 127.88, 127.52, 126.05, 121.73, 121.61. 
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General Procedure for the Preparation of the 4-chloro-2-pyridylquinazoline 
derivatives 44-46. 
The corresponding 2-pyridylquinazolin-4(3H)-one derivative (10 mmol) was added to 
phosphorus oxychloride (30 mL, 0.32 mol) and stirred for 10 min at room temperature. 
The mixture was then refluxed for 4-8 h and the reaction monitored by TLC. After 
completion of the reaction, excess POCl3 was removed under reduced pressure and the 
residue poured into 50 mL ice water. Subsequently, 50 mL DCM was added while stirring 
and the pH of the mixture slowly adjusted to 7 with 25% ammonium solution. With a 
separatory funnel, the organic phase was collected, washed with 50 mL brine and dried 
over MgSO4. The solvent was removed under reduced pressure and the obtained solid 
recrystallized from isopropanol. 
 
4-chloro-2-(pyridin-2-yl)quinazoline (44).  
 
Molecular weight: 241.68 g/mol 
 
The compound was synthesized from 41 (2.23 g, 10 mmol) as described in the general 
procedure for 44-46 to yield 44 as a white solid (2.15 g, 89%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.77 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.47 (dt, J = 7.9, 1.1 Hz, 1H), 8.21 – 
8.14 (m, 1H), 8.09 (td, J = 7.8, 1.7 Hz, 1H), 7.87 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 7.82 (dd, 
J = 7.9, 1.5 Hz, 1H), 7.67 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.57 (ddd, J = 8.2, 7.0, 1.3 Hz, 
1H). 13C NMR (126 MHz, DMSO) δ 160.88, 150.11, 148.95, 148.38, 147.83, 138.13, 
134.73, 127.32, 127.24, 126.71, 126.12, 122.33, 121.88. 
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4-chloro-2-(pyridin-3-yl)quinazoline (45).  
 
Molecular weight: 241.68 g/mol 
 
The compound was synthesized from 42 (2.23 g, 10 mmol) as described in the general 
procedure for 44-46 to yield 45 as a white solid (2.27 g, 94%). 1H NMR (500 MHz, 
DMSO-d6) δ 9.29 (d, J = 2.2 Hz, 1H), 8.74 (dd, J = 4.8, 1.6 Hz, 1H), 8.49 (dt, J = 8.0, 2.0 
Hz, 1H), 8.16 (dd, J = 7.9, 1.5 Hz, 1H), 7.84 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 7.78 – 7.72 
(m, 1H), 7.61 – 7.49 (m, 2H). 13C NMR (126 MHz, DMSO) δ 162.22, 151.93, 150.91, 
148.88, 148.60, 135.50, 134.79, 128.85, 127.66, 127.05, 126.00, 123.62, 121.26. 
 
4-chloro-2-(pyridin-4-yl)quinazoline (46).  
 
Molecular weight: 241.68 g/mol 
 
The compound was synthesized from 3 (2.23 g, 10 mmol) as described in the general 
procedure for 44-46 to yield 46 as a white solid (2.18 g, 90%). 1H NMR (500 MHz, 
DMSO-d6) δ 9.05 – 8.96 (m, 2H), 8.54 – 8.46 (m, 2H), 8.20 (dd, J = 8.0, 1.4 Hz, 1H), 
7.90 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.83 (dd, J = 8.3, 1.2 Hz, 1H), 7.62 (ddd, J = 8.1, 7.1, 
1.2 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 161.98, 149.36, 147.97, 145.50, 144.99, 
135.06, 128.19, 128.08, 126.12, 123.99, 121.78. 
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6-methyl-2-(pyridin-4-yl)pyrimidin-4(3H)-one (47). 
 
Molecular weight: 187.20 g/mol 
 
To a solution of isonicotinimidamide hydrochloride (158 mg, 1 mmol) in methanol (5 
mL) was added sodium methoxide (54.0 mg, 1 mmol) and stirred for 10 min at room 
temperature. After adding methyl acetoacetate (116 mg, 1 mmol) the mixture was 
transferred into a microwave tube, sealed and heated to 70 °C at 60 watt microwave 
irradiation for 4 h. After cooling to room temperature, the pH of the mixture was adjusted 
with 1 M hydrochloric acid to 7 and the formed precipitate filtered off with suction. The 
solid was washed with water and dried in vacuo to give 47 as a white solid (76.8 mg, 
41%). 1H NMR (500 MHz, DMSO-d6) δ 12.59 (s, 1H), 8.80 – 8.66 (m, 2H), 8.09 – 7.99 
(m, 2H), 6.37 (s, 1H), 2.39 – 2.24 (m, 3H). 13C NMR (126 MHz, DMSO) δ 150.39, 
121.62, 23.48. 
 
6-methyl-2-phenylpyrimidin-4(3H)-one (48).  
 
Molecular weight: 186.21 g/mol 
 
This compound was synthesized according to the procedure described for 47. Instead of 
isonicotinimidamide hydrochloride, benzimidamide hydrochloride (157 mg, 1 mmol) 
was used in the first step to yield 48 as a white solid (89.4 mg, 48%). 1H NMR (500 MHz, 
DMSO-d6) δ 12.47 (s, 1H), 8.22 – 7.99 (m, 2H), 7.60 – 7.42 (m, 3H), 6.19 (s, 1H), 2.26 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 164.72, 163.86, 157.15, 132.92, 131.61, 128.70, 
127.88, 110.03, 23.63. 
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General Procedure for the Preparation of the 2-substituted 4-chloro-6-
methylpyrimidine derivatives 49-50.  
The compounds were synthesized according to the method described in the general 
methods for compounds 44-46 from the corresponding 2-substituted 6-methyl-pyrimidin-
4(3H)-ones 47 and 48. Complete chlorination was achieved within 4 h. 
 
4-chloro-6-methyl-2-(pyridin-4-yl)pyrimidine (49).  
 
Molecular weight: 205.65 g/mol 
 
The compound was synthesized from 47 (1.87 g, 10 mmol) as described in the general 
procedure for 49-50 to yield 49 as a white solid (1.79 g, 87%). 1H NMR (600 MHz, 
DMSO-d6) δ 8.81 – 8.74 (m, 2H), 8.21 – 8.16 (m, 2H), 7.69 (d, J = 0.7 Hz, 1H), 2.58 (s, 
3H). 13C NMR (151 MHz, DMSO) δ 170.58, 162.06, 160.86, 150.79, 143.04, 121.75, 
120.74, 23.73. 
 
4-chloro-6-methyl-2-phenylpyrimidine (50).  
 
Molecular weight: 204.66 g/mol 
 
The compound was synthesized from 48 (1.86 g, 10 mmol) as described in the general 
procedure for 49-50 to yield 50 as a white solid (1.90 g, 93%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.39 – 8.27 (m, 2H), 7.60 – 7.45 (m, 4H), 2.55 (d, J = 0.6 Hz, 3H). 13C NMR 
(126 MHz, DMSO) δ 170.05, 163.83, 160.56, 135.88, 131.62, 128.91, 128.08, 119.01, 
23.75. 
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General Procedure for the Preparation of the substituted 4-anilinoquinazolines 51-
81. 
The corresponding 4-chloroquinazoline derivative 44-46 (1 mmol) was added to 
isopropanol (5 mL) with the corresponding substituted aniline derivative (1 mmol) and 
sealed in a microwave tube. The mixture was heated by 100 watt microwave irradiation 
to 110 °C for a period of 15 – 30 min until completion of the reaction as indicated by 
TLC. The formed precipitate was filtered off, washed with 10 mL isopropanol and dried 
in vacuo. If no precipitate is formed, the solvent was removed under reduced pressure and 
the remaining solid recrystallized from ethanol. 
 
N-(3-nitrophenyl)-2-(pyridin-2-yl)quinazolin-4-amine (51). 
N
N
HN
N
NO2
 
Molecular weight: 343.35 g/mol 
 
The compound was synthesized from 44 (242 mg, 1 mmol) and 3-nitroaniline (138 mg, 
1 mmol) as described in the general procedure for compounds 51-81 to yield 51 as a 
yellow solid (292 mg, 85%), mp 274-275 °C. 1H NMR (500 MHz, DMSO-d6) δ 12.09 (s, 
1H), 9.09 (dd, J = 8.4, 1.3 Hz, 1H), 9.02 (t, J = 2.2 Hz, 1H), 8.93 (ddd, J = 4.8, 1.7, 0.9 
Hz, 1H), 8.43 (dt, J = 7.9, 1.1 Hz, 1H), 8.39 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 8.33 (dd, J = 
8.5, 1.1 Hz, 1H), 8.24 – 8.17 (m, 2H), 8.14 (ddd, J = 8.5, 7.1, 1.2 Hz, 1H), 7.89 (ddd, J = 
8.3, 7.1, 1.2 Hz, 1H), 7.86 – 7.78 (m, 2H). 13C NMR (126 MHz, DMSO) δ 159.82, 154.93, 
149.40, 148.32, 147.96, 141.44, 139.41, 138.53, 136.44, 130.22, 128.80, 128.20, 124.95, 
124.66, 122.07, 120.62, 118.80, 113.81. Anal. Calcd. for C19H13N5O2: C, 66.47; H, 3.82; 
N, 20.40. Found: C, 66.38 ; H, 4.19; N, 20.16.  
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N-(3-nitrophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (52). 
 
Molecular weight: 343.35 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and 3-nitroaniline (138 mg, 
1 mmol) as described in the general procedure for compounds 51-81 to yield 52 as a 
yellow-beige solid (278 mg, 81%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.51 
(s, 1H), 9.61 (s, 1H), 9.17 (t, J = 2.2 Hz, 1H), 8.99 (dt, J = 8.1, 1.9 Hz, 1H), 8.84 (d, J = 
4.9 Hz, 1H), 8.68 (dt, J = 8.4, 1.0 Hz, 1H), 8.36 (ddd, J = 8.2, 2.2, 0.9 Hz, 1H), 8.04 (ddd, 
J = 8.2, 2.3, 0.9 Hz, 1H), 8.01 – 7.95 (m, 2H), 7.81 (dd, J = 8.0, 5.0 Hz, 1H), 7.79 – 7.72 
(m, 2H). 13C NMR (126 MHz, DMSO) δ 158.22, 156.37, 149.89, 148.03, 140.38, 134.86, 
134.27, 130.07, 128.16, 128.10, 127.34, 125.06, 123.45, 118.37, 116.52, 114.33. Anal. 
Calcd. for C19H13N5O2: C, 66.47; H, 3.82; N, 0.40. Found: C, 66.73; H, 4.10; N, 20.14. 
 
N-(3-nitrophenyl)-2-(pyridin-4-yl)quinazolin-4-amine (53). 
 
Molecular weight: 343.35 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 3-nitroaniline (138 mg, 
1 mmol) as described in the general procedure for compounds 51-81 to yield 53 as a 
yellow solid (264 mg, 77%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.59 (s, 
1H), 9.16 (t, J = 2.2 Hz, 1H), 8.97 (d, J = 5.6 Hz, 2H), 8.73 (dt, J = 8.3, 1.0 Hz, 1H), 8.71 
10 Experimental section 278
– 8.64 (m, 2H), 8.37 (ddd, J = 8.2, 2.2, 0.9 Hz, 1H), 8.07 – 7.97 (m, 3H), 7.83 – 7.73 (m, 
2H). 13C NMR (126 MHz, DMSO) δ 158.39, 155.47, 150.50, 150.01, 148.02, 145.51, 
140.31, 134.39, 128.71, 128.23, 123.83, 123.59, 118.44, 116.61, 114.72. Anal. Calcd. 
for C19H13N5O2: C, 66.47; H, 3.82; N, 20.40. Found: C, 66.33; H, 4.20; N, 20.20.  
 
N-(4-nitrophenyl)-2-(pyridin-4-yl)quinazolin-4-amine (54). 
 
Molecular weight: 343.35 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and 4-nitroaniline (138 mg, 
1 mmol) as described in the general procedure for compounds 51-81 to yield 54 as a 
yellow solid (247 mg, 72%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.72 (s, 
1H), 9.64 – 9.55 (m, 1H), 9.13 (dt, J = 8.1, 1.8 Hz, 1H), 8.98 – 8.87 (m, 1H), 8.76 (dd, J 
= 8.3, 1.0 Hz, 1H), 8.39 – 8.33 (m, 2H), 8.33 – 8.27 (m, 2H), 8.04 – 7.94 (m, 3H), 7.76 
(ddd, J = 8.3, 5.5, 2.7 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.21, 155.55, 149.84, 
146.35, 145.56, 144.68, 142.58, 140.77, 135.17, 134.55, 128.02, 127.71, 126.16, 124.74, 
123.82, 121.89, 114.63. Anal. Calcd. for C19H13N5O2: C, 66.47; H, 3.82; N, 20.40. 
Found: C, 66.52; H, 3.66; N, 20.15.  
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3-((2-(pyridin-2-yl)quinazolin-4-yl)amino)benzonitrile (55). 
 
Molecular weight: 323.36 g/mol 
 
The compound was synthesized from 44 (242 mg, 1 mmol) and 3-aminobenzonitrile (118 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 55 as a 
light yellow solid (242 mg, 75%), mp 261-263 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 12.27 (s, 1H), 9.15 (dd, J = 8.3, 1.3 Hz, 1H), 8.92 (ddd, J = 4.8, 1.8, 0.9 Hz, 
1H), 8.39 (t, J = 1.9 Hz, 1H), 8.33 (dd, J = 8.5, 1.1 Hz, 1H), 8.31 – 8.24 (m, 2H), 8.20 
(td, J = 7.7, 1.7 Hz, 1H), 8.13 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.87 (ddd, J = 8.3, 7.1, 1.2 
Hz, 1H), 7.84 – 7.79 (m, 2H), 7.77 (t, J = 7.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
159.95, 154.85, 149.49, 148.15, 140.91, 139.27, 138.10, 136.52, 130.28, 129.88, 129.39, 
128.78, 128.23, 127.91, 125.17, 124.47, 121.62, 118.51, 113.66, 111.70. Anal. Calcd. 
for C20H13N5: C, 74.29; H, 4.05; N, 21.66. Found: C, 74.05; H, 4.34; N, 21.50.  
 
3-((2-(pyridin-3-yl)quinazolin-4-yl)amino)benzonitrile (56). 
 
Molecular weight: 323.36 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and 3-aminobenzonitrile (118 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 56 as a 
yellow solid (252 mg, 78%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.17 (s, 
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1H), 9.52 (s, 1H), 8.68 (ddd, J = 9.9, 4.9, 3.0 Hz, 2H), 8.57 (dt, J = 8.4, 1.1 Hz, 1H), 8.45 
(t, J = 1.8 Hz, 1H), 8.27 (ddd, J = 8.3, 2.2, 1.1 Hz, 1H), 7.96 – 7.90 (m, 2H), 7.73 – 7.65 
(m, 2H), 7.62 (dt, J = 7.7, 1.3 Hz, 1H), 7.55 (ddd, J = 7.9, 4.7, 0.9 Hz, 1H). 13C NMR 
(126 MHz, DMSO) δ 158.07, 157.46, 151.20, 150.50, 149.29, 140.20, 135.21, 133.90, 
133.61, 130.14, 128.41, 127.25, 126.96, 126.84, 125.33, 123.79, 123.22, 118.92, 114.23, 
111.52. Anal. Calcd. for C20H13N5: C, 74.29; H, 4.05; N, 21.66. Found: C, 74.27; H, 
4.22; N, 21.46.  
 
3-((2-(pyridin-4-yl)quinazolin-4-yl)amino)benzonitrile (57). 
 
Molecular weight: 323.36 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 3-aminobenzonitrile (118 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 57 as a 
yellow solid (252 mg, 78%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.62 (s, 
1H), 9.04 – 8.94 (m, 2H), 8.81 – 8.72 (m, 1H), 8.68 – 8.60 (m, 2H), 8.36 (t, J = 1.8 Hz, 
1H), 8.31 (dt, J = 7.8, 1.9 Hz, 1H), 8.03 – 7.95 (m, 2H), 7.77 (ddd, J = 8.3, 5.7, 2.5 Hz, 
1H), 7.71 – 7.63 (m, 2H). 13C NMR (126 MHz, DMSO) δ 158.53, 155.14, 151.52, 149.76, 
144.32, 139.81, 134.40, 130.14, 128.50, 128.27, 127.73, 127.50, 125.84, 124.17, 123.78, 
118.81, 114.68, 111.57. Anal. Calcd. for C20H13N5: C, 74.29; H, 4.05; N, 21.66. Found: 
C, 74.66; H, 4.32; N, 21.40.  
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4-((2-(pyridin-3-yl)quinazolin-4-yl)amino)benzonitrile (58). 
 
Molecular weight: 323.36 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and 4-aminobenzonitrile (118 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 58 as a 
light yellow solid (278 mg, 86%), mp 285-287 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.75 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 9.12 (dt, J = 8.1, 1.8 Hz, 1H), 8.95 
(dd, J = 5.4, 1.5 Hz, 1H), 8.83 – 8.74 (m, 1H), 8.24 – 8.16 (m, 2H), 8.05 – 7.94 (m, 3H), 
7.93 – 7.85 (m, 2H), 7.73 (ddd, J = 8.3, 6.6, 1.6 Hz, 1H). 13C NMR (126 MHz, DMSO) 
δ 158.33, 155.20, 149.10, 145.78, 144.00, 143.32, 141.35, 135.13, 134.58, 133.01, 
127.72, 127.46, 126.38, 124.01, 122.68, 119.22, 114.50, 105.79. Anal. Calcd. for 
C20H13N5: C, 74.29; H, 4.05; N, 21.66. Found: C, 74.42; H, 4.33; N, 21.33.  
 
N-(3-methoxyphenyl)-2-(pyridin-2-yl)quinazolin-4-amine (59). 
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized from 44 (242 mg, 1 mmol) and 3-methoxyaniline (123 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 59 as a 
yellow solid (207 mg, 63%), mp 115-117 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.83 (s, 
1H), 8.78 – 8.68 (m, 1H), 8.64 (d, J = 8.2 Hz, 1H), 8.44 (dt, J = 8.0, 1.1 Hz, 1H), 8.27 (t, 
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J = 2.2 Hz, 1H), 8.00 – 7.86 (m, 3H), 7.66 (ddd, J = 8.3, 6.6, 1.5 Hz, 1H), 7.56 (ddd, J = 
8.2, 2.0, 0.9 Hz, 1H), 7.50 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 6.69 
(ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 3.88 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.64, 
159.04, 158.13, 155.79, 150.57, 149.63, 141.08, 136.93, 133.43, 129.24, 128.63, 126.73, 
124.81, 123.53, 123.14, 114.46, 113.67, 109.90, 107.03, 55.28. Anal. Calcd. for 
C20H16N4O: C, 73.15; H, 4.91; N, 17.06. Found: C, 73.43; H, 5.27; N, 16.99. 
 
N-(3-methoxyphenyl)-2-(pyridin-3-yl)quinazolin-4-amine (60). 
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and 3-methoxyaniline (123 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 60 as a 
light yellow solid (213 mg, 65%), mp 182-184 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.88 
(s, 1H), 9.56 (d, J = 2.0 Hz, 1H), 8.72 – 8.65 (m, 2H), 8.60 (dt, J = 8.4, 1.1 Hz, 1H), 7.92 
– 7.85 (m, 2H), 7.70 (t, J = 2.3 Hz, 1H), 7.67 – 7.61 (m, 1H), 7.58 – 7.50 (m, 2H), 7.36 
(t, J = 8.1 Hz, 1H), 6.76 (ddd, J = 8.2, 2.6, 0.8 Hz, 1H), 3.82 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 159.55, 158.11, 157.59, 151.06, 150.39, 149.33, 140.48, 135.16, 133.80, 
133.55, 129.37, 128.30, 126.50, 123.71, 123.22, 114.59, 114.34, 109.75, 107.91, 55.25. 
Anal. Calcd. for C20H16N4O: C, 73.15; H, 4.91; N, 17.06. Found: C, 73.20; H, 4.82; N, 
17.11. 
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N-(3-methoxyphenyl)-2-(pyridin-4-yl)quinazolin-4-amine (61). 
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 3-methoxyaniline (123 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 61 as a 
light beige solid (230 mg, 70%), mp 202-203 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.92 
(s, 1H), 8.79 – 8.69 (m, 2H), 8.61 (dt, J = 8.4, 1.0 Hz, 1H), 8.32 – 8.24 (m, 2H), 7.97 – 
7.86 (m, 2H), 7.72 – 7.64 (m, 2H), 7.56 (ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 7.37 (t, J = 8.1 
Hz, 1H), 6.76 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 3.83 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 159.57, 158.27, 157.38, 150.36, 150.28, 145.68, 140.41, 133.64, 129.40, 128.51, 
126.99, 123.25, 121.85, 114.60, 109.93, 107.82, 55.28. Anal. Calcd. for C20H16N4O: C, 
73.15; H, 4.91; N, 17.06. Found: C, 73.42; H, 4.69; N,17.00. 
 
N-(4-methoxyphenyl)-2-(pyridin-4-yl)quinazolin-4-amine (62). 
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 4-methoxyaniline (123 
mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 62 as a 
light yellow solid (233 mg, 71%), mp 233-235 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 9.89 (s, 1H), 8.76 – 8.68 (m, 2H), 8.56 (dt, J = 8.2, 1.0 Hz, 1H), 8.28 – 8.20 
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(m, 2H), 7.93 – 7.85 (m, 2H), 7.85 – 7.76 (m, 2H), 7.65 (ddd, J = 8.3, 4.7, 3.4 Hz, 1H), 
7.09 – 7.00 (m, 2H), 3.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.35, 157.47, 156.07, 
150.31, 150.18, 145.74, 133.44, 131.95, 128.39, 126.78, 124.35, 123.16, 121.85, 114.51, 
113.88, 55.40. Anal. Calcd. for C20H16N4O: C, 73.15; H, 4.91; N, 17.06. Found: C, 
73.43; H, 5.01; N, 16.75. 
 
N-(3,4-dimethoxyphenyl)-2-(pyridin-2-yl)quinazolin-4-amine (63). 
 
Molecular weight: 358.40 g/mol 
 
The compound was synthesized from 44 (242 mg, 1 mmol) and 3,4-dimethoxyaniline 
(153 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 63 
as a yellow solid (204 mg, 57%), mp 191-193 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.82 
(s, 1H), 8.72 (ddd, J = 4.7, 1.9, 0.9 Hz, 1H), 8.65 – 8.57 (m, 1H), 8.45 (dt, J = 7.9, 1.1 
Hz, 1H), 8.37 (d, J = 2.5 Hz, 1H), 7.96 (td, J = 7.7, 1.8 Hz, 1H), 7.94 – 7.85 (m, 2H), 7.65 
(ddd, J = 8.3, 6.6, 1.6 Hz, 1H), 7.50 (ddd, J = 7.5, 4.7, 1.2 Hz, 1H), 7.43 (dd, J = 8.7, 2.5 
Hz, 1H), 7.00 (d, J = 8.7 Hz, 1H), 3.91 (s, 3H), 3.78 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 158.96, 157.89, 155.67, 149.50, 148.49, 145.07, 136.87, 133.31, 128.33, 126.55, 
124.80, 123.47, 123.03, 114.34, 113.28, 112.00, 107.24, 55.92, 55.58. Anal. Calcd. for 
C21H18N4O2: C, 70.38; H, 5.06; N, 15.63. Found: C, 70.01; H, 5.31; N, 15.95. 
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N-(3,4-dimethoxyphenyl)-2-(pyridin-3-yl)quinazolin-4-amine (64). 
 
Molecular weight: 358.40 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and 3,4-dimethoxyaniline 
(153 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 64 
as a yellow solid (240 mg, 67%), mp 201-202 °C. 1H NMR (500 MHz, DMSO-d6) δ 
10.76 (s, 1H), 9.51 (d, J = 2.2 Hz, 1H), 8.97 (dt, J = 8.1, 1.8 Hz, 1H), 8.89 (dd, J = 5.1, 
1.6 Hz, 1H), 8.77 (d, J = 8.2 Hz, 1H), 8.11 (d, J = 8.3 Hz, 1H), 7.99 (ddd, J = 8.4, 7.0, 1.3 
Hz, 1H), 7.87 (dd, J = 8.1, 5.1 Hz, 1H), 7.75 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.59 (d, J = 
2.4 Hz, 1H), 7.40 (dd, J = 8.6, 2.5 Hz, 1H), 7.07 (d, J = 8.7 Hz, 1H), 3.81 (s, 3H), 3.81 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 158.48, 155.72, 148.55, 146.65, 134.80, 131.12, 
127.69, 125.22, 123.96, 115.80, 113.78, 111.79, 108.56, 55.89, 55.80. Anal. Calcd. for 
C21H18N4O2: C, 70.38; H, 5.06; N, 15.63. Found: C, 70.41; H, 4.93; N, 15.34.  
 
N-(3,4-dimethoxyphenyl)-2-(pyridin-4-yl)quinazolin-4-amine (65). 
 
Molecular weight: 358.40 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 3,4-dimethoxyaniline 
(153 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 65 
as a yellow solid (219 mg, 61%), mp 134-135 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.86 
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(s, 1H), 8.78 – 8.69 (m, 2H), 8.58 (dt, J = 8.5, 1.0 Hz, 1H), 8.31 – 8.24 (m, 2H), 7.93 – 
7.86 (m, 2H), 7.72 – 7.61 (m, 2H), 7.46 (dd, J = 8.6, 2.5 Hz, 1H), 7.06 (d, J = 8.7 Hz, 
1H), 3.83 (s, 3H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.22, 157.47, 150.33, 
148.52, 145.80, 133.50, 132.46, 128.44, 126.85, 123.14, 121.86, 114.58, 111.96, 107.75, 
55.92, 55.69. Anal. Calcd. for C21H18N4O2: C, 70.38; H, 5.06; N, 15.63. Found: C, 
70.70; H, 5.05; N, 15.28. 
 
2-(pyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (66). 
 
Molecular weight: 366.35 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 3-(trifluoromethyl)aniline 
(161 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 66 
as a white solid (322 mg, 88%), mp 249-250 °C (decomp.). 1H NMR (500 MHz, DMSO-
d6) δ 10.21 (s, 1H), 8.74 (d, J = 5.0 Hz, 2H), 8.62 (dt, J = 8.3, 1.0 Hz, 1H), 8.57 (d, J = 
2.0 Hz, 1H), 8.32 – 8.24 (m, 2H), 8.21 (dd, J = 8.3, 2.0 Hz, 1H), 7.99 – 7.88 (m, 2H), 7.76 
– 7.65 (m, 2H), 7.52 (ddd, J = 7.8, 1.9, 0.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
158.20, 157.16, 150.36, 150.33, 145.45, 140.10, 133.89, 129.87, 129.37 (d, J = 31.6 Hz), 
128.60, 127.25, 125.65, 123.24, 121.81, 120.01 (d, J = 3.9 Hz), 118.54 (d, J = 4.1 Hz), 
114.54. Anal. Calcd. for C20H13F3N4: C, 65.57; H, 3.58; N, 15.29. Found: C, 65.53; H, 
3.93; N, 14.90. 
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2-(pyridin-4-yl)-N-(4-(trifluoromethyl)phenyl)quinazolin-4-amine (67). 
 
Molecular weight: 366.35 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 4-(trifluoromethyl)aniline 
(161 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 67 
as a white solid (308 mg, 84%), mp 264-265 °C (decomp.). 1H NMR (500 MHz, DMSO-
d6) δ 10.22 (s, 1H), 8.83 – 8.68 (m, 2H), 8.64 (dt, J = 8.4, 1.1 Hz, 1H), 8.34 – 8.27 (m, 
2H), 8.28 – 8.19 (m, 2H), 7.98 – 7.91 (m, 2H), 7.87 – 7.80 (m, 2H), 7.72 (ddd, J = 8.3, 
5.4, 2.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.19, 157.24, 150.40, 150.36, 145.47, 
143.03, 133.95, 128.60, 127.29, 125.93 (d, J = 3.6 Hz), 123.59 (d, J = 32.1 Hz), 123.36, 
121.99, 121.89, 114.63. Anal. Calcd. for C20H13F3N4: C, 65.57; H, 3.58; N, 15.29. 
Found: C, 65.29; H, 3.86; N, 15.20.  
 
N-(4-methoxy-3-(trifluoromethyl)phenyl)-2-(pyridin-4-yl)quinazolin-4-amine (68). 
 
Molecular weight: 396.37 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 4-methoxy-3-
(trifluoromethyl)aniline (191 mg, 1 mmol) as described in the general procedure for 
compounds 51-81 to yield 68 as a light beige solid (226 mg, 57%), mp 256-257 °C 
(decomp.). 1H NMR (500 MHz, DMSO-d6) δ 10.06 (s, 1H), 8.76 – 8.68 (m, 2H), 8.57 
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(dt, J = 8.4, 1.1 Hz, 1H), 8.39 (d, J = 2.7 Hz, 1H), 8.28 – 8.22 (m, 2H), 8.17 (dd, J = 9.0, 
2.7 Hz, 1H), 7.95 – 7.88 (m, 2H), 7.69 (ddd, J = 8.3, 5.0, 3.2 Hz, 1H), 7.40 (d, J = 9.1 Hz, 
1H), 3.94 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.16, 157.26, 153.33, 150.25, 
150.20, 145.62, 133.68, 131.98, 128.51, 127.73, 127.05, 124.95, 123.13, 122.79, 121.80, 
120.94 (d, J = 5.8 Hz), 116.59 (d, J = 30.2 Hz), 114.46, 113.36, 56.49. Anal. Calcd. for 
C21H15F3N4O: C, 63.63; H, 3.81; N, 14.14. Found: C, 63.87; H, 3.87; N, 13.76. 
 
N-(3-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (69). 
 
Molecular weight: 316.34 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and 3-fluoroaniline (111 mg, 
1 mmol) as described in the general procedure for compounds 51-81 to yield 69 as a 
yellow solid (253 mg, 80%), mp 272-274 °C (decomp.) . 1H NMR (500 MHz, DMSO-
d6) δ 10.60 (s, 1H), 9.52 (d, J = 2.0 Hz, 1H), 9.04 (dt, J = 8.1, 1.9 Hz, 1H), 8.91 (dd, J = 
5.3, 1.5 Hz, 1H), 8.76 (d, J = 8.2 Hz, 1H), 8.10 – 8.01 (m, 1H), 8.01 – 7.98 (m, 1H), 7.98 
– 7.92 (m, 1H), 7.89 (dt, J = 11.6, 2.4 Hz, 1H), 7.82 – 7.76 (m, 1H), 7.74 (ddd, J = 8.1, 
6.6, 1.3 Hz, 1H), 7.51 (td, J = 8.2, 6.8 Hz, 1H), 7.06 (td, J = 8.5, 2.6 Hz, 1H). 13C NMR 
(126 MHz, DMSO) δ 163.07, 161.15, 158.49, 155.66, 145.18, 140.38 (d, J = 10.9 Hz), 
134.51, 130.28 (d, J = 9.4 Hz), 127.57, 126.83, 125.76, 123.82, 118.79, 111.16 (d, J = 
21.2 Hz), 109.82 (d, J = 25.7 Hz). Anal. Calcd. for C19H13FN4: C, 72.14; H, 4.14; N, 
17.71. Found: C, 72.13; H, 4.38; N, 17.69. 
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3-((2-(pyridin-4-yl)quinazolin-4-yl)amino)benzenesulfonyl fluoride (70). 
 
Molecular weight: 380.40 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 3-aminobenzenesulfonyl 
fluoride (175 mg, 1 mmol) as described in the general procedure for compounds 51-81 to 
yield 70 as a yellow solid (293 mg, 77%), mp 291-292 °C (decomp.). 1H NMR (600 
MHz, DMSO-d6) δ 10.40 (s, 1H), 9.14 (t, J = 1.9 Hz, 1H), 8.73 (d, J = 5.1 Hz, 2H), 8.62 
(d, J = 8.4 Hz, 1H), 8.42 (dt, J = 7.2, 2.1 Hz, 1H), 8.35 – 8.26 (m, 2H), 8.01 – 7.92 (m, 
2H), 7.92 – 7.83 (m, 2H), 7.74 (ddd, J = 8.2, 5.5, 2.7 Hz, 1H). 13C NMR (151 MHz, 
DMSO) δ 158.10, 157.08, 150.40, 150.39, 145.24, 141.04, 134.10, 131.85 (d, J = 23.1 
Hz), 131.00, 128.96, 128.69, 127.46, 123.27, 122.78, 121.91, 120.60, 114.54. Anal. 
Calcd. for C19H13FN4O2S: C, 59.99; H, 3.44; N, 14.73. Found: C, 60.36; H, 3.68; N, 
14.48.  
 
N1,N1-dimethyl-N3-(2-(pyridin-3-yl)quinazolin-4-yl)benzene-1,3-diamine (71). 
 
Molecular weight: 341.42 g/mol 
 
The compound was synthesized from 5 (242 mg, 1 mmol) and N1,N1-dimethylbenzene-
1,3-diamine (136 mg, 1 mmol) as described in the general procedure for compounds 51-
81 to yield 71 as a light brown solid (201 mg, 59%), mp 202-203 °C. 1H NMR (500 MHz, 
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DMSO-d6) δ 10.87 (s, 1H), 9.62 – 9.48 (m, 1H), 9.18 (d, J = 8.1 Hz, 1H), 9.02 – 8.90 (m, 
1H), 8.83 (dd, J = 8.5, 1.4 Hz, 1H), 8.11 (d, J = 8.3 Hz, 1H), 8.01 (ddd, J = 8.4, 5.9, 1.3 
Hz, 3H), 7.76 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.62 (s, 1H), 7.51 (t, J = 8.1 Hz, 1H), 7.25 
(s, 1H), 3.09 (s, 6H). 13C NMR (126 MHz, DMSO) δ 158.64, 155.19, 141.28, 139.26, 
134.84, 129.86, 127.86, 126.07, 124.09, 114.05, 43.50. Anal. Calcd. for C21H19N5: C, 
73.88; H, 5.61; N, 20.51. Found: C, 73.97; H, 5.37; N, 20.25. 
 
3-((2-(pyridin-4-yl)quinazolin-4-yl)amino)phenol (72). 
 
Molecular weight: 314.35 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 3-aminophenol (109 mg, 
1 mmol) as described in the general procedure for compounds 51-81 to yield 72 as a 
yellow solid (148 mg, 47%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.13 (s, 
1H), 9.60 (s, 1H), 8.97 – 8.91 (m, 2H), 8.70 (dt, J = 8.4, 0.9 Hz, 1H), 8.65 – 8.58 (m, 2H), 
8.01 – 7.90 (m, 2H), 7.73 (ddd, J = 8.3, 6.5, 1.7 Hz, 1H), 7.44 (t, J = 2.2 Hz, 1H), 7.36 
(ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.25 (t, J = 8.0 Hz, 1H), 6.64 (ddd, J = 8.1, 2.4, 1.0 Hz, 
1H). 13C NMR (126 MHz, DMSO) δ 158.52, 157.73, 155.80, 149.34, 145.76, 139.73, 
134.05, 129.32, 128.07, 127.80, 123.76, 123.64, 114.66, 113.64, 111.75, 109.97. Anal. 
Calcd. for C19H14N4O: C, 72.60; H, 4.49; N, 17.82. Found: C, 72.86; H, 4.63; N, 17.44. 
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4-((2-(pyridin-4-yl)quinazolin-4-yl)amino)phenol (73). 
 
Molecular weight: 314.35 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and 4-aminophenol (109 mg, 
1 mmol) as described in the general procedure for compounds 51-81 to yield 73 as a 
yellow solid (182 mg, 58%), mp 293-295 °C (decomp). 1H NMR (500 MHz, DMSO-d6) 
δ 10.34 (s, 1H), 9.52 (s, 1H), 8.96 (d, J = 5.7 Hz, 2H), 8.73 – 8.63 (m, 1H), 8.63 – 8.50 
(m, 2H), 8.00 (dd, J = 8.4, 1.3 Hz, 1H), 7.95 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.72 (ddd, J 
= 8.2, 6.9, 1.4 Hz, 1H), 7.67 – 7.56 (m, 2H), 6.94 – 6.84 (m, 2H). 13C NMR (126 MHz, 
DMSO) δ 158.67, 155.44, 154.95, 134.17, 129.56, 127.91, 125.22, 123.92, 123.64, 
115.27, 114.43. Anal. Calcd. for C19H14N4O: C, 72.60; H, 4.49; N, 17.82. Found: C, 
72.69; H, 4.67; N, 17.54. 
 
(4-((2-(pyridin-3-yl)quinazolin-4-yl)amino)phenyl)methanol (74). 
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and (3-aminophenyl)methanol 
(123 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 74 
as a yellow solid (210 mg, 64%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.65 
(s, 1H), 9.56 (d, J = 2.1 Hz, 1H), 9.07 (dt, J = 8.1, 1.9 Hz, 1H), 8.92 (dd, J = 5.2, 1.6 Hz, 
10 Experimental section 292
1H), 8.83 – 8.73 (m, 1H), 8.08 (d, J = 8.3 Hz, 1H), 8.05 – 7.97 (m, 2H), 7.91 (dd, J = 8.1, 
5.2 Hz, 1H), 7.82 – 7.73 (m, 2H), 7.45 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 7.5 Hz, 1H), 4.63 
(s, 2H). 13C NMR (126 MHz, DMSO) δ 158.57, 155.67, 143.33, 138.17, 134.59, 128.37, 
127.59, 125.53, 123.86, 122.98, 121.58, 121.35, 114.05, 62.87. Anal. Calcd. for 
C20H16N4O: C, 73.15; H, 4.91; N, 17.06. Found: C, 73.17; H, 5.07; N, 16.83.  
 
(4-((2-(pyridin-4-yl)quinazolin-4-yl)amino)phenyl)methanol (75). 
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and (3-aminophenyl)methanol 
(123 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 75 
as a yellow solid (200 mg, 61%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.36 
(s, 1H), 8.97 (d, J = 5.7 Hz, 2H), 8.80 – 8.60 (m, 3H), 8.06 (t, J = 1.9 Hz, 1H), 8.03 – 7.90 
(m, 2H), 7.81 – 7.68 (m, 2H), 7.42 (t, J = 7.8 Hz, 1H), 7.19 – 7.12 (m, 1H), 4.62 (s, 2H). 
13C NMR (126 MHz, DMSO) δ 158.52, 155.29, 149.20, 144.54, 143.25, 138.58, 134.15, 
128.31, 128.03, 124.18, 123.66, 122.49, 121.13, 121.01, 114.64, 62.91. Anal. Calcd. for 
C20H16N4O: C, 73.15; H, 4.91; N, 17.06. Found: C, 73.06; H, 5.27; N, 16.69.  
 
2-nitro-4-((2-(pyridin-3-yl)quinazolin-4-yl)amino)phenol (76). 
 
Molecular weight: 359.35 g/mol 
10 Experimental section  293
The compound was synthesized from 45 (242 mg, 1 mmol) and 4-amino-2-nitrophenol 
(154 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 76 
as a yellow-orange solid (223 mg, 62%), mp 284-286 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.83 (s, 1H), 10.06 (s, 1H), 9.56 (dd, J = 2.2, 0.9 Hz, 1H), 8.78 (d, J = 2.7 
Hz, 1H), 8.74 – 8.70 (m, 1H), 8.68 (dd, J = 4.7, 1.7 Hz, 1H), 8.54 (dt, J = 8.4, 1.1 Hz, 
1H), 8.04 (dd, J = 9.0, 2.7 Hz, 1H), 7.92 – 7.86 (m, 2H), 7.68 – 7.61 (m, 1H), 7.56 – 7.50 
(m, 1H), 7.24 (d, J = 9.0 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.02, 157.53, 151.12, 
150.34, 149.39, 148.98, 135.68, 135.27, 133.66, 133.64, 131.04, 130.26, 128.35, 126.63, 
123.71, 123.12, 119.39, 118.37, 114.18. Anal. Calcd. for C19H13N5O3: C, 63.51; H, 3.65; 
N, 19.49. Found: C, 63.90; H, 3.81; N, 19.21.  
 
methyl 3-((2-(pyridin-3-yl)quinazolin-4-yl)amino)benzoate (77). 
 
Molecular weight: 356.39 g/mol 
 
The compound was synthesized from 45 (242 mg, 1 mmol) and methyl 3-aminobenzoate 
(151 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 77 
as a light yellow solid (282 mg, 79%), mp 233-234 °C. 1H NMR (600 MHz, DMSO-d6) 
δ 10.73 (s, 1H), 9.55 (d, J = 2.1 Hz, 1H), 9.09 (dt, J = 8.2, 1.8 Hz, 1H), 8.92 (dd, J = 5.4, 
1.5 Hz, 1H), 8.84 – 8.70 (m, 2H), 8.20 (ddd, J = 8.1, 2.3, 1.1 Hz, 1H), 8.08 – 8.01 (m, 
1H), 8.01 – 7.90 (m, 2H), 7.80 (dt, J = 7.8, 1.3 Hz, 1H), 7.74 (ddd, J = 8.3, 6.9, 1.3 Hz, 
1H), 7.62 (t, J = 7.9 Hz, 1H), 3.92 (s, 3H). 13C NMR (151 MHz, DMSO) δ 166.27, 158.50, 
155.45, 145.09, 140.34, 139.04, 134.64, 130.15, 129.24, 127.71, 127.32, 126.54, 125.87, 
125.16, 123.91, 123.36, 114.20, 52.56. Anal. Calcd. for C21H16N4O2: C, 70.77; H, 4.53; 
N, 15.72. Found: C, 71.08; H, 4.62; N, 15.49. 
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methyl 3-((2-(pyridin-4-yl)quinazolin-4-yl)amino)benzoate (78). 
 
Molecular weight: 356.39 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and methyl 3-aminobenzoate 
(151 mg, 1 mmol) as described in the general procedure for compounds 51-81 to yield 78 
as a yellow solid (256 mg, 76%), mp 251-252 °C (decomp.). 1H NMR (600 MHz, DMSO-
d6) δ 10.46 (s, 1H), 9.01 – 8.94 (m, 2H), 8.81 (t, J = 2.0 Hz, 1H), 8.75 (d, J = 8.3 Hz, 1H), 
8.71 – 8.65 (m, 2H), 8.22 (ddd, J = 8.1, 2.3, 1.1 Hz, 1H), 8.04 – 7.95 (m, 2H), 7.83 – 7.74 
(m, 2H), 7.63 (t, J = 7.9 Hz, 1H), 3.93 (s, 3H). 13C NMR (151 MHz, DMSO) δ 166.32, 
158.44, 155.33, 151.08, 149.69, 144.88, 139.39, 134.28, 130.13, 129.24, 128.49, 128.17, 
126.90, 124.77, 124.01, 123.66, 123.00, 114.72, 52.50. Anal. Calcd. for C21H16N4O2: C, 
70.77; H, 4.53; N, 15.72. Found: C, 70.92; H, 4.63; N, 15.72.  
 
tert-butyl 3-((2-(pyridin-4-yl)quinazolin-4-yl)amino)benzoate (79). 
 
Molecular weight: 398.47 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and methyl tert-butyl 3-
aminobenzoate (193 mg, 1 mmol) as described in the general procedure for compounds 
51-81 to yield 79 as a yellow solid (255 mg, 64%), mp >300 °C. 1H NMR (600 MHz, 
DMSO-d6) δ 10.20 (s, 1H), 8.81 – 8.74 (m, 2H), 8.68 – 8.61 (m, 1H), 8.34 – 8.26 (m, 2H), 
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8.18 – 8.09 (m, 2H), 8.05 – 7.99 (m, 2H), 7.99 – 7.91 (m, 2H), 7.72 (ddd, J = 8.2, 5.8, 2.4 
Hz, 1H), 1.57 (s, 9H). 13C NMR (151 MHz, DMSO) δ 164.83, 158.14, 157.32, 150.51, 
150.42, 145.40, 143.50, 133.93, 129.97, 128.59, 127.26, 126.08, 123.39, 121.92, 121.29, 
114.69, 80.52, 28.05. Anal. Calcd. for C24H22N4O2: C, 72.34; H, 5.57; N, 14.06. Found: 
C, 72.50; H, 5.88; N, 13.99.  
 
3-((2-(pyridin-3-yl)quinazolin-4-yl)amino)benzoic acid (80). 
 
Molecular weight: 342.36 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and methyl 3-aminobenzoic 
acid (137 mg, 1 mmol) as described in the general procedure for compounds 51-81 to 
yield 80 as a yellow-beige solid (147 mg, 43%), mp >300 °C. 1H NMR (500 MHz, 
DMSO-d6) δ 13.07 (s, 1H), 10.48 (s, 1H), 9.11 – 8.88 (m, 2H), 8.84 (t, J = 1.9 Hz, 1H), 
8.81 – 8.61 (m, 3H), 8.20 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 8.11 – 7.90 (m, 2H), 7.90 – 7.68 
(m, 2H), 7.62 (t, J = 7.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 167.30, 158.45, 155.43, 
150.75, 149.63, 145.07, 139.22, 134.20, 131.32, 128.97, 128.40, 128.06, 126.52, 124.93, 
123.96, 123.60, 123.35, 114.69. Anal. Calcd. for C20H14N4O2: C, 70.17; H, 4.12; N, 
16.37. Found: C, 70.27; H, 4.44; N, 16.45. 
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4-((2-(pyridin-3-yl)quinazolin-4-yl)amino)benzoic acid (81). 
 
Molecular weight: 342.36 g/mol 
 
The compound was synthesized from 46 (242 mg, 1 mmol) and methyl 4-aminobenzoic 
acid (137 mg, 1 mmol) as described in the general procedure for compounds 51-81 to 
yield 81 as a brown-beiges solid (188 mg, 55%), mp >300 °C. 1H NMR (500 MHz, 
DMSO-d6) δ 12.51 (s, 1H), 10.52 (s, 1H), 9.03 – 8.95 (m, 2H), 8.78 (dd, J = 8.3, 1.1 Hz, 
1H), 8.74 – 8.68 (m, 2H), 8.16 – 8.09 (m, 2H), 8.08 – 8.03 (m, 2H), 8.03 – 7.95 (m, 2H), 
7.77 (ddd, J = 8.2, 6.1, 2.1 Hz, 1H).13C NMR (126 MHz, DMSO) δ 167.06, 158.39, 
155.19, 151.54, 149.82, 144.33, 143.10, 134.32, 130.22, 128.52, 128.23, 125.94, 124.29, 
123.79, 121.79, 114.84. Anal. Calcd. for C20H14N4O2: C, 70.17; H, 4.12; N, 16.37. 
Found: C, 70.49; H, 4.38; N, 16.25.  
 
General Procedure for the Preparation of the 2-substituted 6-methyl-4-
anilinopyrimidines 82-88. 
To the corresponding 2-substituted 6-methyl-4-chloropyrimidine derivatives 49 and 50 
(1 mmol) isopropanol (5 mL) was added together with the corresponding substituted 
aniline (1 mmol) and sealed in a microwave tube. The mixture was heated by 100 watt 
microwave irradiation to 110 °C for a period of 15 – 30 min until completion of the 
reaction as indicated by TLC. The formed precipitate was filtered off, washed with 10 
mL isopropanol and dried in vacuo. If no precipitate was formed, the solvent was removed 
under reduced pressure and the remaining solid recrystallized from acetone. 
 
 
 
 
10 Experimental section  297
3-((6-methyl-2-(pyridin-4-yl)pyrimidin-4-yl)amino)benzonitrile (82).  
 
Molecular weight: 287.33 g/mol 
 
The compound was synthesized from 49 (206 mg, 1 mmol) and methyl 3-
aminobenzonitrile (118 mg, 1 mmol) as described in the general procedure for 
compounds 82-88 to yield 82 as a white solid (135 mg, 47%), mp >300 °C. 1H NMR 
(600 MHz, DMSO-d6) δ 9.97 (s, 1H), 8.73 (d, J = 4.8 Hz, 2H), 8.21 (t, J = 1.9 Hz, 1H), 
8.18 – 8.10 (m, 2H), 8.07 – 7.95 (m, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.47 (dt, J = 7.7, 1.2 
Hz, 1H), 6.69 (s, 1H), 2.43 (s, 3H). 13C NMR (151 MHz, DMSO) δ 165.92, 160.79, 
160.63, 150.37, 145.11, 140.84, 130.41, 125.74, 124.33, 122.48, 121.70, 119.00, 111.78, 
105.53, 23.89. Anal. Calcd. for C17H13N5: C, 71.06; H, 4.56; N, 24.37. Found: C, 71.17; 
H, 4.37; N, 24.07. 
 
N-(3-methoxyphenyl)-6-methyl-2-(pyridin-4-yl)pyrimidin-4-amine (83). 
 
Molecular weight: 292.34 g/mol 
 
The compound was synthesized from 49 (206 mg, 1 mmol) and methyl 3-methoxyaniline 
(123 mg, 1 mmol) as described in the general procedure for compounds 82-88 to yield 83 
as a light beige solid (140 mg, 48%), mp 227-229 (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.23 (s, 1H), 9.04 – 8.95 (m, 2H), 8.63 – 8.53 (m, 2H), 7.43 (t, J = 2.2 Hz, 
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1H), 7.34 – 7.23 (m, 2H), 6.85 (s, 1H), 6.66 (ddd, J = 7.6, 2.4, 1.3 Hz, 1H), 3.78 (s, 3H), 
2.45 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.56, 161.03, 159.77, 158.51, 144.39, 
140.62, 129.77, 124.02, 112.63, 108.92, 106.14, 105.87, 55.22, 23.33. Anal. Calcd. for 
C17H16N4O: C, 69.85; H, 5.52; N, 19.17. Found: C, 69.53; H, 5.71; N, 19.52. 
 
N-(4-methoxyphenyl)-6-methyl-2-(pyridin-4-yl)pyrimidin-4-amine (84). 
 
Molecular weight: 292.34 g/mol 
 
The compound was synthesized from 49 (206 mg, 1 mmol) and methyl 4-methoxyaniline 
(123 mg, 1 mmol) as described in the general procedure for compounds 82-88 to yield 84 
as a light beige solid (114 mg, 39%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.59 
(s, 1H), 8.81 – 8.76 (m, 2H), 8.29 – 8.24 (m, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.00 – 6.94 
(m, 2H), 6.59 (d, J = 0.8 Hz, 1H), 3.76 (s, 3H), 2.39 (d, J = 0.7 Hz, 3H). 13C NMR (126 
MHz, DMSO) δ 148.81, 122.31, 114.30, 55.39, 23.61. Anal. Calcd. for C17H16N4O: C, 
69.85; H, 5.52; N, 19.17. Found: C, 69.53; H, 5.71; N, 19.52. 
 
3-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (85).  
 
Molecular weight: 286.34 g/mol 
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The compound was synthesized from 50 (205 mg, 1 mmol) and methyl 3-
aminobenzonitrile (118 mg, 1 mmol) as described in the general procedure for 
compounds 82-88 to yield 85 as a white solid (157 mg, 55%), mp 290-291 °C (decomp.). 
1H NMR (500 MHz, DMSO-d6) δ 10.87 (s, 1H), 8.33 – 8.17 (m, 3H), 8.02 (d, J = 8.1 Hz, 
1H), 7.69 – 7.47 (m, 5H), 6.83 (s, 1H), 2.52 (s, 3H). 13C NMR (126 MHz, DMSO) δ 
160.90, 132.20, 130.53, 128.92, 128.41, 118.76, 111.89, 104.43. Anal. Calcd. for 
C18H14N4: C, 75.50.85; H, 4.93; N, 19.57. Found: C, 75.82; H, 5.24; N, 19.38. 
 
4-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (86).  
 
Molecular weight: 286.34 g/mol 
 
The compound was synthesized from 50 (205 mg, 1 mmol) and methyl 4-
aminobenzonitrile (118 mg, 1 mmol) as described in the general procedure for 
compounds 82-88 to yield 86 as a white solid (180 mg, 63%), mp 262-264 °C (decomp.). 
1H NMR (600 MHz, DMSO-d6) δ 11.41 (s, 1H), 8.36 – 8.22 (m, 2H), 8.02 (d, J = 8.4 Hz, 
2H), 7.94 – 7.82 (m, 2H), 6.98 (s, 1H), 2.55 (s, 3H). 13C NMR (151 MHz, DMSO) δ 
161.20, 160.87, 133.80, 132.83, 129.36, 129.07, 121.26, 119.47, 25.96. Anal. Calcd. for 
C18H14N4: C, 75.50; H, 4.93; N, 19.57. Found: C, 75.74; H, 5.22; N, 19.22. 
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4-((6-methyl-2-phenylpyrimidin-4-yl)amino)-2-nitrophenol (87).  
 
Molecular weight: 322.32 g/mol 
 
The compound was synthesized from 50 (205 mg, 1 mmol) and methyl 4-amino-2-
nitrophenol (154 mg, 1 mmol) as described in the general procedure for compounds 82-
88 to yield 87 as a yellow solid (168 mg, 52%), mp 276-278 °C (decomp.). 1H NMR (600 
MHz, DMSO-d6) δ 11.07 (s, 1H), 8.61 (s, 1H), 8.35 – 8.25 (m, 2H), 7.76 (d, J = 8.9 Hz, 
1H), 7.68 (t, J = 7.3 Hz, 1H), 7.61 (t, J = 7.6 Hz, 2H), 7.26 (d, J = 9.0 Hz, 1H), 6.82 (s, 
1H), 2.53 (s, 3H). 13C NMR (151 MHz, DMSO) δ 129.02, 128.77, 119.90. Anal. Calcd. 
for C17H14N4O3: C, 63.35; H, 4.38; N, 17.38. Found: C, 63.63; H, 4.73; N, 17.26. 
 
6-methyl-N,2-diphenylpyrimidin-4-amine (88).  
 
Molecular weight: 261.33 g/mol 
 
The compound was synthesized from 50 (205 mg, 1 mmol) and methyl aniline (93 mg, 1 
mmol) as described in the general procedure for compounds 82-88 to yield 88 as a white 
solid (165 mg, 63%), mp 250-251 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.09 
(s, 1H), 8.32 – 8.19 (m, 2H), 7.86 – 7.64 (m, 3H), 7.62 (dd, J = 8.3, 6.6 Hz, 2H), 7.50 – 
7.39 (m, 2H), 7.21 (t, J = 7.4 Hz, 1H), 6.86 (s, 1H), 2.54 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 161.03, 159.79, 137.90, 132.75, 129.21, 129.02, 128.74, 125.00, 121.88, 
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104.02, 20.08. Anal. Calcd. for C17H15N3; C, 78.13; H, 5.79; N, 16.08. Found: C, 78.05; 
H, 5.63; N, 16.00. 
 
10.1.1.3 Synthesis of 2,4-Substituted quinazolines 
 
General Procedure for the Preparation of the 2-phenylquinazolin-4(3H)-one 
derivatives 91-97. A mixture of anthranilamide (2.72 g, 20 mmol), the corresponding 
pyridinecarboxaldehyde (20 mmol), iodine (3.17 g, 25 mmol), anhydrous potassium 
carbonate (2.76 g, 20 mmol) and 20 mL DMF was stirred at 70-90 °C for 4-8 h. The end 
of the reaction was monitored by TLC and the mixture poured on crushed ice to form a 
precipitate. Incomplete precipitation can be prevented by adjusting the pH with 
concentrated HCl solution to about 7. After filtration of the precipitate, it was thoroughly 
washed with 100 mL of a 20% sodium thiosulfate solution followed by 100 mL of hot 
distilled water. Purification was performed by recrystallization from ethanol.    
 
2-(3-nitrophenyl)quinazolin-4(3H)-one (91).  
 
Molecular weight: 267.24 g/mol 
 
The title compound was synthesized from 3-nitrobenzaldehyde (3.02 g, 20 mmol) as 
described in the general procedure for 91-97 to yield 91 as a white solid (5,18 g, 97%). 
1H NMR (500 MHz, DMSO-d6) δ 12.63 (s, 1H), 9.02 (t, J = 2.1 Hz, 1H), 8.61 (ddd, J = 
7.9, 1.8, 1.0 Hz, 1H), 8.40 (ddd, J = 8.2, 2.3, 1.0 Hz, 1H), 8.18 (ddd, J = 7.8, 1.5, 0.5 Hz, 
1H), 7.88 – 7.81 (m, 2H), 7.79 (dd, J = 8.0, 1.7 Hz, 1H), 7.55 (ddd, J = 8.2, 7.0, 1.3 Hz, 
1H). 13C NMR (126 MHz, DMSO) δ 161.90, 150.46, 148.18, 148.03, 134.42, 134.38, 
133.72, 130.00, 127.35, 126.83, 125.70, 125.41, 122.45, 121.15. 
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2-(4-nitrophenyl)quinazolin-4(3H)-one (92).  
 
Molecular weight: 267.24 g/mol 
 
The title compound was synthesized from 4-nitrobenzaldehyde (3.02 g, 20 mmol) as 
described in the general procedure for 91-97 to yield 92 as a white solid (4,92 g, 92%). 
1H NMR (500 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.44 – 8.34 (m, 4H), 8.18 (dd, J = 8.1, 
1.3 Hz, 1H), 7.87 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.79 (dd, J = 7.9, 1.0 Hz, 1H), 7.57 (ddd, 
J = 8.2, 7.1, 1.2 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.21, 150.91, 149.11, 148.42, 
138.71, 134.88, 129.42, 127.83, 127.45, 126.03, 123.73, 121.36. 
 
3-(4-oxo-3,4-dihydroquinazolin-2-yl)benzonitrile (93).  
 
Molecular weight: 247.26 g/mol 
 
The title compound was synthesized from 3-formylbenzonitrile (2.62 g, 20 mmol) as 
described in the general procedure for 91-97 to yield 93 as a white solid (4,25 g, 86%). 
1H NMR (500 MHz, DMSO-d6) δ 12.66 (s, 1H), 8.58 (m, 1H), 8.48 (m, 1H), 8.16 (m, 
1H), 8.04 (m, 1H), 7.85 (m, 1H), 7.76 (m, 2H), 7.54 (m, 1H). 13C NMR (126 MHz, 
DMSO) δ 162.21, 150.91, 149.11, 148.42, 138.71, 134.88, 129.42, 127.83, 127.45, 
126.03, 123.73, 121.36. 13C NMR (126 MHz, DMSO) δ 148.54, 134.74, 132.54, 131.58, 
130.04, 127.67, 127.11, 126.01, 118.40, 111.90, 99.64. 
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2-(2-methoxyphenyl)quinazolin-4(3H)-one (94).  
 
Molecular weight: 252.27 g/mol 
 
The title compound was synthesized from 2-methoxybenzaldehyde (2.72 g, 20 mmol) as 
described in the general procedure for 91-97 to yield 94 as a white solid (4,14 g, 82%). 
1H NMR (500 MHz, DMSO-d6) δ 12.05 (s, 1H), 8.14 (dd, J = 8.0, 1.6 Hz, 1H), 7.82 (ddd, 
J = 8.6, 7.1, 1.6 Hz, 1H), 7.70 (ddd, J = 10.3, 7.8, 1.5 Hz, 2H), 7.57 – 7.47 (m, 2H), 7.19 
(dd, J = 8.5, 1.0 Hz, 1H), 7.09 (td, J = 7.5, 1.0 Hz, 1H), 3.86 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 161.31, 157.29, 152.44, 149.16, 134.51, 132.33, 130.56, 127.50, 126.65, 
125.89, 122.76, 121.14, 120.56, 112.04, 55.93. 
 
2-(3-methoxyphenyl)quinazolin-4(3H)-one (95).  
 
Molecular weight: 252.27 g/mol 
 
The title compound was synthesized from 3-methoxybenzaldehyde (2.72 g, 20 mmol) as 
described in the general procedure for 91-97 to yield 95 as a white solid (4,24 g, 82%). 
1H NMR (500 MHz, Chloroform-d) δ 11.01 (s, 1H), 8.34 – 8.24 (m, 1H), 7.86 – 7.76 (m, 
2H), 7.76 – 7.67 (m, 2H), 7.52 – 7.41 (m, 2H), 7.11 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 3.94 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 163.36, 160.19, 151.42, 149.38, 134.86, 134.14, 
130.14, 128.03, 126.85, 126.35, 120.95, 119.35, 118.20, 112.07, 55.58. 
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2-(4-methoxyphenyl)quinazolin-4(3H)-one (96).  
 
Molecular weight: 252.27 g/mol 
 
The title compound was synthesized from 4-methoxybenzaldehyde (2.72 g, 20 mmol) as 
described in the general procedure for 91-97 to yield 96 as a white solid (3,73 g, 82%). 
1H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.24 – 8.15 (m, 2H), 8.12 (ddd, J = 7.9, 
1.6, 0.7 Hz, 1H), 7.80 (ddd, J = 8.2, 7.1, 1.6 Hz, 1H), 7.69 (ddd, J = 8.2, 1.2, 0.6 Hz, 1H), 
7.47 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 7.12 – 7.03 (m, 2H), 3.84 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 162.44, 161.99, 152.03, 134.61, 129.56, 127.31, 126.20, 125.93, 124.95, 
120.79, 114.11, 55.58. 
 
2-(3,4-dimethoxyphenyl)quinazolin-4(3H)-one (97). 
 
Molecular weight: 282.30 g/mol 
 
The title compound was synthesized from 3,4-dimethoxybenzaldehyde (3.32 g, 20 mmol) 
as described in the general procedure for 91-97 to yield 97 as a white solid (4,07 g, 72%). 
1H NMR (500 MHz, DMSO-d6) δ 12.39 (s, 1H), 8.12 (dd, J = 8.0, 1.6 Hz, 1H), 7.86 (dd, 
J = 8.5, 2.2 Hz, 1H), 7.83 – 7.75 (m, 2H), 7.70 (dd, J = 8.3, 1.2 Hz, 1H), 7.47 (ddd, J = 
8.1, 7.2, 1.2 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 151.75, 148.71, 134.63, 127.42, 126.23, 125.96, 124.91, 121.29, 120.82, 
111.55, 110.91, 55.85, 55.83. 
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General Procedure for the Preparation of the 4-chloro-2-phenylquinazoline 
derivatives 98-104. The corresponding 2-phenylquinazolin-4(3H)-one derivative 91-97 
(10 mmol) was added to phosphorous trichloride (30 mL, 0.32 mol) and stirred for 10 
min at room temperature. The mixture was then refluxed for 4-8 h and the reaction 
monitored by TLC. After completion of the reaction, excess POCl3 was removed under 
reduced pressure and 50 mL ice water added. Subsequently, 50 mL DCM was added 
while stirring and the pH of the mixture slowly adjusted to 7 with 25% ammonium 
solution. The organic phase was collected, with a separatory funnel, washed with 50 mL 
brine and dried under MgSO4. The solvent was removed under reduced pressure and the 
obtained solid recrystallized from isopropanol. 
 
4-chloro-2-(3-nitrophenyl)quinazoline (98).  
 
Molecular weight: 285.69 g/mol 
 
The title compound was synthesized from 1 (2.67 g, 10 mmol) as described in the general 
procedure for 98-104 to yield 98 as white solid (2.31 g, 81%). 1H NMR (500 MHz, 
DMSO-d6) δ 9.19 (t, J = 2.0 Hz, 1H), 8.92 – 8.84 (m, 1H), 8.51 – 8.38 (m, 1H), 8.33 (d, 
J = 8.3 Hz, 1H), 8.28 – 8.11 (m, 2H), 7.90 (q, J = 7.8 Hz, 2H). 13C NMR (126 MHz, 
DMSO) δ 162.54, 156.94, 151.14, 148.55, 137.79, 136.44, 134.26, 130.87, 130.19, 
128.84, 125.95, 125.89, 122.54, 122.32. 
 
4-chloro-2-(4-nitrophenyl)quinazoline (99).  
 
Molecular weight: 285.69 g/mol 
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The title compound was synthesized from 2 (2.67 g, 10 mmol) as described in the general 
procedure for 98-104 to yield 99 as light yellow solid (2.19 g, 77%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.69 (d, J = 8.4 Hz, 2H), 8.40 (d, J = 7.9 Hz, 2H), 8.31 (d, J = 8.6 Hz, 1H), 
8.24 – 8.08 (m, 2H), 7.91 (d, J = 8.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.47, 
157.08, 151.13, 149.25, 141.89, 136.43, 130.40, 129.49, 128.94, 125.88, 124.20, 122.27. 
 
3-(4-chloroquinazolin-2-yl)benzonitrile (100).  
 
Molecular weight: 265.70 g/mol 
 
The title compound was synthesized from 93 (2.47 g, 10 mmol) as described in the general 
procedure for 98-104 to yield 100 as white solid (2.39 g, 90%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.59 – 8.56 (m, 1H), 8.48 (ddd, J = 8.0, 1.9, 1.1 Hz, 1H), 8.18 – 8.14 (m, 
1H), 8.06 – 8.03 (m, 1H), 7.88 – 7.83 (m, 1H), 7.79 – 7.74 (m, 2H), 7.58 – 7.53 (m, 1H). 
13C NMR (126 MHz, DMSO) δ 162.48, 157.13, 151.17, 137.34, 136.40, 134.81, 132.70, 
131.58, 130.54, 130.11, 128.82, 125.88, 122.28, 118.51, 112.35.  
 
4-chloro-2-(2-methoxyphenyl)quinazoline (101).  
 
Molecular weight: 270.72 g/mol 
 
The title compound was synthesized from 94 (2.52 g, 10 mmol) as described in the general 
procedure for 98-104 to yield 101 as light yellow solid (2.38 g, 88%). 1H NMR (500 
MHz, DMSO-d6) δ 8.15 (dd, J = 8.0, 1.5 Hz, 1H), 7.84 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 
7.74 – 7.67 (m, 2H), 7.59 – 7.51 (m, 2H), 7.20 (dd, J = 8.5, 0.9 Hz, 1H), 7.10 (td, J = 7.5, 
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1.0 Hz, 1H), 3.86 (s, 3H). 13C NMR (126 MHz, DMSO) δ 161.25, 157.31, 152.76, 148.31, 
134.67, 132.59, 130.64, 126.85, 125.99, 122.21, 121.02, 120.58, 112.09, 55.98. 
 
4-chloro-2-(3-methoxyphenyl)quinazoline (102).  
 
Molecular weight: 270.72 g/mol 
 
The title compound was synthesized from 95 (2.52 g, 10 mmol) as described in the general 
procedure for 98-104 to yield 102 as light yellow solid (2.51 g, 93%). 1H NMR (500 
MHz, DMSO-d6) δ 8.31 – 8.25 (m, 1H), 8.15 – 8.10 (m, 2H), 8.10 – 8.06 (m, 1H), 8.00 
(dd, J = 2.7, 1.5 Hz, 1H), 7.84 (ddd, J = 8.2, 6.2, 1.9 Hz, 1H), 7.49 (t, J = 8.0 Hz, 1H), 
7.16 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 162.02, 
159.84, 158.80, 151.29, 137.55, 136.06, 130.16, 129.51, 128.69, 125.76, 121.98, 120.80, 
117.51, 113.12, 55.44. 
 
4-chloro-2-(4-methoxyphenyl)quinazoline (103).  
 
Molecular weight: 270.72 g/mol 
 
The title compound was synthesized from 96 (2.52 g, 10 mmol) as described in the general 
procedure for 98-104 to yield 103 as light yellow solid (2.46 g, 91%). 1H NMR (500 
MHz, DMSO-d6) δ 8.21 – 8.09 (m, 3H), 7.94 – 7.83 (m, 2H), 7.56 (ddd, J = 8.1, 6.4, 2.0 
Hz, 1H), 7.17 – 7.11 (m, 2H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 162.91, 
161.60, 153.92, 135.23, 130.62, 127.10, 126.25, 124.68, 120.26, 114.28, 55.78. 
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4-chloro-2-(3,4-dimethoxyphenyl)quinazoline (104).  
 
Molecular weight: 300.74 g/mol 
 
The title compound was synthesized from 7 (2.82 g, 10 mmol) as described in the general 
procedure for 98-104 to yield 104 as light yellow solid (2.13 g, 71%). 1H NMR (500 
MHz, DMSO-d6) δ 8.16 (ddd, J = 7.9, 1.6, 0.6 Hz, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.91 – 
7.85 (m, 2H), 7.83 (d, J = 2.3 Hz, 1H), 7.56 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H), 7.17 (d, J = 
8.6 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 161.52, 153.90, 
152.79, 148.65, 135.26, 127.16, 126.27, 124.54, 122.61, 120.20, 111.75, 111.58, 55.99, 
55.98. 
 
General Procedure for the Preparation of the 4-anilino-2-phenylquinazoline 
derivatives 105-152. 
The corresponding 4-chloroquinazoline derivative 98-104 (1 mmol) was added to 
isopropanol (5 mL) with the corresponding substituted aniline derivative (1 mmol) and 
sealed in a microwave tube. The mixture was heated by 100 watt microwave irradiation 
to 110 °C for a period of 15 – 30 min to completion of the reaction, indicated by TLC. 
The formed precipitate was filtered, washed with 10 mL isopropanol and dried in vacuo. 
If no precipitate is formed, the solvent was removed under reduced pressure and the 
remaining solid recrystallized from ethanol. 
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2-(3-nitrophenyl)-N-phenylquinazolin-4-amine (105).  
 
Molecular weight: 342.36 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and aniline (931 mg, 10 
mmol) as described in the general procedure for 105-152 to yield 105 as beige-yellow 
solid (2.16 g, 63%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.98 (s, 1H), 9.19 
(dd, J = 2.4, 1.6 Hz, 1H), 8.81 – 8.75 (m, 1H), 8.59 (dt, J = 8.3, 0.9 Hz, 1H), 8.31 (ddd, J 
= 8.2, 2.5, 1.1 Hz, 1H), 7.96 – 7.88 (m, 4H), 7.79 (t, J = 8.0 Hz, 1H), 7.65 (ddd, J = 8.2, 
6.2, 2.0 Hz, 1H), 7.51 – 7.43 (m, 2H), 7.21 (tt, J = 7.4, 1.2 Hz, 1H). 13C NMR (126 MHz, 
DMSO) δ 158.26, 157.05, 150.36, 148.32, 140.15, 139.10, 133.87, 133.63, 130.26, 
128.61, 128.37, 126.71, 124.85, 124.19, 123.28, 122.75, 122.44, 114.38. Anal. Calcd. 
for C20H14N4O2: C, 70.17; H, 4.12; N, 16.37. Found: C, 70.52; H, 4.37; N, 16.07. 
 
N-cyclohexyl-2-(3-nitrophenyl)quinazolin-4-amine (106).  
 
Molecular weight: 348.41 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and cyclohexanamine 
(992 mg, 10 mmol) as described in the general procedure for 105-152 to yield 106 as light 
yellow solid (1.88 g, 54%), mp 186-187 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.23 (dd, 
J = 2.5, 1.6 Hz, 1H), 8.85 (dt, J = 7.8, 1.3 Hz, 1H), 8.37 (dd, J = 8.1, 1.1 Hz, 1H), 8.32 
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(ddd, J = 8.2, 2.5, 1.1 Hz, 1H), 8.09 (d, J = 7.4 Hz, 1H), 7.83 – 7.77 (m, 3H), 7.51 (ddd, 
J = 8.2, 6.1, 2.1 Hz, 1H), 4.38 – 4.25 (m, 1H), 2.12 – 1.78 (m, 4H), 1.71 (d, J = 13.1 Hz, 
1H), 1.54 – 1.37 (m, 4H), 1.30 – 1.15 (m, 1H). 13C NMR (126 MHz, DMSO) δ 159.16, 
157.23, 149.86, 148.26, 140.61, 133.89, 133.01, 130.14, 128.00, 125.82, 124.62, 123.20, 
122.24, 114.19, 50.28, 32.05, 25.55, 25.25. Anal. Calcd. for C20H20N4O2: C, 68.95; H, 
5.79; N, 16.08. Found: C, 69.22; H, 6.03; N, 15.87. 
 
N,2-bis(3-nitrophenyl)quinazolin-4-amine (107).  
 
Molecular weight: 387.36 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 3-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 107 as light yellow 
solid (3.33 g, 86%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.66 (s, 1H), 9.17 
(dd, J = 2.4, 1.7 Hz, 1H), 9.10 (t, J = 2.2 Hz, 1H), 8.88 – 8.81 (m, 1H), 8.69 (dd, J = 8.4, 
1.5 Hz, 1H), 8.36 (dddd, J = 8.1, 4.6, 2.3, 1.0 Hz, 2H), 8.05 (ddd, J = 8.2, 2.3, 0.9 Hz, 
1H), 8.01 (dd, J = 8.4, 1.3 Hz, 1H), 7.97 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.82 (t, J = 8.0 
Hz, 1H), 7.77 – 7.70 (m, 2H). 13C NMR (126 MHz, DMSO) δ 158.30, 156.59, 148.36, 
147.97, 140.19, 134.41, 134.15, 130.43, 129.96, 128.40, 127.38, 125.46, 123.59, 122.64, 
118.59, 116.82, 114.14. Anal. Calcd. for C20H13N5O4: C, 62.02; H, 3.38; N, 18.08. 
Found: C, 62.33; H, 3.51; N, 17.73. 
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2-nitro-4-((2-(3-nitrophenyl)quinazolin-4-yl)amino)phenol (108).  
 
Molecular weight: 403.35 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 4-amino-2-
nitrophenol (1.54, 10 mmol) as described in the general procedure for 105-152 to yield 
108 as orange solid (2.46 g, 61%), mp 299-300 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.91 (s, 1H), 10.26 (s, 1H), 9.13 (dd, J = 2.4, 1.6 Hz, 1H), 8.79 (dt, J = 7.8, 
1.3 Hz, 1H), 8.67 (d, J = 2.7 Hz, 1H), 8.55 (dd, J = 8.2, 1.1 Hz, 1H), 8.33 (ddd, J = 8.1, 
2.5, 1.1 Hz, 1H), 8.05 (dd, J = 9.0, 2.7 Hz, 1H), 7.95 – 7.86 (m, 2H), 7.78 (t, J = 8.0 Hz, 
1H), 7.66 (ddd, J = 8.2, 6.2, 2.0 Hz, 1H), 7.25 (d, J = 9.0 Hz, 1H). 13C NMR (126 MHz, 
DMSO) δ 158.13, 156.72, 149.19, 148.30, 135.67, 134.05, 133.98, 130.60, 130.43, 
130.26, 127.01, 125.19, 123.27, 122.50, 119.26, 118.72, 114.06. Anal. Calcd. for 
C20H13N5O5: C, 59.56; H, 3.25; N, 17.36. Found: C, 59.73; H, 3.47; N, 17.14. 
 
3-((2-(3-nitrophenyl)quinazolin-4-yl)amino)benzonitrile (109).  
 
Molecular weight: 367.37 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 3-aminobenzonitrile 
(1.18, 10 mmol) as described in the general procedure for 105-152 to yield 109 as light 
beige solid (3.09 g, 84%), mp 272-274 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 
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10.24 (s, 1H), 9.14 (dd, J = 2.4, 1.6 Hz, 1H), 8.77 (dt, J = 7.7, 1.4 Hz, 1H), 8.57 (dd, J = 
8.3, 1.1 Hz, 1H), 8.41 (t, J = 1.9 Hz, 1H), 8.34 (ddd, J = 8.2, 2.5, 1.1 Hz, 1H), 8.30 – 8.21 
(m, 1H), 7.98 – 7.88 (m, 2H), 7.80 (t, J = 8.0 Hz, 1H), 7.73 – 7.60 (m, 3H). 13C NMR 
(126 MHz, DMSO) δ 158.11, 156.80, 150.29, 148.31, 140.05, 139.78, 133.96, 133.79, 
130.29, 130.01, 128.35, 127.38, 127.06, 127.02, 125.43, 125.01, 123.26, 122.35, 118.74, 
114.24, 111.57. Anal. Calcd. for C21H13N5O2: C, 68.66; H, 3.57; N, 19.06. Found: C, 
69.00; H, 3.90; N, 18.94. 
 
N-(3-methoxyphenyl)-2-(3-nitrophenyl)quinazolin-4-amine (110).  
 
Molecular weight: 372.38 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 3-methoxyaniline 
(1.23 g, 10 mmol) as described in the general procedure for 105-152 to yield 110 as 
yellow solid (3.09 g, 84%), mp 189-191 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.94 (s, 
1H), 9.20 (t, J = 2.0 Hz, 1H), 8.83 (dt, J = 7.9, 1.4 Hz, 1H), 8.60 (d, J = 8.2 Hz, 1H), 8.34 
(ddd, J = 8.2, 2.5, 1.1 Hz, 1H), 7.97 – 7.85 (m, 2H), 7.82 (t, J = 8.0 Hz, 1H), 7.70 – 7.61 
(m, 2H), 7.53 (dd, J = 8.0, 2.0 Hz, 1H), 7.36 (t, J = 8.1 Hz, 1H), 6.78 (dd, J = 7.8, 2.5 Hz, 
1H), 3.83 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.62, 158.24, 157.08, 150.33, 
148.36, 140.20, 133.91, 133.68, 130.27, 129.32, 128.39, 126.76, 124.94, 123.27, 122.35, 
114.72, 114.42, 110.17, 107.88, 55.25. Anal. Calcd. for C21H16N4O3: C, 67.73; H, 4.33; 
N, 15.05. Found: C, 67.64; H, 4.69; N, 14.80. 
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N-(3,4-dimethoxyphenyl)-2-(3-nitrophenyl)quinazolin-4-amine (111). 
 
Molecular weight: 402.41 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 3,4-dimethoxyaniline 
(1.53 g, 10 mmol) as described in the general procedure for 105-152 to yield 111 as 
yellow solid (3.18 g, 75%), mp 184-185 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.88 (s, 
1H), 9.18 (dd, J = 2.4, 1.6 Hz, 1H), 8.83 (dt, J = 7.8, 1.3 Hz, 1H), 8.61 – 8.53 (m, 1H), 
8.33 (ddd, J = 8.2, 2.4, 1.1 Hz, 1H), 7.94 – 7.85 (m, 2H), 7.81 (t, J = 8.0 Hz, 1H), 7.70 – 
7.60 (m, 2H), 7.38 (dd, J = 8.6, 2.4 Hz, 1H), 7.04 (d, J = 8.7 Hz, 1H), 3.83 (s, 3H), 3.81 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 158.19, 157.15, 150.21, 148.58, 148.31, 145.75, 
140.33, 133.94, 133.50, 132.37, 130.21, 128.30, 126.59, 124.87, 123.15, 122.27, 114.69, 
114.36, 111.89, 107.80, 55.92, 55.60. Anal. Calcd. for C22H18N4O4: C, 65.66; H, 4.51; 
N, 13.92. Found: C, 65.53; H, 4.88; N, 14.11. 
 
N-(4-bromo-3-methoxyphenyl)-2-(3-nitrophenyl)quinazolin-4-amine (112).  
 
Molecular weight: 451.28 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 4-bromo-3-
methoxyaniline (2.02 g, 10 mmol) as described in the general procedure for 105-152 to 
yield 112 as yellow solid (3.25 g, 72%), mp 190-191 °C (decomp.). 1H NMR (600 MHz, 
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DMSO-d6) δ 10.59 (s, 1H), 9.16 (t, J = 2.0 Hz, 1H), 8.82 (dd, J = 7.7, 1.6 Hz, 1H), 8.72 
(d, J = 8.4 Hz, 1H), 8.40 (dd, J = 8.2, 2.3 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.99 (t, J = 
7.7 Hz, 1H), 7.89 – 7.80 (m, 2H), 7.74 (t, J = 7.6 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.47 
(dd, J = 8.5, 2.3 Hz, 1H), 3.90 (s, 3H). 13C NMR (151 MHz, DMSO) δ 158.77, 156.92, 
155.77, 148.64, 139.66, 135.01, 134.77, 132.95, 130.87, 127.86, 126.18, 124.09, 123.16, 
116.71, 114.34, 107.96, 106.19, 56.64. Anal. Calcd. for C21H15BrN4O3: C, 55.89; H, 
3.35; N, 12.42. Found: C, 55.74; H, 3.59; N, 12.23. 
 
N-(3,4-diethoxyphenyl)-2-(3-nitrophenyl)quinazolin-4-amine (113).  
 
Molecular weight: 430.46 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 3,4-diethoxyaniline 
(1.81 g, 10 mmol) as described in the general procedure for 105-152 to yield 113 as 
orange solid (1.85 g, 43%), mp 272-273 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 11.10 (s, 1H), 9.12 (t, J = 2.0 Hz, 1H), 8.91 – 8.73 (m, 2H), 8.45 (ddd, J = 8.2, 2.3, 1.0 
Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.02 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.88 (t, J = 8.0 Hz, 
1H), 7.76 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.57 (d, J = 2.5 Hz, 1H), 7.34 (dd, J = 8.7, 2.5 
Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H), 4.15 – 4.02 (m, 4H), 1.35 (dt, J = 9.5, 7.0 Hz, 6H). 13C 
NMR (126 MHz, DMSO) δ 158.53, 155.95, 148.22, 148.13, 146.34, 135.25, 134.85, 
130.69, 130.57, 127.94, 126.67, 124.24, 123.49, 116.23, 113.43, 113.31, 110.06, 64.24, 
64.12, 14.93. Anal. Calcd. for C24H22N4O4: C, 66.97; H, 5.15; N, 13.02. Found: C, 
66.89; H, 5.36; N, 13.05. 
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N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(3-nitrophenyl)quinazolin-4-amine 
(114). 
  
Molecular weight: 400.39 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 2,3-
dihydrobenzo[b][1,4]dioxin-6-amine (1.51 g, 10 mmol) as described in the general 
procedure for 105-152 to yield 114 as yellow solid (2.04 g, 51%), mp 267-270 °C 
(decomp.). 1H NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 9.21 – 9.08 (m, 1H), 8.78 
(dt, J = 7.8, 1.3 Hz, 1H), 8.68 (d, J = 8.3 Hz, 1H), 8.40 (ddd, J = 8.2, 2.4, 1.0 Hz, 1H), 
8.05 (d, J = 8.3 Hz, 1H), 7.96 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.85 (t, J = 8.0 Hz, 1H), 
7.71 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.42 (d, J = 2.5 Hz, 1H), 7.36 (dd, J = 8.7, 2.5 Hz, 
1H), 6.96 (d, J = 8.7 Hz, 1H), 4.33 – 4.26 (m, 4H). 13C NMR (126 MHz, DMSO) δ 158.47, 
156.32, 148.28, 143.17, 141.05, 134.65, 134.37, 131.46, 130.49, 127.44, 125.97, 123.82, 
123.12, 116.83, 116.71, 113.74, 112.64, 64.37, 64.29. Anal. Calcd. for C22H16N4O4: C, 
66.00; H, 4.03; N, 13.99. Found: C, 65.93; H, 4.24; N, 13.81. 
 
N-(3-(methylthio)phenyl)-2-(3-nitrophenyl)quinazolin-4-amine (115).  
 
Molecular weight: 388.45 g/mol 
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The title compound was synthesized from 98 (2.85 g, 10 mmol) and 3-(methylthio)aniline 
(1.39 g, 10 mmol) as described in the general procedure for 105-152 to yield 115 as 
yellow solid (3.42 g, 88%), mp 184-185 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.95 (s, 
1H), 9.19 – 9.15 (m, 1H), 8.80 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 8.60 – 8.55 (m, 1H), 8.33 
(ddd, J = 8.2, 2.4, 1.1 Hz, 1H), 7.94 – 7.87 (m, 3H), 7.79 (ddd, J = 8.2, 7.7, 0.4 Hz, 1H), 
7.76 (ddd, J = 8.2, 2.1, 0.9 Hz, 1H), 7.66 (ddd, J = 8.2, 6.3, 1.9 Hz, 1H), 7.40 (t, J = 8.0 
Hz, 1H), 7.09 (ddd, J = 7.9, 1.9, 0.9 Hz, 1H), 2.52 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 158.20, 157.00, 150.33, 148.33, 140.13, 139.72, 138.56, 133.89, 133.70, 130.22, 
129.06, 128.39, 126.78, 124.93, 123.23, 122.32, 121.62, 119.64, 119.05, 114.38, 14.92. 
Anal. Calcd. for C21H16N4O2S: C, 64.93; H, 4.15; N, 14.42. Found: C, 65.25; H, 4.42; 
N, 14.21. 
 
N-(4-(methylthio)phenyl)-2-(3-nitrophenyl)quinazolin-4-amine (116).  
 
Molecular weight: 388.45 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 4-(methylthio)aniline 
(1.39 g, 10 mmol) as described in the general procedure for 105-152 to yield 116 as 
yellow solid (3.22 g, 83%), mp 234-235 °C (decomp.). 1H NMR (600 MHz, DMSO-d6) 
δ 9.95 (s, 1H), 9.14 (t, J = 2.0 Hz, 1H), 8.74 (dt, J = 7.8, 1.3 Hz, 1H), 8.53 (d, J = 8.2 Hz, 
1H), 8.28 (ddd, J = 8.1, 2.5, 1.1 Hz, 1H), 7.90 – 7.82 (m, 4H), 7.76 (t, J = 7.9 Hz, 1H), 
7.61 (ddd, J = 8.2, 6.3, 1.9 Hz, 1H), 7.38 – 7.31 (m, 2H), 2.49 (s, 3H). 13C NMR (151 
MHz, DMSO) δ 158.12, 157.02, 150.28, 148.29, 140.08, 136.48, 133.89, 133.62, 132.96, 
130.63, 130.29, 128.32, 126.78, 124.84, 123.31, 122.44, 115.51, 114.37, 40.11, 39.97, 
15.63. Anal. Calcd. for C21H16N4O2S: C, 64.93; H, 4.15; N, 14.42. Found: C, 64.90; H, 
4.42; N, 14.08. 
 
10 Experimental section  317
N1-(2-(3-nitrophenyl)quinazolin-4-yl)benzene-1,3-diamine (117).  
 
Molecular weight: 357.37 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and benzene-1,3-diamine 
(1.08 g, 10 mmol) as described in the general procedure for 105-152 to yield 117 as 
yellow solid (1.57 g, 44%), mp 229-230 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 9.74 (s, 1H), 9.23 (dd, J = 2.4, 1.6 Hz, 1H), 8.82 (ddd, J = 7.8, 1.6, 1.1 Hz, 1H), 8.65 – 
8.53 (m, 1H), 8.33 (ddd, J = 8.1, 2.5, 1.1 Hz, 1H), 7.94 – 7.84 (m, 2H), 7.81 (t, J = 8.0 
Hz, 1H), 7.62 (ddd, J = 8.3, 6.5, 1.7 Hz, 1H), 7.23 – 7.18 (m, 1H), 7.15 – 7.01 (m, 2H), 
6.47 – 6.32 (m, 1H), 5.13 (s, 2H). 13C NMR (126 MHz, DMSO) δ 158.27, 157.16, 150.31, 
149.10, 148.35, 140.25, 139.65, 134.01, 133.46, 130.25, 128.83, 128.30, 126.55, 124.78, 
123.30, 122.56, 114.44, 110.62, 110.27, 108.30. Anal. Calcd. for C20H15N5O2: C, 67.22; 
H, 4.23; N, 19.60. Found: C, 67.51; H, 4.33; N, 19.33. 
 
N1,N1-dimethyl-N3-(2-(3-nitrophenyl)quinazolin-4-yl)benzene-1,3-diamine (118).  
 
Molecular weight: 385.43 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and N1,N1-
dimethylbenzene-1,3-diamine (1.36 g, 10 mmol) as described in the general procedure 
for 105-152 to yield 118 as light yellow solid (2.78 g, 72%), mp 243-245 °C (decomp.). 
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1H NMR (500 MHz, DMSO-d6) δ 11.02 (s, 1H), 9.15 (s, 1H), 8.88 (dt, J = 7.9, 1.4 Hz, 
1H), 8.83 (d, J = 8.2 Hz, 1H), 8.45 – 8.41 (m, 1H), 8.17 (d, J = 8.4 Hz, 1H), 8.03 (t, J = 
7.7 Hz, 1H), 7.87 (t, J = 8.0 Hz, 2H), 7.80 – 7.74 (m, 1H), 7.60 (s, 1H), 7.51 (d, J = 8.1 
Hz, 1H), 7.23 (s, 1H), 3.08 (s, 6H). 13C NMR (126 MHz, DMSO) δ 158.74, 156.18, 
148.24, 138.96, 135.14, 134.84, 130.52, 129.79, 127.84, 126.34, 124.18, 123.35, 113.65, 
25.59. Anal. Calcd. for C22H19N5O2: C, 68.56; H, 4.97; N, 18.17. Found: C, 68.61; H, 
5.21; N, 18.43. 
 
N1,N1-diethyl-N3-(2-(3-nitrophenyl)quinazolin-4-yl)benzene-1,3-diamine (119).  
 
Molecular weight: 413.48 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and N1,N1-
diethylbenzene-1,3-diamine (1.64 g, 10 mmol) as described in the general procedure for 
105-152 to yield 119 as dark-yellow solid (2.23 g, 54%), mp 168-170 °C (decomp.). 1H 
NMR (500 MHz, DMSO-d6) δ 9.80 (s, 1H), 9.19 (dd, J = 2.4, 1.6 Hz, 1H), 8.79 (dt, J = 
7.8, 1.3 Hz, 1H), 8.53 (dd, J = 8.2, 1.1 Hz, 1H), 8.31 (ddd, J = 8.2, 2.5, 1.1 Hz, 1H), 7.89 
– 7.80 (m, 2H), 7.78 (t, J = 7.9 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.60 (ddd, J = 10.5, 6.0, 
2.9 Hz, 1H), 6.77 (d, J = 8.4 Hz, 2H), 3.38 (q, J = 6.9 Hz, 4H), 1.14 (t, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, DMSO) δ 158.14, 157.21, 150.20, 148.28, 144.83, 140.39, 133.84, 
133.27, 130.16, 128.19, 127.16, 126.36, 124.72, 124.56, 123.13, 122.50, 114.42, 111.56, 
44.01, 12.58. Anal. Calcd. for C24H23N5O2: C, 69.72; H, 5.61; N, 16.94. Found: C, 
69.42; H, 5.85; N, 16.65. 
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N-(3-((2-(3-nitrophenyl)quinazolin-4-yl)amino)phenyl)acetamide (120).  
 
Molecular weight: 399.41 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and N-(3-
aminophenyl)acetamide (1.50 g, 10 mmol) as described in the general procedure for 105-
152 to yield 120 as light yellow (3.04 g, 76%), mp 251-252 °C. 1H NMR (600 MHz, 
DMSO-d6) δ 10.01 (s, 1H), 9.99 (s, 1H), 9.24 – 9.19 (m, 1H), 8.89 (dt, J = 7.8, 1.3 Hz, 
1H), 8.62 (dd, J = 8.1, 1.2 Hz, 1H), 8.49 (t, J = 2.1 Hz, 1H), 8.33 (ddd, J = 8.1, 2.4, 1.1 
Hz, 1H), 7.96 – 7.87 (m, 2H), 7.79 (t, J = 7.9 Hz, 1H), 7.65 (ddd, J = 8.2, 6.5, 1.7 Hz, 
1H), 7.55 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.29 (ddd, J = 8.1, 2.1, 
1.0 Hz, 1H), 2.07 (s, 3H). 13C NMR (151 MHz, DMSO) δ 168.82, 158.56, 157.44, 150.73, 
148.73, 140.36, 140.08, 139.71, 134.50, 133.98, 130.52, 128.93, 128.70, 127.04, 125.20, 
123.71, 123.13, 117.74, 115.22, 114.74, 113.93, 24.52. Anal. Calcd. for C22H17N5O3: C, 
66.16; H, 4.29; N, 17.53. Found: C, 65.95; H, 4.43; N, 17.24. 
 
2-(3-nitrophenyl)-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (121).  
 
Molecular weight: 410.36 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 3-
(trifluoromethyl)aniline (1.61 g, 10 mmol) as described in the general procedure for 105-
10 Experimental section 320
152 to yield 121 as white-yellow solid (3.45 g, 84%), mp 148-151 °C. 1H NMR (600 
MHz, DMSO-d6) δ 9.17 (t, J = 5.8 Hz, 1H), 9.15 (dd, J = 2.4, 1.6 Hz, 1H), 8.79 (dt, J = 
7.8, 1.3 Hz, 1H), 8.36 – 8.28 (m, 2H), 7.89 – 7.77 (m, 4H), 7.75 (t, J = 7.9 Hz, 1H), 7.61 
– 7.53 (m, 3H). 13C NMR (151 MHz, DMSO) δ 159.87, 157.17, 149.77, 148.27, 141.30, 
140.30, 133.98, 133.37, 131.72, 130.08, 129.59, 129.20 (q, J = 31.5 Hz), 128.18, 126.42, 
124.78, 124.40 (q, J = 272.3 Hz), 124.29 (q, J = 3.8 Hz), 123.76 (q, J = 3.7 Hz), 122.92, 
122.22, 114.16. Anal. Calcd. for C21H13F3N4O2: C, 61.47; H, 3.19; N, 13.89. Found: C, 
61.86; H, 3.37; N, 13.60. 
 
N-(4-methoxy-3-(trifluoromethyl)phenyl)-2-(3-nitrophenyl)quinazolin-4-amine 
(122).  
 
Molecular weight: 440.38 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 4-methoxy-3-
(trifluoromethyl)aniline (1.91 g, 10 mmol) as described in the general procedure for 105-
152 to yield 122 as light yellow solid (2.00 g, 66%), mp 272-275 °C (decomp.). 1H NMR 
(500 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.11 (t, J = 2.0 Hz, 1H), 8.81 – 8.71 (m, 2H), 8.42 
(ddd, J = 8.2, 2.4, 1.1 Hz, 1H), 8.29 (d, J = 2.6 Hz, 1H), 8.15 – 8.05 (m, 2H), 8.00 (ddd, 
J = 8.4, 6.9, 1.2 Hz, 1H), 7.84 (t, J = 8.0 Hz, 1H), 7.75 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 
7.39 (d, J = 9.0 Hz, 1H), 3.95 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.61, 156.22, 
154.35, 148.29, 134.98, 134.46, 130.70, 130.47, 129.07, 127.74, 126.23, 124.77, 124.00, 
123.07, 122.60, 122.21 (d, J = 3.9 Hz), 116.80 (d, J = 30.4 Hz), 113.66, 113.30, 56.58. 
Anal. Calcd. for C22H15F3N4O3: C, 60.00; H, 3.43; N, 12.72. Found: C, 59.88; H, 3.81; 
N, 12.52. 
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N-(4-iodophenyl)-2-(3-nitrophenyl)quinazolin-4-amine (123).  
 
Molecular weight: 468.25 g/mol 
 
The title compound was synthesized from 98 (2.85 g, 10 mmol) and 4-iodoaniline (2.19 
g, 10 mmol) as described in the general procedure for 105-152 to yield 123 as light yellow 
solid (2.58 g, 55%), mp 245-247 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 10.03 
(s, 1H), 9.18 (t, J = 2.0 Hz, 1H), 8.78 (dd, J = 7.8, 1.3 Hz, 1H), 8.56 (d, J = 8.3 Hz, 1H), 
8.33 (dd, J = 8.1, 2.4 Hz, 1H), 7.95 – 7.87 (m, 2H), 7.83 – 7.76 (m, 5H), 7.66 (ddd, J = 
8.3, 6.2, 2.1 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.04, 156.96, 150.31, 148.33, 
139.95, 139.06, 137.26, 133.95, 133.79, 130.39, 128.38, 126.86, 124.92, 124.71, 123.26, 
122.44, 114.39, 87.78. Anal. Calcd. for C20H13IN4O2: C, 51.30; H, 2.80; N, 11.97. 
Found: C, 51.55; H, 2.92; N, 11.79. 
 
N-(3-nitrophenyl)-2-(4-nitrophenyl)quinazolin-4-amine (124).  
 
Molecular weight: 387.36 g/mol 
 
The title compound was synthesized from 99 (2.85 g, 10 mmol) and 3-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 124 as bright 
yellow solid (3.45 g, 89%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.37 (s, 1H), 
9.21 (d, J = 2.4 Hz, 1H), 8.75 – 8.68 (m, 2H), 8.64 (d, J = 8.3 Hz, 1H), 8.39 – 8.34 (m, 
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3H), 8.03 (d, J = 8.1 Hz, 1H), 7.97 (d, J = 5.7 Hz, 2H), 7.80 – 7.71 (m, 2H). 13C NMR 
(126 MHz, DMSO) δ 157.08, 152.37, 134.10, 130.07, 129.15, 128.66, 127.85, 127.42, 
123.84, 123.27, 118.13, 116.25, 114.28. Anal. Calcd. for C20H13N5O4: C, 62.01; H, 3.67; 
N, 18.08. Found: C, 62.04; H, 3.67; N, 17.78. 
 
3-((2-(4-nitrophenyl)quinazolin-4-yl)amino)benzonitrile (125).  
 
Molecular weight: 367.37 g/mol 
 
The title compound was synthesized from 99 (2.85 g, 10 mmol) and 3-aminobenzonitrile 
(1.18 g, 10 mmol) as described in the general procedure for 105-152 to yield 125 as bright 
yellow solid (2.68 g, 73%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.37 (s, 1H), 
8.68 (ddd, J = 8.3, 1.4, 0.6 Hz, 1H), 8.65 – 8.58 (m, 2H), 8.40 (dd, J = 2.2, 1.6 Hz, 1H), 
8.37 – 8.28 (m, 3H), 8.03 – 7.92 (m, 2H), 7.76 – 7.65 (m, 2H), 7.62 (dt, J = 7.6, 1.3 Hz, 
1H). 13C NMR (126 MHz, DMSO) δ 158.14, 156.82, 149.24, 148.75, 143.34, 139.78, 
133.83, 129.76, 128.92, 127.47, 127.15, 127.04, 126.88, 125.37, 123.37, 123.21, 118.38, 
113.89, 111.40. Anal. Calcd. for C21H13N5O4: C, 68.66; H, 3.57; N, 19.06. Found: C, 
68.59; H, 3.71; N, 18.70. 
 
N-(3-methoxyphenyl)-2-(4-nitrophenyl)quinazolin-4-amine (126).  
 
Molecular weight: 372.38 g/mol 
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The title compound was synthesized from 99 (2.85 g, 10 mmol) and 3-methoxyaniline 
(1.23 g, 10 mmol) as described in the general procedure for 105-152 to yield 126 as 
yellow solid (2.57 g, 69%), mp 201-203 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.93 (s, 
1H), 8.69 – 8.64 (m, 2H), 8.64 – 8.59 (m, 1H), 8.41 – 8.35 (m, 2H), 7.97 – 7.90 (m, 2H), 
7.72 – 7.65 (m, 2H), 7.55 (ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 7.37 (t, J = 8.1 Hz, 1H), 6.77 
(ddd, J = 8.3, 2.6, 0.8 Hz, 1H), 3.83 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.58, 
157.32, 150.33, 148.69, 144.50, 140.39, 133.71, 129.43, 129.01, 128.50, 127.02, 123.83, 
123.27, 114.58, 114.35, 110.08, 107.70, 55.29. Anal. Calcd. for C21H16N4O3: C, 67.73; 
H, 4.33; N, 15.05. Found: C, 67.47; H, 4.49; N, 14.83. 
 
N-(3,4-dimethoxyphenyl)-2-(4-nitrophenyl)quinazolin-4-amine (127).  
 
Molecular weight: 402.41 g/mol 
 
The title compound was synthesized from 99 (2.85 g, 10 mmol) and 3,4-dimethoxyaniline 
(1.53 g, 10 mmol) as described in the general procedure for 105-152 to yield 127 as light 
orange solid (3.26 g, 81%), mp 250-251 °C (decomp.). 1H NMR (600 MHz, DMSO-d6) 
δ 10.47 (s, 1H), 8.69 (d, J = 8.3 Hz, 1H), 8.64 – 8.53 (m, 2H), 8.45 – 8.34 (m, 2H), 8.02 
(d, J = 8.4 Hz, 1H), 7.96 (t, J = 7.6 Hz, 1H), 7.72 (t, J = 7.5 Hz, 1H), 7.63 (d, J = 2.5 Hz, 
1H), 7.41 (dd, J = 8.6, 2.5 Hz, 1H), 7.06 (d, J = 8.7 Hz, 1H), 3.81 (d, J = 3.1 Hz, 6H). 13C 
NMR (151 MHz, DMSO) δ 158.30, 156.78, 149.14, 148.53, 146.31, 134.45, 131.58, 
129.56, 127.52, 123.90, 123.68, 115.29, 113.83, 111.82, 108.08, 55.87, 55.75. Anal. 
Calcd. for C22H18N4O4: C, 65.66; H, 4.51; N, 13.92. Found: C, 65.51; H, 4.71; N, 13.77. 
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3-(4-((3-hydroxy-4-methoxyphenyl)amino)quinazolin-2-yl)benzonitrile (128).  
 
Molecular weight: 368.40 g/mol 
 
The title compound was synthesized from 100 (2.67 g, 10 mmol) and 5-amino-2-
methoxyphenol (1.39 g, 10 mmol) as described in the general procedure for 105-152 to 
yield 128 as dark-red solid (2.73 g, 74%), mp 222-223 °C. 1H NMR (500 MHz, DMSO-
d6) δ 9.76 (s, 1H), 9.13 (s, 1H), 8.70 (dt, J = 5.7, 1.7 Hz, 2H), 8.56 – 8.52 (m, 1H), 7.95 
(dt, J = 7.7, 1.5 Hz, 1H), 7.89 – 7.84 (m, 2H), 7.75 – 7.70 (m, 1H), 7.64 – 7.58 (m, 1H), 
7.43 (d, J = 2.6 Hz, 1H), 7.25 (dd, J = 8.6, 2.5 Hz, 1H), 6.99 (d, J = 8.7 Hz, 1H), 3.81 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 158.20, 157.35, 150.23, 146.48, 144.71, 139.73, 
133.67, 133.41, 132.43, 132.37, 131.38, 129.97, 128.25, 126.45, 123.19, 118.90, 114.32, 
113.60, 112.30, 111.77, 111.21, 56.09. Anal. Calcd. for C22H16N4O2: C, 71.73; H, 4.38; 
N, 15.21. Found: C, 71.95; H, 4.74; N, 14.87. 
 
N-(3-((2-(3-cyanophenyl)quinazolin-4-yl)amino)phenyl)acetamide (129).  
 
Molecular weight: 379.42 g/mol 
 
The title compound was synthesized from 100 (2.67 g, 10 mmol) and N-(3-
aminophenyl)acetamide (1.50 g, 10 mmol) as described in the general procedure for 105-
152 to yield 129 as light yellow solid (2.62 g, 69%), mp 256-258 °C (decomp.). 1H NMR 
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(500 MHz, DMSO-d6) δ 10.02 (s, 1H), 9.96 (s, 1H), 8.81 (td, J = 1.7, 0.6 Hz, 1H), 8.80 – 
8.74 (m, 1H), 8.67 (t, J = 2.1 Hz, 1H), 8.61 (dt, J = 8.4, 1.0 Hz, 1H), 7.94 (ddd, J = 7.6, 
1.7, 1.2 Hz, 1H), 7.92 – 7.86 (m, 2H), 7.71 (td, J = 7.8, 0.6 Hz, 1H), 7.64 (ddd, J = 8.3, 
4.7, 3.5 Hz, 1H), 7.45 (ddd, J = 8.1, 2.2, 1.1 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.22 (ddd, 
J = 8.0, 2.0, 1.0 Hz, 1H), 2.11 (s, 3H). 13C NMR (126 MHz, DMSO) δ 168.53, 158.17, 
157.33, 150.39, 139.71, 139.46, 139.41, 133.75, 133.59, 132.51, 131.90, 129.85, 128.59, 
128.34, 126.61, 123.33, 118.91, 117.19, 114.70, 114.35, 113.53, 111.88, 24.16. Anal. 
Calcd. for C23H17N5O: C, 72.81; H, 4.52; N, 18.46. Found: C, 73.13; H, 4.14; N, 18.21. 
 
2-(2-methoxyphenyl)-N-(3-nitrophenyl)quinazolin-4-amine (130).  
 
Molecular weight: 372.38 g/mol 
 
The title compound was synthesized from 101 (2.71 g, 10 mmol) and 3-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 130 as light yellow 
solid (3.20 g, 86%), mp 203-204 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.97 (s, 1H), 
9.05 (d, J = 8.4 Hz, 1H), 8.96 (t, J = 2.2 Hz, 1H), 8.38 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 
8.17 – 8.09 (m, 3H), 7.96 – 7.85 (m, 2H), 7.78 (t, J = 8.2 Hz, 1H), 7.67 (ddd, J = 8.4, 7.4, 
1.8 Hz, 1H), 7.33 (dd, J = 8.5, 0.9 Hz, 1H), 7.17 (td, J = 7.6, 1.0 Hz, 1H), 3.95 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 159.34, 158.04, 156.96, 147.92, 138.52, 136.41, 134.51, 
131.91, 130.26, 130.14, 128.66, 124.93, 120.98, 120.61, 118.77, 112.76, 112.60, 56.38. 
Anal. Calcd. for C21H16N4O3: C, 67.73; H, 4.33; N, 15.05. Found: C, 67.81; H, 4.67; N, 
14.74. 
 
 
 
 
10 Experimental section 326
2-(3-methoxyphenyl)-N-(3-nitrophenyl)quinazolin-4-amine (131).  
 
Molecular weight: 372.38 g/mol 
 
The title compound was synthesized from 102 (2.71 g, 10 mmol) and 3-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 131 as yellow 
solid (3.35 g, 90%), mp 276-278 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.36 
(s, 1H), 9.02 (s, 1H), 8.85 (d, J = 8.3 Hz, 1H), 8.41 – 8.32 (m, 1H), 8.23 (d, J = 8.4 Hz, 
1H), 8.12 (dd, J = 8.3, 2.2 Hz, 1H), 8.09 – 8.01 (m, 2H), 7.99 (t, J = 2.1 Hz, 1H), 7.80 
(td, J = 7.9, 5.2 Hz, 2H), 7.51 (t, J = 8.0 Hz, 1H), 7.22 (dd, J = 8.3, 2.6 Hz, 1H), 3.85 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 159.70, 158.89, 157.73, 147.97, 139.23, 135.53, 
130.16, 130.11, 129.62, 127.90, 124.25, 121.40, 119.85, 118.80, 117.96, 113.73, 113.40, 
55.53. Anal. Calcd. for C21H16N4O3: C, 67.73; H, 4.33; N, 15.05. Found: C, 68.04; H, 
4.53; N, 14.99. 
 
2-(3-methoxyphenyl)-N-(4-nitrophenyl)quinazolin-4-amine (132).  
 
Molecular weight: 372.38 g/mol 
 
The title compound was synthesized from 102 (2.71 g, 10 mmol) and 4-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 132 as light yellow 
(2.87 g, 77%), mp 285-287 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.58 (s, 
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1H), 8.93 (d, J = 8.3 Hz, 1H), 8.41 – 8.30 (m, 3H), 8.30 – 8.20 (m, 2H), 8.11 – 7.99 (m, 
3H), 7.80 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.52 (t, J = 8.2 Hz, 1H), 7.22 (ddd, J = 8.2, 2.5, 
1.1 Hz, 1H), 3.88 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.61, 158.86, 157.52, 144.20, 
143.80, 135.68, 130.23, 127.98, 124.53, 124.45, 123.59, 121.53, 118.98, 113.80, 113.50, 
55.57. Anal. Calcd. for C21H16N4O3: C, 67.73; H, 4.33; N, 15.05. Found: C, 67.63; H, 
4.70; N, 15.14. 
 
N-(3,5-dinitrophenyl)-2-(3-methoxyphenyl)quinazolin-4-amine (133).  
 
Molecular weight: 417.38 g/mol 
 
The title compound was synthesized from 102 (2.71 g, 10 mmol) and 3,5-
dimethoxyaniline (1.53 g, 10 mmol) as described in the general procedure for 105-152 to 
yield 133 as yellow solid (3.84 g, 92%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 
11.21 (s, 1H), 9.47 (d, J = 2.1 Hz, 2H), 8.78 (d, J = 8.3 Hz, 1H), 8.59 (t, J = 2.1 Hz, 1H), 
8.16 – 8.06 (m, 2H), 8.06 – 7.98 (m, 2H), 7.77 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.48 (t, J 
= 8.0 Hz, 1H), 7.18 (ddd, J = 8.1, 2.7, 0.9 Hz, 1H), 3.85 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 159.75, 158.35, 158.10, 148.13, 141.08, 135.03, 129.95, 127.59, 123.75, 
121.63, 121.21, 117.95, 113.69, 113.50, 113.02, 55.48. Anal. Calcd. for C21H15N5O5: C, 
60.43; H, 3.62; N, 16.78. Found: C, 60.73; H, 3.98; N, 16.40. 
 
 
 
 
 
 
10 Experimental section 328
N-(4-fluoro-3-nitrophenyl)-2-(3-methoxyphenyl)quinazolin-4-amine (134).  
 
Molecular weight: 390.37 g/mol 
 
The title compound was synthesized from 102 (2.71 g, 10 mmol) and 4-fluoro-3-
nitroaniline (1.56 g, 10 mmol) as described in the general procedure for 105-152 to yield 
134 as white solid (3.40 g, 87%), mp 269-271 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 11.48 (s, 1H), 8.91 (dd, J = 6.9, 2.7 Hz, 1H), 8.86 (d, J = 8.3 Hz, 1H), 8.32 
(ddd, J = 9.1, 3.9, 2.7 Hz, 1H), 8.26 (d, J = 8.3 Hz, 1H), 8.06 (ddd, J = 8.4, 7.0, 1.3 Hz, 
1H), 8.02 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 7.99 (dd, J = 2.6, 1.6 Hz, 1H), 7.80 (ddd, J = 
8.3, 7.0, 1.2 Hz, 1H), 7.75 (dd, J = 11.1, 9.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.22 (ddd, 
J = 8.4, 2.7, 1.0 Hz, 1H), 3.86 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.69, 158.87, 
157.65, 151.87 (d, J = 261.1 Hz), 136.45 (d, J = 8.1 Hz), 135.63, 134.61, 131.28, 130.16, 
127.97, 124.31, 121.51, 120.72, 120.68, 118.80 (d, J = 22.0 Hz), 113.77, 113.24, 55.59.   
Anal. Calcd. for C21H15FN4O3: C, 64.61; H, 3.87; N, 14.35. Found: C, 64.93; H, 4.08; 
N, 14.15. 
 
3-((2-(3-methoxyphenyl)quinazolin-4-yl)amino)benzonitrile (135).  
 
Molecular weight: 352.40 g/mol 
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The title compound was synthesized from 102 (2.71 g, 10 mmol) and 3-aminobenzonitrile 
(1.18 g, 10 mmol) as described in the general procedure for 105-152 to yield 135 as light 
yellow solid (2.61 g, 74%), mp 257-259 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 11.38 (s, 1H), 8.82 (dd, J = 8.4, 1.2 Hz, 1H), 8.43 (s, 1H), 8.22 (d, J = 8.3 Hz, 1H), 8.19 
(ddd, J = 7.7, 2.2, 1.5 Hz, 1H), 8.06 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H), 7.96 (ddd, J = 7.7, 
1.7, 0.9 Hz, 1H), 7.92 (dd, J = 2.6, 1.6 Hz, 1H), 7.80 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H), 7.77 
– 7.70 (m, 2H), 7.51 (t, J = 8.0 Hz, 1H), 7.22 (ddd, J = 8.2, 2.7, 0.9 Hz, 1H), 3.87 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 159.68, 158.99, 157.56, 138.67, 135.69, 130.22, 130.17, 
129.23, 128.72, 127.99, 127.18, 124.35, 121.30, 119.21, 118.63, 113.52, 113.22, 111.60, 
55.58. Anal. Calcd. for C22H16N4O: C, 74.98; H, 4.58; N, 15.90. Found: C, 75.16; H, 
4.86; N, 15.99. 
 
N-(3-fluorophenyl)-2-(3-methoxyphenyl)quinazolin-4-amine (136).  
 
Molecular weight: 345.38 g/mol 
 
The title compound was synthesized from 102 (2.71 g, 10 mmol) and 3-fluoroaniline 
(1.11 g, 10 mmol) as described in the general procedure for 105-152 to yield 136 as light 
yellow solid (2.07 g, 60%), mp 232-235 °C (decomp.). 1H NMR (600 MHz, DMSO-d6) 
δ 11.49 (s, 1H), 8.90 (d, J = 8.4 Hz, 1H), 8.39 – 8.30 (m, 1H), 8.07 (t, J = 7.7 Hz, 1H), 
8.03 – 7.97 (m, 2H), 7.89 (dt, J = 11.2, 2.3 Hz, 1H), 7.81 (t, J = 7.7 Hz, 1H), 7.75 – 7.69 
(m, 1H), 7.59 – 7.50 (m, 2H), 7.24 (dd, J = 8.4, 2.6 Hz, 1H), 7.16 (td, J = 8.5, 2.6 Hz, 
1H), 3.87 (s, 3H). 13C NMR (151 MHz, DMSO) δ 161.97 (d, J = 242.4 Hz), 159.64, 
159.00, 157.31, 139.19, 135.77, 130.35 (d, J = 9.2 Hz), 130.23, 128.08, 124.51, 121.41, 
120.07, 119.36, 113.83, 113.12, 112.59, 111.32, 55.53. Anal. Calcd. for C21H16FN3O: 
C, 73.03; H, 4.67; N, 12.17. Found: C, 73.27; H, 4.94; N, 11.95. 
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N,2-bis(3-methoxyphenyl)quinazolin-4-amine (137).  
 
Molecular weight: 357.41 g/mol 
 
The title compound was synthesized from 102 (2.71 g, 10 mmol) and 3-methoxyaniline 
(1.23 g, 10 mmol) as described in the general procedure for 105-152 to yield 137 as light 
yellow solid (1.93 g, 54%), mp 133-135 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.94 (s, 
1H), 8.60 (d, J = 8.3 Hz, 1H), 8.07 – 8.01 (m, 2H), 7.93 – 7.86 (m, 2H), 7.75 (t, J = 2.2 
Hz, 1H), 7.63 (ddd, J = 8.3, 5.5, 2.7 Hz, 1H), 7.54 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.43 (t, 
J = 7.9 Hz, 1H), 7.35 (t, J = 8.1 Hz, 1H), 7.08 (ddd, J = 8.1, 2.7, 1.0 Hz, 1H), 6.78 – 6.73 
(m, 1H), 3.85 (s, 3H), 3.82 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.57, 159.54, 
158.70, 158.01, 140.46, 133.60, 129.63, 129.29, 126.32, 123.25, 120.45, 116.74, 114.61, 
114.08, 113.04, 109.53, 108.18, 55.26, 55.20. Anal. Calcd. for C22H19N3O2: C, 73.93; 
H, 5.36; N, 11.76. Found: C, 74.11; H, 5.29; N, 11.61. 
 
N-(3,4-dimethoxyphenyl)-2-(3-methoxyphenyl)quinazolin-4-amine (138).  
 
Molecular weight: 387.44 g/mol 
 
The title compound was synthesized from 102 (2.71 g, 10 mmol) and 3,4-
dimethoxyaniline (1.53 g, 10 mmol) as described in the general procedure for 105-152 to 
yield 138 as light beige solid (2.44 g, 63%), mp 139-141 °C. 1H NMR (500 MHz, DMSO-
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d6) δ 9.74 (s, 1H), 8.54 (dt, J = 8.4, 1.0 Hz, 1H), 8.05 (dt, J = 7.8, 1.1 Hz, 1H), 8.02 (dd, 
J = 2.7, 1.5 Hz, 1H), 7.88 – 7.81 (m, 2H), 7.70 (d, J = 2.5 Hz, 1H), 7.59 (ddd, J = 8.3, 
4.9, 3.3 Hz, 1H), 7.45 (dd, J = 8.7, 2.5 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.06 (ddd, J = 
8.1, 2.8, 1.0 Hz, 1H), 7.03 (d, J = 8.7 Hz, 1H), 3.83 (s, 3H), 3.83 (s, 3H), 3.79 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 159.53, 158.93, 157.88, 150.46, 148.50, 145.51, 140.10, 
133.17, 132.79, 129.49, 128.24, 125.96, 123.01, 120.38, 115.97, 114.44, 114.15, 113.35, 
111.94, 107.77, 55.95, 55.68, 55.24. Anal. Calcd. for C23H21N3O3: C, 71.30; H, 5.46; N, 
10.85. Found: C, 71.27; H, 5.49; N, 10.93. 
 
2-(4-methoxyphenyl)-N-(3-nitrophenyl)quinazolin-4-amine (139).  
 
Molecular weight: 372.38 g/mol 
 
The title compound was synthesized from 103 (2.71 g, 10 mmol) and 3-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 139 as light yellow 
(2.49 g, 67%), mp 282-283 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.55 (s, 
1H), 9.06 (s, 1H), 8.89 (d, J = 8.1 Hz, 1H), 8.53 – 8.39 (m, 2H), 8.39 – 8.02 (m, 4H), 7.82 
(dt, J = 14.1, 6.2 Hz, 2H), 7.23 – 7.11 (m, 2H), 3.90 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 163.44, 158.91, 157.23, 147.95, 138.91, 135.83, 131.30, 130.19, 129.81, 127.74, 
124.44, 120.15, 118.30, 114.62, 112.94, 55.87. Anal. Calcd. for C21H16N4O3: C, 67.73; 
H, 4.33; N, 15.05. Found: C, 67.87; H, 4.67; N, 14.84. 
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3-((2-(4-methoxyphenyl)quinazolin-4-yl)amino)benzonitrile (140).  
 
Molecular weight: 352.40 g/mol 
 
The title compound was synthesized from 103 (2.71 g, 10 mmol) and 3-aminobenzonitrile 
(1.18 g, 10 mmol) as described in the general procedure for 105-152 to yield 140 as light 
yellow solid (2.57 g, 73%), mp 279-281 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 11.75 (s, 1H), 8.92 (d, J = 8.3 Hz, 1H), 8.42 – 8.35 (m, 2H), 8.35 – 8.27 (m, 2H), 8.20 
(ddd, J = 8.1, 2.1, 1.2 Hz, 1H), 8.06 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.83 – 7.67 (m, 3H), 
7.21 – 7.12 (m, 2H), 3.88 (s, 3H). 13C NMR (126 MHz, DMSO) δ 163.64, 159.10, 156.94, 
138.29, 136.03, 131.37, 130.23, 129.59, 129.22, 127.87, 127.72, 124.69, 118.53, 114.64, 
112.70, 111.63, 55.89. Anal. Calcd. for C22H16N4O: C, 74.98; H, 4.58; N, 15.90. Found: 
C, 74.99; H, 4.81; N, 15.75. 
 
N-(3-methoxyphenyl)-2-(4-methoxyphenyl)quinazolin-4-amine (141).  
 
Molecular weight: 357.41 g/mol 
 
The title compound was synthesized from 103 (2.71 g, 10 mmol) and 3-methoxyaniline 
(1.23 g, 10 mmol) as described in the general procedure for 105-152 to yield 141 as 
yellow solid (1.60 g, 45%), mp 211-213 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.19 (s, 
1H), 8.62 (d, J = 8.4 Hz, 1H), 8.38 (dd, J = 8.8, 2.0 Hz, 2H), 7.91 (d, J = 6.7 Hz, 2H), 
7.70 – 7.60 (m, 2H), 7.56 – 7.49 (m, 1H), 7.37 (dd, J = 9.5, 6.8 Hz, 1H), 7.10 (dd, J = 9.4, 
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2.5 Hz, 2H), 6.79 (dd, J = 8.3, 2.5 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 159.55, 158.37, 158.16, 130.10, 129.41, 126.27, 123.51, 114.98, 114.15, 
113.55, 110.45, 108.22, 55.58, 55.32. Anal. Calcd. for C22H19N3O2: C, 73.93; H, 5.36; 
N, 11.76. Found: C, 74.06; H, 5.43; N, 11.53. 
 
N-(3,4-dimethoxyphenyl)-2-(4-methoxyphenyl)quinazolin-4-amine (142).  
 
Molecular weight: 387.44 g/mol 
 
The title compound was synthesized from 103 (2.71 g, 10 mmol) and 3,4-
dimethoxyaniline (1.53 g, 10 mmol) as described in the general procedure for 105-152 to 
yield 142 as orange-yellow solid (2.60 g, 67%), mp 238-239 °C (decomp.). 1H NMR (500 
MHz, DMSO-d6) δ 11.28 (s, 1H), 8.78 (d, J = 8.3 Hz, 1H), 8.43 – 8.30 (m, 2H), 8.23 (d, 
J = 8.3 Hz, 1H), 8.04 (t, J = 7.8 Hz, 1H), 7.77 (t, J = 7.7 Hz, 1H), 7.56 (d, J = 2.4 Hz, 
1H), 7.35 (dd, J = 8.6, 2.4 Hz, 1H), 7.24 – 7.15 (m, 2H), 7.10 (d, J = 8.7 Hz, 1H), 3.88 (s, 
3H), 3.82 (s, 3H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 163.59, 158.45, 156.80, 
148.50, 135.67, 131.24, 127.71, 124.32, 116.48, 114.63, 112.59, 111.64, 109.05, 55.87, 
55.85, 55.79. Anal. Calcd. for C23H21N3O3: C, 73.30; H, 5.46; N, 10.85. Found: C, 
71.60; H, 5.58; N, 10.55. 
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2-(3,4-dimethoxyphenyl)-N-(3-nitrophenyl)quinazolin-4-amine (143).  
 
Molecular weight: 402.41 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 3-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 143 as light yellow 
solid (3.14 g, 78%), mp 274-275 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.60 
(s, 1H), 8.93 (t, J = 2.2 Hz, 1H), 8.86 (d, J = 8.5 Hz, 1H), 8.38 (d, J = 7.8 Hz, 1H), 8.36 
– 8.32 (m, 1H), 8.14 (ddd, J = 14.6, 8.6, 2.2 Hz, 2H), 8.10 – 8.01 (m, 2H), 7.80 (q, J = 
7.7 Hz, 2H), 7.17 (d, J = 8.8 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 158.85, 157.04, 148.92, 147.90, 138.79, 135.87, 130.11, 127.79, 124.46, 
123.62, 120.25, 118.50, 112.84, 112.02, 111.75, 56.04, 55.87. Anal. Calcd. for 
C22H18N4O4: C, 65.66; H, 4.51; N, 13.92. Found: C, 65.85; H, 4.78; N, 13.59. 
 
2-(3,4-dimethoxyphenyl)-N-(4-nitrophenyl)quinazolin-4-amine (144).  
 
Molecular weight: 402.41 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 4-nitroaniline (1.38 
g, 10 mmol) as described in the general procedure for 105-152 to yield 144 as light yellow 
solid (3.30 g, 82%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.53 (s, 1H), 8.86 
(d, J = 8.3 Hz, 1H), 8.38 (dd, J = 9.6, 2.4 Hz, 3H), 8.27 – 8.16 (m, 2H), 8.12 (dd, J = 6.9, 
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2.1 Hz, 2H), 8.05 (t, J = 7.8 Hz, 1H), 7.78 (t, J = 7.7 Hz, 1H), 7.25 – 7.15 (m, 1H), 3.90 
(s, 3H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.66, 157.05, 153.26, 148.87, 
144.04, 135.82, 127.71, 124.49, 124.43, 123.87, 123.53, 113.07, 111.97, 111.85, 55.98, 
55.89. Anal. Calcd. for C22H18N4O4: C, 65.66; H, 4.51; N, 13.92. Found: C, 65.86; H, 
4.43; N, 13.74. 
 
2-(3,4-dimethoxyphenyl)-N-(3,5-dinitrophenyl)quinazolin-4-amine (145).  
 
Molecular weight: 447.41 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 3,5-dinitroaniline 
(1.83 g, 10 mmol) as described in the general procedure for 105-152 to yield 145 as light 
yellow solid (2.82 g, 63%), mp 283-284 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 11.12 (s, 1H), 9.45 (dd, J = 2.1, 1.0 Hz, 2H), 8.76 (d, J = 8.1 Hz, 1H), 8.63 (t, J = 2.1 
Hz, 1H), 8.16 (dd, J = 8.6, 6.6 Hz, 2H), 8.11 (d, J = 2.2 Hz, 1H), 8.00 (ddd, J = 8.4, 7.0, 
1.3 Hz, 1H), 7.74 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 3.89 (s, 3H), 
3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 162.05, 157.97, 157.83, 148.96, 148.02, 
141.03, 134.54, 126.72, 123.41, 122.63, 121.43, 113.17, 112.68, 112.28, 111.79, 55.86, 
55.78. Anal. Calcd. for C22H17N5O6: C, 59.06; H, 3.38; N, 15.65. Found: C, 59.20; H, 
3.55; N, 15.29. 
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4-((2-(3,4-dimethoxyphenyl)quinazolin-4-yl)amino)-2-nitrophenol (146).  
 
Molecular weight: 418.41 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 4-amino-2-
nitrophenol (1.54 g, 10 mmol) as described in the general procedure for 105-152 to yield 
146 as yellow solid (1.92 g, 46%), mp 258-259 °C (decomp.). 1H NMR (600 MHz, 
DMSO-d6) δ 11.53 (s, 1H), 11.30 (s, 1H), 8.79 (d, J = 8.3 Hz, 1H), 8.49 (d, J = 2.6 Hz, 
1H), 8.45 – 8.29 (m, 1H), 8.10 (dd, J = 8.6, 2.2 Hz, 1H), 8.05 – 8.00 (m, 3H), 7.76 (ddd, 
J = 8.3, 7.1, 1.1 Hz, 1H), 7.33 (d, J = 9.0 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 3.87 (s, 3H), 
3.85 (s, 3H). 13C NMR (151 MHz, DMSO) δ 158.65, 156.71, 153.56, 150.54, 148.89, 
136.00, 135.85, 131.71, 128.53, 127.83, 124.43, 123.70, 120.87, 119.28, 112.54, 112.07, 
111.70, 56.05, 55.90. Anal. Calcd. for C22H18N4O5: C, 63.15; H, 4.34; N, 13.39. Found: 
C, 63.38; H, 4.66; N, 13.08. 
 
3-((2-(3,4-dimethoxyphenyl)quinazolin-4-yl)amino)benzonitrile (147).  
 
Molecular weight: 382.42 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 3-aminobenzonitrile 
(1.18 g, 10 mmol) as described in the general procedure for 105-152 to yield 147 as white 
solid (3.08 g, 80%), mp 289-292 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.30 
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(s, 1H), 8.76 (d, J = 8.3 Hz, 1H), 8.43 (s, 1H), 8.22 (s, 1H), 8.17 (dt, J = 7.9, 1.8 Hz, 1H), 
8.06 (dd, J = 8.5, 2.2 Hz, 2H), 7.96 (d, J = 2.1 Hz, 1H), 7.82 – 7.69 (m, 3H), 7.20 (d, J = 
8.6 Hz, 1H), 3.88 (s, 6H). 13C NMR (126 MHz, DMSO) δ 158.77, 148.90, 130.24, 127.61, 
124.22, 118.63, 112.85, 111.77, 111.71, 56.03, 55.76. Anal. Calcd. for C23H18N4O2: C, 
72.24; H, 4.74; N, 14.65. Found: C, 72.40; H, 5.00; N, 14.33. 
 
2-(3,4-dimethoxyphenyl)-N-(4-methoxy-3-(trifluoromethyl)phenyl)quinazolin-4-
amine (148).  
 
Molecular weight: 455.44 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 4-methoxy-3-
(trifluoromethyl)aniline (1.91 g, 10 mmol) as described in the general procedure for 105-
152 to yield 148 as light yellow solid (2.91 g, 64%), mp 272-273 °C. 1H NMR (500 MHz, 
DMSO-d6) δ 11.64 (s, 1H), 8.86 (d, J = 8.2 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.16 (d, J 
= 2.6 Hz, 1H), 8.11 – 8.01 (m, 4H), 7.77 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.43 (d, J = 9.0 
Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 158.73, 156.61, 155.14, 153.61, 148.89, 135.86, 130.32, 129.66, 127.84, 
126.84, 124.67, 124.56, 123.63, 123.25 (d, J = 3.7 Hz), 122.51, 116.74 (d, J = 30.6 Hz), 
113.26, 112.53, 112.13, 111.63, 56.64, 56.04, 55.92. Anal. Calcd. for C24H20F3N3O3: C, 
63.29; H, 4.43; N, 9.23. Found: C, 63.44; H, 4.49; N, 8.87. 
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2-(3,4-dimethoxyphenyl)-N-(3-methoxyphenyl)quinazolin-4-amine (149).  
 
Molecular weight: 387.44 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 3-methoxyaniline 
(1.23 g, 10 mmol) as described in the general procedure for 105-152 to yield 149 as 
yellow solid (2.13 g, 55%), mp 144-145 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.86 (s, 
1H), 8.56 (dt, J = 8.3, 1.0 Hz, 1H), 8.10 – 8.05 (m, 2H), 7.89 – 7.81 (m, 2H), 7.75 (t, J = 
2.3 Hz, 1H), 7.61 – 7.53 (m, 2H), 7.35 (t, J = 8.1 Hz, 1H), 7.13 – 7.06 (m, 1H), 6.75 (ddd, 
J = 8.2, 2.5, 0.8 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.81 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 159.54, 158.74, 157.81, 151.23, 148.66, 140.56, 133.44, 129.25, 125.76, 
123.20, 121.30, 114.60, 113.82, 111.54, 111.28, 108.99, 108.43, 55.76, 55.39, 55.28. 
Anal. Calcd. for C23H21N3O3: C, 71.30; H, 5.46; N, 10.85. Found: C, 71.58; H, 5.31; N, 
10.58. 
 
N-(4-bromo-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)quinazolin-4-amine (150).  
 
Molecular weight: 466.34 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 4-bromo-3-
methoxyaniline (2.02 g, 10 mmol) as described in the general procedure for 105-152 to 
yield 150 as yellow solid (3.68 g, 79%), mp 254-256 °C. 1H NMR (500 MHz, DMSO-
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d6) δ 11.37 (s, 1H), 8.80 (d, J = 8.2 Hz, 1H), 8.37 (d, J = 8.3 Hz, 1H), 8.13 – 8.01 (m, 
3H), 7.78 (t, J = 7.7 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.47 (dd, 
J = 8.5, 2.3 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.87 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 158.69, 156.80, 155.46, 153.47, 148.88, 138.13, 135.82, 
132.67, 127.76, 124.35, 123.60, 117.85, 112.72, 112.15, 111.85, 109.13, 107.48, 56.51, 
56.04, 55.97. Anal. Calcd. for C23H20BrN3O3: C, 59.24; H, 4.32; N, 9.01. Found: C, 
59.03; H, 4.54; N, 8.98. 
 
2-(3,4-dimethoxyphenyl)-N-(3-fluorophenyl)quinazolin-4-amine (151).  
 
Molecular weight: 375.40 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 3-fluoroaniline 
(1.11 g, 10 mmol) as described in the general procedure for 105-152 to yield 151 as light 
yellow solid (2.89 g, 77%), 266-268 °C (decomp.). 1H NMR (600 MHz, DMSO-d6) δ 
11.39 (s, 1H), 8.81 (d, J = 8.4 Hz, 1H), 8.33 (s, 1H), 8.11 (dd, J = 8.5, 2.2 Hz, 1H), 8.05 
(dd, J = 13.3, 5.0 Hz, 2H), 7.89 (dt, J = 11.1, 2.3 Hz, 1H), 7.78 (t, J = 7.7 Hz, 1H), 7.69 
(dd, J = 8.1, 1.9 Hz, 1H), 7.56 (td, J = 8.2, 6.7 Hz, 1H), 7.22 (d, J = 8.6 Hz, 1H), 7.17 (td, 
J = 8.5, 2.6 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H). 13C NMR (151 MHz, DMSO) δ 162.79, 
161.19, 158.78, 156.91, 148.91, 135.88, 130.41 (d, J = 9.3 Hz), 127.81, 124.44, 123.28, 
120.21, 112.75, 111.92 (d, J = 22.2 Hz), 56.09, 55.72. Anal. Calcd. for C22H18FN3O2: 
C, 70.39; H, 4.83; N, 11.19. Found: C, 70.14; H, 4.53; N, 11.39. 
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3-((2-(3,4-dimethoxyphenyl)quinazolin-4-yl)amino)benzenesulfonyl fluoride (152).  
 
Molecular weight: 439.46 g/mol 
 
The title compound was synthesized from 104 (3.01 g, 10 mmol) and 3-
aminobenzenesulfonyl fluoride (1.75 g, 10 mmol) as described in the general procedure 
for 105-152 to yield 152 as bright yellow solid (3.25 g, 74%), mp 225-227 °C. 1H NMR 
(500 MHz, DMSO-d6) δ 11.74 (s, 1H), 8.89 (d, J = 8.4 Hz, 1H), 8.79 (t, J = 2.0 Hz, 1H), 
8.48 – 8.39 (m, 2H), 8.11 (d, J = 2.2 Hz, 1H), 8.09 – 8.01 (m, 3H), 7.94 (t, J = 8.1 Hz, 
1H), 7.79 (ddd, J = 8.3, 7.1, 1.1 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 3.88 (s, 6H). 13C NMR 
(126 MHz, DMSO) δ 158.93, 156.99, 153.50, 148.93, 139.22, 135.99, 131.91 (d, J = 23.7 
Hz), 131.57, 131.04, 127.87, 125.18, 124.55, 123.77, 123.18, 112.83, 112.15, 111.62, 
56.04, 56.02. Anal. Calcd. for C22H18FN3O4S: C, 60.13; H, 4.13; N, 9.56. Found: C, 
60.02; H, 4.43; N, 9.20. 
 
10.1.1.4 Synthesis of 2,4-Substituted Pyrido[2,3-d]pyrimidines 
 
General Procedure for the Preparation of compounds 153-155. To mixture of methyl 
2-aminonicotinate (4.90 g, 32 mmol) and Et3N (5.5 mL, 38 mmol) in CHCl3 (40 mL) was 
slowly added the corresponding acyl chloride (32 mmol) at 0 °C and subsequently stirred 
for 12 h at room temperature. The mixture was diluted with CHCl3 and extracted in a 
separatory funnel using saturated NaHCO3 followed by brine. The organic phase was then 
dried over MgSO4 and evaporated under reduced pressure. The resulting residue was 
recrystallized from a mixture of AcOEt and petroleum ether. 
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methyl 2-benzamidonicotinate (153).  
 
Molecular weight: 256.26 g/mol 
 
The compound was synthesized according to the general procedure for compounds 153-
155 using benzoyl chloride (4.50 g, 32 mmol) to yield 153 as a white solid (5.66 g, 69%). 
1H NMR (500 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.60 (dd, J = 4.8, 1.9 Hz, 1H), 8.16 (dd, 
J = 7.7, 1.9 Hz, 1H), 8.03 – 7.93 (m, 2H), 7.80 – 7.72 (m, 1H), 7.64 – 7.57 (m, 1H), 7.45 
(dd, J = 7.5, 0.9 Hz, 1H), 7.35 (dd, J = 7.7, 4.8 Hz, 1H), 3.70 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 166.45, 165.91, 151.31, 149.64, 138.98, 133.86, 132.26, 128.63, 127.97, 
120.49, 120.45, 52.29, 40.04. 
 
methyl 2-(3-methoxybenzamido)nicotinate (154).  
 
Molecular weight: 286.29 g/mol 
 
The compound was synthesized according to the general procedure for compounds 153-
155 using 3-methoxybenzoyl chloride (5.46 g, 32 mmol) to yield 154 as a white solid 
(7.24 g, 79%). 1H NMR (500 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.60 (ddd, J = 4.7, 1.9, 
0.7 Hz, 1H), 8.15 (ddd, J = 7.7, 1.9, 0.7 Hz, 1H), 7.64 – 7.52 (m, 2H), 7.44 (t, J = 7.9 Hz, 
1H), 7.35 (ddd, J = 7.7, 4.8, 0.7 Hz, 1H), 7.17 (ddt, J = 8.1, 2.4, 0.8 Hz, 1H), 3.84 (s, 3H), 
3.71 (s, 3H). 13C NMR (126 MHz, DMSO) δ 166.44, 165.61, 159.39, 151.28, 149.55, 
138.98, 135.20, 129.79, 120.58, 120.53, 120.24, 118.34, 112.91, 55.49, 52.29. 
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methyl 2-(nicotinamido)nicotinate (155).  
 
Molecular weight: 257.25 g/mol 
 
The compound was synthesized according to the general procedure for compounds 153-
155 using nicotinoyl chloride (4.53 g, 32 mmol) to yield 155 as a white solid (5.60 g, 
68%). 1H NMR (500 MHz, DMSO-d6) δ 11.27 (s, 1H), 9.11 (dd, J = 2.4, 0.9 Hz, 1H), 
8.78 (dd, J = 4.8, 1.6 Hz, 1H), 8.62 (dd, J = 4.8, 1.9 Hz, 1H), 8.31 (ddd, J = 8.0, 2.4, 1.7 
Hz, 1H), 8.17 (dd, J = 7.7, 1.9 Hz, 1H), 7.57 (ddd, J = 7.9, 4.9, 0.9 Hz, 1H), 7.39 (dd, J = 
7.7, 4.9 Hz, 1H), 3.70 (s, 3H). 13C NMR (126 MHz, DMSO) δ 166.26, 164.86, 152.75, 
151.31, 149.07, 149.01, 139.07, 135.72, 129.50, 123.72, 121.04, 120.90, 52.31. 
 
General Procedure for the Preparation of compounds 156-158. To a solution of the 
corresponding compound 153-155 (10 mmol) in MeOH (200 mL) was added 28% 
aqueous NH3 (250 mL). The mixture was stirred for 24 h, concentrated to about half the 
initial volume and the formed precipitate filtered with suction.  
 
2-phenylpyrido[2,3-d]pyrimidin-4(3H)-one (156).  
 
Molecular weight: 223.24 g/mol 
 
The compound was synthesized according to the general procedure for compounds 156-
158 from 153 (2.56 g, 10 mmol) to yield 156 as a white solid (1.43 g, 64%). 1H NMR 
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(500 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.96 (dd, J = 4.5, 2.0 Hz, 1H), 8.52 (dd, J = 7.8, 
2.0 Hz, 1H), 8.25 – 8.13 (m, 2H), 7.65 – 7.60 (m, 1H), 7.60 – 7.55 (m, 2H), 7.53 (dd, J = 
7.9, 4.5 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 163.12, 156.20, 155.56, 135.60, 132.60, 
132.04, 128.79, 128.20, 122.34, 116.28. 
 
2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4(3H)-one (157).  
 
Molecular weight: 253.26 g/mol 
 
The compound was synthesized according to the general procedure for compounds 156-
158 from 154 (2.86 g, 10 mmol) to yield 157 as a white solid (1.90 g, 75%). 1H NMR 
(500 MHz, DMSO-d6) δ 12.77 (s, 1H), 8.96 (dd, J = 4.6, 2.0 Hz, 1H), 8.52 (dd, J = 7.8, 
2.1 Hz, 1H), 7.82 (ddt, J = 7.8, 1.9, 0.9 Hz, 1H), 7.78 (t, J = 2.1 Hz, 1H), 7.53 (ddd, J = 
7.8, 4.5, 0.8 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.18 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 3.87 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 163.01, 159.51, 158.80, 156.26, 155.22, 135.60, 
133.88, 129.95, 122.39, 120.55, 118.38, 116.38, 112.86, 55.56. 
 
2-(pyridin-3-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (158).  
 
Molecular weight: 224.22 g/mol 
 
The compound was synthesized according to the general procedure for compounds 156-
158 from 155 (2.57 g, 10 mmol) to yield 158 as a white solid (1.28 g, 57%). 1H NMR 
(600 MHz, DMSO-d6) δ 13.14 – 12.84 (m, 1H), 9.31 (d, J = 2.4 Hz, 1H), 8.97 (dd, J = 
4.6, 2.0 Hz, 1H), 8.78 (dd, J = 4.8, 1.6 Hz, 1H), 8.60 – 8.48 (m, 2H), 7.60 (ddd, J = 8.0, 
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4.8, 0.9 Hz, 1H), 7.55 (dd, J = 7.8, 4.5 Hz, 1H). 13C NMR (151 MHz, DMSO) δ 156.26, 
154.13, 152.41, 149.11, 135.85, 135.68, 128.68, 123.72, 122.69, 116.55. 
 
General Procedure for the Preparation of compounds 159-161. The corresponding 
compound 156-158 (10 mmol) was added to phosphorous trichloride (30 mL, 0.32 mol) 
and stirred for 10 min at room temperature. The mixture was then refluxed for 4-8 h and 
the reaction monitored by TLC. After completion of the reaction, excess POCl3 was 
removed under reduced pressure and 50 mL ice water added. Subsequently, 50 mL DCM 
was added while stirring and the pH of the mixture slowly adjusted to 7 with 25% 
ammonium solution. The organic phase was collected with a separatory funnel, washed 
with 50 mL brine and dried under MgSO4. The solvent was removed under reduced 
pressure and the obtained solid recrystallized from isopropanol.  
 
4-chloro-2-phenylpyrido[2,3-d]pyrimidine (159).  
 
Molecular weight: 241.68 g/mol 
 
The compound was synthesized according to the general procedure for compounds 159-
161 from 156 (2.23 g, 10 mmol) to yield 7 as a white solid (2.30 g, 95%). 1H NMR (600 
MHz, DMSO-d6) δ 9.03 (dd, J = 5.1, 1.9 Hz, 1H), 8.77 (dd, J = 7.8, 1.9 Hz, 1H), 8.31 – 
8.19 (m, 2H), 7.71 (dd, J = 7.8, 5.0 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.60 (dd, J = 8.4, 7.0 
Hz, 2H). 13C NMR (151 MHz, DMSO) δ 162.02, 157.87, 156.14, 152.61, 139.63, 132.89, 
131.76, 128.99, 128.60, 122.63, 117.69. 
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4-chloro-2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidine (160).  
 
Molecular weight: 271.70 g/mol 
 
The compound was synthesized according to the general procedure for compounds 159-
161 from 157 (2.35 g, 10 mmol) to yield 160 as a white solid (2.28 g, 84%). 1H NMR 
(500 MHz, DMSO-d6) δ 9.01 (dd, J = 4.9, 2.0 Hz, 1H), 8.70 (ddd, J = 7.9, 3.3, 1.9 Hz, 
1H), 7.84 (ddd, J = 7.8, 1.7, 0.9 Hz, 1H), 7.79 (dd, J = 2.6, 1.7 Hz, 1H), 7.69 – 7.62 (m, 
1H), 7.50 (t, J = 8.0 Hz, 1H), 7.22 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 3.87 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 162.32, 159.55, 156.86, 153.74, 138.38, 133.26, 130.10, 122.56, 
120.83, 118.91, 117.29, 113.14, 55.63. 
 
4-chloro-2-(pyridin-3-yl)pyrido[2,3-d]pyrimidine (161).  
 
Molecular weight: 242.67 g/mol 
 
The compound was synthesized according to the general procedure for compounds 159-
161 from 158 (2.24 g, 10 mmol) to yield 161 as a white solid (2.14 g, 88%). 1H NMR 
(600 MHz, DMSO-d6) δ 9.42 (d, J = 2.3 Hz, 1H), 9.02 (dd, J = 4.7, 2.0 Hz, 1H), 8.93 (dd, 
J = 5.2, 1.6 Hz, 1H), 8.80 (dt, J = 8.2, 1.9 Hz, 1H), 8.64 (dd, J = 7.9, 2.0 Hz, 1H), 7.88 
(dd, J = 8.1, 5.1 Hz, 1H), 7.65 (dd, J = 7.9, 4.7 Hz, 1H). 13C NMR (151 MHz, DMSO) δ 
162.47, 157.35, 154.96, 153.98, 149.22, 146.25, 139.64, 137.32, 129.77, 125.24, 123.10, 
117.25. 
 
 
10 Experimental section 346
General Procedure for the Preparation of compounds 162-197. 
The corresponding 4-chloro derivative 159-161 (1 mmol) was added to isopropanol (5 
mL) with the corresponding substituted aniline derivative (1 mmol) and sealed in a 
microwave tube. The mixture was heated by 100 watt microwave irradiation to 110 °C 
for a period of 2 – 10 min to completion of the reaction, indicated by TLC. The formed 
precipitate was filtered, washed with 10 mL isopropanol and dried in vacuo. If no 
precipitate is formed, the solvent was removed under reduced pressure and the remaining 
solid recrystallized from ethanol. 
 
N,2-diphenylpyrido[2,3-d]pyrimidin-4-amine (162).  
 
Molecular weight: 298.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and aniline (93.1 mg, 1 mmol) to yield 162 as a bright 
yellow solid (283 mg, 95%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 10.98 (s, 
1H), 9.36 (dd, J = 8.2, 1.7 Hz, 1H), 9.12 (dd, J = 4.6, 1.7 Hz, 1H), 8.43 – 8.35 (m, 2H), 
7.98 – 7.88 (m, 2H), 7.77 (dd, J = 8.2, 4.6 Hz, 1H), 7.63 – 7.54 (m, 3H), 7.54 – 7.47 (m, 
2H), 7.27 (tt, J = 7.4, 1.2 Hz, 1H). 13C NMR (151 MHz, DMSO) δ 162.33, 159.33, 
155.81, 155.28, 138.19, 135.81, 135.53, 132.13, 128.79, 125.28, 123.26, 122.20, 109.65. 
Anal. Calcd. for C19H14N4: C, 76.49; H, 4.73; N, 18.78. Found: C, 76.22; H, 4.94; N, 
18.62. 
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N-(3-nitrophenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (163).  
 
Molecular weight: 343.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-nitroaniline (138 mg, 1 mmol) to yield 163 as a 
bright yellow solid (278 mg, 81%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.21 
(s, 1H), 9.48 (d, J = 8.3 Hz, 1H), 9.21 (t, J = 2.2 Hz, 1H), 9.16 (dd, J = 4.6, 1.8 Hz, 1H), 
8.54 – 8.44 (m, 2H), 8.41 (ddd, J = 8.1, 2.2, 0.9 Hz, 1H), 8.06 (ddd, J = 8.3, 2.3, 0.9 Hz, 
1H), 7.83 – 7.69 (m, 2H), 7.65 – 7.51 (m, 3H). 13C NMR (126 MHz, DMSO) δ 162.55, 
159.03, 156.08, 154.74, 147.91, 136.04, 135.77, 131.70, 129.68, 128.59, 128.48, 128.14, 
121.79, 118.67, 116.69, 109.60. Anal. Calcd. for C19H13N5O2: C, 66.47; H, 3.82; N, 
20.40. Found: C, 66.74; H, 4.13; N, 20.39. 
 
2-nitro-4-((2-phenylpyrido[2,3-d]pyrimidin-4-yl)amino)phenol (164).  
 
Molecular weight: 359.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 4-amino-2-nitrophenol (154 mg, 1 mmol) to yield 
164 as a yellow solid (313 mg, 87%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 
11.08 (s, 1H), 11.01 (s, 1H), 9.29 (dd, J = 8.3, 1.8 Hz, 1H), 9.12 (dd, J = 4.6, 1.7 Hz, 1H), 
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8.79 (d, J = 2.7 Hz, 1H), 8.49 – 8.40 (m, 2H), 8.04 (dd, J = 9.0, 2.7 Hz, 1H), 7.77 (dd, J 
= 8.2, 4.6 Hz, 1H), 7.64 – 7.59 (m, 1H), 7.56 (dd, J = 8.2, 6.5 Hz, 2H), 7.30 (d, J = 8.9 
Hz, 1H). 13C NMR (151 MHz, DMSO) δ 162.39, 159.05, 155.26, 149.67, 135.90, 135.81, 
135.39, 132.17, 130.36, 129.94, 128.89, 122.22, 119.46, 119.18, 109.61. Anal. Calcd. 
for C19H13N5O3: C, 63.51; H, 3.65; N, 19.49. Found: C, 63.38; H, 3.77; N, 19.26. 
 
N-(4-nitrophenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (165).  
 
Molecular weight: 343.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 4-nitroaniline (138 mg, 1 mmol) to yield 165 as a 
yellow solid (313 mg, 87%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 10.76 (s, 
1H), 9.17 (d, J = 6.4 Hz, 2H), 8.53 – 8.47 (m, 2H), 8.43 – 8.37 (m, 2H), 8.34 – 8.27 (m, 
2H), 7.78 – 7.73 (m, 1H), 7.61 – 7.57 (m, 3H). 13C NMR (126 MHz, DMSO) δ 162.29, 
158.83, 158.08, 155.95, 145.21, 142.62, 137.03, 133.90, 131.08, 128.45, 128.34, 124.32, 
121.60, 121.37, 109.35. Anal. Calcd. for C19H13N5O2: C, 66.47; H, 3.82; N, 20.40. 
Found: C, 66.69; H, 4.12; N, 20.03. 
 
3-((2-phenylpyrido[2,3-d]pyrimidin-4-yl)amino)benzonitrile (166).  
 
Molecular weight: 323.36 g/mol 
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The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-aminobenzonitrile (118 mg, 1 mmol) to yield 166 
as a light yellow solid (304 mg, 94%), mp 299-300 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.69 (s, 1H), 9.19 – 9.08 (m, 2H), 8.47 (t, J = 1.9 Hz, 1H), 8.45 – 8.36 (m, 
2H), 8.25 (dt, J = 8.1, 1.9 Hz, 1H), 7.78 – 7.63 (m, 3H), 7.62 – 7.51 (m, 3H). 13C NMR 
(126 MHz, DMSO) δ 162.35, 159.20, 157.72, 156.01, 139.61, 136.93, 134.29, 131.66, 
130.21, 128.78, 128.49, 127.83, 127.11, 125.62, 122.05, 118.73, 111.55, 109.39. Anal. 
Calcd. for C20H13N5: C, 74.29; H, 4.05; N, 21.66. Found: C, 74.46; H, 4.16; N, 21.56. 
 
4-((2-phenylpyrido[2,3-d]pyrimidin-4-yl)amino)benzonitrile (167).  
 
Molecular weight: 323.36 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 4-aminobenzonitrile (118 mg, 1 mmol) to yield 167 
as a bright yellow solid (288 mg, 89%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 
10.83 (s, 1H), 9.25 (d, J = 8.3 Hz, 1H), 9.17 (d, J = 4.4 Hz, 1H), 8.49 – 8.41 (m, 2H), 8.21 
(d, J = 8.5 Hz, 2H), 7.99 – 7.91 (m, 2H), 7.78 (dd, J = 8.2, 4.5 Hz, 1H), 7.63 – 7.54 (m, 
3H). 13C NMR (151 MHz, DMSO) δ 164.64, 162.57, 159.14, 143.18, 136.73, 133.18, 
131.84, 128.94, 128.72, 122.41, 122.16, 119.16, 109.84, 106.02. Anal. Calcd. for 
C20H13N5: C, 74.29; H, 4.05; N, 21.66. Found: C, 74.17; H, 4.21; N, 21.47. 
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N-(3-methoxyphenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (168).  
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-methoxyaniline (123 mg, 1 mmol) to yield 168 as 
a yellow solid (286 mg, 87%), mp 261-262 °C (decomp.). 1H NMR (600 MHz, DMSO-
d6) δ 10.80 (s, 1H), 9.31 (dd, J = 8.3, 1.8 Hz, 1H), 9.13 (dd, J = 4.6, 1.7 Hz, 1H), 8.47 – 
8.39 (m, 2H), 7.77 (dd, J = 8.2, 4.6 Hz, 1H), 7.67 (s, 1H), 7.65 – 7.54 (m, 3H), 7.52 (ddd, 
J = 8.0, 1.9, 0.9 Hz, 1H), 7.40 (t, J = 8.1 Hz, 1H), 6.83 (dd, J = 8.2, 2.5 Hz, 1H), 3.82 (d, 
J = 0.7 Hz, 3H). 13C NMR (151 MHz, DMSO) δ 162.40, 159.58, 159.24, 155.31, 139.50, 
136.04, 135.40, 132.13, 129.58, 128.87, 128.80, 122.19, 115.19, 111.07, 109.69, 108.48, 
55.37. Anal. Calcd. for C20H16N4O: C, 73.15; H, 4.91; N, 17.06. Found: C, 73.09; H, 
5.11; N, 16.87.  
 
N-(4-methoxyphenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (169).  
 
Molecular weight: 328.38 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 4-methoxyaniline (123 mg, 1 mmol) to yield 169 as 
an orange solid (246 mg, 75%), mp 300-302 °C (decomp.). 1H NMR (600 MHz, DMSO-
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d6) δ 10.88 (s, 1H), 9.25 (dd, J = 8.3, 1.8 Hz, 1H), 9.10 (dd, J = 4.6, 1.7 Hz, 1H), 8.45 – 
8.31 (m, 2H), 7.86 – 7.78 (m, 2H), 7.75 (dd, J = 8.2, 4.6 Hz, 1H), 7.64 – 7.50 (m, 3H), 
7.13 – 7.03 (m, 2H), 3.81 (s, 3H). 13C NMR (151 MHz, DMSO) δ 162.48, 159.51, 157.21, 
155.72, 136.02, 135.35, 132.46, 131.28, 129.17, 125.18, 122.52, 114.34, 109.80, 55.82. 
Anal. Calcd. for C20H16N4O: C, 73.15; H, 4.91; N, 17.06. Found: C, 73.09; H, 5.11; N, 
16.87.  
 
N-(3,4-dimethoxyphenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (170).  
 
Molecular weight: 358.40 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3,4-dimethoxyaniline (153 mg, 1 mmol) to yield 
170 as a red solid (262 mg, 73%), mp 275-276 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.78 (s, 1H), 9.33 – 9.17 (m, 1H), 9.16 – 9.01 (m, 1H), 8.50 – 8.32 (m, 2H), 
7.75 (dd, J = 8.2, 4.5 Hz, 1H), 7.68 (d, J = 2.5 Hz, 1H), 7.65 – 7.49 (m, 3H), 7.43 (dd, J 
= 8.7, 2.5 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 162.18, 158.98, 155.36, 148.51, 146.51, 135.82, 135.66, 134.96, 132.15, 
131.41, 128.82, 122.18, 115.20, 111.84, 109.52, 108.04, 55.90, 55.71. Anal. Calcd. for 
C21H18N4O2: C, 70.38; H, 5.06; N, 15.63. Found: C, 70.34; H, 5.17; N, 15.37. 
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N-(3-(methylthio)phenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (171).  
 
Molecular weight: 344.44 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-(methylthio)aniline (139 mg, 1 mmol) to yield 171 
as a yellow solid (317 mg, 92%), mp 275-276 °C (decomp.). 1H NMR (600 MHz, DMSO-
d6) δ 10.93 (s, 1H), 9.36 (dd, J = 8.3, 1.7 Hz, 1H), 9.21 – 9.06 (m, 1H), 8.50 – 8.33 (m, 
2H), 7.96 (s, 1H), 7.77 (dd, J = 8.2, 4.6 Hz, 1H), 7.76 – 7.68 (m, 1H), 7.65 – 7.51 (m, 
3H), 7.43 (t, J = 7.9 Hz, 1H), 7.18 – 7.08 (m, 1H), 2.53 (s, 3H). 13C NMR (151 MHz, 
DMSO) δ 162.37, 159.25, 155.92, 155.23, 138.89, 138.69, 135.95, 135.62, 132.17, 
129.27, 128.82, 122.55, 122.20, 120.21, 119.48, 109.73, 14.92. Anal. Calcd. for 
C20H16N4S: C, 69.74; H, 4.68; N, 16.27. Found: C, 70.02; H, 4.81; N, 16.10. 
 
3-((2-phenylpyrido[2,3-d]pyrimidin-4-yl)amino)phenol (172).  
 
Molecular weight: 314.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-aminophenol (109 mg, 1 mmol) to yield 172 as an 
orange solid (207 mg, 66%), mp 248-249 °C. 1H NMR (600 MHz, DMSO-d6) δ 10.84 (s, 
1H), 9.68 (s, 1H), 9.35 (dd, J = 8.2, 1.7 Hz, 1H), 9.11 (dd, J = 4.6, 1.7 Hz, 1H), 8.51 – 
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8.34 (m, 2H), 7.76 (dd, J = 8.2, 4.6 Hz, 1H), 7.65 – 7.50 (m, 3H), 7.42 (t, J = 2.2 Hz, 1H), 
7.37 (dd, J = 7.9, 1.9 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 6.68 (dd, J = 8.1, 2.3 Hz, 1H). 13C 
NMR (151 MHz, DMSO) δ 162.34, 159.25, 157.76, 155.62, 155.16, 139.11, 135.73, 
135.62, 132.17, 129.39, 128.95, 128.85, 122.17, 113.92, 112.50, 110.31, 109.69. Anal. 
Calcd. for C19H14N4O: C, 72.60; H, 4.49; N, 17.82. Found: C, 72.70; H, 4.20; N, 17.46. 
 
4-((2-phenylpyrido[2,3-d]pyrimidin-4-yl)amino)phenol (173).  
 
Molecular weight: 314.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 4-aminophenol (109 mg, 1 mmol) to yield 173 as a 
yellow-orange solid (245 mg, 78%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 
11.71 (s, 1H), 9.56 (dd, J = 8.3, 1.7 Hz, 1H), 9.12 (dd, J = 4.8, 1.6 Hz, 1H), 8.31 (dd, J = 
8.1, 1.3 Hz, 2H), 7.85 (dd, J = 8.2, 4.8 Hz, 1H), 7.70 – 7.62 (m, 3H), 7.60 (dd, J = 8.3, 
7.0 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 161.63, 158.99, 
155.99, 154.66, 152.29, 136.88, 133.35, 133.18, 129.27, 129.05, 128.47, 125.62, 122.89, 
115.34, 109.81. Anal. Calcd. for C19H14N4O: C, 72.60; H, 4.49; N, 17.82. Found: C, 
72.51; H, 4.71; N, 17.63. 
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N-(3-((2-phenylpyrido[2,3-d]pyrimidin-4-yl)amino)phenyl)acetamide (174).  
 
Molecular weight: 355.40 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and N-(3-aminophenyl)acetamide (150 mg, 1 mmol) to 
yield 174 as a yellow solid (316 mg, 89%), mp >300 °C. 1H NMR (600 MHz, DMSO-
d6) δ 10.95 (s, 1H), 10.16 (s, 1H), 9.35 (dd, J = 8.2, 1.8 Hz, 1H), 9.11 (dd, J = 4.6, 1.7 
Hz, 1H), 8.52 – 8.39 (m, 2H), 8.34 (t, J = 2.1 Hz, 1H), 7.76 (dd, J = 8.2, 4.6 Hz, 1H), 7.68 
– 7.57 (m, 2H), 7.55 (dd, J = 8.3, 6.6 Hz, 2H), 7.40 (t, J = 8.0 Hz, 1H), 7.37 – 7.29 (m, 
1H), 2.09 (s, 3H). 13C NMR (151 MHz, DMSO) δ 168.57, 162.41, 159.35, 155.68, 
155.16, 139.83, 138.39, 135.70, 135.67, 132.13, 129.08, 128.80, 128.77, 122.16, 118.16, 
116.08, 114.14, 109.68, 24.19. Anal. Calcd. for C21H17N5O: C, 70.97; H, 4.82; N, 19.71. 
Found: C, 70.85; H, 4.91; N, 19.41. 
 
2-phenyl-N-(3-(trifluoromethyl)phenyl)pyrido[2,3-d]pyrimidin-4-amine (175).  
 
Molecular weight: 366.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-(trifluoromethyl)aniline (161 mg, 1 mmol) to yield 
175 as a bright yellow solid (333 mg, 91%), mp >300 °C. 1H NMR (500 MHz, DMSO-
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d6) δ 10.92 (s, 1H), 9.35 (ddd, J = 8.3, 1.8, 0.8 Hz, 1H), 9.13 (dd, J = 4.6, 1.8 Hz, 1H), 
8.59 (d, J = 2.0 Hz, 1H), 8.49 – 8.37 (m, 2H), 8.28 – 8.15 (m, 1H), 7.78 – 7.68 (m, 2H), 
7.63 – 7.47 (m, 4H). 13C NMR (126 MHz, DMSO) δ 162.31, 159.05, 156.71, 155.13, 
139.30, 136.39, 134.88, 131.46, 129.28 (d, J = 31.6 Hz), 128.35, 125.83, 124.06 (d, J = 
272.4 Hz), 121.65, 120.49 (d, J = 3.8 Hz), 118.90 (d, J = 4.0 Hz), 109.35. Anal. Calcd. 
for C20H13F3N4: C, 65.57; H, 3.58; N, 15.29. Found: C, 65.66; H, 3.80; N, 15.20. 
 
N-(3-fluorophenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (176).  
 
Molecular weight: 316.34 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-fluoroaniline (111 mg, 1 mmol) to yield 176 as a 
bright yellow solid (269 mg, 85%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.92 
(s, 1H), 9.34 (dd, J = 8.3, 1.8 Hz, 1H), 9.14 (dd, J = 4.6, 1.7 Hz, 1H), 8.48 – 8.33 (m, 2H), 
7.95 (dt, J = 11.5, 2.3 Hz, 1H), 7.82 – 7.72 (m, 2H), 7.64 – 7.49 (m, 4H), 7.08 (tdd, J = 
8.5, 2.7, 0.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.08 (d, J = 241.8 Hz), 161.12, 
159.25, 156.34, 155.32, 140.20 (d, J = 10.9 Hz), 136.27, 135.55, 132.04, 130.38 (d, J = 
9.4 Hz), 128.81 (d, J = 23.9 Hz), 122.17, 118.62, 111.42 (d, J = 21.0 Hz), 109.71 (d, J = 
25.9 Hz). Anal. Calcd. for C19H13FN4: C, 72.14; H, 4.14; N, 17.71. Found: C, 72.41; H, 
4.28; N, 17.53. 
 
 
 
 
 
 
10 Experimental section 356
N-(3-chlorophenyl)-2-phenylpyrido[2,3-d]pyrimidin-4-amine (177).  
 
Molecular weight: 332.79 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 159 (242 mg, 1 mmol) and 3-chloroaniline (128 mg, 1 mmol) to yield 177 as a 
bright yellow solid (280 mg, 84%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 10.79 
(s, 1H), 9.25 (dd, J = 8.3, 1.7 Hz, 1H), 9.19 – 9.09 (m, 1H), 8.48 – 8.38 (m, 2H), 8.19 (t, 
J = 2.1 Hz, 1H), 7.90 (dd, J = 8.2, 2.0 Hz, 1H), 7.77 (dd, J = 8.2, 4.5 Hz, 1H), 7.65 – 7.55 
(m, 3H), 7.53 (t, J = 8.1 Hz, 1H), 7.30 (dd, J = 7.9, 2.0 Hz, 1H). 13C NMR (151 MHz, 
DMSO) δ 162.78, 159.55, 155.87, 140.35, 136.78, 135.45, 133.33, 132.31, 130.79, 
129.22, 129.01, 124.78, 122.77, 122.49, 121.45, 109.98. Anal. Calcd. for C19H13ClN4: 
C, 68.57; H, 3.94; N, 16.84. Found: C, 68.52; H, 4.03; N, 16.66. 
 
2-(3-methoxyphenyl)-N-(3-nitrophenyl)pyrido[2,3-d]pyrimidin-4-amine (178).  
 
Molecular weight: 373.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-nitroaniline (138 mg, 1 mmol) to yield 178 as a 
light yellow solid (310 mg, 83%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.14 
(s, 1H), 9.36 (d, J = 8.1 Hz, 1H), 9.18 (d, J = 4.6 Hz, 1H), 9.11 (t, J = 2.3 Hz, 1H), 8.38 
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(d, J = 7.7 Hz, 1H), 8.09 (t, J = 7.4 Hz, 2H), 8.00 (t, J = 2.0 Hz, 1H), 7.88 – 7.73 (m, 2H), 
7.49 (t, J = 8.0 Hz, 1H), 7.18 (dd, J = 8.3, 2.6 Hz, 1H), 3.84 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 162.37, 159.69, 159.19, 155.33, 148.00, 139.77, 137.66, 135.77, 130.11, 
130.00, 128.60, 122.30, 121.31, 119.16, 118.38, 116.91, 113.31, 109.87, 55.33. Anal. 
Calcd. for C20H15N5O3: C, 64.34; H, 4.05; N, 18.76. Found: C, 64.26; H, 4.31; N, 18.52. 
 
4-((2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)amino)-2-nitrophenol (179).  
 
Molecular weight: 389.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 4-amino-2-nitrophenol (154 mg, 1 mmol) to yield 
179 as a light orange solid (296 mg, 76%), mp 295-297 °C (decomp.). 1H NMR (600 
MHz, DMSO-d6) δ 11.08 (s, 1H), 11.01 (s, 1H), 9.27 (d, J = 8.2 Hz, 1H), 9.12 (d, J = 4.5 
Hz, 1H), 8.67 (dd, J = 2.8, 1.5 Hz, 1H), 8.14 – 7.99 (m, 2H), 7.99 – 7.87 (m, 1H), 7.76 
(dd, J = 8.3, 4.7 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.29 (d, J = 8.9 Hz, 1H), 7.23 – 7.07 
(m, 1H), 3.83 (s, 3H). 13C NMR (151 MHz, DMSO) δ 162.05, 159.60, 159.05, 155.33, 
149.68, 137.29, 135.84, 135.26, 130.53, 129.91, 129.85, 122.23, 121.32, 119.35, 119.20, 
118.42, 113.29, 109.57, 55.30. Anal. Calcd. for C20H15N5O4: C, 61.69; H, 3.88; N, 
17.99. Found: C, 61.83; H, 4.04; N, 17.72.  
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3-((2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)amino)benzonitrile (180).  
 
Molecular weight: 353.39 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-aminobenzonitrile (118 mg, 1 mmol) to yield 180 
as a yellow solid (286 mg, 81%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.99 
(s, 1H), 9.28 (d, J = 8.2 Hz, 1H), 9.17 (s, 1H), 8.50 (s, 1H), 8.22 (d, J = 7.1 Hz, 1H), 8.03 
(d, J = 7.8 Hz, 1H), 7.97 (s, 1H), 7.81 (s, 1H), 7.71 (d, J = 6.6 Hz, 2H), 7.48 (t, J = 8.1 
Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 3.87 (s, 3H). 13C NMR (126 MHz, DMSO) δ 162.23, 
159.63, 137.70, 130.22, 129.96, 127.51, 125.89, 122.28, 121.11, 118.73, 118.55, 112.95, 
111.57, 55.34. Anal. Calcd. for C21H15N5O: C, 71.38; H, 4.28; N, 19.82. Found: C, 
71.65; H, 4.60; N, 19.57.  
 
4-((2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)amino)benzonitrile (181).  
 
Molecular weight: 353.39 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 4-aminobenzonitrile (118 mg, 1 mmol) to yield 181 
as a yellow solid (304 mg, 86%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.35 
(s, 1H), 9.52 (dd, J = 8.3, 1.8 Hz, 1H), 9.18 (dd, J = 4.7, 1.7 Hz, 1H), 8.29 – 8.16 (m, 2H), 
10 Experimental section  359
8.02 (dt, J = 7.8, 1.3 Hz, 1H), 8.00 – 7.89 (m, 3H), 7.85 (dd, J = 8.3, 4.7 Hz, 1H), 7.50 (t, 
J = 8.0 Hz, 1H), 7.19 (ddd, J = 8.3, 2.8, 0.9 Hz, 1H), 3.87 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 162.51, 159.64, 159.10, 155.55, 154.73, 142.76, 137.20, 136.99, 133.05, 
130.13, 122.95, 122.36, 121.34, 119.06, 118.64, 113.33, 110.26, 106.60, 55.38. Anal. 
Calcd. for C21H15N5O: C, 71.38; H, 4.28; N, 19.82. Found: C, 71.29; H, 4.58; N, 19.59. 
 
3-((2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)amino)phenol (182).  
 
Molecular weight: 344.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-aminophenol (109 mg, 1 mmol) to yield 182 as a 
yellow-orange solid (276 mg, 80%), mp 250-251 °C. 1H NMR (500 MHz, DMSO-d6) δ 
10.79 (s, 1H), 9.63 (s, 1H), 9.30 (dd, J = 8.3, 1.8 Hz, 1H), 9.11 (dd, J = 4.6, 1.7 Hz, 1H), 
8.10 – 7.93 (m, 2H), 7.76 (dd, J = 8.2, 4.6 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.43 (t, J = 
2.2 Hz, 1H), 7.35 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.16 (ddd, J = 
8.2, 2.7, 0.9 Hz, 1H), 6.68 (ddd, J = 8.0, 2.4, 0.9 Hz, 1H), 3.85 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 161.93, 159.57, 159.15, 157.75, 155.76, 155.27, 139.13, 137.18, 135.38, 
129.94, 129.31, 122.18, 121.27, 118.56, 113.91, 113.32, 112.44, 110.37, 109.66, 55.30. 
Anal. Calcd. for C20H16N4O2: C, 69.76; H, 4.68; N, 16.27. Found: C, 69.95; H, 5.00; N, 
16.35. 
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4-((2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)amino)phenol (183).  
 
Molecular weight: 344.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 4-aminophenol (109 mg, 1 mmol) to yield 183 as an 
orange solid (265 mg, 77%), mp 270-272 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 10.57 (s, 1H), 9.11 (dd, J = 8.3, 1.8 Hz, 1H), 9.06 (dd, J = 4.5, 1.8 Hz, 1H), 8.01 – 7.92 
(m, 2H), 7.68 (dd, J = 8.2, 4.5 Hz, 1H), 7.67 – 7.60 (m, 2H), 7.45 (t, J = 7.9 Hz, 1H), 7.13 
(ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 6.93 – 6.84 (m, 2H), 3.84 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 161.77, 159.49, 159.11, 156.65, 155.66, 155.04, 137.75, 134.13, 129.83, 
129.56, 125.00, 121.94, 121.04, 117.94, 115.16, 113.37, 109.27, 55.27. Anal. Calcd. for 
C20H16N4O2: C, 69.76; H, 4.68; N, 16.27. Found: C, 69.69; H, 4.93; N, 16.17.  
 
N-(3,4-dimethoxyphenyl)-2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine 
(184).  
 
Molecular weight: 388.43 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3,4-dimethoxyaniline (153 mg, 1 mmol) to yield 
184 as an orange solid (346 mg, 89%), mp 251-252 °C. 1H NMR (600 MHz, DMSO-d6) 
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δ 10.88 (s, 1H), 9.28 (dd, J = 8.3, 1.8 Hz, 1H), 9.09 (dd, J = 4.6, 1.7 Hz, 1H), 8.01 (dt, J 
= 7.8, 1.2 Hz, 1H), 7.97 (dd, J = 2.7, 1.5 Hz, 1H), 7.75 (dd, J = 8.2, 4.6 Hz, 1H), 7.65 (d, 
J = 2.4 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.43 (dd, J = 8.6, 2.4 Hz, 1H), 7.17 (ddd, J = 
8.2, 2.7, 1.0 Hz, 1H), 7.06 (d, J = 8.7 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H). 
13C NMR (151 MHz, DMSO) δ 161.78, 159.59, 158.94, 155.59, 155.36, 148.50, 146.56, 
137.11, 135.04, 131.35, 129.93, 122.22, 121.19, 118.04, 115.39, 113.82, 111.77, 109.54, 
108.22, 55.92, 55.75, 55.41. Anal. Calcd. for C22H20N4O3: C, 68.03; H, 5.19; N, 14.42. 
Found: C, 68.26; H, 5.34; N, 14.08. 
 
2-(3-methoxyphenyl)-N-(3-(methylthio)phenyl)pyrido[2,3-d]pyrimidin-4-amine 
(185).  
 
Molecular weight: 374.46 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-(methylthio)aniline (139 mg, 1 mmol) to yield 185 
as a red solid (345 mg, 92%), mp 275-276 °C (decomp.). 1H NMR (600 MHz, DMSO-
d6) δ 11.07 (s, 1H), 9.37 (dd, J = 8.2, 1.7 Hz, 1H), 9.10 (dd, J = 4.6, 1.7 Hz, 1H), 7.98 
(ddd, J = 7.7, 1.6, 1.0 Hz, 1H), 7.95 (dd, J = 2.7, 1.6 Hz, 1H), 7.92 – 7.86 (m, 2H), 7.76 
(dd, J = 8.2, 4.6 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.43 – 7.35 (m, 2H), 7.16 (ddd, J = 8.2, 
2.7, 1.0 Hz, 1H), 3.84 (s, 3H), 2.52 (s, 3H). 13C NMR (151 MHz, DMSO) δ 161.87, 
159.53, 159.01, 155.53, 155.19, 137.00, 135.55, 135.35, 134.61, 129.98, 126.45, 123.83, 
122.22, 121.24, 118.45, 113.37, 109.69, 55.32, 15.32. Anal. Calcd. for C21H18N4OS: C, 
67.36; H, 4.85; N, 14.96. Found: C, 67.27; H, 4.96; N, 14.60. 
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N-(3-((2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)amino)phenyl)acetamide 
(186).  
 
Molecular weight: 385.43 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and N-(3-aminophenyl)acetamide (150 mg, 1 mmol) to 
yield 186 as a yellow (304 mg, 79%), mp 278-280 °C (decomp.). 1H NMR (600 MHz, 
DMSO-d6) δ 11.46 (s, 1H), 10.22 (s, 1H), 9.51 (dd, J = 8.2, 1.7 Hz, 1H), 9.15 (dd, J = 
4.8, 1.6 Hz, 1H), 8.28 (d, J = 2.2 Hz, 1H), 8.02 (dt, J = 7.8, 1.2 Hz, 1H), 7.94 (dd, J = 2.7, 
1.6 Hz, 1H), 7.86 (dd, J = 8.2, 4.8 Hz, 1H), 7.58 (dq, J = 7.8, 3.4, 2.3 Hz, 1H), 7.48 (t, J 
= 8.0 Hz, 1H), 7.44 – 7.34 (m, 2H), 7.20 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 3.83 (s, 3H), 2.08 
(s, 3H). 13C NMR (151 MHz, DMSO) δ 168.64, 161.92, 159.56, 159.33, 154.53, 153.55, 
139.86, 137.77, 137.11, 135.63, 130.08, 128.77, 122.65, 121.75, 119.31, 118.70, 116.67, 
114.62, 113.65, 110.01, 55.32, 24.14. Anal. Calcd. for C22H19N5O2: C, 68.56; H, 4.97; 
N, 18.17. Found: C, 68.66; H, 5.30; N, 17.97. 
 
N-(3-fluorophenyl)-2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine (187).  
 
Molecular weight: 346.37 g/mol 
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The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-fluoroaniline (111 mg, 1 mmol) to yield 187 as a 
yellow solid (312 mg, 90%), mp 282-284 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 11.43 (s, 1H), 9.58 (dd, J = 8.2, 1.7 Hz, 1H), 9.16 (dd, J = 4.8, 1.7 Hz, 1H), 8.06 – 7.92 
(m, 3H), 7.85 (dd, J = 8.2, 4.8 Hz, 1H), 7.78 (ddd, J = 8.2, 2.0, 0.9 Hz, 1H), 7.59 – 7.45 
(m, 2H), 7.19 (ddd, J = 8.2, 2.7, 0.9 Hz, 1H), 7.11 (tdd, J = 8.5, 2.7, 0.9 Hz, 1H), 3.85 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 162.96, 162.30, 161.04, 159.62, 159.17, 154.60, 
154.49, 139.77 (d, J = 11.0 Hz), 137.14, 136.61, 130.32 (d, J = 9.4 Hz), 130.11, 122.44, 
121.31, 119.08 (d, J = 2.5 Hz), 118.95, 113.39, 111.93 (d, J = 20.9 Hz), 110.22 (d, J = 
25.4 Hz), 110.10, 55.30. Anal. Calcd. for C20H15FN4O: C, 69.35; H, 4.37; N, 16.18. 
Found: C, 69.60; H, 4.63; N, 15.82. 
 
N-(4-fluorophenyl)-2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine (188).  
 
Molecular weight: 346.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 4-fluoroaniline (111 mg, 1 mmol) to yield 188 as a 
yellow (291 mg, 84%), mp 283-284 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) δ 
11.43 (s, 1H), 9.48 (dd, J = 8.1, 1.7 Hz, 1H), 9.15 (dd, J = 4.7, 1.7 Hz, 1H), 8.00 – 7.88 
(m, 4H), 7.84 (dd, J = 8.2, 4.7 Hz, 1H), 7.49 (t, J = 8.0 Hz, 1H), 7.41 – 7.29 (m, 2H), 7.19 
(ddd, J = 8.4, 2.6, 1.0 Hz, 1H), 3.84 (s, 3H). 13C NMR (126 MHz, DMSO) δ 161.90, 
159.56 (d, J = 243.0 Hz), 159.57, 159.33, 154.85, 154.25, 136.54, 136.11, 134.08 (d, J = 
2.3 Hz), 130.10, 125.79 (d, J = 8.2 Hz), 122.55, 121.42, 118.95, 115.49 (d, J = 22.6 Hz), 
113.52, 109.81, 55.39. Anal. Calcd. for C20H15FN4O: C, 69.35; H, 4.37; N, 16.18. 
Found: C, 69.67; H, 4.67; N, 15.83. 
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N-(3,4-difluorophenyl)-2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine (189). 
 
Molecular weight: 364.36 g/mol 
 
 The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3,4-difluoroaniline (129 mg, 1 mmol) to yield 189 
as a yellow solid (317 mg, 87%), mp 283-285 °C (decomp.). 1H NMR (600 MHz, DMSO-
d6) δ 10.98 (s, 1H), 9.29 (d, J = 8.2 Hz, 1H), 9.15 (d, J = 4.6 Hz, 1H), 8.17 (dd, J = 13.1, 
7.5 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.97 (s, 1H), 7.80 (dd, J = 8.2, 4.6 Hz, 1H), 7.71 
(d, J = 8.9 Hz, 1H), 7.57 (q, J = 9.6 Hz, 1H), 7.49 (t, J = 8.0 Hz, 1H), 7.17 (d, J = 8.2 Hz, 
1H), 3.86 (s, 3H). 13C NMR (151 MHz, DMSO) δ 162.22, 159.63, 159.16, 155.33, 
137.42, 135.61, 135.60, 130.06, 122.32, 121.16, 119.66 (d, J = 2.1 Hz), 118.53, 117.48 
(d, J = 17.7 Hz), 113.23, 112.38 (d, J = 21.3 Hz), 109.69, 55.28. Anal. Calcd. for 
C20H14F2N4O: C, 65.93; H, 3.87; N, 15.38. Found: C, 65.96; H, 4.13; N, 15.05. 
 
2-(3-methoxyphenyl)-N-(3-(trifluoromethyl)phenyl)pyrido[2,3-d]pyrimidin-4-
amine (190).  
 
Molecular weight: 396.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-(trifluoromethyl)aniline (161 mg, 1 mmol) to yield 
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190 as a bright yellow solid (381 mg, 96%), mp 283-285 °C (decomp.). 1H NMR (500 
MHz, DMSO-d6) δ 11.67 (s, 1H), 9.65 (dd, J = 8.3, 1.7 Hz, 1H), 9.18 (dd, J = 4.7, 1.7 
Hz, 1H), 8.49 (d, J = 2.1 Hz, 1H), 8.24 (dt, J = 8.0, 1.4 Hz, 1H), 7.98 (dt, J = 7.7, 1.0 Hz, 
1H), 7.94 (t, J = 2.1 Hz, 1H), 7.88 (dd, J = 8.3, 4.7 Hz, 1H), 7.74 (t, J = 8.0 Hz, 1H), 7.65 
– 7.59 (m, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.20 (dd, J = 8.2, 2.6 Hz, 1H), 3.84 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 162.38, 159.70, 159.31, 154.39, 154.36, 138.85, 137.50, 
136.46, 130.00 (d, J = 6.6 Hz), 129.45 (d, J = 32.0 Hz), 127.50, 126.96, 124.25 (d, J = 
272.1 Hz), 122.53, 121.70 (d, J = 4.2 Hz), 121.00, 119.79 (d, J = 3.7 Hz), 118.78, 113.72, 
110.22, 55.41. Anal. Calcd. for C21H15F3N4O: C, 63.63; H, 3.81; N, 14.14. Found: C, 
63.80; H, 4.04; N, 13.86. 
 
2-(3-methoxyphenyl)-N-(4-(trifluoromethyl)phenyl)pyrido[2,3-d]pyrimidin-4-
amine (191).  
 
Molecular weight: 396.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 4-(trifluoromethyl)aniline (161 mg, 1 mmol) to yield 
191 as a bright yellow solid (333 mg, 84%), mp 286-288 °C (decomp.). 1H NMR (500 
MHz, DMSO-d6) δ 11.55 (s, 1H), 9.62 (dd, J = 8.2, 1.7 Hz, 1H), 9.18 (dd, J = 4.7, 1.7 
Hz, 1H), 8.22 (d, J = 8.5 Hz, 2H), 8.01 (dt, J = 7.6, 1.3 Hz, 1H), 7.95 (dd, J = 2.7, 1.6 Hz, 
1H), 7.92 – 7.81 (m, 3H), 7.50 (t, J = 8.0 Hz, 1H), 7.19 (ddd, J = 8.3, 2.7, 0.9 Hz, 1H), 
3.85 (s, 3H). 13C NMR (126 MHz, DMSO) δ 162.47, 159.60, 159.27, 154.70, 154.39, 
141.82, 137.50, 136.64, 130.16, 127.66, 125.91 (q, J = 3.8 Hz), 125.89, 125.86, 125.50, 
125.15 (d, J = 32.0 Hz), 123.36, 122.44, 121.44, 118.87, 113.44, 110.26, 55.31. Anal. 
Calcd. for C21H15F3N4O: C, 63.63; H, 3.81; N, 14.14. Found: C, 63.95; H, 4.02; N, 13.91. 
 
10 Experimental section 366
N-(3-chlorophenyl)-2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine (192).  
 
Molecular weight: 362.82 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-chloroaniline (128 mg, 1 mmol) to yield 192 as a 
yellow solid (305 mg, 84%), mp 279-282 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 10.99 (s, 1H), 9.33 (d, J = 8.1 Hz, 1H), 9.16 (d, J = 4.5 Hz, 1H), 8.19 (s, 1H), 8.03 (d, 
J = 7.7 Hz, 1H), 7.98 (s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.81 (dd, J = 8.3, 4.7 Hz, 1H), 
7.51 (dt, J = 16.5, 8.1 Hz, 2H), 7.31 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 3.87 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 162.21, 159.66, 159.18, 155.20, 139.78, 135.82, 
132.99, 130.42, 130.02, 124.77, 122.63, 122.33, 121.41, 121.21, 118.64, 113.21, 109.82, 
55.38. Anal. Calcd. for C20H15ClN4O: C, 66.21; H, 4.17; N, 15.44. Found: C, 66.02; H, 
4.51; N, 15.17. 
 
N-(3-bromophenyl)-2-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine (193). 
  
Molecular weight: 407.27 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 160 (272 mg, 1 mmol) and 3-bromoaniline (172 mg, 1 mmol) to yield 193 as a 
yellow solid (289 mg, 71%), mp 283-284 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
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δ 11.44 (s, 1H), 9.53 (s, 1H), 9.19 (s, 1H), 8.31 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.98 – 
7.84 (m, 3H), 7.58 – 7.43 (m, 3H), 7.22 (d, J = 8.1 Hz, 1H), 3.87 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 162.27, 159.67, 159.21, 139.46, 136.27, 130.71, 130.12, 128.14, 125.93, 
122.59, 122.22, 121.44, 121.29, 119.14, 113.44, 110.14, 55.49. Anal. Calcd. for 
C20H15BrN4O: C, 58.98; H, 3.71; N, 13.76. Found: C, 58.82; H, 3.95; N, 13.51. 
 
N-(3-nitrophenyl)-2-(pyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine (194).  
 
Molecular weight: 344.33 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 161 (272 mg, 1 mmol) and 3-nitroaniline (138 mg, 1 mmol) to yield 194 as a 
light yellow solid (227 mg, 66%), mp 283-284 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 11.06 (s, 1H), 9.62 (s, 1H), 9.38 – 9.29 (m, 1H), 9.20 (s, 1H), 9.12 (s, 2H), 
8.93 (s, 1H), 8.39 (d, J = 7.5 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.96 (s, 1H), 7.85 – 7.73 
(m, 2H). 13C NMR (126 MHz, DMSO) δ 160.93, 160.31, 159.23, 157.23, 150.13, 149.00, 
148.18, 140.96, 138.92, 134.80, 130.76, 129.01, 125.57, 123.10, 119.41, 117.49, 110.58. 
Anal. Calcd. for C18H12N6O2: C, 62.79; H, 3.51; N, 24.41. Found: C, 63.03; H, 3.85; N, 
24.17.   
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N-(4-nitrophenyl)-2-(pyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine (195).  
 
Molecular weight: 344.33 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 161 (272 mg, 1 mmol) and 4-nitroaniline (138 mg, 1 mmol) to yield 195 as a 
yellow solid (241 mg, 70%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.01 (s, 
1H), 9.62 (d, J = 2.0 Hz, 1H), 9.29 (dd, J = 8.3, 1.8 Hz, 1H), 9.19 (dd, J = 4.4, 1.8 Hz, 
1H), 9.08 (dt, J = 8.1, 1.9 Hz, 1H), 8.92 (dd, J = 5.2, 1.6 Hz, 1H), 8.40 – 8.34 (m, 2H), 
8.32 – 8.27 (m, 2H), 7.94 (dd, J = 8.2, 5.2 Hz, 1H), 7.78 (dd, J = 8.3, 4.4 Hz, 1H). 13C 
NMR (126 MHz, DMSO) δ 159.42, 159.39, 158.38, 156.82, 147.65, 145.78, 145.20, 
142.83, 140.27, 134.68, 134.42, 125.88, 124.77, 122.74, 122.00, 110.18. Anal. Calcd. 
for C18H12N6O2: C, 62.79; H, 3.51; N, 24.41. Found: C, 62.70; H, 3.80; N, 24.17. 
 
N-(3-fluorophenyl)-2-(pyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine (196).  
 
Molecular weight: 317.33 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 161 (272 mg, 1 mmol) and 4-fluoroaniline (111 mg, 1 mmol) to yield 196 as a 
yellow solid (209 mg, 66%), mp 293-294 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 10.75 (s, 1H), 9.55 (d, J = 2.1 Hz, 1H), 9.27 (dd, J = 8.3, 1.8 Hz, 1H), 9.16 (dd, J = 4.5, 
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1.8 Hz, 1H), 8.98 (dt, J = 8.1, 1.8 Hz, 1H), 8.90 (dd, J = 5.4, 1.6 Hz, 1H), 7.95 – 7.85 (m, 
2H), 7.83 – 7.74 (m, 2H), 7.53 (td, J = 8.2, 6.8 Hz, 1H), 7.07 (tdd, J = 8.5, 2.6, 0.9 Hz, 
1H). 13C NMR (126 MHz, DMSO) δ 162.13 (d, J = 241.7 Hz), 159.83, 159.48, 157.86, 
156.15, 148.23, 146.18, 140.32 (d, J = 11.0 Hz), 139.52, 134.66, 130.40 (d, J = 9.4 Hz), 
125.58, 122.52, 118.61, 111.31 (d, J = 21.0 Hz), 109.98, 109.65 (d, J = 25.8 Hz). Anal. 
Calcd. for C18H12FN5: C, 68.13; H, 3.81; N, 22.07. Found: C, 68.00; H, 4.18; N, 21.86. 
 
3-((2-(pyridin-3-yl)pyrido[2,3-d]pyrimidin-4-yl)amino)phenol (197).  
 
Molecular weight: 315.34 g/mol 
 
The compound was synthesized according to the general procedure for compounds 162-
197 from 161 (272 mg, 1 mmol) and 3-aminophenol (109 mg, 1 mmol) to yield 197 as a 
yellow solid (249 mg, 79%), mp 253-255 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.43 (s, 
1H), 9.56 (dd, J = 2.2, 0.8 Hz, 2H), 9.19 (dd, J = 8.3, 1.8 Hz, 1H), 9.13 (dd, J = 4.5, 1.8 
Hz, 1H), 8.92 (dt, J = 8.1, 1.8 Hz, 1H), 8.85 (dd, J = 5.1, 1.6 Hz, 1H), 7.81 (dd, J = 8.1, 
5.0 Hz, 1H), 7.74 (dd, J = 8.2, 4.5 Hz, 1H), 7.44 (t, J = 2.1 Hz, 1H), 7.34 (ddd, J = 8.0, 
2.0, 1.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 6.66 (ddd, J = 8.0, 2.4, 1.0 Hz, 1H). 13C NMR 
(126 MHz, DMSO) δ 160.29, 159.47, 158.55, 157.83, 155.93, 147.38, 139.47, 138.64, 
134.59, 134.04, 130.74, 129.50, 125.10, 122.34, 113.66, 112.18, 110.02, 109.95. Anal. 
Calcd. for C18H13N5O: C, 68.75; H, 4.35; N, 21.85. Found: C, 68.56; H, 4.16; N, 22.21. 
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10.1.1.5 Synthesis of 2,4-Substituted 6-nitroquinazolines 
 
2-amino-5-nitrobenzamide (198). 
 
Molecular weight: 181.15 g/mol 
 
To a solution of 2-amino-5-nitrobenzoic acid (1.80 g, 10 mmol) in 100 mL dry 
tetrahydrofurane (THF) was slowly added triphosgene (1.19 g, 4 mmol) while stirring at 
room temperature. The mixture was then refluxed under moisture exclusion for 3 h. Under 
stirring, a constant stream of ammonia gas was bubbled through the mixture for 30 min 
at 50 °C. Then, 50 mL of water was added and the precipitate filtered off. Additional 
product was obtained by concentrating the mixture under reduced pressure to one half of 
the initial volume to yield 198 as bright yellow crystals (1.58 g, 87%). 1H NMR (500 
MHz, DMSO-d6) δ 12.97 (s, 1H), 8.84 (d, J = 2.7 Hz, 1H), 8.56 (dd, J = 9.0, 2.7 Hz, 1H), 
8.27 – 8.19 (m, 2H), 7.92 (d, J = 9.0 Hz, 1H), 7.68 – 7.62 (m, 1H), 7.58 (dd, J = 8.3, 6.7 
Hz, 2H). 13C NMR (126 MHz, DMSO) δ 160.74, 155.16, 152.43, 144.86, 132.40, 128.86, 
128.65, 128.24, 127.99, 126.66, 122.18, 121.22.  
 
General Procedure for the Preparation of compounds 199-204. A mixture of 2-amino-
5-nitrobenzamide 198 (3.62 g, 20 mmol), the corresponding aldehyde derivative (20 
mmol), iodine (3.17 g, 25 mmol), anhydrous potassium carbonate (2.76 g, 20 mmol) and 
20 ml DMF was stirred at 90 - 110 °C for 8-24 h. The end of the reaction was monitored 
by TLC and the mixture poured on crushed ice to form a precipitate. Incomplete 
precipitation can be prevented by adjusting the pH with concentrated HCl solution to 7. 
After filtration of the precipitate, it was thoroughly washed with 100 mL of a 20% sodium 
thiosulfate solution followed by 100 mL of hot distilled water. Purification was performed 
by recrystallization from ethanol.    
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6-nitro-2-phenylquinazolin-4(3H)-one (199).  
 
Molecular weight: 267.24 g/mol 
 
The compound was synthesized from 198 (3.62 g, 20 mmol) and benzaldehyde (2.12 g, 
20 mmol) as described in the general procedure for compounds 199-204 to yield 199 as 
a yellow solid (3.85 g, 72%). 1H NMR (500 MHz, DMSO-d6) δ 12.97 (s, 1H), 8.84 (d, J 
= 2.7 Hz, 1H), 8.56 (dd, J = 9.0, 2.7 Hz, 1H), 8.27 – 8.19 (m, 2H), 7.92 (d, J = 9.0 Hz, 
1H), 7.68 – 7.62 (m, 1H), 7.58 (dd, J = 8.3, 6.7 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 
144.86, 132.40, 132.24, 128.86, 128.65, 128.39, 122.18. 
 
6-nitro-2-(pyridin-3-yl)quinazolin-4(3H)-one (200).  
 
Molecular weight: 268.23 g/mol 
 
The compound was synthesized from 198 (3.62 g, 20 mmol) and nicotinaldehyde (2.14 
g, 20 mmol) as described in the general procedure for compounds 199-204 to yield 200 
as a yellow-orange solid (3.70 g, 69%). 1H NMR (500 MHz, DMSO-d6) δ 9.58 – 9.44 
(m, 1H), 8.82 (d, J = 2.8 Hz, 1H), 8.67 (dt, J = 7.9, 2.0 Hz, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 
1H), 8.24 (dd, J = 9.0, 2.8 Hz, 1H), 7.94 (s, 1H), 7.58 (d, J = 9.0 Hz, 1H), 7.45 (ddd, J = 
7.9, 4.7, 0.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 171.52, 163.89, 162.42, 156.83, 
150.48, 149.70, 141.89, 135.45, 135.21, 127.35, 125.06, 123.24, 120.82. 
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6-nitro-2-(pyridin-4-yl)quinazolin-4(3H)-one (201).  
 
Molecular weight: 268.23 g/mol 
 
The compound was synthesized from 198 (3.62 g, 20 mmol) and isonicotinaldehyde (2.14 
g, 20 mmol) as described in the general procedure for compounds 199-204 to yield 201 
as a yellow solid (2.74 g, 51%). 1H NMR (500 MHz, DMSO-d6) δ 13.18 (s, 1H), 8.82 
(dd, J = 8.1, 4.1 Hz, 3H), 8.57 (dd, J = 9.2, 2.7 Hz, 1H), 8.16 – 8.07 (m, 2H), 7.95 (d, J = 
9.3 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 161.62, 154.18, 152.54, 150.51, 145.35, 
139.58, 129.56, 128.73, 122.09, 121.96, 121.77. 
 
6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (202).  
 
Molecular weight: 335.24 g/mol 
 
The compound was synthesized from 198 (3.62 g, 20 mmol) and 3-
(trifluoromethyl)benzaldehyde (3.48 g, 20 mmol) as described in the general procedure 
for compounds 199-204 to yield 202 as a yellow solid (5.16 g, 77%). 1H NMR (500 MHz, 
DMSO-d6) δ 13.18 (s, 1H), 8.82 (d, J = 2.7 Hz, 1H), 8.59 – 8.53 (m, 2H), 8.50 (ddd, J = 
8.2, 2.0, 1.1 Hz, 1H), 8.00 (ddt, J = 7.9, 1.9, 1.0 Hz, 1H), 7.97 – 7.91 (m, 1H), 7.87 – 7.77 
(m, 1H). 13C NMR (126 MHz, DMSO) δ 161.67, 154.51, 152.69, 145.07, 133.26, 132.33, 
130.07, 129.61 (d, J = 32.3 Hz), 129.37, 128.71 (d, J = 3.5 Hz), 128.65, 127.25, 125.04 
(d, J = 3.8 Hz), 122.92, 122.07, 121.36. 
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2-(3-methoxyphenyl)-6-nitroquinazolin-4(3H)-one (203).  
 
Molecular weight: 297.27 g/mol 
 
The compound was synthesized from 198 (3.62 g, 20 mmol) and 3-methoxybenzaldehyde 
(2.72 g, 20 mmol) as described in the general procedure for compounds 199-204 to yield 
203 as a yellow solid (4.88 g, 82%). 1H NMR (500 MHz, DMSO-d6) δ 12.94 (s, 1H), 
8.83 (d, J = 2.7 Hz, 1H), 8.52 (dd, J = 9.0, 2.8 Hz, 1H), 7.88 (d, J = 8.9 Hz, 1H), 7.85 
(ddd, J = 7.8, 1.7, 0.9 Hz, 1H), 7.80 (t, J = 2.2 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.18 
(ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 3.86 (s, 3H). 13C NMR (126 MHz, DMSO) δ 161.65, 
161.42, 159.51, 153.03, 144.84, 142.84, 133.43, 130.00, 128.61, 122.13, 120.75, 118.60, 
113.11, 55.59. 
 
2-(3,4-dimethoxyphenyl)-6-nitroquinazolin-4(3H)-one (204).  
 
Molecular weight: 327.30 g/mol 
 
The compound was synthesized from 198 (3.62 g, 20 mmol) and 3,4-
dimethoxybenzaldehyde (3.32 g, 20 mmol) as described in the general procedure for 
compounds 199-204 to yield 204 as a yellow solid (4.19 g, 64%). 1H NMR (500 MHz, 
DMSO-d6) δ 12.81 (s, 1H), 8.80 (d, J = 2.7 Hz, 1H), 8.50 (dd, J = 9.0, 2.8 Hz, 1H), 7.94 
(dd, J = 8.5, 2.2 Hz, 1H), 7.88 – 7.82 (m, 2H), 7.13 (d, J = 8.7 Hz, 1H), 3.88 (s, 3H), 3.85 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 162.24, 155.65, 153.41, 152.49, 148.72, 144.28, 
128.86, 128.42, 124.35, 122.24, 122.18, 120.68, 111.58, 111.20, 55.89, 55.87. 
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General Procedure for the Preparation of compounds 205-210.  
The corresponding 2-substituted 6-nitroquinazolin-4(3H)-one derivative 199-204 (10 
mmol) was added to phosphorous trichloride (30 mL, 0.32 mol) and stirred for 10 min at 
room temperature. The mixture was then refluxed for 4-12 h and the reaction monitored 
by TLC. After completion of the reaction, excess POCl3 was removed under reduced 
pressure and 50 mL ice water added. Subsequently, 50 mL DCM was added while stirring 
and the pH of the mixture slowly adjusted to 7 with 25% ammonium solution. With a 
separatory funnel, the organic phase was collected, washed with 50 mL brine and dried 
under MgSO4. The solvent was removed under reduced pressure and the obtained solid 
recrystallized from isopropanol. 
 
3-(6-nitro-4-oxo-3,4-dihydroquinazolin-2-yl)benzonitrile (205).  
 
Molecular weight: 285.69 g/mol 
 
The compound was synthesized from 199 (2.67 g, 10 mmol) as described in the general 
procedure for compounds 205-210 to yield 205 as a yellow solid (2.46 g, 86%). 1H NMR 
(500 MHz, DMSO-d6) δ 8.83 (d, J = 2.7 Hz, 1H), 8.55 (dd, J = 9.0, 2.8 Hz, 1H), 8.24 – 
8.19 (m, 2H), 7.91 (d, J = 9.0 Hz, 1H), 7.67 – 7.62 (m, 1H), 7.60 – 7.55 (m, 2H). 13C 
NMR (126 MHz, DMSO) δ 161.74, 155.85, 152.97, 144.85, 132.41, 132.16, 129.19, 
128.85, 128.64, 128.39, 122.16, 121.14. 
 
4-chloro-6-nitro-2-(pyridin-3-yl)quinazoline (206).  
 
Molecular weight: 286.68 g/mol 
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The compound was synthesized from 200 (2.68 g, 10 mmol) as described in the general 
procedure for compounds 205-210 to yield 206 as an orange solid (2.38 g, 83%). 1H NMR 
(500 MHz, DMSO-d6) δ 9.38 (dd, J = 2.3, 0.8 Hz, 1H), 8.88 (dd, J = 5.0, 1.6 Hz, 1H), 
8.82 (d, J = 2.7 Hz, 1H), 8.72 (ddd, J = 8.1, 2.3, 1.6 Hz, 1H), 8.60 – 8.54 (m, 1H), 7.94 
(d, J = 8.8 Hz, 1H), 7.79 (ddd, J = 8.1, 5.1, 0.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
161.49, 153.56, 152.52, 150.29, 147.22, 145.21, 138.43, 129.36, 129.20, 128.77, 124.70, 
122.09, 121.42. 
 
4-chloro-6-nitro-2-(pyridin-4-yl)quinazoline (207).  
 
Molecular weight: 286.68 g/mol 
 
The compound was synthesized from 201 (2.68 g, 10 mmol) as described in the general 
procedure for compounds 205-210 to yield 207 as an orange solid (2.12 g, 74%). 1H NMR 
(500 MHz, DMSO-d6) δ 13.21 (s, 1H), 8.85 – 8.81 (m, 2H), 8.57 (dd, J = 9.0, 2.7 Hz, 
1H), 8.18 – 8.10 (m, 2H), 7.95 (d, J = 9.0 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
161.55, 153.98, 152.46, 150.07, 145.44, 140.03, 129.63, 128.80, 122.10, 121.81. 
 
4-chloro-6-nitro-2-(3-(trifluoromethyl)phenyl)quinazoline (208).  
 
Molecular weight: 353.69 g/mol 
 
The compound was synthesized from 202 (3.35 g, 10 mmol) as described in the general 
procedure for compounds 205-210 to yield 208 as a yellow solid (3.18 g, 90%). 1H NMR 
(600 MHz, DMSO-d6) δ 8.81 (d, J = 2.7 Hz, 1H), 8.59 – 8.52 (m, 2H), 8.52 – 8.46 (m, 
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1H), 8.03 – 7.97 (m, 1H), 7.94 (d, J = 8.9 Hz, 1H), 7.82 (t, J = 7.9 Hz, 1H). 13C NMR 
(151 MHz, DMSO) δ 161.68, 154.53, 152.67, 145.14, 133.24, 132.40, 130.14, 129.66 (d, 
J = 32.5 Hz), 129.42, 128.80 (d, J = 3.8 Hz), 128.74, 125.09 (t, J = 3.9 Hz), 123.16, 
122.13, 121.40. 
 
4-chloro-2-(3-methoxyphenyl)-6-nitroquinazoline (209).  
 
Molecular weight: 315.71 g/mol 
 
The compound was synthesized from 203 (2.97 g, 10 mmol) as described in the general 
procedure for compounds 205-210 to yield 209 as a yellow solid (2.81 g, 89%). 1H NMR 
(500 MHz, DMSO-d6) δ 8.83 (d, J = 2.7 Hz, 1H), 8.55 (dd, J = 9.0, 2.8 Hz, 1H), 7.92 (d, 
J = 9.0 Hz, 1H), 7.83 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 7.78 (dd, J = 2.6, 1.7 Hz, 1H), 7.49 
(t, J = 8.0 Hz, 1H), 7.20 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 3.87 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 161.74, 159.51, 155.56, 152.89, 144.87, 133.42, 130.02, 129.23, 128.65, 
122.15, 121.18, 120.77, 118.63, 113.14, 55.61. 
 
4-chloro-2-(3,4-dimethoxyphenyl)-6-nitroquinazoline (210).  
 
Molecular weight: 345.74 g/mol 
 
The compound was synthesized from 7 (3.27 g, 10 mmol) as described in the general 
procedure for compounds 205-210 to yield 210 as a yellow solid (2.75 g, 71%). 1H NMR 
(500 MHz, DMSO-d6) δ 8.79 (d, J = 2.7 Hz, 1H), 8.50 (dd, J = 9.0, 2.7 Hz, 1H), 7.92 (dd, 
J = 8.5, 2.2 Hz, 1H), 7.89 – 7.77 (m, 2H), 7.13 (d, J = 8.6 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 
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3H). 13C NMR (126 MHz, DMSO) δ 161.80, 155.29, 153.05, 152.61, 148.73, 144.43, 
128.80, 128.59, 123.85, 122.26, 122.19, 120.66, 111.60, 111.20, 55.91, 55.89. 
 
General Procedure for the Preparation of compounds 211-239. The corresponding 2 
substituted 4-chloroquinazoline 205-210 (1 mmol) and a substituted aniline (1 mmol) 
were added to a 50 mL microwave tube and suspended in 25 mL isopropanol. The tube 
was sealed and the reaction mixture stirred under 100 watt microwave irradiation at 110 
°C for 20-40 min. Completion of the reaction was monitored by TLC. After cooling, a 
precipitate was formed and filtered off by suction. Recrystallization was carried out with 
ethanol. 
 
6-nitro-N,2-diphenylquinazolin-4-amine (211).  
 
Molecular weight: 342.36 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and aniline (0.93 g, 10 mmol) to yield 211 as an orange 
solid (2.40 g, 70%), mp 264-265 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.47 (s, 1H), 
9.65 (d, J = 2.5 Hz, 1H), 8.53 (dd, J = 9.2, 2.5 Hz, 1H), 8.46 – 8.36 (m, 2H), 7.96 (d, J = 
9.2 Hz, 1H), 7.94 – 7.89 (m, 2H), 7.58 – 7.44 (m, 5H), 7.23 (tt, J = 7.4, 1.1 Hz, 1H). 13C 
NMR (126 MHz, DMSO) δ 162.32, 159.06, 154.21, 144.24, 138.67, 137.59, 131.33, 
129.68, 128.69, 128.49, 126.90, 124.59, 122.90, 121.05, 113.35. Anal. Calcd. for 
C20H14N4O2: C, 70.17; H, 4.12; N, 16.37. Found: C, 70.32; H, 4.26; N, 16.17. 
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2-nitro-4-((6-nitro-2-phenylquinazolin-4-yl)amino)phenol (212).  
 
Molecular weight: 403.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 4-amino-2-nitrophenol (1.54 g, 10 mmol) to yield 
212 as an orange-red solid (2.58 g, 64%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) 
δ 10.90 (s, 1H), 10.56 (s, 1H), 9.61 (d, J = 2.5 Hz, 1H), 8.80 (d, J = 2.7 Hz, 1H), 8.54 (dd, 
J = 9.2, 2.4 Hz, 1H), 8.51 – 8.44 (m, 2H), 8.04 (dd, J = 9.0, 2.7 Hz, 1H), 7.98 (d, J = 9.2 
Hz, 1H), 7.60 – 7.46 (m, 3H), 7.26 (d, J = 9.0 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
162.19, 158.80, 154.07, 149.22, 144.31, 137.40, 135.70, 131.45, 130.49, 130.16, 129.76, 
128.67, 128.57, 127.00, 120.86, 119.39, 118.70, 113.25. Anal. Calcd. for C20H13N5O5: 
C, 59.56; H, 3.25; N, 17.36. Found: C, 59.69; H, 3.01; N, 17.22. 
 
3-((6-nitro-2-phenylquinazolin-4-yl)amino)benzonitrile (213).  
 
Molecular weight: 367.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 3-aminobenzonitrile (1.18 g, 10 mmol) to yield 213 
as a yellow solid (2.98 g, 81%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.03 (s, 
1H), 9.69 (d, J = 2.4 Hz, 1H), 8.59 (dd, J = 9.2, 2.4 Hz, 1H), 8.48 – 8.31 (m, 3H), 8.24 
10 Experimental section  379
(dt, J = 7.5, 2.1 Hz, 1H), 8.11 (d, J = 9.1 Hz, 1H), 7.78 – 7.65 (m, 2H), 7.64 – 7.47 (m, 
3H). 13C NMR (126 MHz, DMSO) δ 161.54, 159.13, 152.28, 144.68, 139.27, 136.16, 
132.05, 130.19, 128.83, 128.70, 128.48, 128.22, 127.67, 127.57, 126.17, 121.14, 118.71, 
113.20, 111.57. Anal. Calcd. for C21H13N5O2: C, 68.66; H, 3.57; N, 19.06. Found: C, 
68.70; H, 3.90; N, 18.75. 
 
4-((6-nitro-2-phenylquinazolin-4-yl)amino)benzonitrile (214).  
 
Molecular weight: 367.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 4-aminobenzonitrile (1.18 g, 10 mmol) to yield 214 
as a yellow solid (2.53 g, 69%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 10.93 (s, 
1H), 9.71 (d, J = 2.4 Hz, 1H), 8.60 (dd, J = 9.2, 2.4 Hz, 1H), 8.47 – 8.41 (m, 2H), 8.22 – 
8.14 (m, 2H), 8.08 (d, J = 9.1 Hz, 1H), 7.99 – 7.92 (m, 2H), 7.61 – 7.52 (m, 3H). 13C 
NMR (151 MHz, DMSO) δ 161.79, 159.03, 153.14, 144.64, 143.02, 136.60, 133.08, 
131.84, 129.13, 128.88, 128.70, 127.53, 122.69, 121.20, 119.12, 113.45, 106.12. Anal. 
Calcd. for C21H13N5O2: C, 68.66; H, 3.57; N, 19.06. Found: C, 68.59; H, 3.80; N, 18.79. 
 
3-((6-nitro-2-phenylquinazolin-4-yl)amino)phenol (215).  
 
Molecular weight: 358.36 g/mol 
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The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 3-aminophenol (1.09 g, 10 mmol) to yield 215 as a 
yellow solid (2.39 g, 66%), mp 277-278 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 10.35 (s, 1H), 9.67 (d, J = 2.4 Hz, 1H), 9.53 (s, 1H), 8.53 (dd, J = 9.2, 2.5 Hz, 1H), 8.49 
– 8.41 (m, 2H), 7.96 (d, J = 9.1 Hz, 1H), 7.57 – 7.48 (m, 3H), 7.43 (t, J = 2.2 Hz, 1H), 
7.38 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 6.64 (ddd, J = 8.1, 2.4, 1.0 
Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.38, 159.03, 157.67, 154.22, 144.25, 139.70, 
137.63, 131.33, 129.67, 129.29, 128.67, 128.60, 126.89, 121.11, 113.59, 113.41, 111.76, 
109.95. Anal. Calcd. for C20H14N4O3: C, 67.03; H, 3.94; N, 15.63. Found: C, 67.24; H, 
4.17; N, 15.41. 
 
4-((6-nitro-2-phenylquinazolin-4-yl)amino)benzene-1,2-diol (216).  
 
Molecular weight: 374.36 g/mol 
 
The compound was synthesized from a solution of 218 (4.02 g, 10 mmol) in dry DCM 
kept at – 60 °C under moisture exclusion. Boron tribromide was slowly added under 
stirring via a dropping funnel within 30 min and the cooling bath removed. After another 
12 h stirring at room temperature, the solvent was evaporated under reduced pressure and 
the obtained solid recrystallized from 75% ethanol to yield 216 as red solid (3.14 g, 84%), 
mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.62 (d, J = 2.5 Hz, 1H), 
9.07 (s, 1H), 8.86 (s, 1H), 8.52 (dd, J = 9.2, 2.5 Hz, 1H), 8.47 – 8.39 (m, 2H), 7.93 (d, J 
= 9.2 Hz, 1H), 7.56 – 7.48 (m, 3H), 7.34 (d, J = 2.5 Hz, 1H), 7.14 (dd, J = 8.5, 2.5 Hz, 
1H), 6.82 (d, J = 8.5 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 162.48, 158.90, 154.19, 
145.08, 144.09, 142.75, 137.70, 131.25, 130.22, 129.42, 128.61, 128.59, 126.77, 121.02, 
115.24, 114.44, 113.35, 111.57. Anal. Calcd. for C20H14N4O4: C, 64.17; H, 3.77; N, 
14.97. Found: C, 64.15; H, 3.67; N, 14.67. 
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N-(3-methoxyphenyl)-6-nitro-2-phenylquinazolin-4-amine (217).  
 
Molecular weight: 372.38 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 3-methoxyaniline (1.23 g, 10 mmol) to yield 217 as 
an orange solid (2.20 g, 59%), mp 242-243 °C. 1H NMR (600 MHz, DMSO-d6) δ 10.42 
(s, 1H), 9.66 (d, J = 2.4 Hz, 1H), 8.53 (dd, J = 9.1, 2.4 Hz, 1H), 8.49 – 8.39 (m, 2H), 7.97 
(d, J = 9.1 Hz, 1H), 7.67 (s, 1H), 7.62 – 7.48 (m, 4H), 7.38 (t, J = 8.1 Hz, 1H), 6.80 (dd, 
J = 8.1, 2.4 Hz, 1H), 3.83 (s, 3H). 13C NMR (151 MHz, DMSO) δ 162.27, 159.53, 158.98, 
154.18, 144.28, 139.95, 137.61, 131.39, 129.73, 129.41, 128.67, 128.47, 126.93, 121.02, 
114.87, 113.40, 110.49, 108.09, 55.30. Anal. Calcd. for C21H16N4O3: C, 67.73; H, 4.33; 
N, 15.05. Found: C, 67.48; H, 4.25; N, 14.85. 
 
N-(3,4-dimethoxyphenyl)-6-nitro-2-phenylquinazolin-4-amine (218).  
 
Molecular weight: 402.41 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 3,4-dimethoxyaniline (1.53 g, 10 mmol) to yield 218 
as a red-orange solid (3.10 g, 77%), mp 238-240 °C. 1H NMR (500 MHz, DMSO-d6) δ 
10.35 (s, 1H), 9.63 (d, J = 2.5 Hz, 1H), 8.51 (dd, J = 9.2, 2.4 Hz, 1H), 8.49 – 8.42 (m, 
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2H), 7.94 (d, J = 9.2 Hz, 1H), 7.68 (d, J = 2.5 Hz, 1H), 7.57 – 7.47 (m, 3H), 7.43 (dd, J = 
8.7, 2.4 Hz, 1H), 7.06 (d, J = 8.7 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 162.36, 158.78, 154.19, 148.45, 145.98, 144.16, 137.71, 131.99, 131.31, 
129.60, 128.60, 128.46, 126.81, 120.91, 114.76, 113.35, 111.85, 107.81, 55.89, 55.66. 
Anal. Calcd. for C22H18N4O4: C, 65.66; H, 4.51; N, 13.92. Found: C, 65.74; H, 4.88; N, 
13.55. 
 
N-(3-((6-nitro-2-phenylquinazolin-4-yl)amino)phenyl)acetamide (219).  
 
Molecular weight: 399.41 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and N-(3-aminophenyl)acetamide (1.50 g, 10 mmol) to 
yield 219 as a yellow solid (2.80 g, 70%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) 
δ 10.83 (s, 1H), 10.09 (s, 1H), 9.73 (d, J = 2.4 Hz, 1H), 8.60 (dd, J = 9.2, 2.5 Hz, 1H), 
8.54 – 8.39 (m, 2H), 8.33 (t, J = 2.1 Hz, 1H), 8.08 (d, J = 9.2 Hz, 1H), 7.67 – 7.47 (m, 
4H), 7.41 (t, J = 8.1 Hz, 1H), 7.31 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 2.09 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 168.54, 161.74, 159.20, 152.19, 144.58, 139.80, 138.46, 136.12, 
131.93, 128.97, 128.76, 128.09, 127.54, 121.33, 118.20, 115.93, 114.17, 113.29, 24.18. 
Anal. Calcd. for C22H17N5O3: C, 66.16; H, 4.29; N, 17.53. Found: C, 66.26; H, 4.53; N, 
17.25. 
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N-(3-fluorophenyl)-6-nitro-2-phenylquinazolin-4-amine (220).  
 
Molecular weight: 360.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 3-fluoroaniline (1.11 g, 10 mmol) to yield 220 as a 
yellow solid (3.17 g, 88%), mp 288-289 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 11.10 (s, 1H), 9.73 (d, J = 2.5 Hz, 1H), 8.61 (dd, J = 9.2, 2.4 Hz, 1H), 8.51 – 8.36 (m, 
2H), 8.18 (d, J = 9.2 Hz, 1H), 7.89 (dt, J = 11.4, 2.3 Hz, 1H), 7.75 (ddd, J = 8.2, 2.0, 0.9 
Hz, 1H), 7.67 – 7.42 (m, 4H), 7.10 (tdd, J = 8.4, 2.5, 0.9 Hz, 1H). 13C NMR (126 MHz, 
DMSO) δ 162.01 (d, J = 241.9 Hz), 161.25, 159.12, 144.76, 139.82 (d, J = 11.1 Hz), 
135.45, 132.28, 130.31 (d, J = 9.4 Hz), 128.86, 127.86, 127.48, 121.23, 118.97, 113.18, 
111.73 (d, J = 20.9 Hz), 110.12 (d, J = 26.0 Hz). Anal. Calcd. for C20H13FN4O2: C, 
66.66; H, 3.64; N, 15.55. Found: C, 66.30; H, 3.92; N, 15.30. 
 
6-nitro-2-phenyl-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (221).  
 
Molecular weight: 410.36 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 3-(trifluoromethyl)aniline (1.61 g, 10 mmol) to yield 
221 as a yellow solid (3.08 g, 75%), mp 278-279 °C (decomp.). 1H NMR (600 MHz, 
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DMSO-d6) δ 10.65 (s, 1H), 9.65 (d, J = 2.4 Hz, 1H), 8.57 (d, J = 2.0 Hz, 1H), 8.54 (dd, J 
= 9.1, 2.4 Hz, 1H), 8.43 (dt, J = 7.1, 1.4 Hz, 2H), 8.20 – 8.13 (m, 1H), 7.98 (dd, J = 9.1, 
1.8 Hz, 1H), 7.71 (t, J = 8.0 Hz, 1H), 7.59 – 7.53 (m, 2H), 7.53 – 7.47 (m, 2H). 13C NMR 
(151 MHz, DMSO) δ 162.10, 158.99, 154.15, 144.44, 139.67, 137.40, 131.57, 129.91 (d, 
J = 5.2 Hz), 129.40 (d, J = 31.6 Hz), 128.71, 128.47, 127.13, 125.94, 124.44 (d, J = 272.5 
Hz), 120.98, 120.55 (d, J = 3.7 Hz), 118.99 (d, J = 4.0 Hz), 113.37. Anal. Calcd. for 
C21H13F3N4O2: C, 61.47; H, 3.19; N, 13.65. Found: C, 61.77; H, 3.35; N, 13.44. 
 
3-((6-nitro-2-phenylquinazolin-4-yl)amino)benzoic acid (222).  
 
Molecular weight: 386.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 205 (2.86 g, 10 mmol) and 3-aminobenzoic acid (1.37 g, 10 mmol) to yield 222 
as a yellow solid (2.43 g, 63%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.97 (s, 
1H), 9.71 (d, J = 2.5 Hz, 1H), 8.58 (dd, J = 9.2, 2.4 Hz, 1H), 8.47 – 8.35 (m, 2H), 8.14 – 
7.99 (m, 5H), 7.67 – 7.44 (m, 3H). 13C NMR (126 MHz, DMSO) δ 167.01, 161.57, 
159.04, 152.15, 144.67, 142.47, 136.04, 132.03, 130.16, 128.88, 128.83, 128.30, 127.63, 
126.64, 122.28, 121.25, 113.35. Anal. Calcd. for C21H14N4O4: C, 65.28; H, 3.65; N, 
14.50. Found: C, 65.58; H, 3.88; N, 14.29.  
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3-((6-nitro-2-(pyridin-4-yl)quinazolin-4-yl)amino)benzonitrile (223).  
 
Molecular weight: 368.36 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 10 (2.87 g, 10 mmol) and 3-aminobenzonitrile (1.18 g, 10 mmol) to yield 223 
as a yellow solid (2.65 g, 72%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.97 (s, 
1H), 9.67 (d, J = 2.4 Hz, 1H), 8.98 – 8.92 (m, 2H), 8.59 (dd, J = 9.2, 2.4 Hz, 1H), 8.55 – 
8.49 (m, 2H), 8.28 (q, J = 1.4 Hz, 1H), 8.27 – 8.20 (m, 1H), 8.05 (d, J = 9.1 Hz, 1H), 7.72 
– 7.67 (m, 2H). 13C NMR (126 MHz, DMSO) δ 159.40, 158.49, 153.32, 149.88, 145.51, 
145.40, 139.14, 130.33, 130.25, 128.34, 127.66, 126.09, 124.07, 121.03, 118.67, 114.02, 
111.67. Anal. Calcd. for C22H14N6O2: C, 65.21; H, 3.28; N, 22.82. Found: C, 65.43; H, 
3.49; N, 22.44. 
 
N-(3-methoxyphenyl)-6-nitro-2-(pyridin-3-yl)quinazolin-4-amine (224).  
 
Molecular weight: 373.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 206 (2.87 g, 10 mmol) and 3-methoxyaniline (1.23 g, 10 mmol) to yield 224 as 
a yellow solid (2.17 g, 58%), mp 268-269 °C (decomp.). 1H NMR (500 MHz, DMSO-
d6) δ 10.38 (s, 1H), 9.56 (d, J = 2.5 Hz, 1H), 9.48 – 9.44 (m, 1H), 8.67 (dd, J = 4.7, 1.8 
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Hz, 1H), 8.59 (dt, J = 7.8, 2.0 Hz, 1H), 8.46 (dd, J = 9.0, 2.5 Hz, 1H), 7.88 (d, J = 9.1 Hz, 
1H), 7.58 (t, J = 2.2 Hz, 1H), 7.52 – 7.42 (m, 2H), 7.35 (t, J = 8.1 Hz, 1H), 6.78 (ddd, J 
= 8.2, 2.5, 0.9 Hz, 1H), 3.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 160.63, 159.49, 
158.85, 153.77, 151.66, 149.59, 144.39, 139.70, 135.54, 132.91, 129.66, 129.34, 126.89, 
123.69, 120.89, 114.95, 113.47, 110.43, 108.29, 55.29. Anal. Calcd. for C20H15N5O3: C, 
64.34; H, 4.05; N, 18.76. Found: C, 64.26; H, 4.16; N, 19.10. 
 
N-(4-methoxyphenyl)-6-nitro-2-(pyridin-3-yl)quinazolin-4-amine (225).  
 
Molecular weight: 373.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 206 (2.87 g, 10 mmol) and 4-methoxyaniline (1.23 g, 10 mmol) to yield 225 as 
a yellow solid (2.24 g, 60%), mp 269-270 °C (decomp.). 1H NMR (500 MHz, DMSO-
d6) δ 10.54 (s, 1H), 9.50 (d, J = 2.6 Hz, 1H), 9.47 (dd, J = 2.1, 0.9 Hz, 1H), 8.66 (dd, J = 
4.7, 1.7 Hz, 1H), 8.62 (dt, J = 7.9, 1.9 Hz, 1H), 8.42 (dd, J = 9.1, 2.5 Hz, 1H), 7.79 (d, J 
= 9.1 Hz, 1H), 7.75 – 7.68 (m, 2H), 7.50 (ddd, J = 7.9, 4.7, 0.9 Hz, 1H), 7.08 – 6.94 (m, 
2H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO) δ 161.04, 158.51, 155.77, 154.68, 
151.32, 149.68, 143.63, 135.52, 133.70, 128.69, 126.37, 124.72, 123.61, 121.23, 115.36, 
113.72, 55.38. Anal. Calcd. for C20H15N5O3: C, 64.34; H, 4.05; N, 18.76. Found: C, 
64.48; H, 4.00; N, 18.39. 
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N-(4-methoxyphenyl)-6-nitro-2-(pyridin-4-yl)quinazolin-4-amine (226). 
 
Molecular weight: 373.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 207 (2.87 g, 10 mmol) and 4-methoxyaniline (1.23 g, 10 mmol) to yield 226 as 
an orange-red solid (2.31 g, 62%), mp 297-299 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.71 (s, 1H), 9.67 (d, J = 2.4 Hz, 1H), 9.02 – 8.84 (m, 2H), 8.61 – 8.48 (m, 
3H), 8.03 (dd, J = 9.1, 1.2 Hz, 1H), 7.83 – 7.69 (m, 2H), 7.06 (dq, J = 9.4, 2.6, 1.8 Hz, 
2H), 3.82 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.30, 158.77, 156.69, 153.35, 
150.11, 145.36, 145.24, 130.91, 129.98, 127.32, 124.79, 124.06, 121.01, 114.05, 113.97, 
55.42. Anal. Calcd. for C20H15N5O3: C, 64.34; H, 4.05; N, 18.76. Found: C, 64.56; H, 
4.27; N, 18.49. 
 
6-nitro-N-phenyl-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (227).  
 
Molecular weight: 410.36 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and aniline (0.93 g, 10 mmol) to yield 227 as a yellow 
solid (3.08 g, 75%), mp 238-240 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 
9.63 (d, J = 2.5 Hz, 1H), 8.68 (dq, J = 1.4, 0.8 Hz, 1H), 8.64 (dd, J = 7.8, 1.6 Hz, 1H), 
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8.53 (dd, J = 9.2, 2.5 Hz, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.92 – 7.84 (m, 3H), 7.80 – 7.68 
(m, 1H), 7.53 – 7.40 (m, 2H), 7.31 – 7.20 (m, 1H). 13C NMR (126 MHz, DMSO) δ 
160.63, 159.11, 153.96, 144.53, 138.52, 138.42, 132.01, 129.97, 129.79, 129.51 (d, J = 
31.7 Hz), 129.13, 128.56, 127.66 (d, J = 3.3 Hz), 127.52, 127.03, 125.35, 124.86, 124.71 
(d, J = 3.9 Hz), 123.13, 120.99, 113.55. Anal. Calcd. for C21H13F3N4O2: C, 61.71; H, 
3.29; N, 13.31. Found: C, 61.47; H, 3.19; N, 13.65. 
 
2-nitro-4-((6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4-yl)amino)phenol 
(228).  
 
 
Molecular weight: 471.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 4-amino-2-nitrophenol (1.54 g, 10 mmol) to yield 
228 as a yellow solid (3.25 g, 69%), mp 280-281 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.89 (s, 1H), 10.50 (s, 1H), 9.49 (d, J = 2.5 Hz, 1H), 8.66 – 8.57 (m, 3H), 
8.46 (dd, J = 9.1, 2.4 Hz, 1H), 7.97 (dd, J = 9.0, 2.7 Hz, 1H), 7.91 (d, J = 9.1 Hz, 1H), 
7.85 (ddt, J = 7.7, 1.9, 1.0 Hz, 1H), 7.73 – 7.66 (m, 1H), 7.20 (d, J = 9.0 Hz, 1H). 13C 
NMR (126 MHz, DMSO) δ 160.45, 158.71, 153.68, 149.33, 144.48, 138.27, 135.57, 
132.08, 130.15, 130.12, 129.81 (d, J = 3.5 Hz), 129.67, 129.41, 127.71, 127.69, 126.98, 
124.61, 124.58, 124.21 (d, J = 272.4 Hz), 120.69, 119.19, 118.72, 113.34. Anal. Calcd. 
for C21H12F3N5O5: C, 53.51; H, 2.57; N, 14.86. Found: C, 53.75; H, 2.61; N, 14.59. 
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6-nitro-N-(3-nitrophenyl)-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (229). 
 
Molecular weight: 455.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 3-nitroaniline (1.38 g, 10 mmol) to yield 229 as a 
yellow solid (3.92 g, 86%), mp 278-279 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.87 (s, 
1H), 9.69 (s, 1H), 9.10 (d, J = 2.6 Hz, 1H), 8.74 (d, J = 16.3 Hz, 2H), 8.63 – 8.56 (m, 1H), 
8.30 (d, J = 8.2 Hz, 1H), 8.08 (t, J = 8.1 Hz, 2H), 7.93 (d, J = 8.0 Hz, 1H), 7.77 (q, J = 
8.2 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 160.46, 159.11, 153.84, 147.92, 144.79, 
138.27, 132.17, 130.07, 129.98, 128.39, 127.89, 127.35, 124.65, 120.93, 118.85, 116.87. 
Anal. Calcd. for C21H12F3N5O4: C, 55.39; H, 2.66; N, 15.38. Found: C, 55.35; H, 2.61; 
N, 15.08. 
 
6-nitro-N-(4-nitrophenyl)-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (230).  
 
 
Molecular weight: 455.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 4-nitroaniline (1.38 g, 10 mmol) to yield 230 as a 
bright yellow solid (3.23 g, 71%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.86 
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(s, 1H), 9.63 (d, J = 2.4 Hz, 1H), 8.68 (s, 1H), 8.66 (d, J = 7.9 Hz, 1H), 8.57 (dd, J = 9.1, 
2.5 Hz, 1H), 8.36 – 8.30 (m, 2H), 8.25 – 8.19 (m, 2H), 8.05 (d, J = 9.2 Hz, 1H), 7.91 (d, 
J = 7.7 Hz, 1H), 7.80 (q, J = 8.3, 7.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 160.41, 
158.98, 153.87, 145.14, 144.84, 142.85, 138.11, 132.24, 130.25, 130.09, 129.73, 129.48, 
127.92, 127.89, 127.41, 124.69, 124.66, 124.54, 123.17, 122.09, 121.00, 120.32, 120.27, 
113.76. Anal. Calcd. for C21H12F3N5O4: C, 55.39; H, 2.66; N, 15.38. Found: C, 55.42; 
H, 2.67; N, 15.12. 
 
3-((6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4-yl)amino)phenol (231).  
 
Molecular weight: 426.36 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 3-aminophenol (1.09 g, 10 mmol) to yield 231 as a 
yellow solid (3.54 g, 83%), mp 275-278 °C (decomp.). 1H NMR (500 MHz, DMSO-d6) 
δ 10.64 (s, 1H), 9.68 (d, J = 2.6 Hz, 1H), 8.55 (dd, J = 9.2, 2.4 Hz, 1H), 8.46 (ddd, J = 
6.4, 3.1, 1.4 Hz, 2H), 8.20 – 8.09 (m, 2H), 8.11 – 8.03 (m, 2H), 8.00 (d, J = 9.2 Hz, 1H), 
7.65 – 7.48 (m, 3H). 13C NMR (126 MHz, DMSO) δ 165.49, 162.17, 158.92, 154.15, 
144.43, 143.31, 137.35, 131.46, 130.01, 129.85, 128.80, 128.57, 127.10, 125.07, 121.73, 
121.08, 113.46. Anal. Calcd. for C21H13F3N4O3: C, 59.16; H, 3.07; N, 13.14. Found: C, 
59.29; H 
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N-(3-methoxyphenyl)-6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine 
(232).  
 
Molecular weight: 440.38 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 3-methoxyaniline (1.23 g, 10 mmol) to yield 232 as 
a yellow solid (3.21 g, 73%), mp 207-209 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.48 
(s, 1H), 9.62 (d, J = 2.5 Hz, 1H), 8.71 – 8.63 (m, 2H), 8.52 (dd, J = 9.1, 2.5 Hz, 1H), 7.98 
(d, J = 9.2 Hz, 1H), 7.92 – 7.85 (m, 1H), 7.75 (tt, J = 7.5, 0.8 Hz, 1H), 7.60 (t, J = 2.2 Hz, 
1H), 7.47 (ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 7.36 (t, J = 8.1 Hz, 1H), 6.81 (ddd, J = 8.2, 2.5, 
0.9 Hz, 1H), 3.81 (s, 3H). 13C NMR (126 MHz, DMSO) δ 160.63, 159.56, 159.06, 153.91, 
144.56, 139.65, 138.57, 132.04, 129.94, 129.82, 129.55 (d, J = 31.8 Hz), 129.29, 129.17, 
127.72, 127.69, 127.04, 125.35, 124.69, 124.66, 123.19, 120.96, 115.09, 113.59, 110.62, 
108.51, 55.27. Anal. Calcd. for C22H15F3N4O3: C, 60.00; H, 3.43; N, 12.72. Found: C, 
59.99; H, 3.34; N, 12.34. 
 
N-(3,4-dimethoxyphenyl)-6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine 
(233).  
 
Molecular weight: 470.41 g/mol 
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The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 3,4-dimethoxyaniline (1.53 g, 10 mmol) to yield 233 
as a red solid (2.78 g, 59%), mp 217-218 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.45 (s, 
1H), 9.59 (d, J = 2.4 Hz, 1H), 8.69 – 8.59 (m, 2H), 8.50 (dd, J = 9.2, 2.5 Hz, 1H), 7.95 
(d, J = 9.2 Hz, 1H), 7.92 – 7.83 (m, 1H), 7.78 – 7.70 (m, 1H), 7.60 (d, J = 2.4 Hz, 1H), 
7.35 (dd, J = 8.6, 2.5 Hz, 1H), 7.02 (d, J = 8.7 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 160.66, 158.88, 153.68, 148.51, 146.22, 144.45, 138.56, 
132.09, 131.62, 129.89, 129.53, 129.47 (d, J = 31.8 Hz), 127.69, 127.66, 127.52, 126.96, 
124.59 (d, J = 3.7 Hz), 124.28 (d, J = 272.4 Hz), 120.87, 115.10, 113.52, 111.70, 107.98, 
55.88, 55.60. Anal. Calcd. for C23H17F3N4O4: C, 58.73; H, 3.64; N, 11.91. Found: C, 
58.53; H, 3.63; N, 11.58. 
 
N-(3-(methylthio)phenyl)-6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine 
(234).  
 
Molecular weight: 456.44 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 3-(methylthio)aniline (1.39 g, 10 mmol) to yield 234 
as an orange solid (3.56 g, 78%), mp 209-211 °C. 1H NMR (600 MHz, DMSO-d6) δ 
10.48 (s, 1H), 9.58 (d, J = 2.5 Hz, 1H), 8.68 – 8.61 (m, 2H), 8.50 (dd, J = 9.1, 2.4 Hz, 
1H), 7.96 (d, J = 9.1 Hz, 1H), 7.90 – 7.83 (m, 2H), 7.76 – 7.70 (m, 1H), 7.66 (ddd, J = 
8.1, 2.1, 0.9 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.12 (ddd, J = 7.9, 1.9, 0.9 Hz, 1H), 2.51 
(s, 3H). 13C NMR (151 MHz, DMSO) δ 160.55, 159.03, 153.87, 144.53, 139.01, 138.64, 
138.49, 132.06, 129.89, 129.82, 129.56 (d, J = 31.8 Hz), 129.03, 127.76, 127.05, 125.16, 
124.61 (d, J = 4.0 Hz), 123.35, 122.17, 120.91, 120.12, 119.36, 113.54, 14.94. Anal. 
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Calcd. for C22H15F3N4O2S: C, 57.89; H, 3.31; N, 12.27. Found: C, 57.99; H, 3.25; N, 
12.03.  
 
N-(3-fluorophenyl)-6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (235). 
 
Molecular weight: 428.35 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and 3-fluoroaniline (1.11 g, 10 mmol) to yield 235 as a 
yellow solid (3.47 g, 81%), mp 238-239 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.52 (s, 
1H), 9.54 (d, J = 2.5 Hz, 1H), 8.61 (td, J = 1.7, 0.8 Hz, 1H), 8.59 (dd, J = 7.8, 1.5 Hz, 
1H), 8.48 (dd, J = 9.1, 2.5 Hz, 1H), 7.98 – 7.82 (m, 3H), 7.77 – 7.68 (m, 1H), 7.65 (ddd, 
J = 8.1, 2.0, 0.9 Hz, 1H), 7.46 (td, J = 8.2, 6.8 Hz, 1H), 7.04 (tdd, J = 8.4, 2.6, 0.8 Hz, 
1H). 13C NMR (126 MHz, DMSO) δ 163.02, 161.10, 160.41, 158.86, 153.76, 144.55, 
140.25 (d, J = 11.0 Hz), 138.30, 131.89, 130.08, 130.01, 129.92, 129.84, 129.67, 129.42, 
129.16, 127.72, 127.69, 127.47, 127.04, 125.30, 124.65 (d, J = 3.9 Hz), 123.14, 120.81, 
118.32 (d, J = 2.3 Hz), 113.43, 111.05 (d, J = 21.0 Hz), 109.62 (d, J = 26.2 Hz). Anal. 
Calcd. for C21H12F4N4O2: C, 58.88; H, 2.82; N, 13.08. Found: C, 58.91; H, 2.73; N, 
12.81. 
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N-(3-((6-nitro-2-(3-(trifluoromethyl)phenyl)quinazolin-4-
yl)amino)phenyl)acetamide (236).  
 
Molecular weight: 467.41 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 208 (3.54 g, 10 mmol) and N-(3-aminophenyl)acetamide (1.50 g, 10 mmol) to 
yield 236 as a yellow solid (2.85 g, 61%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) 
δ 10.63 (s, 1H), 10.04 (s, 1H), 9.68 (d, J = 2.5 Hz, 1H), 8.80 – 8.63 (m, 2H), 8.55 (dd, J 
= 9.2, 2.5 Hz, 1H), 8.43 (t, J = 2.1 Hz, 1H), 8.01 (d, J = 9.1 Hz, 1H), 7.89 (dd, J = 7.9, 
1.5 Hz, 1H), 7.75 (t, J = 7.8 Hz, 1H), 7.53 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 7.37 (t, J = 8.0 
Hz, 1H), 7.29 (ddd, J = 8.0, 2.1, 1.1 Hz, 1H), 2.07 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 168.46, 160.66, 159.16, 153.79, 144.58, 139.76, 138.62, 138.32, 132.32, 129.91, 
129.62, 129.39, 129.14, 128.55, 127.75, 127.73, 127.12, 125.02, 124.99, 124.28 (d, J = 
272.3 Hz), 121.14, 117.85, 115.55, 114.05, 113.58, 24.10. Anal. Calcd. for 
C23H16F3N5O3: C, 59.10; H, 3.45; N, 14.98. Found: C, 59.42; H, 3.59; N, 14.73. 
 
4-((2-(3-methoxyphenyl)-6-nitroquinazolin-4-yl)amino)benzonitrile (237).  
 
Molecular weight: 397.39 g/mol 
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The compound was synthesized according to the general procedure for compounds 211-
239 from 209 (3.16 g, 10 mmol) and 4-aminobenzonitrile (1.18 g, 10 mmol) to yield 237 
as a yellow solid (2.34 g, 59%), mp 184-186 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.63 
(s, 1H), 9.56 (d, J = 2.4 Hz, 1H), 8.50 (dt, J = 9.0, 2.8 Hz, 1H), 8.20 – 8.11 (m, 2H), 7.99 
– 7.92 (m, 2H), 7.91 – 7.87 (m, 3H), 7.40 (t, J = 7.9 Hz, 1H), 7.09 (ddd, J = 8.2, 2.7, 0.9 
Hz, 1H), 3.83 (s, 3H). 13C NMR (126 MHz, DMSO) δ 161.71, 159.53, 158.73, 154.03, 
144.44, 143.21, 138.64, 132.93, 129.90, 129.81, 127.11, 122.36, 120.96, 120.91, 119.15, 
117.66, 113.42, 113.05, 105.82, 55.20. Anal. Calcd. for C22H15N5O3: C, 66.49; H, 3.80; 
N, 17.62. Found: C, 66.24; H, 4.00; N, 17.33. 
 
N-(3-fluorophenyl)-2-(3-methoxyphenyl)-6-nitroquinazolin-4-amine (238).  
 
Molecular weight: 390.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 209 (3.16 g, 10 mmol) and 3-fluoroaniline (1.11 g, 10 mmol) to yield 238 as a 
yellow-orange solid (3.44 g, 88%), mp 276-277 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.51 (s, 1H), 9.61 (d, J = 2.5 Hz, 1H), 8.51 (dd, J = 9.2, 2.5 Hz, 1H), 8.05 
– 7.91 (m, 4H), 7.71 (ddd, J = 8.3, 2.0, 0.9 Hz, 1H), 7.49 (td, J = 8.3, 6.9 Hz, 1H), 7.42 
(t, J = 7.9 Hz, 1H), 7.10 (ddd, J = 8.2, 2.8, 1.0 Hz, 1H), 7.03 (tdd, J = 8.4, 2.6, 0.9 Hz, 
1H), 3.83 (s, 3H). 13C NMR (126 MHz, DMSO) δ 162.07 (d, J = 241.3 Hz), 161.84, 
159.53, 158.80, 154.04, 144.34, 140.53 (d, J = 11.1 Hz), 138.88, 130.13 (d, J = 9.4 Hz), 
129.81, 129.74, 126.96, 120.91, 120.82, 118.26, 118.24, 117.70, 113.32, 112.96, 110.83 
(d, J = 21.1 Hz), 109.47 (d, J = 26.2 Hz), 55.08. Anal. Calcd. for C21H15FN4O3: C, 64.61; 
H, 3.87; N, 14.35. Found: C, 64.84; H, 3.93; N, 14.23. 
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2-(3,4-dimethoxyphenyl)-6-nitro-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine 
(239).  
 
Molecular weight: 470.41 g/mol 
 
The compound was synthesized according to the general procedure for compounds 211-
239 from 210 (3.46 g, 10 mmol) and 3-(trifluoromethyl)aniline (1.61 g, 10 mmol) to yield 
239 as an orange solid (3.39 g, 72%), mp >300 °C. 1H NMR (600 MHz, DMSO-d6) δ 
10.63 (s, 1H), 9.64 (d, J = 2.4 Hz, 1H), 8.54 (dd, J = 9.2, 2.4 Hz, 1H), 8.41 (d, J = 2.0 Hz, 
1H), 8.31 – 8.23 (m, 1H), 8.07 (dd, J = 8.4, 2.0 Hz, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.97 
(d, J = 9.1 Hz, 1H), 7.72 (t, J = 8.0 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.08 (d, J = 8.5 Hz, 
1H), 3.85 (s, 3H), 3.84 (s, 3H). 13C NMR (126 MHz, DMSO) δ 161.85, 158.65, 154.21, 
152.00, 148.67, 143.93, 139.69, 129.79, 129.74, 129.51, 126.94, 126.09, 125.46, 123.29, 
122.15, 120.91, 120.49 (d, J = 3.5 Hz), 118.73 (d, J = 3.8 Hz), 112.94, 111.36, 55.74, 
55.38. Anal. Calcd. for C23H17F3N4O4: C, 58.73; H, 3.64; N, 11.91. Found: C, 58.79; H, 
3.92; N, 11.65. 
 
General Procedure for the Preparation of compounds 240-244. The corresponding 2- 
and 4-substituted 6-nitroquinazoline derivative (1 mmol) was dissolved in dry THF (200 
mL) and added to a pressure vessel together with 1% (by weight of the educt) of palladium 
on activated charcoal. After evacuating and flushing the vessel with N2 three times, it was 
pressurized with hydrogen gas (4 bar) and sealed. The mixture was stirred for 24 h at 
room temperature until completion of the reaction indicated by TLC. Charcoal was 
removed by several filtration cycles and the remaining solvent evaporated under reduced 
pressure to obtain the corresponding compound as a solid product. Purification was 
carried out by column chromatography using DCM and methanol as eluent.  
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N4-(3-methoxyphenyl)-2-(pyridin-3-yl)quinazoline-4,6-diamine (240).  
 
Molecular weight: 343.39 g/mol 
 
The compound was synthesized according to the general procedure for compounds 240-
244 from 224 (3.73 g, 10 mmol) to yield 240 as a yellow solid (1.65 g, 45%), mp 209-
211 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.50 (dd, J = 2.1, 0.9 Hz, 1H), 9.44 (s, 1H), 
8.68 – 8.57 (m, 2H), 7.72 (t, J = 2.3 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.56 – 7.52 (m, 
1H), 7.49 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H), 7.41 (d, J = 2.4 Hz, 1H), 7.33 (d, J = 8.2 Hz, 
1H), 7.31 – 7.25 (m, 1H), 6.69 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 5.65 (s, 2H), 3.81 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 159.53, 156.25, 152.87, 150.10, 148.73, 147.73, 143.12, 
141.26, 134.36, 134.31, 129.28, 125.01, 124.04, 123.60, 115.91, 113.89, 108.86, 107.15, 
101.49, 55.17. Anal. Calcd. for C20H17N5O: C, 69.96; H, 4.99; N, 20.40. Found: C, 
69.83; H, 5.21; N, 20.47. 
 
N4-(4-methoxyphenyl)-2-(pyridin-3-yl)quinazoline-4,6-diamine (241).  
 
Molecular weight: 343.39 g/mol 
 
The compound was synthesized according to the general procedure for compounds 240-
244 from 225 (3.73 g, 10 mmol) to yield 241 as a yellow solid (2.13 g, 62%), mp 202-
203 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.45 (d, J = 2.1 Hz, 1H), 9.39 (s, 1H), 8.63 – 
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8.54 (m, 2H), 7.86 – 7.75 (m, 2H), 7.60 (d, J = 8.8 Hz, 1H), 7.47 (dd, J = 7.8, 4.8 Hz, 
1H), 7.40 (d, J = 2.4 Hz, 1H), 7.25 (dd, J = 8.9, 2.2 Hz, 1H), 7.07 – 6.95 (m, 2H), 5.60 (s, 
2H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO) δ 156.46, 155.47, 153.04, 149.97, 
148.75, 147.55, 142.90, 139.28, 134.36, 132.88, 129.15, 125.01, 123.69, 123.54, 115.72, 
113.74, 101.63, 55.36. Anal. Calcd. for C20H17N5O: C, 69.96; H, 4.99; N, 20.40. Found: 
C, 70.16; H, 5.32; N, 20.56.  
 
N4-phenyl-2-(3-(trifluoromethyl)phenyl)quinazoline-4,6-diamine (242).  
 
Molecular weight: 380.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 240-
244 from 227 (4.10 g, 10 mmol) to yield 242 as a beige solid (2.40 g, 63%), mp 191-192 
°C. 1H NMR (500 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.67 (d, J = 1.7 Hz, 1H), 8.62 (dd, J 
= 7.8, 1.5 Hz, 1H), 7.96 – 7.90 (m, 2H), 7.80 – 7.74 (m, 1H), 7.75 – 7.68 (m, 1H), 7.66 
(d, J = 8.8 Hz, 1H), 7.45 – 7.37 (m, 3H), 7.28 (dd, J = 8.9, 2.3 Hz, 1H), 7.12 (tt, J = 7.4, 
1.2 Hz, 1H), 5.66 (s, 2H). 13C NMR (126 MHz, DMSO) δ 156.36, 153.02, 147.79, 143.11, 
140.02, 139.96, 130.84, 129.71, 129.35 (d, J = 31.5 Hz), 129.35, 128.42, 125.77 (d, J = 
3.5 Hz), 125.58, 124.05, 123.57 (d, J = 3.8 Hz), 123.25, 122.00, 115.90, 101.52. Anal. 
Calcd. for C21H15F3N4: C, 66.31; H, 3.98; N, 14.73. Found: C, 66.42; H, 4.07; N, 14.45. 
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3-((6-amino-2-(3-(trifluoromethyl)phenyl)quinazolin-4-yl)amino)phenol (243).  
 
Molecular weight: 396.37 g/mol 
 
The compound was synthesized according to the general procedure for compounds 240-
244 from 231 (4.26 g, 10 mmol) to yield 243 as a yellow solid (2.89 g, 73%), mp 190-
192 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.72 (s, 1H), 8.42 – 8.36 (m, 2H), 8.21 – 8.13 
(m, 2H), 8.04 – 7.99 (m, 2H), 7.65 (d, J = 8.9 Hz, 1H), 7.54 – 7.47 (m, 2H), 7.47 – 7.38 
(m, 2H), 7.30 (dd, J = 8.9, 2.4 Hz, 1H), 5.66 (s, 2H). 13C NMR (126 MHz, DMSO) δ 
165.65, 155.88, 154.46, 147.57, 144.96, 143.68, 138.77, 130.03, 129.50, 129.30, 128.53, 
127.34, 124.37, 123.37, 120.23, 115.87, 101.34. Anal. Calcd. for C21H15F3N4O: C, 
63.63; H, 3.81; N, 14.14. Found: C, 63.49; H, 4.14; N, 14.08. 
 
N4-(3-methoxyphenyl)-2-(3-(trifluoromethyl)phenyl)quinazoline-4,6-diamine (244).  
 
Molecular weight: 410.40 g/mol 
 
The compound was synthesized according to the general procedure for compounds 240-
244 from 232 (4.40 g, 10 mmol) to yield 244 as a beige solid (2.42 g, 59%), mp 203-205 
°C. 1H NMR (500 MHz, DMSO-d6) δ 9.46 (s, 1H), 8.71 – 8.61 (m, 2H), 7.81 – 7.75 (m, 
1H), 7.74 – 7.68 (m, 2H), 7.66 (d, J = 8.9 Hz, 1H), 7.50 (ddd, J = 8.1, 2.0, 0.9 Hz, 1H), 
7.41 (d, J = 2.4 Hz, 1H), 7.33 – 7.26 (m, 2H), 6.69 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 5.67 
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(s, 2H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.54, 156.27, 152.97, 147.80, 
143.08, 141.20, 140.04, 130.86, 129.65, 129.50, 129.35, 129.24, 129.10, 127.71, 125.80, 
125.55, 124.07, 123.50, 123.38, 115.95, 113.95, 108.99, 107.22, 101.46, 55.11. Anal. 
Calcd. for C22H17F3N4O: C, 64.39; H, 4.18; N, 13.65. Found: C, 64.32; H, 4.29; N, 13.40. 
 
General Procedure for the Preparation of compounds 245-248.  
The corresponding 6-amino-derivative 240 or 241 (10 mmol) was dissolved in a solution 
of 20 mL TAM in 80 mL THF under nitrogen in a Schlenk flask. The temperature was 
adjusted with a cooling bath to 0 °C and a solution of two (20 mmol, for 245) or one 
equivalent (10 mmol, for 246-248) of the corresponding acid chloride in THF added drop 
wise, respectively. After 30 min the cooling bath was removed and the solution was 
stirred for further 6-12 h. Completion of the reaction was monitored by TLC and the 
excess THF removed under reduced pressure. Water was added to the mixture until 
precipitation of the product was visible. The formed precipitate was then filtered with 
suction and washed thoroughly with water. Recrystallization of the product was carried 
out with MeOH/H2O to yield compounds 245-248.   
 
(E)-acetic (E)-N-(4-((3-methoxyphenyl)amino)-2-(pyridin-3-yl)quinazolin-6-
yl)acetimidic anhydride (245).  
 
Molecular weight: 427.46 g/mol 
 
The compound was synthesized according to the general procedure for compounds 245-
248 from 240 (4.28 g, 10 mmol) and acetyl chloride (0.78 g, 20 mmol) to yield 245 as a 
beige-white solid (3.16 g, 74%), mp 242-244 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.50 
(s, 1H), 9.56 (s, 1H), 8.77 – 8.67 (m, 2H), 8.60 (d, J = 2.3 Hz, 1H), 8.17 – 8.08 (m, 2H), 
7.58 (dd, J = 7.7, 5.0 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.04 – 6.96 (m, 2H), 3.74 (s, 3H), 
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2.15 (s, 3H), 2.10 (s, 3H). 13C NMR (126 MHz, DMSO) δ 170.67, 169.36, 162.31, 
158.82, 156.77, 151.46, 149.33, 149.09, 139.44, 135.17, 133.36, 132.55, 129.45, 128.62, 
124.03, 120.74, 114.87, 111.37, 55.49, 24.32, 22.98. Anal. Calcd. for C24H21N5O3: C, 
67.44; H, 4.95; N; 16.38. Found: C, 67.72; H, 5.20; N; 16.07. 
 
N-(4-((3-methoxyphenyl)amino)-2-(pyridin-3-yl)quinazolin-6-yl)-3-nitrobenzamide 
(246).  
 
Molecular weight: 492.50 g/mol 
 
The compound was synthesized according to the general procedure for compounds 245-
248 from 240 (4.28 g, 10 mmol) and 3-nitrobenzoyl chloride (1.86 g, 10 mmol) to yield 
246 as a beige-white solid (3.99 g, 81%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) 
δ 10.97 (s, 1H), 9.97 (s, 1H), 9.55 (d, J = 1.9 Hz, 1H), 8.98 – 8.84 (m, 2H), 8.68 (td, J = 
6.9, 5.8, 1.9 Hz, 2H), 8.56 – 8.42 (m, 2H), 8.10 (dd, J = 8.9, 2.2 Hz, 1H), 7.94 (d, J = 8.8 
Hz, 1H), 7.89 (t, J = 8.0 Hz, 1H), 7.67 (t, J = 2.3 Hz, 1H), 7.59 – 7.50 (m, 2H), 7.36 (t, J 
= 8.1 Hz, 1H), 6.75 (dd, J = 8.3, 2.5 Hz, 1H), 3.82 (s, 3H). 13C NMR (126 MHz, DMSO) 
δ 163.56, 159.52, 157.89, 156.81, 150.94, 149.21, 148.00, 147.77, 140.64, 136.43, 
135.92, 135.00, 134.30, 133.77, 130.53, 129.31, 128.78, 128.76, 126.57, 123.71, 122.51, 
114.55, 114.51, 109.63, 107.84, 55.22. Anal. Calcd. for C27H20N6O4: C, 65.85; H, 4.09; 
N; 17.06. Found: C, 65.73; H, 4.37 N; 17.03. 
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N-(4-((4-methoxyphenyl)amino)-2-(pyridin-3-yl)quinazolin-6-yl)-3-nitrobenzamide 
(247).  
 
Molecular weight: 492.50 g/mol 
 
The compound was synthesized according to the general procedure for compounds 245-
248 from 241 (4.28 g, 10 mmol) and 3-nitrobenzoyl chloride (1.86 g, 10 mmol) to yield 
247 as a yellow solid (3.35 g, 68%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 
11.03 (s, 1H), 9.96 (s, 1H), 9.50 (d, J = 2.1 Hz, 1H), 8.93 (s, 1H), 8.90 (s, 1H), 8.67 – 
8.62 (m, 2H), 8.51 (s, 1H), 8.48 (d, J = 8.2 Hz, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.90 (d, J = 
8.7 Hz, 2H), 7.81 (d, J = 8.4 Hz, 2H), 7.55 – 7.48 (m, 1H), 7.04 (d, J = 8.5 Hz, 2H), 3.80 
(s, 3H). 13C NMR (126 MHz, DMSO) δ 163.51, 158.01, 156.92, 155.93, 150.81, 149.22, 
148.00, 147.62, 136.30, 135.96, 135.01, 134.31, 133.85, 132.24, 130.49, 128.63, 128.50, 
126.53, 124.30, 123.66, 122.55, 114.57, 114.37, 113.79, 55.38. Anal. Calcd. for 
C27H20N6O4: C, 65.85; H, 4.09; N, 17.06. Found: C, 65.61; H, 4.44; N, 16.77. 
 
N-(4-((3-methoxyphenyl)amino)-2-(pyridin-3-yl)quinazolin-6-yl)-3-nitrobenzamide 
(248).  
 
Molecular weight: 448.49 g/mol 
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The compound was synthesized according to the general procedure for compounds 245-
248 from 240 (4.28 g, 10 mmol) and nicotinoyl chloride (1.42 g, 10 mmol) to yield 248 
as a yellow solid (2.56 g, 57%), mp 204-206 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.96 
(s, 1H), 9.55 (d, J = 2.0 Hz, 1H), 9.21 (d, J = 2.3 Hz, 1H), 8.94 (d, J = 2.2 Hz, 1H), 8.80 
(dd, J = 4.8, 1.5 Hz, 1H), 8.75 – 8.65 (m, 2H), 8.39 (dt, J = 7.8, 2.1 Hz, 1H), 8.05 (dd, J 
= 8.9, 2.2 Hz, 1H), 7.93 (d, J = 8.9 Hz, 1H), 7.67 (t, J = 2.3 Hz, 1H), 7.62 (ddd, J = 7.9, 
4.8, 0.9 Hz, 1H), 7.58 – 7.51 (m, 2H), 7.36 (t, J = 8.1 Hz, 1H), 6.80 – 6.70 (m, 1H), 3.82 
(d, J = 0.8 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 164.29, 159.54, 157.90, 156.75, 
152.53, 150.94, 149.22, 148.86, 147.70, 140.69, 136.59, 135.59, 135.00, 133.80, 130.26, 
129.31, 128.79, 128.64, 123.78, 123.73, 114.58, 114.55, 114.25, 109.63, 107.86, 55.24. 
Anal. Calcd. for C26H20N6O2: C, 69.63; H, 4.50; N, 18.74. Found: C, 69.91; H, 4.77; N, 
18.36. 
 
10.1.1.6 Synthesis of differently modified 2,4-substituted 
quinazolines 
 
General Procedure for the Preparation Compounds 249-250. A mixture of 
anthranilamide (2.72 g, 20 mmol), the corresponding five-membered heterocycle bearing 
a 2-carbaldehyd residue (20 mmol), iodine (3.17 g, 25 mmol), anhydrous potassium 
carbonate (2.76 g, 20 mmol) and 20 ml DMF was stirred at 70-90 °C for 4-8 h. The end 
of the reaction was monitored by TLC and the mixture poured on crushed ice to form a 
precipitate. Incomplete precipitation can be prevented by adjusting the pH with 
concentrated HCl solution to about 7. After filtration of the precipitate, it was thoroughly 
washed with 100 mL of a 20% sodium thiosulfate solution followed by 100 mL of hot 
distilled water. Purification was performed by recrystallization from ethanol.    
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2-(thiophen-2-yl)quinazolin-4(3H)-one (249). 
 
Molecular weight: 228.27 g/mol 
 
The compound was synthesized from anthranilamide (136 mg, 1 mmol) and thiophene-
2-carbaldehyde (112 mg, 1 mmol) as described in the general procedure for compounds 
249-250 to yield 249 as a white solid (199 mg, 87%). 1H NMR (500 MHz, DMSO-d6) δ 
12.61 (s, 1H), 8.22 (dd, J = 3.8, 1.1 Hz, 1H), 8.11 (ddd, J = 7.9, 1.6, 0.6 Hz, 1H), 7.85 
(dd, J = 5.0, 1.1 Hz, 1H), 7.79 (ddd, J = 8.2, 7.1, 1.6 Hz, 1H), 7.68 – 7.60 (m, 1H), 7.48 
(ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.23 (dd, J = 5.0, 3.8 Hz, 1H). 13C NMR (126 MHz, 
DMSO) δ 161.93, 148.01, 142.56, 137.52, 134.79, 132.26, 129.51, 128.61, 127.04, 
126.44, 126.11, 121.01.  
 
2-(1H-pyrrol-2-yl)quinazolin-4(3H)-one (250). 
 
Molecular weight: 211.22 g/mol 
 
The compound was synthesized from anthranilamide (136 mg, 1 mmol) and 1H-pyrrole-
2-carbaldehyde (95.1 mg, 1 mmol) as described in the general procedure for compounds 
249-250 to yield 250 as a white solid (118 mg, 56%). 1H NMR (500 MHz, DMSO-d6) δ 
12.17 (s, 1H), 11.70 (s, 1H), 8.08 (dd, J = 7.9, 1.5 Hz, 1H), 7.75 (ddd, J = 8.5, 7.1, 1.6 
Hz, 1H), 7.60 (dt, J = 8.2, 0.8 Hz, 1H), 7.39 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 7.30 (ddd, J 
= 3.9, 2.5, 1.5 Hz, 1H), 7.03 (td, J = 2.7, 1.4 Hz, 1H), 6.20 (dt, J = 3.8, 2.4 Hz, 1H). 13C 
NMR (126 MHz, DMSO) δ 161.98, 149.40, 146.50, 134.57, 126.54, 126.06, 125.30, 
124.39, 123.95, 120.60, 112.59, 109.84.  
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General Procedure for the Preparation of compounds derivatives 251-252. 
The corresponding 2-substituted quinazolinon derivative 249-250 (10 mmol) was added 
to phosphorous trichloride (30 mL, 0.32 mol) and stirred for 10 min at room temperature. 
The mixture was then refluxed for 4-8 h and the reaction monitored by TLC. After 
completion of the reaction, excess POCl3 was removed under reduced pressure and 50 
mL ice water added. Subsequently, 50 mL DCM was added while stirring and the pH of 
the mixture slowly adjusted to 7 with 25% ammonium solution. With a separatory funnel, 
the organic phase was collected, washed with 50 mL brine and dried under MgSO4. The 
solvent was removed under reduced pressure and the obtained solid recrystallized from 
isopropanol. 
 
4-chloro-2-(thiophen-2-yl)quinazoline (251). 
 
Molecular weight: 246.71 g/mol 
 
The compound was synthesized from 249 (228 mg, 1 mmol) as described in the general 
procedure for compounds 251-252 to yield 251 as a white solid (175 mg, 71%). 1H NMR 
(500 MHz, DMSO-d6) δ 8.23 (dd, J = 3.8, 1.1 Hz, 1H), 8.11 (dd, J = 7.9, 1.4 Hz, 1H), 
7.86 (dd, J = 5.0, 1.1 Hz, 1H), 7.79 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.65 (dt, J = 8.0, 0.7 
Hz, 1H), 7.48 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.22 (dd, J = 5.1, 3.8 Hz, 1H). 13C NMR 
(126 MHz, DMSO) δ 161.93, 148.55, 148.07, 137.35, 134.82, 132.36, 129.66, 128.62, 
126.89, 126.47, 126.12, 120.98. 
 
4-chloro-2-(1H-pyrrol-2-yl)quinazoline (252). 
 
Molecular weight: 229.67 g/mol 
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The compound was synthesized from 250 (211 mg, 1 mmol) as described in the general 
procedure for compounds 251-252 to yield 252 as a white solid (106 mg, 46%). 1H NMR 
(500 MHz, DMSO-d6) δ 9.58 (dd, J = 2.2, 0.9 Hz, 1H), 8.79 – 8.71 (m, 2H), 8.33 – 8.27 
(m, 1H), 8.18 – 8.12 (m, 2H), 7.88 (ddd, J = 8.2, 5.8, 2.3 Hz, 1H), 7.65 – 7.57 (m, 1H). 
13C NMR (126 MHz, DMSO) δ 162.34, 157.51, 151.18, 149.38, 136.29, 135.65, 131.77, 
129.90, 128.72, 125.85, 124.11, 122.19. 
 
General Procedure for the Preparation of compounds 253-261. 
The corresponding 4-chloroquinazoline derivative 251-252 (1 mmol) was added to 
isopropanol (5 mL) with the corresponding substituted aniline derivative (1 mmol) and 
sealed in a microwave tube. The mixture was heated by 100 watt microwave irradiation 
to 110 °C for a period of 15 – 30 min to completion of the reaction, indicated by TLC. 
The formed precipitate was filtered, washed with 10 mL isopropanol and dried in vacuo. 
If no precipitate is formed, the solvent was removed under reduced pressure and the 
remaining solid recrystallized from ethanol. 
 
N-(3-nitrophenyl)-2-(thiophen-2-yl)quinazolin-4-amine (253). 
 
Molecular weight: 348.38 g/mol 
 
The compound was synthesized from 251 (246 mg, 1 mmol) and 3-nitroaniline (138 mg, 
1 mmol) as described in the general procedure for compounds 253-261 to yield 253 as a 
white-yellowish solid (275 mg, 79%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 
11.02 (s, 1H), 9.10 (s, 1H), 8.74 (d, J = 8.1 Hz, 1H), 8.40 (s, 1H), 8.34 (ddd, J = 8.1, 2.1, 
0.9 Hz, 1H), 8.13 – 8.04 (m, 2H), 8.00 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.95 (d, J = 5.0 Hz, 
1H), 7.78 (t, J = 8.2 Hz, 1H), 7.73 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.32 (dd, J = 4.9, 3.8 
Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.38, 147.95, 135.23, 130.05, 129.20, 128.93, 
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127.15, 124.06, 119.33, 117.39, 113.39. Anal. Calcd. for C18H12N4O2S: C, 62.40; H, 
3.85; N, 15.69. Found: C, 62.06; H, 3.47; N, 16.08. 
 
N-(4-nitrophenyl)-2-(thiophen-2-yl)quinazolin-4-amine (254). 
 
Molecular weight: 348.38 g/mol 
 
The compound was synthesized from 251 (246 mg, 1 mmol) and 4-nitroaniline (138 mg, 
1 mmol) as described in the general procedure for compounds 253-261 to yield 254 as a 
light-yellow solid (244 mg, 70%), mp >300 °C. 1H NMR (500 MHz, DMSO-d6) δ 10.75 
(s, 1H), 8.69 (d, J = 7.9 Hz, 1H), 8.37 (d, J = 7.1 Hz, 2H), 8.31 (d, J = 7.7 Hz, 2H), 8.21 
(s, 1H), 7.97 (s, 2H), 7.86 (d, J = 4.0 Hz, 1H), 7.70 (s, 1H), 7.31 – 7.24 (m, 1H). 13C NMR 
(126 MHz, DMSO) δ 134.79, 128.99, 126.83, 124.65, 123.86, 122.00, 113.84. Anal. 
Calcd. for C18H12N4O2S: C, 62.06; H, 3.47; N, 16.08. Found: C, 62.01; H, 3.81; N, 15.71. 
 
3-((2-(thiophen-2-yl)quinazolin-4-yl)amino)benzonitrile (255). 
 
Molecular weight: 328.39 g/mol 
 
The compound was synthesized from 251 (246 mg, 1 mmol) and 3-aminobenzonitrile 
(118 mg, 1 mmol) as described in the general procedure for compounds 253-261 to yield 
255 as a light-yellow solid (210 mg, 64%), mp 296-297 °C (decomp.). 1H NMR (500 
MHz, DMSO-d6) δ 11.34 (s, 1H), 8.81 (d, J = 8.3 Hz, 1H), 8.58 (s, 1H), 8.46 (t, J = 1.8 
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Hz, 1H), 8.29 – 8.13 (m, 2H), 8.10 – 7.95 (m, 2H), 7.79 – 7.65 (m, 3H), 7.34 (dd, J = 5.0, 
3.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 165.60, 158.68, 153.34, 138.62, 135.72, 
130.15, 129.53, 128.95, 128.28, 127.49, 126.99, 124.42, 118.63, 113.07, 111.56. Anal. 
Calcd. for C19H12N4S: C, 69.49; H, 3.68; N, 17.06. Found: C, 69.30; H, 4.06; N, 16.99. 
 
N-(3,4-dimethoxyphenyl)-2-(thiophen-2-yl)quinazolin-4-amine (256). 
 
Molecular weight: 363.44 g/mol 
 
The compound was synthesized from 251 (246 mg, 1 mmol) and 3,4-dimethoxyanilin 
(153 mg, 1 mmol) as described in the general procedure for compounds 253-261 to yield 
256 as a yellow solid (244 mg, 67%), mp 250-251 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 10.97 (s, 1H), 8.70 (d, J = 8.3 Hz, 1H), 8.51 (s, 1H), 8.10 (s, 1H), 8.00 (t, J 
= 7.4 Hz, 2H), 7.73 (t, J = 7.7 Hz, 1H), 7.55 (d, J = 2.5 Hz, 1H), 7.38 (dd, J = 8.6, 2.4 Hz, 
1H), 7.34 (t, J = 4.5 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 158.18, 148.48, 129.42, 124.19, 112.97, 111.60, 108.68, 
55.88, 55.86. Anal. Calcd. for C20H17N3O2S: C, 66.10; H, 4.72; N, 11.56. Found: C, 
66.31; H, 4.99; N, 11.64. 
 
N-(3-fluorophenyl)-2-(thiophen-2-yl)quinazolin-4-amine (257). 
N
N
HN
S
F
 
Molecular weight: 321.37 g/mol 
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The compound was synthesized from 251 (246 mg, 1 mmol) and 3-fluoroaniline (111 mg, 
1 mmol) as described in the general procedure for compounds 253-261 to yield 257 as a 
light-yellow solid (247 mg, 77%), mp 292-293 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 11.29 (s, 1H), 8.84 (d, J = 8.2 Hz, 1H), 8.69 (s, 1H), 8.27 (d, J = 8.3 Hz, 
1H), 8.10 – 7.98 (m, 2H), 7.92 (dt, J = 11.5, 2.4 Hz, 1H), 7.81 – 7.66 (m, 2H), 7.54 (td, J 
= 8.2, 6.7 Hz, 1H), 7.35 (dd, J = 5.0, 3.8 Hz, 1H), 7.14 (td, J = 8.4, 2.6 Hz, 1H). 13C NMR 
(126 MHz, DMSO) δ 161.96 (d, J = 242.2 Hz), 158.65, 153.07, 139.25, 139.18, 135.79, 
130.27 (d, J = 9.3 Hz), 129.58, 127.55, 124.53, 119.62, 113.00, 112.40 (d, J = 22.4 Hz), 
110.92 (d, J = 27.8 Hz). Anal. Calcd. for C18H12FN3S: C, 67.27; H, 3.76; N, 13.08. 
Found: C, 67.22; H, 3.98; N, 12.76. 
 
N-(3-((2-(thiophen-2-yl)quinazolin-4-yl)amino)phenyl)acetamide (258). 
 
 
Molecular weight: 360.44 g/mol 
 
The compound was synthesized from 251 (246 mg, 1 mmol) and N-(3-
aminophenyl)acetamide (150 mg, 1 mmol) as described in the general procedure for 
compounds 253-261 to yield 258 as a light-yellow solid (288 mg, 80%), mp >300 °C. 1H 
NMR (500 MHz, DMSO-d6) δ 11.33 (s, 1H), 10.18 (s, 1H), 8.94 – 8.62 (m, 2H), 8.30 (d, 
J = 8.4 Hz, 1H), 8.11 (t, J = 1.9 Hz, 1H), 8.03 (dd, J = 8.9, 7.0 Hz, 2H), 7.74 (t, J = 7.5 
Hz, 1H), 7.59 (dt, J = 6.8, 2.1 Hz, 1H), 7.52 – 7.38 (m, 2H), 7.34 (dd, J = 5.0, 3.9 Hz, 
1H), 2.08 (s, 3H). 13C NMR (126 MHz, DMSO) δ 168.58, 158.75, 152.74, 139.80, 
137.30, 135.78, 133.14, 129.49, 128.66, 127.56, 124.55, 119.28, 116.93, 115.00, 112.79, 
24.15. Anal. Calcd. for C20H16N4OS: C, 66.65; H, 4.47; N, 15.54. Found: C, 66.72; H, 
4.65; N, 15.30. 
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3-((2-(1H-pyrrol-2-yl)quinazolin-4-yl)amino)benzonitrile (259). 
 
Molecular weight: 311.35 g/mol 
 
The compound was synthesized from 252 (230 mg, 1 mmol) and 3-aminobenzonitrile 
(118 mg, 1 mmol) as described in the general procedure for compounds 253-261 to yield 
259 as a light-yellow solid (177 mg, 57%), mp 172-173 °C. 1H NMR (500 MHz, DMSO-
d6) δ 10.80 (s, 1H), 9.49 (d, J = 2.0 Hz, 1H), 9.04 (dt, J = 8.1, 1.8 Hz, 1H), 8.92 (dd, J = 
5.3, 1.6 Hz, 1H), 8.78 (dd, J = 8.5, 1.3 Hz, 1H), 8.37 (q, J = 1.3, 0.9 Hz, 1H), 8.30 (dt, J 
= 7.4, 2.1 Hz, 1H), 8.03 (dd, J = 8.5, 1.4 Hz, 1H), 7.99 – 7.91 (m, 2H), 7.78 – 7.63 (m, 
3H). 13C NMR (126 MHz, DMSO) δ 158.50, 155.42, 144.76, 140.44, 139.57, 134.58, 
130.12, 127.99, 127.75, 127.65, 126.97, 126.05, 125.92, 123.92, 118.77, 114.19, 111.56. 
Anal. Calcd. for C19H13N5: C, 73.30; H, 4.21; N, 22.49. Found: C, 73.02; H, 4.32; N, 
22.25. 
 
N-(4-methoxyphenyl)-2-(1H-pyrrol-2-yl)quinazolin-4-amine (260). 
 
Molecular weight: 316.36 g/mol 
 
The compound was synthesized from 252 (230 mg, 1 mmol) and 4-methoxyaniline (123 
mg, 1 mmol) as described in the general procedure for compounds 253-261 to yield 260 
as a light-beige solid (155 mg, 49%), mp 268-269 °C (decomp.). 1H NMR (500 MHz, 
DMSO-d6) δ 9.85 (s, 1H), 9.51 (dd, J = 2.1, 0.9 Hz, 1H), 8.73 – 8.59 (m, 2H), 8.54 (dt, J 
10 Experimental section  411
= 8.5, 1.1 Hz, 1H), 7.90 – 7.84 (m, 2H), 7.84 – 7.76 (m, 2H), 7.65 – 7.57 (m, 1H), 7.56 – 
7.47 (m, 1H), 7.10 – 6.98 (m, 2H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 158.21, 
157.69, 156.06, 150.29, 149.33, 135.15, 133.85, 133.34, 132.01, 128.18, 126.28, 124.40, 
123.65, 123.13, 114.24, 113.85, 55.40. Anal. Calcd. for C19H16N4O: C, 72.13; H, 5.10; 
N, 17.71. Found: C, 72.36; H, 4.94; N, 17.45. 
 
N-(3,4-dimethoxyphenyl)-2-(1H-pyrrol-2-yl)quinazolin-4-amine (261). 
 
Molecular weight: 346.39 g/mol 
 
The compound was synthesized from 252 (230 mg, 1 mmol) and 3,4-dimethoxyaniline 
(153 mg, 1 mmol) as described in the general procedure for compounds 253-261 to yield 
261 as a light-yellow solid (184 mg, 53%), mp 161-163 °C. 1H NMR (500 MHz, DMSO-
d6) δ 9.82 (s, 1H), 9.56 (s, 1H), 8.69 (dt, J = 8.0, 1.9 Hz, 2H), 8.56 (dt, J = 8.5, 1.1 Hz, 
1H), 7.89 – 7.84 (m, 2H), 7.66 (d, J = 2.5 Hz, 1H), 7.65 – 7.60 (m, 1H), 7.54 (dd, J = 7.8, 
4.8 Hz, 1H), 7.44 (dd, J = 8.7, 2.5 Hz, 1H), 7.06 (d, J = 8.7 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 
3H). 13C NMR (126 MHz, DMSO) δ 158.06, 157.68, 150.99, 150.28, 149.32, 148.49, 
145.64, 135.12, 133.38, 132.52, 128.22, 126.34, 123.10, 114.60, 114.28, 111.95, 107.80, 
55.92, 55.65. Anal. Calcd. for C20H18N4O2: C, 69.35; H, 5.24; N, 16.17. Found: C, 69.16; 
H, 5.24; N, 16.17. 
 
General Procedure for the Preparation of 2-phenylquinazolin-4-amine (262). 
 
Molecular weight: 221.26 g/mol 
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2-aminobenzonitrile (1.03 g, 10 mmol), benzonitrile (1.03 g, 10 mmol) and t-BuOK (112 
mg, 1 mmol) were transferred to a microwave tube and sealed. The mixture was heated 
at 150 watt microwave irradiation to 180 °C, held for 2 min at this temperature and then 
poured into ice water. The formed precipitate was filtered off under suction and the solid 
recrystallized from methanol to yield 262 as a slightly yellow solid (951 mg, 43%), mp 
149-151 °C. 1H NMR (500 MHz, DMSO-d6) δ 8.48 – 8.42 (m, 2H), 8.23 (dt, J = 8.2, 1.2 
Hz, 1H), 7.90 – 7.72 (m, 4H), 7.50 – 7.42 (m, 4H). 13C NMR (126 MHz, DMSO) δ 
162.20, 159.84, 150.50, 138.70, 133.04, 130.00, 128.23, 127.93, 127.77, 125.21, 123.69, 
113.38. Anal. Calcd. for C14H11N3: C, 76.00; H, 5.01; N, 18.99. Found: C, 76.35; H, 
5.10; N, 18.66. 
 
General Procedure for the Preparation of compound 263-266. 
Compound 262 (2.21 g, 10 mmol) was dissolved in a mixture of triethylamine (10.1 g, 
0.1 mol) and THF (50 mL) and chilled to 0 °C. A dilution of the corresponding substituted 
benzoyl chloride (10 mmol) in THF was slowly added while stirring with a dropping 
funnel under exclusion of moisture and the mixture then allowed to warm up to room 
temperature. After 12 h excess solvent was evaporated under reduced pressure and 50 mL 
water added. The formed precipitate was filtered under suction and the product purified 
by column chromatography with DCM/MeOH as eluent.  
 
N-(2-phenylquinazolin-4-yl)benzamide (263). 
 
Molecular weight: 325.37 g/mol 
 
The compound was synthesized from 262 (221 mg, 1 mmol) and benzoyl chloride (141 
mg, 1 mmol) as described in the general procedure for compounds 263-266 to yield 263 
as a light-yellow solid (153 mg, 47%), 157-159 °C. 1H NMR (500 MHz, DMSO-d6) δ 
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11.31 (s, 1H), 8.43 – 8.33 (m, 2H), 8.22 (d, J = 8.3 Hz, 1H), 8.06 – 7.96 (m, 4H), 7.70 – 
7.63 (m, 2H), 7.59 – 7.54 (m, 2H), 7.51 (d, J = 5.7 Hz, 3H). 13C NMR (126 MHz, DMSO) 
δ 168.05, 159.20, 159.09, 151.88, 137.34, 134.60, 134.19, 132.39, 130.91, 128.68, 
128.62, 128.53, 128.25, 128.16, 127.15, 125.72, 117.41. Anal. Calcd. for C21H15N3O: 
C, 77.52; H, 4.65; N, 12.91. Found: C, 77.71; H, 4.94; N, 12.71. 
 
2-nitro-N-(2-phenylquinazolin-4-yl)benzamide (264). 
 
Molecular weight: 370.37 g/mol 
 
The compound was synthesized from 262 (221 mg, 1 mmol) and 2-nitrobenzoyl chloride 
(186 mg, 1 mmol) as described in the general procedure for compounds 263-266 to yield 
264 as a light-yellow solid (181 mg, 49%), mp 205-206 °C. 1H NMR (600 MHz, DMSO-
d6) δ 11.81 (s, 1H), 8.56 (dt, J = 8.4, 1.0 Hz, 1H), 8.28 (dd, J = 8.6, 1.2 Hz, 1H), 8.02 – 
7.94 (m, 2H), 7.88 (td, J = 7.5, 1.2 Hz, 1H), 7.85 – 7.74 (m, 4H), 7.70 (ddd, J = 8.3, 5.5, 
2.6 Hz, 1H), 7.48 – 7.41 (m, 1H), 7.36 (t, J = 7.6 Hz, 2H). 13C NMR (151 MHz, DMSO) 
δ 167.70, 158.87, 156.97, 151.78, 145.83, 137.41, 135.38, 135.05, 134.41, 131.16, 
130.82, 128.75, 128.71, 128.66, 128.17, 127.69, 124.95, 124.72, 115.22. Anal. Calcd. 
for C21H14N4O3: C, 68.10; H, 3.81; N, 15.13. Found: C, 68.39; H, 3.90; N, 14.86. 
 
3-nitro-N-(2-phenylquinazolin-4-yl)benzamide (265). 
 
Molecular weight: 370.37 g/mol 
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The compound was synthesized from 262 (221 mg, 1 mmol) and 3-nitrobenzoyl chloride 
(186 mg, 1 mmol) as described in the general procedure for compounds 263-266 to yield 
265 as a light-yellow solid (303 mg, 82%), mp 230-233 °C. 1H NMR (500 MHz, DMSO-
d6) δ 11.68 (s, 1H), 8.86 (s, 1H), 8.49 (ddd, J = 8.2, 2.4, 1.0 Hz, 2H), 8.38 (s, 2H), 8.27 
(s, 1H), 8.03 (dt, J = 14.9, 8.2 Hz, 2H), 7.86 (t, J = 8.0 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 
7.53 (s, 3H). 13C NMR (126 MHz, DMSO) δ 166.04, 159.15, 158.66, 151.98, 147.95, 
137.22, 135.76, 134.87, 134.81, 131.02, 130.45, 128.74, 128.32, 128.13, 127.30, 126.80, 
125.76, 123.31, 117.34. Anal. Calcd. for C21H14N4O3: C, 68.10; H, 3.81; N, 15.13. 
Found: C, 68.05; H, 4.18; N, 14.97. 
 
4-nitro-N-(2-phenylquinazolin-4-yl)benzamide (266). 
 
Molecular weight: 370.37 g/mol 
 
The compound was synthesized from 262 (221 mg, 1 mmol) and 4-nitrobenzoyl chloride 
(186 mg, 1 mmol) as described in the general procedure for compounds 263-266 to yield 
266 as a light-yellow solid (285 mg, 77%), mp 233-235 °C. 1H NMR (500 MHz, DMSO-
d6) δ 11.68 (s, 1H), 8.43 – 8.29 (m, 3H), 8.28 – 8.15 (m, 4H), 8.09 – 7.95 (m, 2H), 7.75 – 
7.65 (m, 1H), 7.48 (d, J = 10.6 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.13, 158.97, 
158.38, 151.88, 149.45, 140.44, 137.16, 134.80, 131.00, 129.87, 128.63, 128.31, 128.04, 
127.32, 125.45, 123.75, 116.87. Anal. Calcd. for C21H14N4O3: C, 68.10; H, 3.81; N, 
15.13. Found: C, 68.27; H, 3.90; N, 14.80. 
 
General Procedure for the Preparation of compounds 267-274. 
4-chloroquinazoline (164 mg, 1 mmol) was added to isopropanol (5 mL) with the 
corresponding substituted aniline derivative (1 mmol) and sealed in a microwave tube. 
The mixture was heated by 100 watt microwave irradiation to 110 °C for a period of 15 
– 30 min to completion of the reaction, indicated by TLC. The formed precipitate was 
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filtered, washed with 10 mL isopropanol and dried in vacuo. If no precipitate is formed, 
the solvent was removed under reduced pressure and the remaining solid recrystallized 
from ethanol. 
 
N-phenylquinazolin-4-amine (267). 
 
Molecular weight: 221.26 g/mol 
 
The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and aniline 
(93.1 mg, 1 mmol) as described in the general procedure for compounds 267-274 to yield 
267 as a white solid (184 mg, 83%), mp 226-227 °C. 1H NMR (500 MHz, DMSO-d6) δ 
9.76 (s, 1H), 8.61 – 8.49 (m, 2H), 7.94 – 7.81 (m, 3H), 7.78 (dd, J = 8.3, 1.3 Hz, 1H), 
7.63 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.44 – 7.33 (m, 2H), 7.13 (tt, J = 7.4, 1.2 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ 157.91, 154.61, 149.82, 139.28, 133.09, 128.56, 127.92, 
126.33, 123.86, 123.10, 122.60, 115.30. Anal. Calcd. for C14H11N3: C, 76.00; H, 5.01; 
N, 18.99. Found: C, 76.15; H, 5.05; N, 18.65. 
 
2-nitro-4-(quinazolin-4-ylamino)phenol (268). 
 
 
Molecular weight: 282.26 g/mol 
 
The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and 4-
amino-2-nitrophenol (109 mg, 1 mmol) as described in the general procedure for 
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compounds 267-274 to yield 268 as a yellow solid (208 mg, 74%), mp 288-289 °C 
(decomp.). 1H NMR (500 MHz, DMSO-d6) δ 11.97 (s, 1H), 11.39 (s, 1H), 9.04 – 8.96 
(m, 1H), 8.95 (s, 1H), 8.33 (d, J = 2.7 Hz, 1H), 8.09 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H), 8.00 
(dd, J = 8.5, 1.2 Hz, 1H), 7.93 (dd, J = 9.0, 2.7 Hz, 1H), 7.84 (ddd, J = 8.3, 7.1, 1.2 Hz, 
1H), 7.32 (d, J = 8.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 159.99, 151.05, 150.85, 
138.50, 136.42, 136.18, 131.97, 128.80, 128.00, 125.14, 121.40, 119.67, 119.33, 113.58. 
Anal. Calcd. for C14H10N4O3: C, 59.57; H, 3.57; N, 19.85. Found: C, 59.43; H, 3.80; N, 
19.68. 
 
4-(quinazolin-4-ylamino)phenol (269). 
 
 
Molecular weight: 237.26 g/mol 
 
The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and 4-
aminophenol (109 mg, 1 mmol) as described in the general procedure for compounds 
267-274 to yield 269 as a bright yellow solid (157 mg, 66%), mp >300 °C. 1H NMR (500 
MHz, DMSO-d6) δ 11.61 (s, 1H), 9.75 (s, 1H), 8.99 – 8.72 (m, 2H), 8.07 (t, J = 7.8 Hz, 
1H), 7.96 (d, J = 8.3 Hz, 1H), 7.82 (t, J = 7.7 Hz, 1H), 7.59 – 7.38 (m, 2H), 6.96 – 6.77 
(m, 2H). 13C NMR (126 MHz, DMSO) δ 159.57, 156.45, 150.92, 138.31, 136.14, 128.61, 
127.76, 126.45, 124.88, 119.55, 115.38, 113.46. Anal. Calcd. for C14H11N3O: C, 70.87; 
H, 4.67; N, 17.71. Found: C, 71.24; H, 5.00; N, 17.37. 
 
4-(quinazolin-4-ylamino)benzonitrile (270). 
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Molecular weight: 246.27 g/mol 
 
The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and 4-
aminobenzonitrile (118 mg, 1 mmol) as described in the general procedure for 
compounds 267-274 to yield 270 as a light yellow solid (185 mg, 75%), mp >300 °C. 1H 
NMR (500 MHz, DMSO-d6) δ 12.04 (s, 1H), 9.34 – 8.80 (m, 2H), 8.09 (td, J = 17.4, 15.8, 
7.9 Hz, 4H), 8.02 – 7.68 (m, 3H). 13C NMR (126 MHz, DMSO) δ 160.08, 151.17, 141.46, 
139.49, 136.54, 132.98, 128.86, 125.33, 124.91, 120.27, 118.80, 114.02, 108.29. Anal. 
Calcd. for C15H10N4: C, 73.16; H, 4.09; N, 22.75. Found: C, 73.00; H, 4.32; N, 22.50. 
 
N-(3-methoxyphenyl)quinazolin-4-amine (271). 
 
Molecular weight: 251.29 g/mol 
 
The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and 3-
methoxyaniline (123 mg, 1 mmol) as described in the general procedure for compounds 
267-274 to yield 271 as a yellow solid (204 mg, 81%), mp 235-237 °C. 1H NMR (500 
MHz, DMSO-d6) δ 11.86 (s, 1H), 9.07 (dd, J = 8.5, 1.2 Hz, 1H), 8.92 (s, 1H), 8.09 (ddd, 
J = 8.3, 7.0, 1.2 Hz, 1H), 8.06 – 7.98 (m, 1H), 7.84 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.45 
– 7.32 (m, 3H), 6.94 – 6.84 (m, 1H), 3.78 (s, 3H). 13C NMR (126 MHz, DMSO) δ 160.00, 
159.49, 150.89, 138.60, 137.85, 136.30, 129.58, 128.67, 125.25, 119.64, 117.19, 113.60, 
112.20, 111.09, 55.44. Anal. Calcd. for C15H13N3O: C, 71.70; H, 5.21; N, 16.72. Found: 
C, 72.01; H, 5.56; N, 16.44. 
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N-(3-(methylthio)phenyl)quinazolin-4-amine (272). 
 
Molecular weight: 267.35 g/mol 
 
The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and 3-
(methylthio)aniline (139 mg, 1 mmol) as described in the general procedure for 
compounds 267-274 to yield 272 as a bright yellow solid (230 mg, 89%), mp 233-234 
°C. 1H NMR (500 MHz, DMSO-d6) δ 11.82 (s, 1H), 9.08 – 9.00 (m, 1H), 8.92 (s, 1H), 
8.09 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 8.05 – 7.97 (m, 1H), 7.84 (ddd, J = 8.4, 7.1, 1.3 Hz, 
1H), 7.69 (t, J = 1.9 Hz, 1H), 7.55 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 
7.20 (ddd, J = 7.9, 1.9, 1.0 Hz, 1H), 2.50 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.95, 
151.07, 139.05, 138.87, 137.46, 136.20, 129.22, 128.59, 125.13, 123.97, 122.03, 121.30, 
119.97, 113.67, 14.84. Anal. Calcd. for C15H13N3S: C, 67.39; H, 4.90; N, 15.72. Found: 
C, 67.36; H, 5.10; N, 15.35. 
 
N-(3-fluorophenyl)quinazolin-4-amine (273). 
 
Molecular weight: 239.25 g/mol 
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The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and 3-
fluoroaniline (111 mg, 1 mmol) as described in the general procedure for compounds 267-
274 to yield 273 as a light yellow solid (199 mg, 83%), mp 266-267 °C (decomp.). 1H 
NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 9.08 (dt, J = 8.4, 0.9 Hz, 1H), 8.98 (s, 1H), 
8.11 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 8.04 (dd, J = 8.4, 1.3 Hz, 1H), 7.86 (ddd, J = 8.3, 7.1, 
1.2 Hz, 1H), 7.76 (ddd, J = 10.9, 2.5, 1.9 Hz, 1H), 7.65 (ddd, J = 8.1, 2.0, 0.9 Hz, 1H), 
7.52 (td, J = 8.2, 6.6 Hz, 1H), 7.16 (tdd, J = 8.6, 2.6, 0.9 Hz, 1H). 13C NMR (126 MHz, 
DMSO) δ 161.87 (d, J = 242.7 Hz), 160.08, 151.09, 138.94, 138.57 (d, J = 10.8 Hz), 
136.44, 130.41 (d, J = 9.2 Hz), 128.79, 125.26, 120.77, 119.93, 113.73, 113.34 (d, J = 
21.0 Hz), 111.99 (d, J = 25.3 Hz). Anal. Calcd. for C14H10FN3: C, 70.28; H, 4.21; N, 
17.56. Found: C, 70.39; H, 4.59; N, 17.31. 
 
N-(3-(quinazolin-4-ylamino)phenyl)acetamide (274). 
 
Molecular weight: 278.32 g/mol 
 
The compound was synthesized from 4-chloroquinazoline (165 mg, 1 mmol) and N-(3-
aminophenyl)acetamide (150 mg, 1 mmol) as described in the general procedure for 
compounds 267-274 to yield 274 as a yellow solid (256 mg, 92%), mp >300 °C. 1H NMR 
(500 MHz, DMSO-d6) δ 11.94 – 11.75 (m, 1H), 10.30 (s, 1H), 8.98 (dd, J = 8.5, 1.3 Hz, 
1H), 8.90 (s, 1H), 8.09 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H), 8.05 – 7.98 (m, 2H), 7.84 (ddd, J 
= 8.4, 7.0, 1.2 Hz, 1H), 7.50 (pd, J = 4.3, 2.0 Hz, 1H), 7.42 – 7.30 (m, 2H), 2.07 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 168.67, 160.14, 150.87, 139.97, 138.49, 136.80, 136.34, 
128.91, 128.73, 125.14, 120.02, 119.57, 117.62, 115.83, 113.52, 24.14. Anal. Calcd. for 
C16H14N4O: C, 69.05; H, 5.07 N, 20.13. Found: C, 69.21; H, 5.37; N, 19.87. 
 
General procedure for the preparation of the dimers 275-276 based on a 2-(4-
nitrophenyl)quinazoline scaffold. 
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Precursor 99 (2 mmol) was dissolved in isopropanol and a triethylamine (2 mmol) added 
to the mixture. Following ethane-1,2-diamine (1 mmol, for 275) or propane-1,3-diamine 
(1 mmol, for 276) in 100 mL isopropanol were slowly added under stirring via dropping 
funnel over 2 h to the refluxing mixture, which was kept under moisture exclusion. After 
4-6 h refluxing the mixture was allowed to cool yielding crystals of the corresponding 
product. If necessary, purification is carried out by re-crystallization from ethanol.  
N1,N2-bis(2-(4-nitrophenyl)quinazolin-4-yl)ethane-1,2-diamine (275).  
 
 
Molecular weight: 558.56 g/mol 
 
The compound was synthesized from 99 (571.38 mg, 2 mmol) and ethane-1,2-diamine 
(120.20 mg, 2 mmol) as described in the general procedure for compounds 275-276 to 
yield 275 as a yellow solid (430 mg, 77%), mp >300 °C. 1H NMR (500 MHz, DMSO-
d6) δ 8.62 – 8.55 (m, 4H), 8.47 (s, 2H), 8.19 – 8.12 (m, 6H), 7.77 – 7.72 (m, 4H), 7.44 
(ddd, J = 8.2, 5.9, 2.2 Hz, 2H), 4.19 – 4.13 (m, 4H). 13C NMR (126 MHz, DMSO) δ 
160.17, 157.26, 149.55, 148.21, 144.59, 132.55, 128.57, 127.77, 125.69, 122.90, 122.52, 
114.00, 40.02. Anal. Calcd. for C30H22N8O4: C, 64.51; H, 3.97 N, 20.06. Found: C, 
64.81; H, 4.18; N, 20.02. 
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N1,N3-bis(2-(4-nitrophenyl)quinazolin-4-yl)propane-1,3-diamine (276). 
 
Molecular weight: 572.59 g/mol 
 
The compound was synthesized from 99 (571.38 mg, 2 mmol) and propane-1,3-diamine 
(148.26 mg, 2 mmol) as described in the general procedure for compounds 275-276 to 
yield 275 as a yellow solid (395 mg, 69%), mp >300 °C. 1H NMR (500 MHz, DMSO-
d6) δ 8.49 (t, J = 5.6 Hz, 2H), 8.47 – 8.40 (m, 4H), 8.26 (dd, J = 8.4, 1.3 Hz, 2H), 8.08 – 
8.01 (m, 4H), 7.73 (ddd, J = 8.2, 6.8, 1.3 Hz, 2H), 7.68 (dd, J = 8.3, 1.4 Hz, 2H), 7.50 
(ddd, J = 8.3, 6.8, 1.4 Hz, 2H), 3.90 (q, J = 6.5 Hz, 4H), 2.23 (p, J = 6.7 Hz, 2H). 13C 
NMR (126 MHz, DMSO) δ 159.95, 157.24, 149.66, 148.25, 144.66, 132.85, 128.64, 
128.09, 126.10, 123.22, 122.77, 114.09, 38.41, 28.66. Anal. Calcd. for C31H24N8O4: C, 
65.03; H, 4.23 N, 19.57. Found: C, 65.22; H, 4.21; N, 19.28. 
 
General procedure for the preparation of 4-N-methylanilino-2-phenylquinazoline 
derivatives 277-280. Preparation of the precursors was carried out according to the 
general method described below. Compounds were not further characterized as they are 
already described in literature. 197, 198 Second step was carried out with some modifications 
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according to literature.218 Therefore, 4-chloro-2-phenylquinazoline (1 mmol) and the 
corresponding substituted aniline (1 mmol) were added to a 50 mL microwave tube and 
suspended in 25 mL isopropanol. The tube was sealed and the reaction mixture stirred 
under 100 watt microwave irradiation at 110 °C for 30 min. Completion of the reaction 
was monitored by TLC. After cooling, a precipitate was formed and filtered off by 
suction. If no precipitate was formed, the solvent was removed by rotary evaporation and 
the obtained solids recrystallized from 75% EtOH.   
The corresponding synthesized 4-Substituted-2-phenylquinazoline derivative 30, 31, 35 
or 40 (1 mmol) was subsequently dissolved in the necessary amount of dried DMF using 
a round bottom flask equipped with a drying tube and an ultrasonic bath at 50 °C. The 
solution was then cooled with an ice bath to 0 °C and sodium hydride (1.5 mmol) followed 
by methyl iodide (1.5 mmol) were added under stirring. After 1h the mixture was allowed 
to warm up to room temperature and stirred for another 2-6 h. After completion of the 
reaction, excess DMF was evaporated and ice-water added to induce precipitation. Solids 
were collected by suction and either re-crystallized from ethanol or purified by column 
chromatography using DCM as eluent.  
 
N-methyl-N-(3-nitrophenyl)-2-phenylquinazolin-4-amine (277). 
 
Molecular weight: 356.39 g/mol 
 
The compound was synthesized from 30 (342.36 mg, 1 mmol), sodium hydride (36.0 mg, 
1.5 mmol) and methyl iodide (212.91 mg, 1.5 mmol) as described in the general procedure 
for compounds 277-280 to yield 277 as a yellow solid (281 mg, 79%), mp 132-133 °C. 
1H NMR (600 MHz, Chloroform-d) δ 8.71 – 8.55 (m, 2H), 8.16 – 7.99 (m, 3H), 7.65 (dt, 
J = 8.3, 4.1 Hz, 1H), 7.56 – 7.49 (m, 3H), 7.46 (t, J = 8.1 Hz, 1H), 7.37 (dd, J = 8.0, 2.2 
Hz, 1H), 7.11 (d, J = 4.1 Hz, 2H), 3.83 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 162.15, 
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159.62, 152.27, 149.62, 149.26, 137.54, 132.81, 130.75, 130.41, 130.39, 128.91, 128.54, 
128.50, 125.55, 125.52, 120.04, 119.15, 115.26, 42.07. Anal. Calcd. for C21H16N4O2: C, 
70.77; H, 4.53 N, 15.72. Found: C, 70.63; H, 4.38; N, 15.90. 
 
 
N-methyl-N-(4-nitrophenyl)-2-phenylquinazolin-4-amine (278). 
 
Molecular weight: 356.39 g/mol 
 
The compound was synthesized from 31 (342.36 mg, 1 mmol), sodium hydride (36.0 mg, 
1.5 mmol) and methyl iodide (212.91 mg, 1.5 mmol) as described in the general procedure 
for compounds 277-280 to yield 278 as a yellow solid (299 mg, 84%), mp 173-174 °C. 
1H NMR (600 MHz, Chloroform-d) δ 8.70 – 8.55 (m, 2H), 8.17 (d, J = 8.6 Hz, 3H), 7.76 
– 7.68 (m, 1H), 7.52 (h, J = 3.8 Hz, 3H), 7.22 (p, J = 9.0, 8.1 Hz, 2H), 7.16 (d, J = 8.6 
Hz, 2H), 3.86 (d, J = 2.3 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 162.56, 159.87, 159.81, 
153.58, 152.02, 143.44, 137.25, 133.38, 131.02, 128.59, 126.13, 125.43, 122.23, 116.01, 
41.31. Anal. Calcd. for C21H16N4O2: C, 70.77; H, 4.53 N, 15.72. Found: C, 70.91; H, 
4.46; N, 15.87. 
 
4-(methyl(2-phenylquinazolin-4-yl)amino)benzonitrile (279). 
 
Molecular weight: 336.40 g/mol 
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The compound was synthesized from 35 (322.37 mg, 1 mmol), sodium hydride (36.0 mg, 
1.5 mmol) and methyl iodide (212.91 mg, 1.5 mmol) as described in the general procedure 
for compounds 277-280 to yield 279 as a yellow solid (313 mg, 93%), mp 201-203 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.61 – 8.46 (m, 2H), 7.95 (dd, J = 8.5, 1.3 Hz, 1H), 
7.82 – 7.72 (m, 3H), 7.55 (dtd, J = 10.6, 4.9, 4.4, 1.6 Hz, 3H), 7.41 – 7.33 (m, 2H), 7.30 
(ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.21 (dd, J = 8.4, 1.3 Hz, 1H), 3.76 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 162.37, 158.91, 152.35, 151.98, 137.77, 133.87, 133.29, 130.71, 
128.90, 128.63, 128.11, 126.02, 125.65, 123.90, 118.85, 115.84, 106.47, 41.00. Anal. 
Calcd. for C22H16N4: C, 78.55; H, 4.79 N, 16.66. Found: C, 78.69; H, 4.59; N, 16.76. 
 
N-(3-fluorophenyl)-N-methyl-2-phenylquinazolin-4-amine (280). 
 
Molecular weight: 329.38 g/mol 
 
The compound was synthesized from 40 (315.35 mg, 1 mmol), sodium hydride (36.0 mg, 
1.5 mmol) and methyl iodide (212.91 mg, 1.5 mmol) as described in the general procedure 
for compounds 277-280 to yield 279 as a yellow solid (260 mg, 79%), mp 109-111 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.61 – 8.46 (m, 2H), 7.95 (dd, J = 8.5, 1.3 Hz, 1H), 
7.82 – 7.72 (m, 3H), 7.55 (dtd, J = 10.6, 4.9, 4.4, 1.6 Hz, 3H), 7.41 – 7.33 (m, 2H), 7.30 
(ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.21 (dd, J = 8.4, 1.3 Hz, 1H), 3.76 (s, 3H). 13C NMR 
(500 MHz, DMSO-d6) δ 8.60 – 8.49 (m, 2H), 7.87 (dd, J = 8.5, 1.2 Hz, 1H), 7.70 (ddd, J 
= 8.4, 6.9, 1.4 Hz, 1H), 7.57 – 7.49 (m, 3H), 7.42 (td, J = 8.2, 6.7 Hz, 1H), 7.26 (dt, J = 
10.5, 2.3 Hz, 1H), 7.19 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.13 (tdd, J = 8.5, 2.5, 0.9 Hz, 1H), 
7.10 – 7.04 (m, 2H), 3.71 (s, 3H). 13C NMR (126 MHz, DMSO) δ 162.90 (d, J = 245.2 
Hz), 161.73, 158.63, 152.15, 149.85 (d, J = 10.0 Hz), 138.08, 132.71, 131.53 (d, J = 9.5 
Hz), 130.54, 128.71, 128.55, 128.09, 125.74, 125.25, 121.55, 115.19, 113.04 (d, J = 21.0 
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Hz), 112.68 (d, J = 23.0 Hz), 41.91. Anal. Calcd. for C21H16FN3: C, 76.58; H, 4.90 N, 
12.76. Found: C, 76.44; H, 4.78; N, 12.50. 
 
 
10.1.2 Materials and Methods 
 
Chemicals employed for the synthesis of all precursors and final compounds were 
purchased from Acros Organics (Geel, Belgium), Alfa Aesar (Karlsruhe, Germany), 
Sigma-Aldrich (Steinheim, Germany), Merck (Darmstadt, Germany) or TCI 
(Zwijndrecht, Belgium). 
 
Reaction progress was monitored by thin layer chromatography (TLC) using an 
aluminum plate coated with silica gel 60 F254 (Merck Millipore, Billerica, MA, USA). As 
eluent a mixture of dichloromethane and methanol (9:1) was used for most of the 
compounds. The fluorescent indicator in the silica gel shows a bright background in UV 
light which enables the detection of compounds as black spots upon absorption. For this 
purpose, a UV cabinet with an excitation wavelength of 254 nm was used.  
 
Column chromatography was utilized for purification of some compounds. Therefore, 
chromatography columns of different lengths depending on the experimental parameters 
(eluent, yield…) were filled with silica gel 60 (40-63 µm, Merck) as stationary phase with 
the desired amount. Embedments of air were removed by gentle shaking followed by 
carefully adding the chosen mobile phase. The silica gel was homogenously coated with 
the mobile phase and slightly compressed by adding pressure via a hand pump. On top of 
the stationary phase a layer of see sand was added to preserve the surface of the column 
material and enable readily addition of the compound, which was initially solved in a 
small amount of mobile phase. The purification was performed under slight pressure and 
the obtained fractions sorted by monitoring the process by TLC. Fractions containing the 
target compound were collected and the solvent evaporated under reduced pressure to 
yield the corresponding solid compound.         
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NMR-Spectroscopy was applied to confirm the identity of all compounds. For this 
purpose 1H and 13C spectra were either obtained on a Bruker Advance 500 MHZ (500/126 
MHz) or a Bruker Advance 600 MHZ (600/151 MHz). Compounds were either dissolved 
in DMSO-d6 or chloroform-d1, which were also used as internal standards, and the 
chemical shifts (δ) given in ppm. Assignment of the 13C signals was performed by 
distortionless enhancement by polarization transfer (DEPT) and attached proton test 
(APT). Signal multiplicity is indicated as singlet (s), doublet (d), doublet of doublets (dd), 
triplet of doublets (td), triplet (t), doublet of triplets (dt), quartet (q) and multiplet (m) and 
the coupling constants J are given in Hz.  
 
Elemental analysis was utilized to determine the purity of the test measuring with a Vario 
EL V24 CHN Elemental Analyzer (Elementar Analysesysteme GmbH, Hanau, 
Germany). All values found were in the range of ±0.4% of the theoretical values, unless 
indicated. 
 
10.2 Biological investigation 
10.2.1 Cell culture 
 
Cell culture in general was performed under sterile conditions using a laminar flow 
cabinet. All supplements employed for culturing were either bought sterile or prepared 
under sterile conditions to avoid bacterial growth and other contamination.   
 
10.2.1.1 MDCK II wild-type and ABCG2/BCRP overexpressing cell 
line 
 
The MDCK II cell lines (Madin-Darby canine kidney) with overexpression of ABCG2 
and the parental cell line were received as a kind gift of Dr. A. Schinkel (The Netherlands 
Cancer Institute, Amsterdam, The Netherlands). MDCK II ABCG2/BCRP cells were 
generated by transfection of the canine kidney epithelial cell line MDCK II with human 
wild-type cDNA C-terminally linked to the cDNA of the green fluorescent protein (GFP). 
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Cell culture was performed with Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (FBS), 50 µg/mL streptomycin, 50 U/mL penicillin 
G and 2 mM L-glutamine. Cells were incubated in T75 or T175 tissue culture flasks in a 
humidified atmosphere at 37 °C and 5% CO2 containing 20 or 30 mL of culture medium, 
respectively. At a confluence of about 80-90%, the cells were harvested as described 
below in the section “subculturing”. Acidification of the medium by cellular processes 
was additionally controlled visually by inspecting its color. The supplemented phenyl red 
indicator changes from a pink color to yellow. To sustain the resistance of the cells, they 
were cultured for less than 25 passages.  
Subculturing of the cells was performed at a confluence of 80-90% by removing the 
culture medium in a sterile laminar flow cabinet using suction. The remaining medium 
was washed by adding 5 mL PBS with gentle shaking. After removing the liquids by 
suction, 3-5 mL Trypsin solution was added according to the size of the flask followed 
by a 10 minute incubation period in the incubator to detach the cells from the bottom. 
After about half of the cells were detached, they were collected by washing them off with 
7-10 mL culture medium and transferring the cell suspension to a 50 mL centrifugation 
tube for centrifugation at 1200 x g for 4 minutes at 4 °C. Subsequently, the supernatants 
were removed from the formed cell pellet by suction and the pellet resuspended in 5 mL 
fresh medium. The so prepared cells can be used for further culturing or for cell based 
assays. Counting of the cells was performed with a CASY1 model TT. Therefor, 20 µL 
of a cell suspension was thoroughly mixed with 10 mL sterile filtered Casy ton solution 
and measured with a 150 µm capillary. In order to exclude cell debris and agglomerates 
the cells were counted according to their size between 8 and 40 µm. Subsequently, the 
desired amount of cells was centrifuged in a 1.5 mL Eppendorf reaction vessel and the 
supernatants discarded. KHP was used to resuspend the cell pellet and the procedure 
repeated with KHB two more times to yield a cell suspension of washed cells in KHB.    
Cryoconservation was performed by resuspending the cells after centrifugation (see 
“subculturing” above) in a mixture of 90% culture medium and 10% DMSO. For each 
cryovial 1 mL of the prepared cell suspension containing a cell density of about 5-10 
million cells was used. The cryovials were then quickly transferred to a -80 °C freezer to 
reduce the toxic effect of the DMSO. After 48 h the cryovials were transferred to a liquid 
nitrogen tank to allow preservative storage for longer time periods.  
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Defrosting of the cells was performed by allowing the cryovials which were taken from 
the liquid nitrogen tank to warm up in a 37 °C water bath. As soon as the containments 
liquidate, the obtained cell suspension was immediately transferred to a T75 tissue culture 
flask, together with 20 mL of cell culture medium. After 24 h, the old medium was 
replaced with fresh medium and the cells were cultured for 1-2 more passages before 
using them in cell based assays. 
 
10.2.1.2 PLB-985 (ABCG2 overexpressing) 
 
PLB-985 cells were established from the peripheral blood of a 38-year-old woman with 
acute myeloid leukemia (AML FAB M4) in relapse in the year 1985 and were a kind gift 
of Csilla Özvegy-Laczka (National Medical Center, Institute of Haematology and 
Immunology, Membrane Research Group, Hungarian Academy of Sciences, 1113 
Budapest, Hungary). According to the DNA fingerprint, PLB-985 is a subclone of cell 
line HL-60.  
Cell culture was carried out in RPMI 1640 medium with 10% FBS, 50 mg/mL 
streptomycin, 50 U/mL penicillin G and 2 mM L-glutamine under a 5% CO2 humidified 
atmosphere at 37 °C. Cells were cultured in T25, T75 and T175 tissue culture flasks and 
do not attach to the bottom. Cell density was maintained at 0.3 million cells to 1.5 million 
cells per mL. Doubling of the suspension cells was achieved within 24 h and the cell 
density needed to be monitored after two days whether it was necessary to replace the 
medium of the suspension cells. Acidification of the medium by cellular processes was 
additionally controlled visually by inspecting its color. The supplemented phenyl red 
indicator changes from a pink color to yellow. To sustain the resistance of the cells, they 
were cultured for less than 20 passages.    
Subculturing of the cells was performed by centrifugation of the cell suspension in a 50 
mL centrifugation tube (266 x g, 4 °C, 4 min) obtaining a cell pellet. The supernatants 
were removed from the formed cell pellet by suction and the pellet re-suspended in 5 mL 
fresh medium. The so prepared cells can be used for further culturing or for cell based 
assays. Counting of the cells was performed as described in chapter 10.2.1.1.  
Cryoconservation of the cells was performed by resuspending the cells after 
centrifugation (see “subculturing” above) in a mixture of 70% culture medium, 20% FBS 
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and 10% DMSO. The prepared cell suspension was added in 1 mL aliquots to cryovials 
at a cell density of 5-10 million cells/mL and immediately stored at -80 °C for 48 h. 
Subsequently, the cryovials were stored in a liquid nitrogen tank at -190 °C as backups.  
The so prepared cryovials can later be defrosted by placing them into a 37 °C water bath. 
After liquidation of the mixture it was quickly transferred to a 50 mL centrifugal tube 
containing 10 mL culture medium. After centrifugation (266 x g, 4 °C, 4 min) the 
supernatants were removed and the cell pellet resuspended in 5 mL culture medium. Cells 
were then counted with a CASY1 model TT as described above, transferred to a tissue 
culture flask and the cell density adjusted to 750,000 cells/mL. After 3 passages cells 
were used for cell based assays. 
 
10.2.1.3 A2780 Adr (ABCB1/P-gp overexpressing) 
 
Human ovarian carcinoma cell line A2780adr was purchased from European Collection 
of Animal Cell Culture (ECACC, No 93112520). The cell line shows an overexpression 
of ABCB1 and resistance against doxorubicin.  
Cell culture was performed with RPMI-1640 medium supplemented with 20% FBS, 50 
µg/mL streptomycin, 50 U/mL penicillin G and 2 mM L-glutamine under a 5% CO2 
humidified atmosphere at 37 °C. Acidification of the medium by cellular processes was 
additionally controlled visually by inspecting its color. The supplemented phenyl red 
indicator changes from a pink color to yellow. 
Subculturing was performed as described in chapter 10.2.1.1 in the section 
“subculturing”. To ensure the overexpression of ABCB1, treatment with 100 nmol/L 
doxorubicin was carried out every 10 passages but for less than a total of 40 passages. 
Acidification of the medium by cellular processes was additionally controlled visually by 
inspecting its color. The supplemented phenyl red indicator changes from a pink color to 
yellow. 
Cryoconservation was carried out as described in chapter 10.2.1.1 in the section 
”cryoconservation”.      
 
10.2.1.4 H69AR (ABCC1/MRP1 overexpressing) 
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The small cell lung cancer cell line H69 AR with overexpression of ABCC1 was 
purchased from American Type Culture Collection (ATCC, CRL-11351). Resistant cell 
line H69AR was established from NCI-H69 cells which were grown in the presence of 
increasing concentrations of doxorubicin over 14 month.  
Cell culture was carried out in RPMI-1640 medium with 20% FBS, 50 mg/mL 
streptomycin, 50 U/mL penicillin G and 2 mM L-glutamine and kept under a 5% CO2 
humidified atmosphere at 37 °C. Acidification of the medium by cellular processes was 
additionally controlled visually by inspecting its color. The supplemented phenyl red 
indicator changes from a pink color to yellow. 
Subculturing of the cells was performed according to chapter 10.2.1.1 in the section 
“subculturing”. 
Cryoconservation was carried out as described in chapter 10.2.1.1 (section 
“cryoconservation”) using a mixture of 95% culture medium and 5% DMSO to re-
suspend the cells before storing the cells at -80 °C followed by final storage at -190 °C, 
respectively. 
 
10.2.2 Cell based assays 
 
For all cell based assays, stock solutions were prepared from the test compounds using 
DMSO and obtaining a final compound concentration of 10 mM. The preparation of the 
compound dilutions was carried out with sterile filtered KHB. For compounds with low 
solubility in aqueous media methanol was added to yield a final concentration of less than 
5% MeOH in the highest concentration of the corresponding dilution series. Likewise, 
the highest concentration of DMSO in the final concentrations was less than 0.1%.   
 
10.2.2.1 Buffers used for cell based assays 
 
Krebs-HEPES buffer (KHB) was used for most of the call based assays to prepare the 
compound dilutions or maintain the cell viability during the assays. KHB contains no 
supplements of dyes or enzymes which may influence the corresponding assay. 
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Preparation of KHB was carried out with a mixture of chemicals listed in Table 30 to 
yield a 5X concentrated solution which can be stored at -20 °C for later application. 
 
Table 30: Chemicals for the Preparation of Krebs-HEPES Buffer. 
 
Chemical  
(molecular formula) 
Molecular 
weight 
[g/mol] 
Conc. 5X 
solution  
[mM] 
Weigh in for 5X 
solution (500 mL)  
[g] 
Sodium chloride (NaCl) 58.44 593 17.33 
Potassium chloride (KCl) 74.55 5.64 0.876 
Monopotassium phosphate (KH2PO4) 136.09 6.00 0.408 
Sodium bicarbonate (NaHCO3) 84.01 21 0.882 
D-glucose-monohydrate (C6H12O6*H2O) 198.17 58.5 5.796 
HEPES, free acid (C8H18N2O4S) 238.31 50 5.958 
 
 
Preparation of the buffer was carried out by adding the weighted chemicals to a 500 mL 
volumetric flask together with a magnetic stirrer and 450 mL distilled water. The mixture 
was stirred until complete solution of the solid components and the pH adjusted with 0.1 
N NaOH (aq) to 7.4. Subsequently, the volume was added up under stirring with distilled 
water to a final volume of 500 mL and the obtained 5X KHB solution stored as 50 mL 
aliquots at -20 °C.  
Preparation of the 1X KHB solution was carried out by adding 100 mL of the 5X KHB 
to a 500 mL volumetric flask and adding 650 µL of 1M calcium chloride (final conc. 2.50 
mmol) followed by 350 mL distilled water. The mixture was stirred and 600 µL of a 1M 
magnesium sulfate heptahydrate (final conc. 1.20 mM) was added, followed by further 
addition of distilled water to a final volume of 500 mL. The resulting solution was filtered 
sterile using a 0.2 µm membrane filter, obtaining 50 mL aliquots which were sealed and 
frozen at -20 °C for later use.   
Phosphate buffered saline (PBS) was prepared according to the following procedure using 
the chemicals listed in Table 31. Due to its isotonic and nontoxic properties with most 
cells it was applied for the preparation of dilutions and work with cells. 
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Table 31: Chemicals for the Preparation of Phosphate-buffered Saline (PBS) Solution. 
 
Chemical  
(molecular formula) 
Molecular 
weight 
[g/mol] 
Conc. 1X 
solution  
[mM] 
Weigh in for 1X 
solution (100 mL)  
[g] 
Sodium chloride (NaCl) 58.44 137 8.01 
Potassium chloride (KCl) 74.55 2.7 0.20 
Monopotassium phosphate (KH2PO4) 136.09 2.0 0.27 
Disodium phosphate (Na2HPO4) 141.9 10 1.44 
 
Preparation of the buffer was carried out by weighing the listed chemicals in a 1000 mL 
volumetric flask together with a magnetic stirrer and 800 mL distilled water. After 
complete dissolution of the chemicals, the pH was adjusted to 7.4 using 0.1 M NaOH (aq) 
and filled with distilled water to a final volume of 1000 mL. Sterilization of the mixture 
was carried out in an autoclave heating to 121 °C at a pressure of 2 bar over 20 minutes. 
The sterilized KHB was stored at -4 °C and used under sterile conditions.  
 
10.2.2.2 Hoechst 33342 accumulation assay 
 
The Bisbenzimidazole derivative Hoechst 33342 (2’-(4-Ethoxyphenyl)-6-(4-methyl-1-
piperazinyl)-1H,3’H-2,5’-bibenzimidazole) is a fluorescent dye with an excitation 
maximum at 340 nm and an emission maximum at 450 nm.219 Due to the fact that it is 
also a substrate of ABCB1 and ABCG2 it is broadly used in functional efflux assays of 
the mentioned transport proteins.45, 189 By binding of Hoechst to DNA or a lipophilic 
environment like a cell membrane the fluorescence intensity increases drastically by a 
factor of 750 to 1500 compared to an aqueous environment.182,183,184,187, 188 Owing to its 
relatively high lipophilicity, Hoechst 33342 is able to permeate cell membranes. The 
corresponding fluorescence can then be correlated to the concentration of Hoechst 33342 
in a cell. Since its accumulation is restricted by the expression of transport proteins, such 
as ABCG2 and ABCB1, addition of an inhibitor of the corresponding transport protein 
can reduce the efflux rate by inhibiting the transport of Hoechst 33342. Thereby, the 
potency of an inhibitor can be determined by correlation of the compound concentration 
with the obtained fluorescence. A general scheme of a Hoechst 33342 accumulation assay 
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is presented in Figure 117. Overall fluorescence is measured for 120 minutes to ensure 
the steady-state of Hoechst 33342 in the cell is reached, since the increase of the 
fluorescence follows a first order kinetic (hyperbolic).190  
 
Figure 117: Principle of the Hoechst 33342 accumulation assay.  
 
 
Procedure: The Hoechst 33342 accumulation assay was carried out with MDCK II wild-
type and ABCG2 overexpressing cells to investigate the inhibitory effect of the test-
compounds on ABCG2. The procedure is described in earlier studies and was performed 
with small modifications.220,221,222,223,224,225,226,227,228,229,230,231 Cells were cultivated, 
prepared, counted and washed as described in chapter 10.2.1. Approximately 3 million 
washed cells, suspended in KHB, were used for one 96 well microplate. A typical 
pipetting scheme for this assay with two different compounds and a standard inhibitor is 
illustrated in Figure 118. A volume of 160 µL of KHB was added to the rows A, D and 
G. Then the same volume of a cell suspension containing resistant cells or sensitive cells 
(each approx. 30,000 cells/well) was added to B, E, H and C, F, respectively. 
Subsequently, 20 µL of different dilutions of the corresponding compound was added to 
the wells giving a total volume of 180 µL and the plate stored for a preincubation period 
of 30 min at 37 °C and 5% CO2. Then, 20 µL of a 10 µM Hoechst 33342 solution 
(protected from light) was quickly added to each well yielding a final concentration of  
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1 µM Hoechst 33342. The amount of methanol and DMSO in the final concentration was 
chosen not to exceed 5% and 0.1%, respectively. Compound concentrations were varied 
between 10 µM and 1 nM, depending on the potency of a compound, and added from 
column 2 (lowest concentration) to column 12 (highest concentration). Ko143 or WK-
X24 was used as standard to check the reliability of the assay. 
 
 
 
Figure 118: Layout of the 96 microwell plate employed in the Hoechst 33342 accumulation assay. Ko143 
or WK-X24 was used as standard. 
 
 
Measurement of the fluorescence was performed immediately in constant time intervals 
(60 s) up to 120 min with an excitation wavelength of 355 nm and an emission wavelength 
of 460 nm, using a BMG POLARstar or FLUOstar microplate reader. Further parameters 
are given in Table 32. 
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Table 32: Parameters Used for the Measurement of the Fluorescence with a FLUOstar and a POLARstar 
Microplate Reader. 
 
Parameter Value 
Incubation temperature 37 °C 
Excitation wavelength 355 nm 
Emission wavelength 460 nm 
Gain (for FLUOstar) 1700-1800 
Gain (for POLARstar) 45-50 
Required value 20% 
Number of cycles  120 
Cycle time 60 sec 
Number of light flashes 10/sec 
 
 
For the analysis of the data, the fluorescence of the wells containing only compound in 
KHB was subtracted from the fluorescence reading obtained from the MDCK II cells to 
correct for potential fluorescence of the compound. Average of the fluorescence measured 
between 100 and 109 min (steady state) was calculated for each concentration and plotted 
against the logarithm of the compound concentration. Concentration-response curves 
were fitted by nonlinear regression using the four-parameter logistic equation with 
variable Hill slope, or the three-parameter logistic equation with a fixed Hill slope of one, 
whatever equation was statistically preferred (GraphPad Prism, version 5.0, San Diego, 
CA, USA). From the pIC50 values and their standard deviation the IC50 values and 
standard deviations were calculated according to the equation for log-normal distributed 
values.232,233 
 
10.2.2.3 Pheophorbide A accumulation assay 
 
Pheophorbide A (PhA) is a chlorophyll catabolite and proven to be a selective substrate 
of ABCG2, based on ABCG2(-/-) knockout mice studies.234 In contrast to Hoechst 33342 
it is no substrate of ABCB1 and can be excited at a wavelength of 488 nm (e.g. blue argon 
laser) showing a maximum emission at a wavelength of 670 nm.129 PhA is able to pass 
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lipophilic cell membranes leading to an accumulation of the fluorescent dye in the cell. 
This process can be used for flow cytometric assays using ABCG2 overexpressing 
cells.235 The transport protein performs an active efflux of PhA out of the cell, limiting 
the intracellular concentration. The addition of an inhibitor of ABCG2 leads to a higher 
intracellular concentration due to inhibition of the active efflux which is illustrated in 
Figure 119. Hence, the potency of the inhibitor correlates with the observed fluorescence 
in the cell. For the measurement of the fluorescence, a FACSCalibur cell analyzer was 
used. Hereby, the fluorescence of individual cells was measured after sorting and gating 
the cells accordingly.  
 
 
Figure 119: Principle of the Pheophorbide A accumulation assay. 
 
Procedure: Preparation of the assay was similar to the Hoechst 33342 accumulation 
assay but with some modifications. The MDCK II ABCG2 expressing and sensitive cell 
lines were prepared as described in chapter 10.2.1.1 and suspended in KHB. 
Subsequently, 160 µL of the corresponding cell suspension, containing approximately 
45,000 cells, was added to a clear U-shaped 96 well microplate according to the layout 
illustrated in Figure 120.     
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Figure 120: Layout of the 96 microwell plate employed in the Pheophorbide A accumulation assay. 
Ko143 or WK-X24 were used as standard. 
 
Additionally, 20 µl of different compound dilutions were added to the wells as described 
for the Hoechst 33342 accumulation assay above (concentration was adapted to the 
potency of the compounds) and the microplate preincubated for 30 min at 5% CO2 and 
37 °C. Then, 20 µl of a 5 µM pheophorbide A solution (protected from light) was added 
to each well, followed by a 120 min period of incubation to reach steady state. After 
incubation, the cells were resuspended in the wells with a multichannel pipette and the 
fluorescence measured on a FACSCalibur cell analyzer by flow cytometry. Pheophorbide 
A was excited at a wavelength of 488 nm and emission was detected in the FL3 channel 
(≥ 670 nm). Prior to the evaluation of the measured fluorescence of PhA inside the cells, 
a gate was set to exclude agglomerates and cell debris. The IC50 values were then 
calculated by creating concentration-response curves via nonlinear regression, using the 
four-parameter logistic equation with variable Hill-slope. 
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Principles of flow cytometry: The advantage of a flow cytometric measurement of the 
fluorescence is based on the sorting of different cells or particles according to size, 
granularity as well as the emitted fluorescence at very high rates (FACSCalibur: 
analyzing up to 4000 cells/sec). In general, the cell suspensions are gathered from each 
well by a cytometer unit. The sample is then accelerated by a laminar flow of a carrier 
liquid focussing the cells into a consecutive string (hydrodynamic focussing) so that the 
cells pass a laser beam one by one. Detectors collect the scattered light from the laser 
beam as forward scatter (FSC), generated by light diffraction, and side scatter (SSC), 
which is induced by light refraction and light reflection and is detected in a 90° angle to 
the laser beam. The FSC provides information about the relative size of the particle 
whereas the SSC gives information about the relative granularity of a particle. Optical 
filter split the emitted fluorescence of a sample into three specific fluorescence regions 
after which the corresponding relative fluorescence intensity is measured by three 
detectors (FL1, FL2 and FL3). A schematic structure and function of the flow cytometric 
cell analyzer FACSCalibur is depicted in Figure 121.  
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Figure 121: Schematic structure and function of a flow cytometric cell analyzer. 
 
10.2.2.4 Calcein AM assay 
 
Calcein AM is a non-fluorescent, hydrophobic probe containing four acetoxymethyl 
esters (AM) and one lactone function connected as a spiro species. Due to its high 
lipophilicity calcein AM is able to enter cell membranes where the ester functions 
undergo cleavage by unspecific intracellular esterases. Hereby, five carboxylate functions 
are formed under physiological conditions and the conjugated pi-system of the 
fluorescein scaffold is restored. Due to the high hydrophilicity of the resulting calcein 
anion, it is no more able to permeate the cell membrane. Calcein AM is a substrate for 
two of the three major types of mammalian ABC transport proteins, namely ABCB1 and 
ABCC1, but not ABCG2.236, 237,238,239 With regard to ABCC1 it is known that it is able to 
transport a variety of anionic substrates.50 However, the anionic calcein molecule is only 
a poor substrate of ABCC1 and not a substrate of ABCB1 and ABCG2.240  
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By inhibition of ABCB1 or ABCC1 calcein AM accumulates in the cell and forms the 
fluorescent calcein anion which can be measured fluorometrically. The intracellular 
concentration of calcein is mostly dependent on the velocity of the diffusion of calcein 
AM into the cell membrane, the turnover-rate to calcein by esterases, the efflux of calcein 
AM by a transport protein and the concentration of calcein AM. Addition of an inhibitor 
restricts the efflux of calcein AM according to its inhibitory potency. Hence, the increase 
of the intracellular fluorescence correlates directly with the inhibitory potency of a 
compound which is exploited to calculate IC50 values. A schematic view of the underlying 
principle of the calcein AM assay is illustrated in Figure 122. 
 
 
Figure 122: Principle of the calcein AM assay with ABCB1 overexpressing cells. 
 
 
Procedure: The selectivity of the test compounds toward ABCG2 was investigated by 
determining the inhibitory activity against ABCB1 and ABCC1 in the calcein AM assay.  
The ABCB1 overexpressing cell line A2780adr and the ABCC1 overexpressing cell line 
H69AR were used for the assay. Both cell lines were prepared and washed as described 
in chapter 10.2.1.3 and 10.2.1.4. After washing the cells three times with KHB, 90 µL of 
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a suspension containing approximately 30,000 cells was seeded in each well of a colorless 
flat bottom 96 well microplate. Then 10 µL of different compound dilutions was added 
according to the microplate layout in Figure 123 giving a final volume of 100 µL.  
 
 
 
Figure 123: Layout of the microplate used for the calcein AM assay. Each compound was added to a row 
(A-G) as duplicates (2-6 and 8-12), whereas the depicted final concentrations (in µM) are exemplarily for 
compound 1 and the standard. Cyclosporine A was used as standard inhibitor with eleven different 
concentrations.  
 
 
The prepared plates were kept at 5% CO2 and 37 °C for a period of 30 min. After this 
preincubation, 33 µL of a 1.25 µM calcein AM solution (protected from light) was 
quickly added to each well and the fluorescence measured immediately in a 37 °C 
tempered BMG POLARstar OPTIMA or FLUOstar OPTIMA microplate reader. The 
measurement of the fluorescence was carried out for 60 min in constant time intervals (60 
s) using an excitation wavelength of 485 nm and an emission wavelength of 520 nm. 
Further parameters are given in Table 33.  
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Table 33: Parameters used for the Measurement of the Fluorescence with a FLUOstar and a POLARstar 
Microplate Reader. 
 
Parameter Value 
Incubation temperature 37 °C 
Excitation wavelength 485 nm 
Emission wavelength 520 nm 
Gain (for FLUOstar) 1700-1800 
Gain (for POLARstar) 45-50 
Required value 20% 
Number of cycles  90 
Cycle time 60 sec 
Number of light flashes 10/sec 
 
 
The increase of the fluorescence follows a kinetic of pseudo-zero-order (linear) for as 
long as the concentration of calcein AM is nearly unchanged. The slope for each 
concentration was calculated from the initial linear part of the obtained fluorescence time 
curve. Thereby a slope concentration response curve was obtained which could be fitted 
by nonlinear regression, using the four-parameter logistic equation with variable Hill 
slope, or the three-parameter logistic equation with a Hill slope of one, whatever equation 
was statistically preferred. From the pIC50 values and their standard deviation the IC50 
values and standard deviations were calculated according to the equation for log-normal 
distributed values.232,233 
 
10.2.2.5 MTT assay determining the intrinsic cytotoxicity 
 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent is a 
water soluble tetrazolium salt which is used to determine the viability of cells. Since the 
molecule is able to permeate cell membranes the yellow dye is reduced by intracellular 
oxidoreductase enzymes by oxidation of NADH, forming its hydrophobic formazan 
species. This process takes mostly place in active mitochondria and thus, the formation 
of the purple formazan species is correlated with the cell viability.241,242 The concentration 
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of the purple dye can be measured colorimetrically giving information about the cell 
viability. A schematic view of the reduction of MTT by living cells to the formazan 
species is illustrated in Figure 124. 
  
 
 
Figure 124: Principle of the MTT reduction in living cells to a formazan species. 
 
 
Procedure: The intrinsic cytotoxicity of selected compounds was investigated using the 
MTT cytotoxicity assay as described earlier with slight modifications. 
222,225,226,227,228,231,243
 In order to avoid contamination of the medium and the cells, the 
preparation of the assay was carried out under aseptic conditions, using a bench with 
laminar airflow. MDCK II BCRP and sensitive cells were seeded in 96 well tissue culture 
microplates at a density of approximately 2,000 cells per well, suspended in a volume of 
180 µL culture medium, and kept under 5% CO2 at 37 °C for 12 h. The old medium in 
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the microplates was replaced by 180 µL of fresh medium and 20 µL of different 
compound dilutions was added to each well to a final volume of 200 µL. For the dilution 
of the compounds the culture medium was supplemented with small amounts of methanol 
and DMSO, attaining less than 1.8% (MeOH) and 1% (DMSO) volume percent in the 
final volume. Toxic effects caused by the DMSO and methanol content, was determined 
by an additional analogue dilution without compound. Moreover, a positive control with 
medium and 10% (v/v) DMSO as well as a negative control of only medium were carried 
out. The layout of the microplate is illustrated in Figure 125. 
 
 
 
Figure 125: Layout of the microplate used for the MTT cytotoxicity assay. The final compound 
concentrations (in µM) and positive and negative controls are depicted exemplarily in row A. PBS was 
added to the interspace between the wells to reduce evaporation of the medium.  
 
The interspace between the wells was carefully filled with 10 mL of PBS in order to 
reduce evaporation of the medium and the so prepared microplates, were stored at 5% 
CO2 and 37 °C for 72 h. After the incubation period, 40 µL of MTT reagent was added 
to each well and the plate incubated for one hour. After removing the supernatants, 100 
µL of DMSO was added to each well resulting in lysis of the cells and solubilisation of 
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the formed formazan. The absorbance was determined spectrophotometrically at 544 nm 
and a background correction at 710 nm using a BMG POLARstar microplate reader. 
Calculation was carried out with the values of the absorbance, setting the negative control 
as 100% cell viability. Concentration-response curves were fitted by nonlinear regression 
using the four-parameter logistic equation with variable Hill slope, or the three-parameter 
logistic equation with a fixed Hill slope of one, whatever equation was statistically 
preferred (GraphPad Prism, version 5.0, San Diego, CA, USA). From the pIC50 values 
and their standard deviation IC50 values and standard deviations were calculated 
according to the equation for log-normal distributed values.232,233  
 
10.2.2.6 MDR reversal assay with Hoechst 33342 and SN-38 
 
A MDR reversal assay was carried out to determine a compounds ability to reverse 
resistance of ABCG2 expressing MDCK II BCRP cells toward cytotoxic substrates like 
SN-38 and Hoechst 33342. Addition of an inhibitor of ABCG2 to ABCG2 overexpressing 
cells leads to a decreased efflux activity of the transport protein dependent on the potency 
of the compound. In the presence of cytostatic drugs like Hoechst 33342 and SN-38, the 
reduced efflux of those substrates leads to an intracellular accumulation inducing cell 
death. Gradual sensitization of the cells with increasing compound concentrations can be 
derived by measuring the cell viability and enabling the deduction of EC50 values by 
correlation of the cell viability with the corresponding compound concentration.    
 
Procedure: A clear 96 well tissue culture plate was prepared and preincubated for 12 h, 
as described in chapter 10.2.2.5. The old medium was replaced with 160 µL fresh medium 
and 20 µL of a compound dilution in culture medium was added to each row as a 
duplicate. Then, 20 µL of a dilution series of Hoechst 33342 or SN-38 were added column 
wise, adding to a final volume of 200 µL.  
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Figure 126: Layout of the microplate used for the MDR reversal assay with Hoechst 33342 and SN-38. The 
compound concentrations were chosen between 0.01 and 5 µM. The final concentration (in µM) of the 
cytostatic drug is given exemplarily for row A. PBS was added to the interspace between the wells to reduce 
evaporation of the medium. 
 
A positive control was established using 10% (v/v) of DMSO as well as a negative control 
by adding MDCK II BCRP cells and medium without modulator. Further details of the 
plate layout are illustrated in Figure 126. After 72 h of incubation the plates were prepared 
and measured as described in chapter 10.2.2.5.  
 
10.2.2.7 MDR reversal assay with mitoxantrone 
 
Mitoxantrone (MX) is an anthraquinone derivative which is applied among others in 
chemotherapeutic treatment of leukemia, lymphoma, breast and ovarian cancer, acute no 
lymphocytic leukemia, acute myeloid leukemia, and Hodgkin’s lymphoma.244 The MDR 
reversal assay with MX as cytostatic drug and substrate of ABCG2 was carried out similar 
to the Hoechst 33342 and SN-38 efficacy assay described in chapter 10.2.2.6 above. The 
aim of the assay was to investigate the ability of selected compounds to restore sensitivity 
of MDCK II ABCG2 overexpressing cells toward MX. Since MX is a substrate of 
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ABCG2, inhibition of the transport protein leads to a reduced efflux of MX. Owing to the 
increased intracellular accumulation of the cytotoxic drug the cell death is induced. 
Subsequently, the viability of the cells can be measured and correlated to the efficacy of 
an inhibitor.  
 
Procedure: The microplates were prepared only with MDCK II ABCG2 overexpressing 
cells, similar to the procedure described in chapter 10.2.2.6. Here, the cell density was set 
to 3000 cells per well and the used microplate layout is depicted in Figure 127. 
 
 
 
Figure 127: Layout of the microplate used for the MDR reversal assay using mitoxantrone. Final compound 
concentrations (in µM) are given exemplarily in row A. The final concentration of MX was 0.5 mM. PBS 
was added to the interspace between the wells to reduce evaporation of the medium. 
 
After replacement of the old medium with fresh culture medium, 20 µL of different 
compound dilutions were added to the rows. Then, 20 µL of either 5 µM MX or culture 
medium were added as duplicates in an alternating order to the rows yielding a final 
volume of 200 µL and a final concentration of 0.5 µM MX. This concentration was 
chosen after a GI50 value slightly higher than 0.5 µM resulted in a MTT viability assay 
with the ABCG2 overexpressing MDCK II BCRP cell line. For comparison, complete 
cell death was induced by adding 10% (v/v) of DMSO (positive control) to some wells 
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and the negative control was established by using medium without compound. This 
scheme can also be modified using more concentrations of each compound to create 
concentration-response curves. The preparation of the plate, the subsequent measurement 
and the data analysis was carried out as described in chapter 10.2.2.6.        
 
10.2.2.8 Enzyme kinetic investigation 
 
Extended enzyme kinetic experiments were performed with selected compounds to study 
the interaction with the ABCG2 substrate Hoechst 33342. The enzyme kinetic theory 
describes enzymatically catalyzed chemical reactions and can be transferred to the 
transport of substrates by the transport protein ABCG2 in the presence of inhibitors. 
Therefore, the Michaelis-Menten equation, which is used for calculating the rate of 
enzymatic reactions, can be applied to this problem. The equation describes the reaction 
rate  in relation to a substrate concentration [S]. Usually, increasing substrate 
concentrations result in an increasing reaction rate , following a hyperbolic fashion, until 
the maximum velocity Vmax is reached. The Michaelis-Menten constant KM is defined as 
the substrate concentration giving  Vmax. 
 = 	[]
 =  ∙ [] + []  
Equation 1: Michaelis-Menten equation. 
 
Due to the limited concentration range of the substrate, important kinetic parameters like 
the maximum velocity are difficult to deduce from the Michaelis-Menten curve. In 1934 
Lineweaver and Burk invented a method to transform the Michaelis-Menten equation into 
straight lines by using the reciprocal of the equation (Equation 2).245  
 1 = 	  + [] ∙ [] = 	  ∙ 1[] + 1 
Equation 2: Reciprocal of the Michaelis-Menten equation. 
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This representation allows the double reciprocal plot of  versus [] yielding a straight line 
that follows the function  =  + . Hence,  !" can be derived from the slope of 
the function, [] as the intersection with the Y-axis and −  as the intersection with the 
X-axis (compare Figure 128).  
 
 
Figure 128: Double reciprocal plot according to Lineweaver-Burk. 
 
The inhibition of the enzyme activity can follow three mechanisms: In the case of a 
competitive inhibition, the substrate S and the inhibitor I bind to the same site of the 
enzyme. Although I competes with S for the same binding site, sufficiently high substrate 
concentrations are capable to displace I from the active site of the enzyme, resulting in 
constant Vmax values. Here, the KM values increase with higher inhibitor concentrations 
and an intersection on the Y-axis in the Lineweaver-Burk plot is obtained. A non-
competitive inhibition is observed when I binds apart from the active site to the enzyme 
or the enzyme-substrate-complex [ES]. Due to inactivation of [ES] by the inhibitor even 
high substrate concentrations are not able to overcome the inhibition, resulting in different 
Vmax values for different inhibitor concentrations. This results in an intersection of the 
lines in the Lineweaver-Burk plot at the X-axis. A special form of the non-competitive 
11
$%
$[&]'
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inhibition is a “mixed-type” inhibition. Here, the inhibitor binds apart from the substrate 
but still affects the active site, for instance by conformational changes after binding of the 
inhibitor. In this case Vmax and KM vary with different [S] and the obtained lines in the 
Lineweaver-Burk diagram give an intersection in the second or third quadrant of the 
coordinate system. An uncompetitive inhibition is observed, when I only binds to [ES]. 
Higher [S] lead to an increase of [ES] and thus more binding of I to [ES]. Vmax and KM 
values both increase for this type with increasing inhibitor concentrations. The 
Lineweaver-Burk diagrams of a double reciprocal plot with the characteristic straight 
lines to each kinetic type of inhibition are illustrated in Figure 129. 
 
 
 
 
 
 
Figure 129: Double reciprocal plot according to Lineweaver-Burk with increasing inhibitor 
concentrations I1 to I4. Type of interaction with substrate: a) competitive; b) non-competitive; c) non-
competitive mixed-type; d) uncompetitive.  
 
Although, linearization according to Lineweaver-Burk gives direct information on the 
type of interaction, this method has been criticized as being notoriously susceptible to 
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experimental errors, due to the double reciprocal plot. Hence, the results were additionally 
analyzed by using the data for a direct linear plot according to Cornish-Bowden, since 
this method has been claimed to be insensitive to outliers.246 As mentioned before, 
enzyme kinetic reactions obtain in most cases a hyperbolic curve when the reaction 
velocity  is plotted against the substrate concentration [S] due to saturation of the 
enzyme’s active site. The Cornish-Bowden linearization plots the reaction velocity  
against the negative of the substrate concentration [S]. Transformation of the Michaelis-
Menten equation (see Equation 1) results in Equation 3:  
 
  =  +  ∙ []  
Equation 3: Transformation of the Michaelis-Menten equation used for the Cornish-Bowden plot.  
 
Since substrate concentration [S] and reaction velocity  can be directly derived from the 
experimental data, the above equation is solved for KM and Vmax by inserting at least two 
corresponding [S] and  value pairs. Graphic representation of the problem illustrates that 
each straight line consists of one corresponding pair of values, whereas -[S] is plotted on 
the X-axis and  on the Y-axis.  
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Figure 130: Cornish-Bowden plot including a rectangular hyperbolic curve of an Michaelis-Menten 
enzyme kinetic (dashed blue curve) from which the corresponding [S] and  values were plotted on the X- 
and Y-axis, respectively. Connection of those corresponding points forms a family of lines, which yield an 
intersection giving information about KM (red arrow) and Vmax (green arrow). 
 
 
From the intersection of at least two straight lines the values of Vmax and KM are given on 
the corresponding axes (compare Figure 130). In the case of a rectangular hyperbolic 
Michaelis-Menten curve, all generated lines for an inhibitor concentration intersect in the 
same point. Due to experimental error, several intersections for each [S] pair will be 
obtained. For the calculation the median of the intersections is taken to reduce the 
experimental error. In case of negative values, they were replaced by large positive 
values. By the obtained Vmax and KM values for every inhibitor concentration, the kinetic 
interaction between the inhibitor and the substrate can be derived (compare Table 34).   
 
 
'
%
−[&]
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Table 34: Effect of the Type of Inhibitory Enzyme Kinetic on the Values Vmax and KM with Increasing 
Substrate Concentrations. 
 
Type of inhibitory enzyme kinetic Vmax a KM a 
Competitive constant increases 
Non-competitive decreases constant 
Non-competitive-mixed decreases increases 
Uncompetitive decreases decreases 
a: effects on the values are given with increasing substrate concentrations. 
 
 
Procedure: The experiments were carried out with various concentrations of a selected 
compound as well as of Hoechst 33342. Preparation and measurement of the assay was 
performed analogously to the Hoechst 33342 assay described in chapter 10.2.2.2, except 
that the concentration of Hoechst 33342 varied in the range of 0.4 µM to 2.4 µM and the 
different concentrations of the test-compound were adjusted to the corresponding IC50 
value. For this purpose several inhibitor concentrations below the IC50 value were chosen 
together with one higher concentration which reached the top fluorescence value in a 
previous Hoechst 33342 accumulation assay. Each concentration was added row wise to 
the wells (C-H). The response in absence of the investigated compound was used as 
control, carried out in row A and B, whereas row A does not contain cells but only KHB. 
The layout of the microplate is illustrated in Figure 131. 
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Figure 131: Layout of the microplate used for the inhibitory enzyme kinetic assay. 
 
 
Since a transport-protein is involved in this method, the measured fluorescence must be 
adjusted to fit an inhibitory enzymatic kinetic. A typical concentration-response curve of 
compound 54 after subtraction of the background-fluorescence of the substrate Hoechst 
33342 in KHB (row A) from the other rows is illustrated in Figure 132.  
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Figure 132: concentration-response curve of compound 54 with different concentrations of Hoechst 
33342. 
 
Fluorescence increases as increasing compound concentrations restrict the efflux of the 
substrate giving a sigmoidal concentration-response curve. Likewise, increased Hoechst 
33342 concentrations lead to an increase of the fluorescence. The top and bottom values 
to each Hoechst 33342 concentration are then plotted against each other and lines 
generated by linear regression which should intersect with the origin of the coordinate 
system. Since the enzyme kinetic method requires fluorescence values that are 
proportional to the transport velocity  they had to be adjusted according to Equation 4. 
 
  = ()*+, = -./ − 012.34564764	8124 
Equation 4: Adjustment of the transport velocity to the enzyme kinetic method. 
 
The efflux velocity is dependent on the concentration of the inhibitor which restricts the 
transport activity of the transport protein. Calculation of the intracellular concentration of 
the substrate is then carried out according to Equation 5. 
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69: =  =	 [] ∙ 012.-./  
Equation 5: Calculation of the intracellular substrate concentration. 
 
The transport velocity , it can be derived from the fluorescence data by relating the top 
value to the substrate concentration and the fluorescence to the intracellular concentration 
giving Equation 6.  
 
  = [] − 69: 
Equation 6: Reaction velocity calculated from the experimental data. 
 
Thereby,  and S could be calculated and used for the double reciprocal Lineweaver-Burk 
plot. The transformation was carried out with the GraphPad® 5.01 Lineweaver-Burk 
implementation to obtain straight lines as presented in Figure 129 and to evaluate the 
underlying kinetic interaction between an inhibitor and the substrate Hoechst 33342. 
 
10.2.2.9 Conformation sensitive 5D3 antibody binding assay 
 
Conformation-sensitive binding assay was carried out with the monoclonal antibody 
PerCP-CyTM5.5 Mouse Anti-Human CD338. This conjugated primary antibody 
specifically binds to an epitope of ABCG2, the human CD338 antigen and exhibits an 
excitation maximum of 482 nm and an emission maximum of 695 nm. With ABCG2 
expressing cells the 5D3 antibody exhibited a saturable labelling, inhibiting ABCG2 
transport and ATPase function at high concentration. At low concentration the labelling 
correlated with the conformational change of the protein.200 Non-specific staining was 
determined with PerCP-Cy™5.5 Mouse IgG2b κ Isotype Control. The assay was carried 
out with the mammalian PLB-985 acute myeloid leukemia cell line with an 
overexpression of ABCG2 using flow cytometry. Previous studies had shown, that this 
cell line expresses a relatively small amount of ABCG2 in comparison to other cell lines 
but led to the best results with the 5D3 antibody in the presence of Ko143.201 Moreover, 
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the monoclonal antibody can serve as a sensitive tool to study intramolecular changes, 
reflects ATP binding and provides information about the formation of a catalytic 
intermediate, or substrate inhibition within the transport cycle of the ABCG2 protein.200 
Also, it was found that substrates often induced a smaller shift than inhibitors.201  
 
Procedure: For the assay, cells were centrifuged and washed with a solution of DPBS 
containing 0.25% BSA. Subsequently, the cell density was adjusted with further 
DPBS/BSA solution to 2.5 million cells per mL and added in 98 µL portions to 1.5 mL 
Eppendorf reaction tubes. Then, 1 µL of a solution prepared from a compound in DMSO 
in the desired concentration was added to the tube, followed by a 5 minute pre-incubation 
period at 37 °C with shaking at 500 rpm. After pre-incubation, 1 µL of the antibody 
solution (PerCP-Cy™5.5 Mouse Anti-Human CD338 antibody, BD Bioscience) was 
added to the tube to a final volume of 100 µL and the mixture incubated with shaking 
(500 rpm) at 37 °C for another 30 min. Cells were then centrifuged, the supernatants 
removed and the cell-pellet re-suspended in 1 mL DPBS for immediate measurement at 
the FACSCalibur. The measurement was performed using an excitation wavelength of 
488 nm and the fluorescence detected in the FL3 channel (red spectrum). Additionally, a 
control containing the same amount of DMSO as the test samples but without compound 
was established. Thereby, a shift of the fluorescence between cells without compound 
and cells with compound could be observed in most cases. The corrected fluorescence 
was obtained by subtraction of the geometric mean of the obtained fluorescence by the 
isotype-control from the geometric mean of the obtained fluorescence by the 5D3 
antibody. The shift was then calculated for every test compound by subtracting the 
corrected fluorescence obtained in the absence of a compound from the corrected 
fluorescence obtained in the presence of a compound.  
 
10.2.2.10 ATPase activity assay with ABCG2 membranes 
 
ABC transport proteins rely on the hydrolysis of ATP to generate the necessary energy 
for an active efflux of molecules out of cells. The ATPase assay is a colorimetric method 
to detect inorganic phosphate (Pi) which is formed by cleavage of ATP. Hence, the 
formation of Pi is directly linked to the activity of the transporter. For a more accurate 
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correlation of the ATP hydrolysis to the transport activity, few other factors have to be 
taken into account. On the one hand, a basal activity can be measured which is not 
dependent on the transport activity of the protein. On the other hand, a vanadate-
insensitive ATPase can be detected from other unspecific processes, which is obtained by 
adding orthovanadate. It is known that orthovanadate inhibits the ATPase activity of ABC 
transport proteins (vanadate-sensitive ATPase activity) and thus, the specific ATPase 
activity originating from the transport protein can be calculated by subtracting the 
insensitive vanadate ATPase activity from the total ATPase activity. Ko143 was used as 
standard for ATPase inhibition and quercetin was used as positive control with high 
stimulation of ABCG2 transport activity.    
 
Procedure: High Five ™ insect cells were seeded in culture flasks with Express Five® 
medium and were incubated at 27°C. After a few passages when cells were healthy and 
homogenous, cells were counted and about 20 million cells per flask were seeded for 
baculovirus infection with Autographa californica multicapsid nuclear polyhedrosis virus 
(AcMNPV). Cells were harvested 72 hours after infection, centrifuged and afterwards 
membrane preparation was performed.226 Two mL of membrane preparation 
homogenization buffer (50 mM Tris pH 7.5, 2 mM EGTA pH 7.0, 50 mM Mannitol, 2 
mM DTT, 1 mM PMSF, 2 µM pepstatin, 1 µM leupeptin, 1 mM benzamidine) was used 
for 20 million cells. Cells were disrupted by a dounce homogenizer. Cellular debris was 
pelleted by centrifugation at 500 × g for 10 min at 4 °C and discarded. The supernatant 
was centrifuged at 300,000 × g for 30 min at 4 °C to obtain a pellet of enriched plasma 
membranes. Finally membranes were resuspended in 100 µL re-suspension buffer (50 
mM Tris pH 7.5, 1 mM EGTA at pH 7.0, 10% (v/v) glycerol, 0.3 M mannitol, 1 mM 
DTT, 1 mM PMSF, 2 µM pepstatin, 1 µM leupeptin, 1 mM benzamidine) per flask and 
were frozen and stored at −80 °C. ATPase activity measurements of selected compounds 
was performed by a colorimetric ascorbic acid ammonia molybdate reaction.247 
Vanadate-sensitive basal ATPase activity was compared to vanadate-sensitive drug-
stimulated or inhibited activity. Ko143 was used as standard for ATPase inhibition, 
quercetin was used as positive control with high stimulation of ABCG2 transport activity. 
Investigated compounds were dissolved in DMSO, final concentration of DMSO was 1%, 
which showed no observable effect on basal ATPase activity. All measurements were 
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repeated at least three times. All experiments were carried out by Jennifer Gallus and will 
be reviewed in her PhD thesis. 
 
10.2.3 Calculation of concentration-effect curves with 
GraphPad Prism 
 
Calculation of the IC50 and GI50 values were performed with GraphPad® 5.01 software. 
For this purpose the concentration dependent effect values from different experiments 
were transferred to the software and concentration-effect curves calculated with the four 
parameter logistic equation with variable slope or the three parameter logistic equation 
with a fixed slope = 1 (Equation 7: Four parameter logistic equation.). Both models were 
evaluated and chosen depending on the best curve-fit.   
 
 
; = -./ − <.

.1 + 10:>	∙	?@AB*CDEFGHI + <.

. 
Equation 7: Four parameter logistic equation. With the response (Y), compound concentration (X), 
maximum response (Top), minimum baseline response (Bottom), slope of the curve (nH) 
and the concentration where the half-maximal effect is achieved. 
 
Experiments were carried out at least as three independent runs. To evaluate the quality 
of the data, the arithmetic mean was calculated and the corresponding standard deviation 
SD determined as the root of the variance (expected value of the squared deviation from 
the mean) using Equation 8.  
 
5 = J5 = K∑ 9 − 	̅	:9N7 − 1  
Equation 8: Formula used for the standard deviation (SD) calculated from the root of the variance. With 
n = number of measured values; xi = corresponding measured value; O	̅ = arithmetic mean value. 
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10.2.4 Materials 
10.2.4.1 Chemicals  
 
Chemicals Manufacturer Article number 
Bovine serum albumin (BSA) Sigma A 7906 
Calcein AM Sigma 17783 
Calcium chloride dihydrate Merck P 4901 
Cyclosporine A Sigma C 3662 
D-glucosemonohydrate Merck 1040740500 
Dimethylsulfoxid (DMSO) Acros AC19773 
Disodium phosphate Applichem A4732 
Erlotinib  LC Laboratories E 4007 
Gefitinib LC Laboratories G 4408 
HEPES (free acid) Applichem A 3707 
Hoechst 33342 Sigma B 2261 
Hydrochloric acid (0.5 M) Grüssing 23204 
Ko143 Tocris 3241 
Magnesium sulfate heptahydrate Applichem A4101 
Melsept SF Braun 18907 
Methanol Merck 107018 
Mitoxanthron Sigma M 6545 
PerCP-Cy™5.5 Mouse Anti-Human CD338 
antibody 
BD Biosciences 561460 
PerCP-Cy™5.5 Mouse IgG2b, κ Isotype Control BD Biosciences 558304 
Pheophorbide A Fontier Scientic Inc. 15664296 
Potassium chloride Merck 104936 
Potassium phosphate Applichem A 3095 
SN-38 TCI Europe N.V. E0748 
Sodium bicarbonate Merck 106329 
Sodium chloride Merck 106404 
Sodium hydroxide solution (1 M) Grüssing 22195 
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10.2.4.2 Materials for cell culture and assays 
 
Materials Manufacturer Article number 
Amber microtubes with attached pp cap, 1.5 mL Sarstedt 72690004 
CASYton solution Schärfe System 43001 
Conical test tube PP 15 ml, sterile Nerbeplus GmbH 25027001 
Conical test tube PP 50 ml, sterile Nerbeplus GmbH 25707001 
Cryos PP with screw cap, sterile Greiner bio-one 123263 
FACSClean Becton Dickinson 340345 
FACSFlow Becton Dickinson 342003 
FACSRinse Becton Dickinson 340346 
FACS-testtubes Sarstedt 551579 
Fetal bovine serum Sigma F 7524 
Glass pasteur pipettes (230 mm) VWR international 612-1702 
Growth medium D-MEM 5671 Sigma M 5650 
Growth medium RPMI-1640 PAN Biotech GmbH P0416500 
L-Glutamine 200 mmol/l Sigma G 7513 
MaxyClear microtubes, 2.0 mL Axygen scientic MCT-200-C 
Membrane filter 0.2 µm, sterile Whatman 10462200 
Microplate clear PS, 96-Well, flat bottom Greiner bio-one 655098 
Microplate clear PS, 96-Well, U-shape bottom Greiner bio-one 650101 
Microwell SH plate, untreated black, 96F Nunc 237108 
Neutral microtubes with attached pp cap, 1.5 mL Sarstedt 7269001 
Natural pipette tips, 1.0-5.0 mL Bulk Starlab I1009-5000 
Norm-Ject 10 mL syringe Henke Sass Wolf 4100-000V0 
Norm-Ject 20 mL syringe Henke Sass Wolf 4200-000V0 
Penicillin-Streptomycin solution Sigma P0781 
Serological pipette 10 mL, sterile Sarstedt 86.1254.001 
Serological pipette 25 mL, sterile Sarstedt 86.1685.001 
TipOne 0.1-10.0 µL natural pipette tips Starlab S1111-3000 
TipOne 101-1000 µL natural pipette tips Starlab S1111-2020 
TipOne 1-200 µL yellow pipette tips Starlab S1111-0006 
Tissue culture flasks, 175 cm², sterile, filter cap Greiner bio-one 660175 
Tissue culture flasks, 25 cm², sterile, filter cap Greiner bio-one 690175 
Tissue culture flasks, 75 cm², sterile, filter cap Greiner bio-one 658175 
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Tissue culture plate, 96-Well, flat bottom with 
lid, sterile 
Sarstedt 831835 
Trypsin-EDTA solution PAN Biotech GmbH P100231SP 
 
10.2.4.3 Instruments 
 
Instruments Manufacturer Serial number 
Accu-Jet suction pump Brand 441938 
Avanti centrifuge J-25 Beckman JHY97G35 
Axiovert 25 microscope Zeiss 660197 
CASY1 model TT Schaerfe System SC1 TT 
CO2 cell MMM Group - 
Discover-SP W/Activent CEM DC8032 
FACSCalibur Becton Dickinson E3231 
FLUOstar Optima fluorescence BMG Lab Technologies 4131164  
FLUOstar Optima fluorescence BMG Lab Technologies 4132279 
Laminar flow cabinet (model: 
Antares 48) 
Steril S.p.A. 10155/1996 
Luminescence Spectrometer LS55 Perkin Elmer 69542 
pH-Meter 744 Metrohm 20506 
Pipette 0.1-2.5 µL Eppendorf 3638475 
Pipette 100-1000 µL Eppendorf 4741196 
Pipette 20-200 µL Eppendorf 3534296 
Pipette 2-20 µL Eppendorf 3407866 
Pipette 500-5000 µL Eppendorf 3615095 
POLARstar Galaxy fluorescence 
plate reader 
BMG Lab Technologies 4030639 
RH basic magnetic stirrer IKA Labortechnik 3061661 
Vacuum pump BVC21 Brand 08E12592 
Vortex stirrer Minishaker Vacuubrand 2.88069E+13 
Waterbath type 1083 GFL 11530203 
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11 Appendix 
11.1 List of Abbreviations 
 
ABC transporter  ATP binding cassette transporter 
ALD    adrenoleukodystrophy 
ATCC    American Type Culture Collection 
ATP    adenosine-5´-triphosphate 
APT    attached proton test 
BBB    blood-brain barrier 
BCRP    breast cancer resistance protein, ABCG2 
BSA    bovine serum albumin 
Calcein AM   calcein acetoxymethyl ester 
CDCl3    deuterated chloroform 
CsA    cyclosporine A 
d    doublet 
dd    doublet of doublets 
DEPT    distorsionless enhancement by polarisation transfer 
DMEM   Dulbecco’s modified Eagle medium 
DMF    dimethylformamide 
DMSO   dimethylsulfoxide 
DNA    deoxyribonucleic acid 
DPBS    Dulbecco’s phosphate buffered saline 
dt    doublet of triplets 
EC50    half-maximal effective concentration 
ECACC   European Collection of Authenticated Cell Cultures 
EGFR    epidermal growth factor receptor 
ER    endoplasmic reticulum 
FACS    fluorescence-activated cell scanning 
FBS    fetal bovine serum 
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FRET    fluorescence resonance energy transfer 
FSC    forward scatter 
FTC    Fumitremorgin C 
GI50    compound concentration leading to a cell survival of 50% 
GFP    green fluorescent protein 
GSH    glutathione 
HBA    hydrogen bond acceptor 
HBD    hydrogen bond donor 
HCl    hydrochloric acid 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV    human immunodeficiency virus 
IC50    compound concentration leading to 50% inhibition 
IAAP    [I125]iodoarylazidoprazosine 
KHB    krebs-HEPES buffer 
KOH    potassium Hydroxide 
LTC4    Leukotriene C4 
m    multiplet 
MDR    multidrug resistance 
MRP1     Multidrug Resistance related Protein 1 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
MTX methotrexate 
MX mitoxantrone 
MXR mitoxantrone resistance protein 
n.a. not active 
NADH nicotineamide adenine dinucleotide (reduced form) 
NaOH sodium hydroxide 
n.d. not determined  
n.d.a. no data available 
n.t. not tested 
NBD nucleotide binding domain 
NMR nuclear magnetic resonance 
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PBS phosphate buffered saline 
PDT photodynamic therapy 
P-gp    permeability glycoprotein, ABCB1 
PhA    pheophorbide A 
PhIP    2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
ppm    parts per million 
q    quartet 
RT    room temperature 
s    singlet 
SAR    structure-activity relationship 
SD    standard deviation 
SNP    single-nucleotide polymorphism  
SSC    side scatter 
t    triplet  
td    triplet of doublets 
TKI    tyrosine kinase inhibitor 
TLC    thin layer chromatography 
TMD    transmembrane domain 
TR    therapeutic ratio 
wt    wild type 
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